

SEEGER WEISS LLP
CHRISTOPHER A. SEEGER
JENNIFER SCULLION
55 Challenger Road, 6th Floor
Ridgefield Park, NJ 07660
Telephone: 212/584-0700
212/584-0799 (fax)

Local Counsel

ROBBINS GELLER RUDMAN
& DOWD LLP
JAMES E. BARZ
FRANK A. RICHTER
200 South Wacker Drive, 31st Floor
Chicago, IL 60606
Telephone: 312/674-4674
312/674-4676 (fax)

Lead Counsel for Plaintiffs

UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY

In re VALEANT PHARMACEUTICALS)
INTERNATIONAL, INC. SECURITIES)
LITIGATION)

Master No. 3:15-cv-07658-MAS-LHG

CLASS ACTION

This Document Relates To:)

Judge Michael A. Shipp
Magistrate Judge Lois H. Goodman

SECURITIES CLASS ACTION.)
_____)

Special Master Dennis M. Cavanaugh,
U.S.D.J. (ret.)

DECLARATION OF CHRISTOPHER
A. SEEGER IN SUPPORT OF
MOTIONS FOR (1) FINAL
APPROVAL OF CLASS ACTION
SETTLEMENT AND PLAN OF
ALLOCATION; AND (2) AN
AWARD OF ATTORNEYS' FEES
AND EXPENSES AND AWARDS
TO PLAINTIFFS PURSUANT TO
15 U.S.C. §78U-4(A)(4)

CHRISTOPHER A. SEEGER, under penalty of perjury, declares and certifies as follows:

1. I am a member of the bar of the State of New Jersey and am admitted to practice before this Court. I am a member of the law firm of Seeger Weiss LLP, one of the counsel of record for Lead Plaintiff in the above-entitled action. I have personal knowledge of the matters stated herein and, if called upon, I could and would competently testify thereto.

2. I make this Declaration based on my personal knowledge in support of Motions for (1) Final Approval of Class Action Settlement and Plan of Allocation; and (2) an Award of Attorneys' Fees and Expenses and Awards to Plaintiffs Pursuant to 15 U.S.C. §78u-4(a)(4).

3. Attached are true and correct copies of the following exhibits:

Exhibit A: Stipulation of Settlement, *In re Valeant Pharmaceuticals International, Inc. Securities Litigation*, No. 15-cv-07658 (Dec. 15, 2019), together with the following Exhibits thereto: Exhibit A – [Proposed] Order Granting Preliminary Approval Pursuant to Fed. R. Civ. P. 23(e)(1) and Permitting Notice to the Class; Exhibit A-1 – Notice of Pendency and Proposed Settlement of Class Action (as updated by agreement of the Settling Parties and approved by the Court); Exhibit A-2 – Proof of Claim of Release; Exhibit A-3 – Summary Notice of Pendency and Proposed Settlement of Class Action; and Exhibit B – [Proposed] Order and Final Judgment.

Exhibit B: ISS Securities Class Action Services, *The Top 100 U.S. Class Action Settlements of All Time, As of December 31, 2018* (2019).

Exhibit C: Stock Price Data for Bausch Health Companies (formerly known as Valeant Pharmaceuticals International, Inc.), obtained from *Bloomberg*.

- Exhibit D: Bausch Health Companies Inc., Press Release, “Bausch Health Announces Launch of Private Offering of Senior Notes” (Dec. 17, 2019).
- Exhibit E: Transcript of Preliminary Approval Hearing Before Special Master Dennis M. Cavanaugh, U.S.D.J. (ret.), *In re Valeant Pharmaceuticals International, Inc. Securities Litigation*, No. 15-cv-07658 (Jan. 21, 2020).
- Exhibit F: Letter Submission by Defendants, *In re Valeant Pharmaceuticals International, Inc. Securities Litigation*, No. 15-cv-07658 (Oct. 11, 2019).
- Exhibit G: Stefan Boettrich and Svetlana Starykh, NERA Economic Consulting, “Recent Trends in Securities Class Action Litigation: 2018 Full-Year Review” (Jan. 29, 2019).
- Exhibit H: Memorandum of Law In Support of Lead Plaintiff’s Motion for Class Certification, *In re Valeant Pharmaceuticals International, Inc. Securities Litigation*, No. 15-cv-07658 (Sept. 28, 2018).
- Exhibit I: Wells Fargo Securities, Equity Research, “Altman Z-Score Screen: Valeant Still an Outlier” (Feb. 8, 2017).
- Exhibit J: Sarah N. Lynch and Bill Berkrot, Reuters, “Ackman, Valeant pledge reforms after spiking drug prices” (Apr. 26, 2016).
- Exhibit K: Seeking Alpha, “Valeant Pharmaceuticals: Is Bankruptcy Ahead?” (Apr. 29, 2016).
- Exhibit L: Janeen McIntosh and Svetlana Starykh, NERA Economic Consulting, “Recent Trends in Securities Class Action Litigation: 2019 Full-Year Review” (Jan. 21, 2020).
- Exhibit M: Wells Fargo Securities, Flash Comment, “BHC: Quick Thoughts On Settlement Agreement” (Dec. 16, 2019).
- Exhibit N: Guggenheim Securities, LLC, Flash Note, “Proposed Stock-Drop Settlement Resolves One of Last Major Legacy Legal Issues” (Dec. 16, 2019).

Exhibit O: Bloomberg Intelligence, Bausch Health Credit Research, “Bausch’s \$1.2 Billion Settlement a Credit Negative: Credit React” (Dec. 16, 2019).

Exhibit P: Objections received by Lead Counsel, *In re Valeant Pharmaceuticals International, Inc. Securities Litigation*, No. 3:15-cv-07658-MAS-LHG (D.N.J.).

In accordance with 28 U.S.C. §1746, I hereby declare under penalty of perjury that the foregoing is true and correct.

DATED: April 22, 2020

s/ Christopher A. Seeger

CHRISTOPHER A. SEEGER

EXHIBIT A

SEEGER WEISS LLP
CHRISTOPHER A. SEEGER
DAVID R. BUCHANAN
55 Challenger Road, 6th Floor
Ridgefield Park, NJ 07660
Telephone: 212/584-0700
212/584-0799 (fax)

Local Counsel

ROBBINS GELLER RUDMAN
& DOWD LLP
JAMES E. BARZ
FRANK A. RICHTER
200 South Wacker Drive, 31st Floor
Chicago, IL 60606
Telephone: 312/674-4674
312/674-4676 (fax)

Lead Counsel for Plaintiffs

[Additional counsel appear on signature page.]

UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY

In re VALEANT)	Master No. 3:15-cv-07658-MAS-LHG
PHARMACEUTICALS)	
INTERNATIONAL, INC.)	<u>CLASS ACTION</u>
SECURITIES LITIGATION)	
_____)	Judge Michael A. Shipp
)	Magistrate Judge Lois H. Goodman
This Document Relates To:)	Special Master Hon. Dennis M. Cavanaugh,
)	U.S.D.J. (Ret.)
Case No. 3:15-cv-07658-MAS-LHG.)	
_____)	STIPULATION OF SETTLEMENT

This Stipulation of Settlement, dated December 15, 2019 (the “Stipulation”), is made and entered into by and among the following: (i) Lead Plaintiff TIAA, on behalf of itself and the Class, by and through Lead Counsel in the Litigation; and (ii) Valeant Pharmaceuticals International, Inc. (“Valeant”) (n/k/a Bausch Health Companies Inc.); J. Michael Pearson (“Pearson”); Howard B. Schiller (“Schiller”); Robert L. Rosiello (“Rosiello”); Deborah Jorn (“Jorn”); Ari S. Kellen (“Kellen”); Tanya Carro (“Carro”); Jeffrey W. Ubben (“Ubben”); Robert A. Ingram (“Ingram”); Ronald H. Farmer (“Farmer”); Colleen Goggins (“Goggins”); Anders Lönner (“Lönner”); Theo Melas-Kyriazi (“Melas-Kyriazi”); Robert N. Power (“Power”); Norma Provencio (“Provencio”); Katharine B. Stevenson (“Stevenson”); Deutsche Bank Securities Inc.; HSBC Securities (USA) Inc.; MUFG Securities Americas Inc. f/k/a Mitsubishi UFJ Securities (USA) Inc.; DNB Markets, Inc.; Barclays Capital Inc.; Morgan Stanley & Co. LLC; RBC Capital Markets, LLC; Suntrust Robinson Humphrey, Inc.; ValueAct Capital Management, L.P. (“ValueAct Capital”); VA Partners I, LLC (“VA Partners”); ValueAct Holdings, L.P. (“ValueAct Holdings”); ValueAct Capital Master Fund, L.P. (“ValueAct Capital Master Fund”); ValueAct Co-Invest Master Fund, L.P. (“ValueAct Co-Invest Fund”) (collectively, the “Defendants”); Goldman Sachs & Co. LLC f/k/a Goldman Sachs & Co.; J.P. Morgan Securities LLC; Merrill Lynch, Pierce, Fenner & Smith Inc.; CIBC World Markets Inc.; Citigroup Global Markets Inc.; DBS Bank Ltd.; TD Securities (USA) LLC;

BMO Capital Markets Corp.; SMBC Nikko Securities America, Inc. (collectively, the “Former Defendants”¹), by and through their counsel of record in the Litigation.² The Stipulation is intended to fully, finally, and forever resolve, discharge, and settle the Released Claims as to the Released Persons, subject to the approval of the Court and the terms and conditions set forth in this Stipulation.

I. THE LITIGATION

The Litigation is currently pending in the United States District Court for the District of New Jersey before the Honorable Michael A. Shipp (the “Court”). The Litigation was referred to Special Master Judge Dennis M. Cavanaugh, U.S.D.J. (ret), on September 10, 2019. The initial complaint in this consolidated action was filed on October 22, 2015. On May 31, 2016, the Court consolidated Civil Action Nos. 15-cv-07679, 15-cv-07746, and 15-cv-07809 with this action and appointed TIAA as Lead Plaintiff and Robbins Geller Rudman & Dowd LLP (“Robbins Geller”) as Lead Counsel.

Plaintiffs filed the Consolidated Complaint for Violations of the Federal Securities Laws (“Complaint”) on June 24, 2016. The Complaint alleges that the

¹ Defendants and Former Defendants include all named defendants in the action except PriceWaterhouseCoopers LLP (“PwC”) which is not a party to this settlement agreement. None of the terms herein shall release any of Plaintiffs’ claims in this action against PwC.

² All capitalized terms not otherwise defined shall have the meanings ascribed to them in §IV.1 herein.

Defendants and Former Defendants are liable for violations of the Securities Act of 1933 and/or the Securities Exchange Act of 1934 resulting from materially false and misleading statements or omissions of material facts necessary to make statements made in public filings and other public statements not misleading. Among other things, Plaintiffs allege that the Defendants and Former Defendants are liable for false and misleading statements regarding Valeant's business operations and financial performance. Plaintiffs further allege that as the truth regarding Valeant's business, operations, and prospects was revealed, artificial inflation was removed from the price of Valeant Securities damaging members of the Class. Defendants and Former Defendants deny each and all of Plaintiffs' allegations. Defendants and Former Defendants contend that they are not liable for any such alleged false or misleading statements and that all information required to be disclosed by the federal securities laws was so disclosed. Defendants also contend that their actions did not cause Plaintiffs' alleged loss, and the Valeant Defendants contend that they did not act with scienter.

The parties vigorously litigated this case for four years. The parties submitted extensive briefing regarding a motion to lift the discovery stay, and after the nearly 300-page consolidated Complaint was filed, the parties briefed and argued six initial motions to dismiss filed by 34 Defendants and Former Defendants. After nearly 400 pages of briefing and a lengthy hearing, the Court denied the motions to dismiss in

substantial part against Defendants, and dismissed all claims against Former Defendants. The parties then engaged in extensive fact and class-related discovery involving Class Representatives, Defendants, and approximately 150 non-parties, which included the exchange of over 13 million pages of documents. Plaintiffs also conducted interviews of former Valeant employees and other third parties and reviewed the public record, including statements submitted as part of Congressional hearings. Plaintiffs moved for class certification on September 28, 2018. Defendants' time to respond to Plaintiffs' motion for class certification has not yet elapsed, and the Court has not yet ruled on Plaintiffs' motion.

Plaintiffs subsequently amended the Complaint to add insider trading claims against the ValueAct Defendants and Defendant Ubben. The ValueAct Defendants and Defendant Ubben moved to dismiss the insider trading claims and after the parties exchanged 70 additional pages of briefing, the Court denied the ValueAct Defendants' motion to dismiss. The ValueAct Defendants and Defendant Ubben deny each and all of Plaintiffs' insider trading allegations.

During the course of the Litigation, the parties engaged an experienced and neutral third-party mediator, Eric D. Green, and held direct settlement discussions. The parties exchanged lengthy and detailed briefs and Lead Counsel met in person with the mediator and counsel for the Valeant Defendants on September 17, 2018, but were unable to reach an agreement. During the following year counsel for the

parties engaged in numerous teleconferences with the mediator. On November 6, 2019, the parties attended another in person mediation after exchanging supplemental mediation briefs. Once again the parties were unable to reach an agreement. Then, in response to a mediator's proposal, on November 22, 2019, the Settling Parties agreed to settle the Litigation with all Defendants and Former Defendants except PwC in return for a cash payment of \$1,210,000,000 for the benefit of the Class, as specified in Section 2 below. This Stipulation (together with the Exhibits hereto) reflects the final and binding agreement between the Settling Parties.

II. LEAD PLAINTIFF'S CLAIMS AND THE BENEFITS OF SETTLEMENT

Lead Plaintiff and Lead Counsel believe that the claims asserted in the Litigation have merit and that the evidence developed to date supports the claims asserted therein. However, Lead Plaintiff and Lead Counsel recognize the expense and risk of continued proceedings necessary to prosecute the Litigation against Defendants through trial and post-trial appeals. Lead Plaintiff and Lead Counsel also have taken into account the uncertain outcome and the risk of litigation, especially in complex actions such as this Litigation, as well as the difficulties and delays inherent in such litigation. Lead Plaintiff and Lead Counsel also are mindful of the inherent problems of proof under and possible defenses to the securities law violations asserted in the Litigation. Lead Plaintiff and Lead Counsel believe that

the Settlement set forth in this Stipulation confers substantial benefits upon the Class. Based on their evaluation, Lead Plaintiff and Lead Counsel have determined that the Settlement set forth in this Stipulation is in the best interests of Lead Plaintiff and the Class.

III. DEFENDANTS' DENIALS OF WRONGDOING AND LIABILITY

Throughout this Litigation, Defendants and Former Defendants have denied, and continue to deny, any and all allegations of fault, liability, wrongdoing, or damages whatsoever arising out of any of the conduct, statements, acts, or omissions alleged, or that could have been alleged, in the Litigation. Defendants and Former Defendants also have denied, and continue to deny, among other allegations, the allegations that Plaintiffs or the Class have suffered any damages, or that Plaintiffs or the Class were harmed by the conduct alleged in the Litigation or that could have been alleged as part of the Litigation. In addition, Defendants maintain that they have meritorious defenses to all claims alleged in the Litigation. Defendants' decision to settle the Litigation is based on the conclusion that it is desirable that the Litigation be fully and finally settled in the manner and upon the terms and conditions set forth in this Stipulation, and that it would be beneficial to avoid the burden, inconvenience, and expense associated with continuing the Litigation, and the uncertainty and risks inherent in any litigation, especially in complex cases like this Litigation.

IV. TERMS OF THE STIPULATION AND AGREEMENT OF SETTLEMENT

NOW, THEREFORE, IT IS HEREBY STIPULATED AND AGREED by and among Lead Plaintiff (for itself and the Class Members) and Defendants and Former Defendants, by and through their counsel, that, subject to the approval of the Court pursuant to Rule 23(e) of the Federal Rules of Civil Procedure, in consideration of the benefits flowing to the parties from the Settlement, the Litigation and the Released Claims shall be finally and fully compromised, settled, and released, and the Litigation shall be dismissed with prejudice, as to all Settling Parties, upon and subject to the terms and conditions of this Stipulation, as follows:

1. Definitions

In addition to the terms defined in the first three paragraphs of this Stipulation, as used in this Stipulation the following terms, when capitalized, have the meanings specified below:

1.1 “Authorized Claimant” means any Class Member who submits a valid claim that is accepted for payment by the Claims Administrator.

1.2 “Canadian Actions” means (i) *Catucci, et al. v. Valeant Pharmaceuticals International, Inc., et al.*, No. 500-06-000783-163 (re-amended operative pleading filed September 12, 2019 in the Superior Court of Quebec (“*Catucci*”)); (ii) any proceedings which may be instituted in Canadian courts by entities that opted out of the authorized class in *Catucci*; (iii) *Blackrock Asset*

Management Canada Limited, et al. v. Valeant Pharmaceuticals International, Inc., et al., No. 500-11-054155-185 (filed March 2, 2018 in the Superior Court of Quebec) and No. 500-17-03749-183 (amended operative pleading filed November 14, 2019 in the Superior Court of Quebec); and (iv) *California State Teachers' Retirement System v. Bausch Health Companies Inc., et al.*, No. 500-17-106044-186 (amended operative pleading filed September 3, 2019 in the Superior Court of Quebec) and No. 500-11-055722-181 (amended operative pleading filed September 3, 2019 in the Superior Court of Quebec), solely with respect to securities at issue in each of the foregoing Canadian Actions acquired outside of the United States without use of securities exchanges or over-the-counter securities markets located in the United States.

1.3 “Claim(s)” means a paper claim submitted on a Proof of Claim and Release form or an electronic claim that is submitted to the Claims Administrator.

1.4 “Claims Administrator” means Gilardi & Co. LLC.

1.5 “Class” means all Persons who purchased or otherwise acquired Valeant Securities between January 4, 2013 and March 15, 2016, inclusive. Excluded from the Class are Defendants and Former Defendants, present and former executive officers of Defendants and Former Defendants, and members of their immediate families, present and former directors of Defendants and Former Defendants, and members of their immediate families, any entity in which a

Defendant or current or former director of a Defendant has control and/or a majority ownership interest, and the legal representatives, heirs, successors or assigns of any such excluded party. For the avoidance of doubt, this exclusion does not extend to: (1) any investment company or pooled investment fund in which a Defendant or Former Defendant may have a direct or indirect interest, or as to which its affiliates may act as an advisor, but of which a Defendant or Former Defendant or its respective affiliates is not a majority owner or does not hold a majority beneficial interest; or (2) any employee benefit plan as to which a Defendant or Former Defendant or its affiliates acts as an investment advisor or otherwise may be a fiduciary; provided, however, that membership in the Class by such investment company, pooled investment fund or employee benefit plan is limited to transactions in Valeant Securities made on behalf of, or for the benefit of, persons other than persons that are excluded from the Class by definition. In other words, Defendants and Former Defendants cannot make a claim on their own behalf for their ownership share in any of the above entities. The Class also excludes: (1) any person or entity which during the Class Period purchased or otherwise acquired Valeant Securities and has been promised or received a payment from or on behalf of the Valeant Defendants related to or arising from litigation related to its Class Period transactions in Valeant Securities other than a payment of attorneys fees or costs to counsel for such person or entity; (2) any Class Member on Exhibit A to the Final Judgment that

validly and timely requested exclusion in accordance with the requirements set by the Court in the Notice of Pendency and Proposed Settlement of Class Action; and (3) anyone on Exhibit B to the Final Judgment who has filed an individual action and not dismissed their claim and sought to be included in the Class.

1.6 “Class Member” or “Member of the Class” means a Person who is defined within the Class as set forth in ¶1.5 above.

1.7 “Class Period” means the period between January 4, 2013 and March 15, 2016, inclusive.

1.8 “Class Representatives” means Lead Plaintiff together with named plaintiffs City of Tucson together with and on behalf of Tucson Supplemental Retirement System (“Tucson”) and IBEW Local Union 481 Defined Contribution Plan and Trust (“IBEW”).

1.9 “Defendants’ Counsel” means, collectively, the law firms of Simpson Thacher & Bartlett LLP; Cooley LLP; Debevoise & Plimpton LLP; Hartmann Doherty Rosa Berman & Bulbulia, LLC; Paul, Weiss, Rifkind, Wharton & Garrison LLP; Schulte Roth & Zabel LLP; Winston & Strawn LLP; O’Melveny Myers LLP; Gibbons P.C.; and McCarter & English LLP.

1.10 “Effective Date,” or the date upon which this Settlement becomes “effective,” means the first date by which all of the events and conditions specified in ¶7.1 of the Stipulation have been met and have occurred or have been waived.

1.11 “Escrow Agent” means the law firm of Robbins Geller Rudman & Dowd LLP or its successor(s).

1.12 “Final” means, with respect to any order or Judgment of the Court, that such order or Judgment represents a final and binding determination of all issues within its scope and has not been reversed, vacated, or modified in any way and is no longer subject to appellate review, either because of disposition on appeal and conclusion of the appellate process or because of passage, without action, of time for seeking appellate review. Without limitation, an order or Judgment becomes final when: (a) either no appeal therefrom has been filed and the time has passed for any notice of appeal to be timely filed therefrom; or (b) an appeal has been filed and either (i) the court of appeals has either affirmed the order or Judgment or dismissed that appeal and the time for any reconsideration or further appellate review has passed; or (ii) a higher court has granted further appellate review and that court has either affirmed the underlying order or Judgment or affirmed the court of appeals’ decision affirming the Judgment or dismissing the appeal. For purposes of this paragraph, an “appeal” shall include any motion for reconsideration or rehearing or petition for a writ of *certiorari* or other writ that may be filed in connection with approval or disapproval of this Settlement. Any appeal or proceeding seeking subsequent judicial review pertaining solely to an order issued with respect to: (i) attorneys’ fees, costs, or expenses or awards to Lead Plaintiff or other Class

Representatives; (ii) the Plan of Allocation (as submitted or subsequently modified); or (iii) the procedures for determining Authorized Claimants' recognized claims, shall not in any way delay, affect, or preclude the time set forth above for the Judgment to become Final, or otherwise preclude the Judgment from becoming Final.

1.13 "Judgment" means the Order and Final Judgment to be rendered by the Court, substantially in the form attached hereto as Exhibit B, as well as any form of final judgment that may be entered by the Court in a form other than the form attached hereto as Exhibit B and where none of the Settling Parties elects to terminate this Settlement by reason of such variance, consistent with the terms of this Stipulation.

1.14 "Lead Counsel" means the law firm of Robbins Geller Rudman & Dowd LLP and any of its members, partners, associates and/or employees.

1.15 "Lead Plaintiff" or "TIAA" has the same meaning as defined in the Amended Complaint filed on September 20, 2018.

1.16 "Litigation" means the consolidated actions captioned *In re Valeant Pharmaceuticals International, Inc. Securities Litigation*, No. 3:15-cv-07658-MAS-LHG, pending in the United States District Court for the District of New Jersey.

1.17 "Net Settlement Fund" means the Settlement Fund less: (i) any Court-awarded attorneys' fees, expenses and charges (including awards to Plaintiffs

pursuant to 15 U.S.C. §78u-4(a)(4) in connection with their representation of the Class), and interest thereon; (ii) Notice and Administration Expenses; (iii) Taxes and Tax Expenses; and (iv) other Court-approved deductions.

1.18 “Person(s)” means an individual, corporation (including all its divisions and subsidiaries thereof), limited liability corporation, professional corporation, partnership, limited partnership, limited liability partnership, limited liability company, joint venture, association, joint stock company, estate, legal representative, trust, unincorporated association, government or any political subdivision or agency thereof, and any business or legal entity and all of their respective spouses, heirs, beneficiaries, executors, administrators, predecessors, successors, representatives, or assignees.

1.19 “Plaintiffs” means Lead Plaintiff and Class Representatives.

1.20 “Plaintiffs’ Counsel” means Lead Counsel and any attorney or firm who has appeared in the Litigation on behalf of any of the Plaintiffs or the Class.

1.21 “Plan of Allocation” means a plan or formula of allocation of the Net Settlement Fund whereby the Net Settlement Fund shall be distributed to Authorized Claimants. Any Plan of Allocation is not part of this Stipulation and neither Defendants, Former Defendants nor their Related Parties shall have any responsibility or liability with respect thereto.

1.22 “Proof of Claim and Release” means the Proof of Claim and Release form for submitting a Claim, which, subject to approval of the Court, shall be substantially in the form attached hereto as Exhibit A-2. A Class Member must complete and submit the Proof of Claim and Release should that Class Member seek to share in a distribution of the Net Settlement Fund.

1.23 “Related Parties” means each Defendant and Former Defendants’ respective present and former parents, subsidiaries, divisions, controlling persons, associates, entities and affiliates and each and all of their respective present and former employees, members, partners, principals, officers, directors, controlling shareholders, agents, attorneys, advisors (including financial or investment advisors), consultants, underwriters, investment bankers, commercial bankers, general or limited partners or partnerships, limited liability companies, members, joint ventures and insurers and reinsurers of each of them; as well as the predecessors, successors, estates, immediate family members, spouses, heirs, executors, trusts, trustees, administrators, agents, legal or personal representatives, assigns, and assignees of each of them, in their capacity as such. Related Parties does not include PwC.

1.24 “Released Claims” means any and all rights, liabilities, suits, debts, obligations, demands, damages, losses, judgment matters, issues, claims (including Unknown Claims), and causes of action of every nature and description whatsoever,

in law, equity, or otherwise, whether accrued or unaccrued, fixed or contingent, liquidated or unliquidated, whether arising under federal, state, local, statutory, common law, foreign law, or any other law, rule, or regulation, and whether class and/or individual in nature, concerning, based on, arising out of, or in connection with both: (i) the purchase or other acquisition of Valeant Securities by Lead Plaintiff or any other Class Member between January 4, 2013 and March 15, 2016, inclusive; and (ii) the allegations, transactions, acts, facts, matters, occurrences, disclosures, statements, filings, representations, omissions, or events that were or could have been alleged or asserted in the Litigation. Released Claims do not include claims to enforce the Settlement, shareholder derivative claims on behalf of Valeant, governmental agency actions against the Released Persons, claims asserted in the RICO Class Action, the Canadian Actions, or the claims that are or could be asserted in this Litigation against PwC.

1.25 “Released Defendants’ Claims” means any and all claims and causes of action of every nature and description whatsoever, including both known claims and Unknown Claims, that arise out of, are based upon, or relate in any way to the institution, prosecution, or settlement of the claims against Defendants or Former Defendants in the Litigation, except for claims relating to the enforcement of the Settlement or contractual or other indemnification rights.

1.26 “Released Persons” means each and all of the Defendants, Former Defendants and their Related Parties. Released Persons does not include PwC.

1.27 “Releasing Plaintiff Party” or “Releasing Plaintiff Parties” means Lead Counsel and each and every plaintiff, Class Member, and counsel to any plaintiff, and each of their respective past or present trustees, officers, directors, partners, employees, contractors, principals, agents, attorneys, predecessors, successors, assigns, representatives, affiliates, insurers, parents, subsidiaries, general or limited partners or partnerships, and limited liability companies; and the spouses, members of the immediate families, representatives, and heirs of any Releasing Plaintiff Party who is an individual, as well as any trust of which any Releasing Plaintiff Party is the settlor or which is for the benefit of any of their immediate family members. Releasing Plaintiff Parties does not include any Person who timely and validly sought exclusion from the Class and remained excluded as of the Effective Date, or any purchaser or acquirer of any Valeant Securities which settled, compromised or otherwise resolved any claims against any Released Person related to such purchaser’s or acquirer’s acquisition of Valeant Securities.

1.28 “RICO Class Action” means *Airconditioning and Refrigeration Industry Health and Welfare Trust Fund v. Valeant Pharmaceuticals Int’l, Inc.*, No. 3:16-cv-03087 (D.N.J. May 27, 2016).

1.29 “Settlement” means the resolution of the Litigation in accordance with the terms and provisions of this Stipulation.

1.30 “Settlement Amount” means One Billion Two Hundred Ten Million Dollars (U.S. \$1,210,000,000.00) to be paid by check(s) and/or wire transfer(s) to the Escrow Agent pursuant to ¶¶2.2 and 2.3 of this Stipulation.

1.31 “Settlement Fund” means the Settlement Amount plus all interest and accretions thereto.

1.32 “Settlement Hearing” means the hearing set by the Court under Rule 23(e)(2) of the Federal Rules of Civil Procedure to consider final approval of the Settlement.

1.33 “Settling Parties” means, collectively, Defendants, Former Defendants and Lead Plaintiff, on behalf of itself and the Class.

1.34 “Stock Underwriter Defendants” means, collectively, Deutsche Bank Securities Inc.; HSBC Securities (USA) Inc.; MUFG Securities Americas Inc. f/k/a Mitsubishi UFJ Securities (USA) Inc.; DNB Markets, Inc.; Barclays Capital Inc.; Morgan Stanley & Co. LLC; RBC Capital Markets, LLC; and Suntrust Robinson Humphrey, Inc.

1.35 “Supplemental Agreement” means the Supplemental Agreement dated December 15, 2019 between TIAA and Valeant.

1.36 “Tax” or “Taxes” mean any and all taxes, fees, levies, duties, tariffs, imposts, and other charges of any kind (together with any and all interest, penalties, additions to tax and additional amounts imposed with respect thereto) imposed by any governmental authority, including, but not limited to, any local, state, and federal taxes.

1.37 “Unknown Claims” means: (a) any and all Released Claims which the Releasing Plaintiff Parties do not know or suspect to exist in his, her, or its favor at the time of the release of the Released Persons, which, if known by him, her, or it, might have affected his, her, or its settlement with and release of the Released Persons, or might have affected his, her, or its decision(s) with respect to the Settlement, including, but not limited to, whether or not to object to this Settlement or seek exclusion from the Class; and (b) any and all Released Defendants’ Claims that the Released Persons do not know or suspect to exist in his, her, or its favor at the time of the release of the Plaintiffs, the Class and Plaintiffs’ Counsel, which, if known by him, her, or it, might have affected his, her, or its settlement and release of Plaintiffs, the Class and Plaintiffs’ Counsel. With respect to (a) any and all Released Claims against the Released Persons, and (b) any and all Released Defendants’ Claims against Plaintiffs, the Class and Plaintiffs’ Counsel, the Settling Parties stipulate and agree that, upon the Effective Date, the Settling Parties shall expressly waive and each Releasing Plaintiff Party and Released Person shall be

deemed to have, and by operation of the Judgment shall have expressly waived, the provisions, rights, and benefits of California Civil Code §1542, which provides:

A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.

The Settling Parties shall expressly waive and each Releasing Plaintiff Party and Released Person shall be deemed to have, and by operation of the Judgment shall have, expressly waived any and all provisions, rights, and benefits conferred by any law of any state or territory of the United States, or principle of common law, which is similar, comparable, or equivalent to California Civil Code §1542. The Releasing Plaintiff Parties and Released Persons acknowledge that they may hereafter discover facts in addition to or different from those which he, she, it or their counsel now knows or believes to be true with respect to the subject matter of the Released Claims or Released Defendants' Claims, but: (a) the Releasing Plaintiff Parties shall expressly fully, finally, and forever waive, compromise, settle, discharge, extinguish, and release, and each Releasing Plaintiff Party shall be deemed to have waived, compromised, settled, discharged, extinguished, and released, and upon the Effective Date, and by operation of the Judgment shall have waived, compromised, settled, discharged, extinguished, and released, fully, finally, and forever, any and all Released Claims against the Released Persons, known or unknown, suspected or

unsuspected, contingent or non-contingent, whether or not concealed or hidden, which now exist, or heretofore have existed, upon any theory of law or equity now existing or coming into existence in the future, including, but not limited to, conduct which is negligent, intentional, with or without malice, or a breach of any duty, law or rule, without regard to the subsequent discovery or existence of such different or additional facts, legal theories, or authorities; and (b) the Released Persons shall expressly fully, finally, and forever waive, compromise, settle, discharge, extinguish, and release, and upon the Effective Date, and by operation of the Judgment shall have waived, compromised, settled, discharged, extinguished, and released, fully, finally, and forever, any and all Released Defendants' Claims against the Plaintiffs, the Class and Plaintiffs' Counsel, known or unknown, suspected or unsuspected, contingent or non-contingent, whether or not concealed or hidden, which now exist, or heretofore have existed, upon any theory of law or equity now existing or coming into existence in the future, including, but not limited to, conduct which is negligent, intentional, with or without malice, or a breach of any duty, law or rule, without regard to the subsequent discovery or existence of such different or additional facts, legal theories, or authorities. This paragraph does not affect any claims for contractual or other indemnification rights between or among the Defendants and Former Defendants. The Settling Parties acknowledge, and the Releasing Plaintiff Parties and Released Persons shall be deemed by operation of the

Judgment to have acknowledged, that the foregoing waiver was separately bargained for and is an essential element of the Settlement of which this release is a part.

1.38 “Valeant Defendants” means Valeant, Rosiello, Kellen, Farmer, Goggins, Ingram, Lönner, Melas-Kyriazi, Power, Provencio, Stevenson, Ubben, Pearson, Schiller, Jorn, and Carro.

1.39 “Valeant Defendants’ Counsel” means Simpson Thacher & Bartlett LLP (“Simpson Thacher”) or any successor counsel to the Valeant Defendants should Simpson Thacher no longer be providing counsel to the Valeant Defendants in connection with the matters herein, and includes the separate counsel for Defendants Jorn (Schulte Roth & Zabel LLP), Carro (Cooley LLP), Schiller (Winston & Strawn LLP), Pearson (Debevoise & Plimpton LLP), and Ubben (O’Melveny & Myers LLP); however, with regard to any notice provision herein notice to Simpson Thacher shall constitute notice to all Valeant Defendants’ Counsel.

1.40 “Valeant Securities” means Valeant equity securities as defined in 15 U.S.C. §78c(11) and 17 C.F.R. §240.3a11-1, and Valeant debt securities, including Valeant common stock; options on Valeant common stock, defined to be the purchase or acquisition of call options and the sale of put options; and the following Valeant senior notes: (1) 5.375% senior notes due 2020; (2) 5.875% senior notes due 2023; (3) 6.125% senior notes due 2025; (4) 5.5% senior notes due 2023; (5) 5.625%

senior notes due 2021; (6) 6.75% senior notes due 2018; (7) 7.5% senior notes due 2021; (8) 6.375% senior notes due 2020; (9) 7.25% senior notes due 2022; (10) 6.75% senior notes due 2021; or (11) 7.0% senior notes due 2020. Valeant Securities does not include securities at issue in the Canadian Actions.

1.41 “ValueAct Defendants” means ValueAct Capital; VA Partners; ValueAct Holdings; ValueAct Capital Master Fund; and ValueAct Co-Invest Fund.

2. The Settlement

2.1 The obligations incurred pursuant to the Stipulation are: (a) subject to approval by the Court and the Judgment becoming Final; and (b) in full and final disposition of the Litigation with respect to the Releasing Plaintiff Parties and Released Persons and any and all Released Claims and Released Defendants’ Claims upon and subject to the terms and conditions set forth herein.

2.2 Valeant shall pay the Settlement Amount of one billion two hundred ten million dollars (\$1,210,000,000) by wire transfer in accordance with the instructions to be provided by the Escrow Agent, as follows:

- (a) \$200,000,000 on or before January 10, 2020;
- (b) an additional \$200,000,000 on or before March 3, 2020; and
- (c) the balance of \$810,000,000 within three (3) business days of

Final Approval of the Settlement by the Court. No other Defendants or Former

Defendants shall have responsibility to pay the Settlement Amount or any portion thereof.

2.3 Valeant shall pay the Settlement Amount to the Escrow Agent plus the interest associated therewith as follows: at the rate of 1.5% per annum (simple interest), which shall begin accruing on January 10, 2020 with respect to any portion of the Settlement Amount that Valeant has not paid to the Escrow Agent by that date until March 3, 2020; and from March 4, 2020, at the rate of 3.5% per annum (simple interest) with respect to any portion of the Settlement Amount that Valeant has not paid to the Escrow Agent by that date; interest shall cease accruing with respect to Valeant on the date the entire Settlement Amount is paid to the Escrow Agent. Valeant may prepay the Settlement Amount at any time.

2.4 In the event Valeant fails to pay the Settlement Amount within the time period provided for in ¶¶2.2 and 2.3, Lead Plaintiff shall have the right to terminate and cancel the Settlement on behalf of itself and the Class. Lead Plaintiff may terminate and cancel the Settlement by providing written notice of its election to do so to the other parties to this Stipulation and returning all monies paid into escrow less funds validly used to pay expenses as provided herein.

2.5 Other than Valeant's obligation to pay or cause to be paid the Settlement Amount into the Settlement Fund as set forth in ¶¶2.2 and 2.3, none of the Released Persons shall have any responsibility for, interest in, or liability

whatsoever with respect to: (i) any act, omission, or determination by Lead Counsel or the Claims Administrator, or any of their respective designees, in connection with the administration of the Settlement or otherwise; (ii) the management, investment, or distribution of the Settlement Fund; (iii) the Plan of Allocation; (iv) the determination, administration, calculation, or payment of any Claims asserted against the Settlement Fund; (v) any loss suffered by, or fluctuation in value of, the Settlement Fund; or (vi) the payment or withholding of any Taxes, expenses, and/or costs incurred in connection with the taxation of the Settlement Fund, distributions or other payments from the Escrow Account, or the filing of any federal, state, or local returns.

2.6 Other than Valeant's obligation to cause the payment of the Settlement Amount in accordance with the terms of ¶¶2.2 and 2.3, none of the Defendants and Former Defendants shall have any obligation to make any payments into the Escrow Account, to any Class Member or to Plaintiffs pursuant to the Stipulation, nor any responsibility or liability with respect to the Escrow Account or the monies maintained in the Escrow Account, including, without limitation, any responsibility or liability related to any fees, Taxes, investment decisions, maintenance, supervision or distribution of any portion of the Settlement Amount.

a. Condition Precedent

2.7 The Settlement is conditioned on the Court granting final approval of the Settlement, and approval of the Settlement becoming Final. Approval of the Settlement becomes Final when the conditions set forth in ¶1.12 are satisfied. The Settlement is not conditioned on any settlement(s), or approval of any settlement(s), of the Canadian Actions, the RICO Class Action, any opt-out action, or Plaintiffs' claims against PwC.

b. The Escrow Agent

2.8 The Escrow Agent shall invest the Settlement Amount deposited pursuant to ¶¶2.2 and 2.3 hereof in United States Agency or Treasury Securities or other instruments backed by the Full Faith & Credit of the United States Government or an Agency thereof, or fully insured by the United States Government or an Agency thereof and shall reinvest the proceeds of these instruments as they mature in similar instruments at their then-current market rates. All risks related to the investment of the Settlement Fund in accordance with the investment guidelines set forth in this paragraph shall be borne by the Settlement Fund, and the Released Persons shall have no responsibility for, interest in, or liability whatsoever with respect to investment decisions or the actions of the Escrow Agent, or any transactions executed by the Escrow Agent. Provided the Escrow Agent invests the Settlement Fund as set forth herein, the Escrow Agent shall have no liability

whatsoever with respect to any investment decision made in connection with the Settlement Fund.

2.9 The Escrow Agent shall not disburse the Settlement Fund except as provided in this Stipulation, by an order of the Court, or with the prior written agreement of the Valeant Defendants' Counsel and Lead Counsel.

2.10 Subject to further order(s) and/or directions as may be made by the Court, or as provided in this Stipulation, the Escrow Agent is authorized to execute such transactions as are consistent with the terms of this Stipulation and shall incur no liability whatsoever for doing so. The Released Persons shall have no responsibility for, interest in, or liability whatsoever with respect to the actions of the Escrow Agent, or any transaction executed by the Escrow Agent.

2.11 All funds held by the Escrow Agent shall be deemed and considered to be in *custodia legis* of the Court, and shall remain subject to the jurisdiction of the Court, until such time as such funds shall be distributed pursuant to this Stipulation and/or further order(s) of the Court.

2.12 Prior to the Effective Date of the Settlement, the Escrow Agent may pay from the Settlement Fund, without further approval from Defendants and/or order of the Court, all costs and expenses actually incurred in connection with providing notice of the Settlement to the Class by mail, publication, and other means, locating Class Members, assisting with the submission of Claims, processing Proof

of Claim and Release forms, administering the Settlement, and paying escrow taxes, fees and costs, if any, up to a maximum of \$2.5 million (“Notice and Administration Expenses”). The \$2.5 million maximum only applies to such costs and expenses paid prior to the Effective Date. After the Effective Date, Lead Counsel may pay all of the costs and expenses actually incurred in connection with the administration of the Settlement Fund without further order of the Court. In the event that the Settlement does not become Final, any money paid or incurred for the above purposes, including any related fees, shall not be returned or repaid to Defendants or their insurers.

2.13 It shall be Lead Counsel’s responsibility to disseminate the Notice, Proof of Claim and Release, and Summary Notice to the Class in accordance with this Stipulation and as ordered by the Court. The Released Persons shall have no responsibility for or liability whatsoever with respect to the Notice and Administration Expenses, nor shall they have any responsibility or liability whatsoever for any claims with respect thereto, including any claims that may arise from any failure of the notice process.

c. Taxes

2.14 (a) The Settling Parties and the Escrow Agent agree to treat the Settlement Fund as being at all times a “qualified settlement fund” within the meaning of Treas. Reg. §1.468B-1, and the regulations promulgated thereunder. The

Settling Parties and the Escrow Agent further agree that the Settlement Fund shall be established pursuant to the Court's subject matter jurisdiction within the meaning of Treas. Reg. §1.468B-1(c)(1). In addition, the Escrow Agent shall timely make such elections as necessary or advisable to carry out the provisions of this ¶2.14, including the "relation-back election" (as defined in Treas. Reg. §1.468B-1) back to the earliest permitted date. Such elections shall be made in compliance with the procedures and requirements contained in such regulations. It shall be the responsibility of the Escrow Agent to timely and properly prepare and deliver the necessary documentation for signature by all necessary parties, and thereafter to cause the appropriate filing to occur.

(b) For the purpose of §1.468B of the Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder, the "administrator" (as defined in Treas. Reg. §1.468B-2(k)(3)) shall be the Escrow Agent. The Escrow Agent shall timely and properly file all informational and other federal, state, or local tax returns necessary or advisable with respect to the earnings on the Settlement Fund (including, without limitation, the returns described in Treas. Reg. §1.468B-2(k)). Such returns (as well as the elections described in ¶2.14(a) hereof) shall be consistent with this ¶2.14 and in all events shall reflect that all Taxes (including any estimated Taxes, interest, or penalties) on the income earned by the Settlement Fund shall be paid out of the Settlement Fund as provided in ¶2.14(c) hereof.

(c) All (i) Taxes (including any estimated Taxes, interest, or penalties) arising with respect to the income earned by the Settlement Fund, including any Taxes or tax detriments that may be imposed upon the Released Persons or their counsel with respect to any income earned by the Settlement Fund for any period, after the deposit of the Settlement Amount, during which the Settlement Fund does not qualify as a “qualified settlement fund” for federal or state income tax purposes, and (ii) expenses and costs incurred in connection with the operation and implementation of this ¶2.14 (including, without limitation, expenses of tax attorneys and/or accountants and mailing and distribution costs and expenses relating to filing (or failing to file) the returns described in this ¶2.14) (“Tax Expenses”), shall be paid out of the Settlement Fund; in all events the Released Persons and their counsel shall have no liability or responsibility whatsoever for the Taxes or the Tax Expenses. The Escrow Agent shall provide Valeant’s Counsel with notice of all anticipated payments of Taxes and Tax Expenses five (5) business days in advance of such payments and cooperate with Valeant’s Counsel regarding the appropriateness of all such payment of Taxes and Tax Expenses. Further, Taxes and Tax Expenses shall be treated as, and considered to be, a cost of administration of the Settlement Fund and shall be timely paid by the Escrow Agent out of the Settlement Fund without prior order from the Court and the Escrow Agent shall be authorized (notwithstanding anything herein to the contrary) to withhold from

distribution to Authorized Claimants any funds necessary to pay such amounts, including the establishment of adequate reserves for any Taxes and Tax Expenses (as well as any amounts that may be required to be withheld under Treas. Reg. §1.468B-2(1)(2)); neither the Released Persons nor their counsel are responsible nor shall they have any liability for any Taxes or Tax Expenses. The Settling Parties hereto agree to cooperate with the Escrow Agent, each other, and their tax attorneys and accountants to the extent reasonably necessary to carry out the provisions of this ¶2.14.

2.15 The Settlement is non-recapture, *i.e.*, it is not a claims-made settlement. If this Settlement is finally approved, the Defendants and Former Defendants will have no ability to get back any of the Settlement Fund for any reason.

d. Termination of Settlement

2.16 In the event that the Settlement is not approved, or is terminated, canceled, or the Effective Date otherwise fails to occur for any reason, including, without limitation, in the event the Judgment does not become Final, the Settlement Fund less Notice and Administration Expenses or Taxes or Tax Expenses paid, incurred, or due and owing pursuant to ¶¶2.12 and 2.14 hereof in connection with the Settlement provided for herein, shall be refunded pursuant to written instructions from the Valeant Defendants' Counsel in accordance with ¶7.4 herein.

2.17 Valeant may elect to terminate the Settlement in the event that valid requests for exclusion from the Class exceed criteria previously agreed upon in the Supplemental Agreement. If the Court requires the filing of the Supplemental Agreement, Valeant and TIAA shall request that it be filed under seal, and no party to this Stipulation will oppose that request.

3. Preliminary Approval Order and Settlement Hearing

3.1 Promptly after execution of this Stipulation, Lead Counsel shall submit this Stipulation together with its Exhibits to the Court forthwith for entry of an order (the “Preliminary Approval Order”), substantially in the form of Exhibit A attached hereto, requesting, *inter alia*, the preliminary approval of the Settlement set forth in this Stipulation, preliminary certification of the Class for settlement purposes only, and approval for the mailing of a settlement notice (the “Notice”) and publication of a summary notice (“Summary Notice”), substantially in the forms of Exhibits A-1 and A-3 attached hereto. The Notice shall include the general terms of the Settlement set forth in this Stipulation, the proposed Plan of Allocation, the general terms of the Fee and Expense Application, as defined in ¶6.1 hereof, and the date of the Settlement Hearing as defined below.

3.2 Lead Counsel shall request that after notice is given, the Court hold a hearing (the “Settlement Hearing”) and approve the Settlement of the Litigation as set forth herein. At or after the Settlement Hearing, Lead Counsel also will request

that the Court approve the proposed Plan of Allocation and the Fee and Expense Application.

4. Releases

4.1 Upon the Effective Date, as defined in ¶1.10 hereof, Lead Plaintiff shall, and each and every Releasing Plaintiff Party shall be deemed to have, and by operation of the Judgment shall have, fully, finally, and forever waived, released, relinquished, discharged, and dismissed each and every one of the Released Claims against each and every one of the Released Persons and shall forever be barred and enjoined from commencing, instituting, prosecuting, or maintaining any and all of the Released Claims against any and all of the Released Persons, whether or not such Releasing Plaintiff Party executes and delivers the Proof of Claim and Release or shares in the Net Settlement Fund. Claims to enforce the terms of this Stipulation are not released.

4.2 Any Proof of Claim and Release that is executed by Class Members shall release all Released Claims against the Released Persons and shall be substantially in the form contained in Exhibit A-2 attached hereto.

4.3 Upon the Effective Date, the Releasing Plaintiff Parties will be forever barred and enjoined from commencing, instituting, prosecuting, or continuing to prosecute any action or other proceeding in any court of law or equity, arbitration

tribunal, or administrative forum, asserting the Released Claims against any of the Released Persons.

4.4 Upon the Effective Date, each of the Released Persons shall be deemed to have, and by operation of the Judgment shall have, fully, finally, and forever released, relinquished, and discharged all Released Defendants' Claims against Plaintiffs, the Class and Plaintiffs' Counsel. Claims to enforce the terms of this Stipulation are not released.

4.5 Upon the Effective Date, to the fullest extent permitted by law, (i) all Persons shall be permanently enjoined, barred and restrained from commencing, instituting, prosecuting, or maintaining any claims, actions, or causes of action for contribution, indemnity or otherwise against any of the Released Persons seeking as damages or otherwise the recovery of all or part of any liability, judgment, or settlement which they pay or are obligated to pay or agree to pay to the Releasing Plaintiff Parties arising out of, relating to or concerning any acts, facts, statements or omissions that were or could have been alleged in the Litigation, both known and Unknown Claims, whether arising under state, federal or foreign law, as claims, cross-claims, counterclaims, third-party claims or otherwise, in the Court or any other federal, state, or foreign court, or in any arbitration proceeding, administrative agency proceeding, tribunal, or any other proceeding or forum; and (ii) all Released Persons shall be permanently enjoined, barred and restrained from commencing,

instituting, prosecuting, or maintaining any claims, actions, or causes of action for contribution, indemnity or otherwise against any Persons seeking as damages or otherwise the recovery of all or part of any liability, judgment or settlement which they pay or are obligated to pay or agree to pay to the Releasing Plaintiff Parties arising out of, relating to, or concerning any acts, facts, statements or omissions that were or could have been alleged in the Litigation, both known and Unknown Claims, whether arising under state, federal or foreign law, as claims, cross-claims, counterclaims, third-party claims or otherwise, in the Court or any other federal, state, or foreign court, or in any arbitration proceeding, administrative agency proceeding, tribunal, or any other proceeding or forum; *provided that* clauses (i) and (ii) of this Paragraph shall not be construed to modify, amend, or supersede any agreements between or among the Released Persons with respect to claims between or among those Released Persons, including, without limitation, any claims for contractual or other indemnification rights, nor limit the Valeant Defendants' ability to pursue insurance recoveries against their insurers for claims relating to this Litigation, including the Settlement Amount and legal fees and costs incurred in connection with the Litigation.

**5. Administration and Calculation of Claims, Final Awards,
and Supervision and Distribution of the Settlement Fund**

5.1 The Claims Administrator, subject to such supervision and direction of Lead Counsel and the Court as may be necessary or as circumstances may require,

shall administer and calculate the Claims submitted by Class Members and shall oversee distribution of the Net Settlement Fund to Authorized Claimants. The Released Persons and Defendants' Counsel shall have no responsibility for or interest in whatsoever with respect to the administration of the Settlement or the actions or decisions of the Claims Administrator, and shall have no liability whatsoever to the Releasing Plaintiff Parties, including Plaintiffs, any other Class Members, or Plaintiffs' Counsel, in connection with such administration, including, but not limited to: (i) any act, omission, or determination by Lead Counsel, the Escrow Agent, and/or the Claims Administrator, or any of their respective designees or agents, in connection with the administration of the Settlement or otherwise; (ii) the management or investment of the Settlement Fund or the Net Settlement Fund, or the distribution of the Net Settlement Fund; (iii) the Plan of Allocation; (iv) the determination, administration, calculation, or payment of any Claims asserted against the Settlement Fund; (v) any losses suffered by, or fluctuations in value of, the Settlement Fund; or (vi) the payment or withholding of any taxes, expenses, and/or costs incurred with the taxation of the Settlement Fund or the filing of any federal, state, or local returns.

5.2 The Settlement Fund shall be applied as follows:

- (a) to pay all Notice and Administration Expenses;
- (b) to pay the Taxes and Tax Expenses;

(c) to pay attorneys' fees and expenses of Plaintiffs' Counsel and awards to Plaintiffs (the "Fee and Expense Award"); and

(d) after the Effective Date, to distribute the Net Settlement Fund to Authorized Claimants as provided by this Stipulation, the Plan of Allocation, or the orders of the Court.

5.3 After the Effective Date, and in accordance with the terms of this Stipulation, the Plan of Allocation, or such further approval and further order(s) of the Court as may be necessary or as circumstances may require, the Net Settlement Fund shall be distributed to Authorized Claimants, subject to and in accordance with the following provisions of this Stipulation.

5.4 Within ninety (90) calendar days after the mailing of the Notice or such other time as may be set by the Court, each Class Member shall be required to submit to the Claims Administrator a completed Proof of Claim and Release, substantially in the form of Exhibit A-2 attached hereto, signed under penalty of perjury and supported by such documents as are specified in the Proof of Claim and Release.

5.5 Except as provided for herein or otherwise ordered by the Court, all Class Members who fail to timely submit a valid Proof of Claim and Release shall be forever barred from receiving any payments pursuant to this Stipulation and the Settlement set forth herein, but will in all other respects be subject to and bound by the provisions of this Stipulation, the releases contained herein, and the Judgment,

and will be barred from bringing any action against the Released Persons concerning the Released Claims. Notwithstanding the foregoing, Lead Counsel shall have the discretion (but not an obligation) to accept late-submitted Claims for processing by the Claims Administrator so long as the distribution of the Net Settlement Fund to Authorized Claimants is not materially delayed thereby. No Person shall have any claim against any Plaintiff, Plaintiffs' Counsel, the Claims Administrator or any Class Member by reason of the exercise or non-exercise of such discretion.

5.6 Each Proof of Claim and Release shall be submitted to and reviewed by the Claims Administrator, who shall determine, in accordance with this Stipulation and the approved Plan of Allocation, the extent, if any, to which each Claim shall be allowed, subject to review by the Court pursuant to ¶5.8 below.

5.7 Proof of Claim and Release forms that do not meet the submission requirements may be rejected. Prior to rejecting a Proof of Claim and Release in whole or in part, the Claims Administrator shall communicate with the claimant in writing to give the claimant the chance to remedy any curable deficiencies in the Proof of Claim and Release submitted. The Claims Administrator, under the supervision of Lead Counsel, shall notify, in a timely fashion and in writing, all claimants whose Claims the Claims Administrator proposes to reject in whole or in part for curable deficiencies, setting forth the reasons therefor, and shall indicate in such notice that the claimant whose Claim is to be rejected has the right to a review

by the Court if the claimant so desires and complies with the requirements of ¶5.8 below.

5.8 If any claimant whose timely Claim has been rejected in whole or in part for curable deficiency desires to contest such rejection, the claimant must, within twenty (20) calendar days after the date of mailing of the notice required in ¶5.7 above, or a lesser period of time if the Claim was untimely, serve upon the Claims Administrator a notice and statement of reasons indicating the claimant's grounds for contesting the rejection along with any supporting documentation, and requesting a review thereof by the Court. If a dispute concerning a Claim cannot be otherwise resolved, Lead Counsel shall thereafter present the claimant's request for review to the Court.

5.9 Each claimant shall be deemed to have submitted to the jurisdiction of the Court with respect to the Person's claim to the Net Settlement Fund. All proceedings with respect to the administration, processing and determination of Claims and the determination of all controversies relating thereto, including disputed questions of law and fact with respect to the validity of Claims, shall be subject to the jurisdiction of the Court, but shall not in any event delay or affect the finality of the Judgment. All Class Members, other claimants, and parties to this Settlement expressly waive trial by jury (to the extent any such right may exist) and any right of appeal or review with respect to such determinations.

5.10 Following the Effective Date, the Net Settlement Fund shall be distributed to the Authorized Claimants substantially in accordance with the Plan of Allocation set forth in the Notice and approved by the Court. No distributions will be made to Authorized Claimants who would otherwise receive a distribution of less than \$10.00. If there is any balance remaining in the Net Settlement Fund after a reasonable period of time after the date of the distribution of the Net Settlement Fund, the Claims Administrator at Lead Counsel's direction shall, if feasible, redistribute such balance among Authorized Claimants who negotiated the checks sent in the initial distribution and who would receive a minimum of \$10.00. These redistributions shall be repeated until the balance remaining in the Net Settlement Fund is *de minimis*. Any *de minimis* balance that still remains in the Net Settlement Fund after such reallocation(s) and payments, which is not feasible or economical to reallocate, shall be donated to any appropriate, non-profit charitable organization(s) unaffiliated with any party or their counsel serving the public interest selected by Lead Counsel.

5.11 The Released Persons shall have no responsibility for, interest in, or liability whatsoever with respect to the distribution of the Net Settlement Fund, the Plan of Allocation, the determination, administration, or calculation of Claims, the payment or withholding of Taxes or Tax Expenses, or any losses incurred in connection therewith. No Person shall have any claim of any kind against the

Released Persons with respect to the matters set forth in ¶¶5.1-5.13 hereof; and the Releasing Plaintiff Parties release the Released Persons from any and all liability and claims arising from or with respect to the administration, investment, or distribution of the Settlement Fund.

5.12 No Person shall have any claim against any Released Persons, any Plaintiff, any counsel to any Plaintiff or the Claims Administrator, or any other Person designated by Lead Counsel based on determinations or distributions made substantially in accordance with this Stipulation and the Settlement contained herein, the Plan of Allocation, or further order(s) of the Court.

5.13 It is understood and agreed by the Settling Parties that any proposed Plan of Allocation of the Net Settlement Fund, including, but not limited to, any adjustments to an Authorized Claimant's Claim set forth therein, is not a part of this Stipulation and is to be considered by the Court separately from the Court's consideration of the fairness, reasonableness, and adequacy of the Settlement set forth in this Stipulation, and any order or proceeding relating to the Plan of Allocation shall not operate to terminate or cancel this Stipulation or affect the finality of the Court's Judgment approving this Stipulation and the Settlement set forth herein, or any other orders entered pursuant to the Stipulation.

6. Plaintiffs' Counsel's Attorneys' Fees and Expenses

6.1 Lead Counsel may submit an application or applications (the "Fee and Expense Application") from the Settlement Fund for: (a) an award of attorneys' fees; plus (b) expenses or charges in connection with prosecuting the Litigation; plus (c) any interest earned on such attorneys' fees and expenses at the same rate and for the same periods as earned by the Settlement Fund (until paid) as may be awarded by the Court. In addition, Plaintiffs may request awards in connection with their representation of the Class pursuant to 15 U.S.C. §78u-4(a)(4). Lead Counsel reserves the right to make additional applications for fees and expenses incurred.

6.2 Any fees and expenses, as awarded by the Court, shall be paid to Lead Counsel from the Settlement Fund, as ordered, immediately after the Court executes the Judgment and an order awarding such fees and expenses, notwithstanding the existence of any timely filed objections thereto or to the Settlement, or potential for appeal therefrom, or collateral attack on the Settlement or any part thereof. Lead Counsel may thereafter allocate the attorneys' fees among Plaintiffs' Counsel in a manner in which it in good faith believes reflects the contributions of such counsel to the initiation, prosecution, and resolution of the Litigation.

6.3 In the event that the Effective Date does not occur, or the Judgment or the order making the Fee and Expense Award is reversed or modified, or this Stipulation is canceled or terminated for any other reason, and such reversal,

modification, cancellation or termination becomes Final and not subject to review, and in the event that the Fee and Expense Award has been paid, then Lead Counsel, including its partners, and such other Plaintiffs' Counsel, including their law firms, partners, and/or shareholders who received any portion of the Fee and Expense Award shall, within ten (10) business days from receiving notice from the Valeant Defendants' Counsel or from a court of appropriate jurisdiction, refund to the Settlement Fund all such fees and expenses previously paid to them from the Settlement Fund, in an amount consistent with such reversal, modification, cancellation or termination, and such fees and expenses shall be distributed from the Settlement Fund in accordance with ¶7.4. Any refunds required pursuant to this ¶6.3 shall be the several obligation of Plaintiffs' Counsel, including their law partners and/or shareholders, to make appropriate refunds or repayments to the Settlement Fund. Each such Plaintiffs' Counsel receiving an award of fees and expenses or Plaintiffs receiving an award pursuant to 15 U.S.C. §78u-4(a)(4), as a condition of receiving such fees, expenses or award on behalf of itself and each partner and/or shareholder of it, agrees that: (a) such Person and its partners, shareholders, and/or members are subject to the jurisdiction of the Court for the purpose of enforcing the provisions of this paragraph; and (b) are severally liable for the full amount of any fees, expenses and/or costs paid to them from the Settlement Fund together with the interest earned thereon. Without limitation, Plaintiffs' Counsel and Plaintiffs and

their partners, shareholders, and/or members agree that the Court may, upon application of Defendants or Former Defendants and notice to Plaintiffs' Counsel, summarily issue orders, including, but not limited to, judgments and attachment orders, and may make appropriate findings of or sanctions for contempt, should any such law firm or any partner, shareholder, or member thereof fail to timely repay fees, interest and expenses pursuant to this paragraph.

6.4 The procedure for and the allowance or disallowance by the Court of any applications by any Plaintiffs' Counsel for attorneys' fees and expenses to be paid out of the Settlement Fund is not part of the Settlement set forth in this Stipulation, and is to be considered by the Court separately from the Court's consideration of the fairness, reasonableness, and adequacy of the Settlement set forth in this Stipulation, and shall have no effect on the terms of the Stipulation or on the validity or enforceability of this Settlement. The approval of the Settlement, and it becoming Final, shall not be contingent on the award of attorneys' fees and expenses, any award to Plaintiffs, Lead Counsel, or Plaintiffs' Counsel, nor any appeals from such awards. Any order or proceeding relating to the Fee and Expense Application, or any appeal from any order relating thereto or reversal or modification thereof, shall not operate to terminate or cancel this Stipulation, or affect or delay the finality of the Judgment approving this Stipulation and the Settlement of the Litigation set forth therein.

6.5 Any fees and/or expenses awarded by the Court shall be paid solely from the Settlement Fund. With the sole exception of Defendants' obligation to pay or cause the Settlement Amount to be paid into the Escrow Account as provided for in ¶¶2.2 and 2.3, the Released Persons shall have no responsibility for, and no liability whatsoever with respect to, any payment of attorneys' fees and/or expenses (including Taxes) to Plaintiffs' Counsel, or any other counsel or Person who receives payment from the Net Settlement Fund.

6.6 The Released Persons shall have no responsibility for, and no liability whatsoever with respect to, the allocation among Plaintiffs' Counsel and/or any other Person who may assert some claim thereto, of any Fee and Expense Award that the Court may make in the Litigation.

6.7 The Released Persons shall have no responsibility for, and no liability whatsoever with respect to, any attorneys' fees, costs, or expenses (including Taxes) incurred by or on behalf of any Class Member, whether or not paid from the Escrow Account.

7. Conditions of Settlement, Effect of Disapproval, Cancellation, or Termination

7.1 The Effective Date of the Settlement shall be conditioned on the occurrence of all of the following events:

(a) the Court has entered the Preliminary Approval Order directing notice to the Class, as required by ¶3.1 hereof;

(b) the Settlement Amount has been deposited into the Escrow Account;

(c) the Court has entered the Judgment, or a judgment substantially in the form of Exhibit B attached hereto; and

(d) the Judgment has become Final, as defined in ¶1.12 hereof.

7.2 Upon the Effective Date, any and all remaining interest or right of the Defendants or Former Defendants in or to the Settlement Fund, if any, shall be absolutely and forever extinguished. If the conditions specified in ¶7.1 hereof are not met, then the Settlement shall be canceled and terminated subject to ¶¶7.4, 7.5 and 7.6 hereof unless Lead Counsel and counsel for the Defendants and Former Defendants mutually agree in writing to proceed with the Settlement.

7.3 The Lead Plaintiff and each of the Defendants shall have the right to terminate the Settlement and this Stipulation by providing written notice of their election to do so (“Termination Notice”) to all other parties hereto within thirty (30) calendar days of: (a) the Court’s refusal to enter the Preliminary Approval Order; (b) the Court’s refusal to approve the Settlement; (c) the Court’s refusal to enter the Judgment; (d) the date upon which the Judgment is reversed or vacated or altered following any appeal taken therefrom, or is successfully collaterally attacked; or (e) the failure of the Effective Date to occur for any reason. Only Valeant possesses the right to terminate the Settlement in the event that valid requests for exclusion

from the Class exceed the criteria set forth in the Supplemental Agreement. For avoidance of doubt, no order of the Court or modification or reversal on appeal of any order of the Court concerning the Plan of Allocation or the amount of any attorney's fees, expenses, and interest awarded by the Court to Lead Counsel or costs and expenses to Plaintiffs shall operate to terminate or cancel this Stipulation or constitute grounds for cancellation or termination of the Stipulation.

7.4 Unless otherwise ordered by the Court, in the event this Stipulation is not approved or this Stipulation or the Settlement is terminated, or canceled, or the Effective Date otherwise fails to occur for any reason, including, without limitation, in the event the Judgment is reversed or vacated or altered following any appeal taken therefrom, within ten (10) business days after written notification of such event is sent by the Valeant Defendants' Counsel or Lead Counsel to the Escrow Agent, the Settlement Fund, less Taxes, Tax Expenses and Notice and Administration Expenses which have either been disbursed pursuant to ¶¶2.12 and/or 2.14 hereof, or are chargeable to the Settlement Fund pursuant to ¶¶2.12 and/or 2.14 hereof, shall be paid by the Escrow Agent to Valeant. Such payment shall be made pursuant to written instructions from a letter executed by the Valeant Defendants' Counsel. The Escrow Agent or its designee shall apply for any tax refund owed on the Settlement Amount and pay the proceeds, after deduction of any fees or expenses incurred in

connection with such application(s) for refund, to Valeant. Such payments shall be pursuant to written instructions from the Valeant Defendants' Counsel.

7.5 In the event that this Stipulation is not approved or this Stipulation or the Settlement is terminated, canceled, or the Effective Date otherwise fails to occur for any reason, the Settling Parties shall be restored to their respective positions in the Litigation as of November 21, 2019. In such event, the terms and provisions of the Stipulation, with the exception of ¶¶1.1-1.41, 2.12-2.14, 2.16-2.17, 6.3-6.4, 7.4-7.6, and 9.6 hereof, shall have no further force and effect with respect to the Settling Parties and shall not be used in this Litigation or in any other proceeding for any purpose, and any judgment or order entered by the Court in accordance with the terms of this Stipulation shall be treated as vacated, *nunc pro tunc*. No order of the Court or modification or reversal on appeal of any order of the Court concerning the Plan of Allocation or any Fee and Expense Award shall operate to terminate or cancel this Stipulation or constitute grounds for cancellation or termination of this Stipulation.

7.6 If the Effective Date does not occur, or if this Stipulation is terminated pursuant to its terms, neither Plaintiffs nor Plaintiffs' Counsel shall have any obligation to repay any amounts disbursed pursuant to ¶¶2.12 or 2.14. In addition, any amounts already incurred pursuant to ¶¶2.12 or 2.14 hereof at the time of such termination or cancellation but which have not been paid, shall be paid by the Escrow

Agent in accordance with the terms of this Stipulation prior to the balance being refunded in accordance with ¶¶2.16 and 7.4 hereof.

8. No Admissions

8.1 Neither the Settlement, this Stipulation (whether or not consummated), including the Exhibits hereto and the Plan of Allocation contained therein (or any other plan of allocation that may be approved by the Court), the negotiations leading to the execution of this Stipulation and the Settlement, nor any proceedings taken pursuant to or in connection with this Stipulation, and/or approval of the Settlement (including any arguments proffered in connection therewith):

(a) shall be offered or received against any Defendant or Former Defendant as evidence of or construed as or deemed to be evidence of any presumption, concession, or admission by any Defendant or Former Defendant of the truth of any allegations by Plaintiffs or any Member of the Class or the validity of any claim that has been or could have been asserted in the Litigation, or the deficiency of any defense that has been or could have been asserted in the Litigation or in any other litigation, including, but not limited to, litigation of the Released Claims, or of any liability, negligence, fault, or wrongdoing of any kind of any of the Defendants or Former Defendants;

(b) shall be referred to for any other reason as against any of the Defendants or Former Defendants, in any civil, criminal, or administrative action or

proceeding, other than in such proceedings as may be necessary to effectuate the provisions of this Stipulation;

(c) shall be offered or received against any Defendant or Former Defendant as evidence of a presumption, concession, or admission of any fault, misrepresentations, or omission with respect to any statement or written document approved or made by any Defendant or Former Defendant, or against Plaintiffs or any Member of the Class as evidence of any infirmity in the claims of Plaintiffs and the Class;

(d) shall be offered or received against any Defendant or Former Defendant as evidence of a presumption, concession, or admission of any liability, negligence, fault, or wrongdoing, or in any way referred to for any other reason as against any of the parties to this Stipulation, in any other civil, criminal, or administrative action or proceeding; provided, however, that if this Stipulation is approved by the Court, Defendants, Former Defendants and their Related Parties may refer to it to effectuate the release granted them hereunder;

(e) shall be offered or received against any Defendant or Former Defendant as evidence of a presumption, concession, or admission that any class, however defined or constituted and whether under Rule 23 of the Federal Rules of Civil Procedure or otherwise, should be certified in the Litigation or in any other

civil action or proceeding, except with respect to the certification of the Class for purposes of the Settlement only; or

(f) shall be construed against Defendants, Former Defendants, Plaintiffs, or the Class as evidence of a presumption, concession, or admission that the consideration to be given hereunder represents the amount which could be or would have been recovered after trial or in any proceeding other than this Settlement.

9. Miscellaneous Provisions

9.1 The Settling Parties: (a) acknowledge that it is their intent to consummate this agreement; and (b) agree to cooperate to the extent reasonably necessary to effectuate and implement all terms and conditions of this Stipulation and to exercise their best efforts to accomplish the foregoing terms and conditions of this Stipulation.

9.2 The Settling Parties intend this Settlement to be a final and complete resolution of all disputes between the Class and the Defendants and Former Defendants with respect to the Litigation. The Settlement shall not be deemed an admission by any Settling Party as to the merits of any claim or defense. The Judgment will contain a finding that, during the course of the Litigation, the Settling Parties and their respective counsel at all times complied with the requirements of Federal Rule of Civil Procedure 11. The Settling Parties agree that the Settlement Amount and the other terms of the Settlement were negotiated in good faith by the

Settling Parties, and reflect a settlement that was reached voluntarily after consultation with competent legal counsel and with the assistance of a neutral third-party mediator, Eric D. Green. The Settling Parties reserve their right to rebut, in a manner that such party determines to be appropriate, any contention made in any public forum regarding the Litigation, including that the Litigation was brought or defended in bad faith or without a reasonable basis.

9.3 Defendants, Former Defendants and/or the Released Persons may file this Stipulation and/or the Judgment from this action in any other action that may be brought against them in order to support a defense or counterclaim based on principles of *res judicata*, collateral estoppel, release, statute of limitations, statute of repose, good faith settlement, judgment bar or reduction, or any theory of claim preclusion or issue preclusion or similar defense or counterclaim, or to effectuate any liability protection under any applicable insurance policy. The Settling Parties may file this Stipulation and/or the Judgment in any action that may be brought to enforce the terms of this Stipulation and/or the Judgment. All Settling Parties submit to the jurisdiction of the Court for purposes of implementing and enforcing the Settlement.

9.4 All agreements made and orders entered during the course of the Litigation relating to the confidentiality of information shall survive this Stipulation.

9.5 All of the Exhibits to this Stipulation are material and integral parts hereof and are fully incorporated herein by this reference.

9.6 This Stipulation, along with its Exhibits, may be amended or modified only by a written instrument signed by or on behalf of all Settling Parties or their respective successors-in-interest.

9.7 Other than the Supplemental Agreement, this Stipulation and the Exhibits attached hereto constitute the entire agreement between Lead Plaintiff, on the one hand, and Defendants and Former Defendants, on the other hand, as to the subject matter hereof and supersede any prior or contemporaneous written or oral agreements or understandings between the Lead Plaintiff, on the one hand, and Defendants and Former Defendants, on the other hand. No representations, warranties, or inducements have been made between the Lead Plaintiff, on the one hand, and Defendants and Former Defendants on the other hand, concerning this Stipulation or its Exhibits, other than the representations, warranties, and covenants contained and memorialized in such documents.

9.8 Except as provided herein, or otherwise agreed to in writing by the parties hereto, each party shall bear his, her, or its own fees and costs.

9.9 Lead Counsel, on behalf of the Class, is expressly authorized by Lead Plaintiff to take all appropriate action required or permitted to be taken by the Class pursuant to this Stipulation to effectuate its terms and also is expressly authorized to

enter into any modifications or amendments to this Stipulation on behalf of the Class which it deems appropriate.

9.10 Each counsel or other Person executing this Stipulation, its Exhibits, or any related Settlement document, on behalf of any party hereto hereby warrants that such Person has the full authority to do so, and that they have the authority to take appropriate action required or permitted to be taken pursuant to the Stipulation to effectuate its terms, without requiring additional consent, approval, or authorization of any other Person, board, entity, tribunal, or other regulatory or governmental authority.

9.11 This Stipulation may be executed in one or more counterparts. All executed counterparts and each of them shall be deemed to be one and the same instrument. A complete set of executed counterparts shall be filed with the Court. Signatures sent by facsimile or pdf'd via e-mail shall be deemed originals.

9.12 All notices, requests, demands, claims, and other communications hereunder shall be in writing and shall be deemed duly given (i) when delivered personally to the recipient, (ii) one (1) business day after being sent to the recipient by UPS overnight courier service (charges prepaid), or (iii) seven (7) business days after being mailed to the recipient by certified or registered mail, return receipt requested and postage prepaid, and addressed to the intended recipient as set forth below:

If to Plaintiffs or to Lead Counsel:

ROBBINS GELLER RUDMAN
& DOWD LLP
THEODORE J. PINTAR
655 West Broadway, Suite 1900
San Diego, CA 92101

If to Valeant Defendants or to Valeant Defendants' Counsel:

SIMPSON THACHER & BARTLETT LLP
CRAIG S. WALDMAN
425 Lexington Avenue
New York, NY 10017

If to Stock Underwriter Defendants' and Former Defendants' Counsel:

PAUL, WEISS, RIFKIND,
WHARTON & GARRISON LLP
RICHARD A. ROSEN
1285 Avenue of the Americas
New York, NY 10019

If to ValueAct Defendants' Counsel:

O'MELVENY MYERS LLP
JONATHAN ROSENBERG
7 Times Square
New York, NY 10036

9.13 This Stipulation shall be binding upon, and inure to the benefit of, the successors and assigns of the Settling Parties.

9.14 The Court shall retain jurisdiction with respect to implementation and enforcement of the terms of this Stipulation, and all Settling Parties submit to the jurisdiction of the Court for purposes of implementing and enforcing the Settlement embodied in this Stipulation and matters related to the Settlement.

9.15 The waiver by one Settling Party of any breach of this Stipulation by any other party shall not be deemed a waiver by any other Settling Party or a waiver of any other prior or subsequent breach of this Stipulation.

9.16 Pending approval of the Court of this Stipulation and its Exhibits, all non-settlement-related proceedings in this Litigation shall be stayed and all Members of the Class shall be barred and enjoined from prosecuting any of the Released Claims against any of the Released Persons.

9.17 This Stipulation and its Exhibits shall be considered to have been negotiated, executed and delivered, and to be wholly performed, in the State of New Jersey and the rights and obligations of the parties to the Stipulation shall be construed and enforced in accordance with, and governed by, the internal, substantive laws of New Jersey without giving effect to its choice-of-law principles, except to the extent that federal law requires that federal law govern.

9.18 The headings herein are used for the purpose of convenience only and are not meant to have legal effect.

9.19 This Stipulation shall not be construed more strictly against one party than another merely by virtue of the fact that it, or any part of it, may have been prepared by counsel for one of the Settling Parties, it being recognized that it is the result of arm's-length negotiations between the Settling Parties and the Settling

Parties have contributed substantially and materially to the preparation of this Stipulation.


9.20 Nothing in the Stipulation, or the negotiations relating thereto, is intended to or shall be deemed to constitute a waiver of any applicable privilege or immunity, including, without limitation, attorney-client privilege, joint defense privilege, or work product protection.

9.21 Unless otherwise provided, the Settling Parties may agree to reasonable extensions of time to carry out any of the provisions of this Stipulation without further order of the Court.

IN WITNESS WHEREOF, the parties hereto have caused the Stipulation to
be executed, by their duly authorized attorneys, dated December 15, 2019.

ROBBINS GELLER RUDMAN
& DOWD LLP
DARREN J. ROBBINS
THEODORE J. PINTAR
ROBERT R. HENSSLER JR.
655 West Broadway, Suite 1900
San Diego, CA 92101
Telephone: 619/231-1058
619/231-7423 (fax)

ROBBINS GELLER RUDMAN
& DOWD LLP
JAMES E. BARZ
FRANK A. RICHTER



JAMES E. BARZ

200 South Wacker Drive, 31st Floor
Chicago, IL 60606
Telephone: 312/674-4674
312/674-4676 (fax)


ROBBINS GELLER RUDMAN
& DOWD LLP
ROBERT J. ROBBINS
KATHLEEN B. DOUGLAS
120 East Palmetto Park Road, Suite 500
Boca Raton, FL 33432
Telephone: 561/750-3000
561/750-3364 (fax)

Lead Counsel for Plaintiffs

SEEGER WEISS LLP
CHRISTOPHER A. SEEGER
DAVID R. BUCHANAN
55 Challenger Road, 6th Floor
Ridgefield Park, NJ 07660
Telephone: 212/584-0700
212/584-0799 (fax)
cseeger@seegerweiss.com
dbuchanan@seegerweiss.com

Local Counsel for Plaintiffs

SIMPSON THACHER & BARTLETT LLP
PAUL C. CURNIN
CRAIG S. WALDMAN



PAUL C. CURNIN

425 Lexington Avenue
New York, NY 10017
Telephone: 212/455-2000
212/455-2502 (fax)

Counsel for Defendants Valeant
Pharmaceuticals International, Inc., Robert
L. Rosiello, Ari S. Kellen, Robert A.
Ingram, Ronald H. Farmer, Colleen
Goggins, Anders Lönner, Theo Melas-
Kyriazi, Robert N. Power, Norma
Provencio, and Katharine B. Stevenson

McCARTER & ENGLISH LLP
RICHARD HERNANDEZ

RICHARD HERNANDEZ

100 Mulberry Street
Newark, NJ 07102
Telephone: 973/848-8615
973/297-6615 (fax)

Counsel for Defendants Valeant
Pharmaceuticals International, Inc.,
Robert L. Rosiello, Ari S. Kellen,
Robert A. Ingram, Ronald H. Farmer,
Colleen Goggins, Anders Lönner, Theo
Melas-Kyriazi, Robert N. Power, Norma
Provencio, Katharine B. Stevenson, and
Tanya Carro

SIMPSON THACHER & BARTLETT LLP
PAUL C. CURNIN
CRAIG S. WALDMAN

PAUL C. CURNIN

425 Lexington Avenue
New York, NY 10017
Telephone: 212/455-2000
212/455-2502 (fax)

Counsel for Defendants Valeant
Pharmaceuticals International, Inc., Robert
L. Rosiello, Ari S. Kellen, Robert A.
Ingram, Ronald H. Farmer, Colleen
Goggins, Anders Lönner, Theo Melas-
Kyriazi, Robert N. Power, Norma
Provencio, and Katharine B. Stevenson

McCARTER & ENGLISH LLP
RICHARD HERNANDEZ



RICHARD HERNANDEZ

100 Mulberry Street
Newark, NJ 07102
Telephone: 973/848-8615
973/297-6615 (fax)

Counsel for Defendants Valeant
Pharmaceuticals International, Inc., Robert
L. Rosiello, Ari S. Kellen, Robert A.
Ingram, Ronald H. Farmer, Colleen
Goggins, Anders Lönner, Theo Melas-
Kyriazi, Robert N. Power, Norma
Provencio, Katharine B. Stevenson, and
Tanya Carro

PAUL, WEISS, RIFKIND, WHARTON
& GARRISON LLP
RICHARD A. ROSEN

1/s/ Richard Rosen ^{MC}

RICHARD A. ROSEN

1285 Avenue of the Americas
New York, NY 10019
Telephone: 212/373-3000
212/757-3990 (fax)

HARTMANN DOHERTY ROSA
BERMAN & BULBULIA, LLC
MARK A. BERMAN
ROBIN D. FINEMAN

Mark A. Berman

MARK A. BERMAN

433 Hackensack Avenue, Suite 1002
Hackensack, NJ 07601
Telephone: 201/441-9056
201/441-9435 (fax)

Counsel for the Stock Underwriter
Defendants and Former Defendants

O'MELVENY MYERS LLP
JONATHAN ROSENBERG

JONATHAN ROSENBERG

7 Times Square
New York, NY 10036
Telephone: 212/326-2000
212/326-2061 (fax)

PAUL, WEISS, RIFKIND, WHARTON
& GARRISON LLP
RICHARD A. ROSEN

RICHARD A. ROSEN

1285 Avenue of the Americas
New York, NY 10019
Telephone: 212/373-3000
212/757-3990 (fax)

HARTMANN DOHERTY ROSA
BERMAN & BULBULIA, LLC
MARK A. BERMAN
ROBIN D. FINEMAN

MARK A. BERMAN

65 Route 4 East
River Edge, NJ 07661
Telephone: 201/441-9056
201/441-9435 (fax)

Counsel for the Stock Underwriter
Defendants and Former Defendants

O'MELVENY MYERS LLP
JONATHAN ROSENBERG


JONATHAN ROSENBERG

7 Times Square
New York, NY 10036
Telephone: 212/326-2000
212/326-2061 (fax)

GIBBONS P.C.
KATE E. JANUKOWICZ



KATE E. JANUKOWICZ

One Gateway Center
Newark, New Jersey 07102
Telephone: 973/596-4913

Counsel for the ValueAct Defendants and
Defendant Jeffrey W. Ubben

DEBEVOISE & PLIMPTON LLP
BRUCE E. YANNETT

BRUCE E. YANNETT

919 Third Avenue
New York, NY 10022
Telephone: 212/909-6000
212/909-6836 (fax)

Counsel for Defendant J. Michael Pearson

COOLEY LLP
WILLIAM J. SCHWARTZ
SARAH LIGHTDALE

WILLIAM J. SCHWARTZ

55 Hudson Yards
New York, NY 10001
Telephone: 212/479-6000
212/479-6275

Counsel for Defendant Tanya Carro

GIBBONS P.C.
KATE E. JANUKOWICZ

KATE E. JANUKOWICZ

One Gateway Center
Newark, New Jersey 07102
Telephone: 973/596-4913

Counsel for the ValueAct Defendants and
Defendant Jeffrey W. Ubben

DEBEVOISE & PLIMPTON LLP
BRUCE E. YANNETT



BRUCE E. YANNETT

919 Third Avenue
New York, NY 10022
Telephone: 212/909-6000
212/909-6836 (fax)

Counsel for Defendant J. Michael Pearson

COOLEY LLP
WILLIAM J SCHWARTZ
SARAH LIGHTDALE

WILLIAM J. SCHWARTZ

55 Hudson Yards
New York, NY 10001
Telephone: 212/479-6000
212/479-6275

Counsel for Defendant Tanya Carro

GIBBONS P.C.
KATE E. JANUKOWICZ

KATE E. JANUKOWICZ

One Gateway Center
Newark, New Jersey 07102
Telephone: 973/596-4913

Counsel for the ValueAct Defendants and
Defendant Jeffrey W. Ubben

DEBEVOISE & PLIMPTON LLP
BRUCE E. YANNETT

BRUCE E. YANNETT

919 Third Avenue
New York, NY 10022
Telephone: 212/909-6000
212/909-6836 (fax)

Counsel for Defendant J. Michael Pearson

COOLEY LLP
WILLIAM J SCHWARTZ
SARAH LIGHTDALE



WILLIAM J. SCHWARTZ

55 Hudson Yards
New York, NY 10001
Telephone: 212/479-6000
212/479-6275

Counsel for Defendant Tanya Carro

SCHULTE ROTH & ZABEL LLP
BARRY A. BOHRER



BARRY A. BOHRER

919 Third Avenue
New York, NY 10022
Telephone: 212/756-2000
212/593-5955 (fax)

Counsel for Defendant Deborah Jorn

WINSTON & STRAWN LLP
JOSEPH L. MOTTO

JOSEPH L. MOTTO

35 W. Wacker Drive
Chicago, IL 60601
Telephone: 312/558-5600
312/558-5700 (fax)

Counsel for Defendant Howard B.
Schiller


SCHULTE ROTH & ZABEL LLP
BARRY A. BOHRER

BARRY A. BOHRER

919 Third Avenue
New York, NY 10022
Telephone: 212/756-2000
212/593-5955 (fax)

Counsel for Defendant Deborah Jorn

WINSTON & STRAWN LLP
JOSEPH L. MOTTO



JOSEPH L. MOTTO

35 W. Wacker Drive
Chicago, IL 60601
Telephone: 312/558-5600
312/558-5700 (fax)

Counsel for Defendant Howard B.
Schiller

EXHIBIT A

SEEGER WEISS LLP
CHRISTOPHER A. SEEGER
DAVID R. BUCHANAN
55 Challenger Road, 6th Floor
Ridgefield Park, NJ 07660
Telephone: 212/584-0700
212/584-0799 (fax)

Local Counsel

ROBBINS GELLER RUDMAN
& DOWD LLP
JAMES E. BARZ
FRANK A. RICHTER
200 South Wacker Drive, 31st Floor
Chicago, IL 60606
Telephone: 312/674-4674
312/674-4676 (fax)

Lead Counsel for Plaintiffs

UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY

In re VALEANT)	Master No. 3:15-cv-07658-MAS-LHG
PHARMACEUTICALS)	
INTERNATIONAL, INC.)	<u>CLASS ACTION</u>
SECURITIES LITIGATION)	
_____)	Judge Michael A. Shipp
)	Magistrate Judge Lois H. Goodman
This Document Relates To:)	Special Master Hon. Dennis M. Cavanaugh,
)	U.S.D.J. (Ret.)
)	
Case No. 3:15-cv-07658-MAS-LHG.)	[PROPOSED] ORDER GRANTING
)	PRELIMINARY APPROVAL PURSUANT
)	TO FED. R. CIV. P. 23(e)(1) AND
_____)	PERMITTING NOTICE TO THE CLASS

EXHIBIT A

WHEREAS, an action pending before this Court is styled *In re Valeant Pharmaceuticals International, Inc. Securities Litigation*, No. 3:15-cv-07658-MAS-LHG (D.N.J.) (the “Litigation”);

WHEREAS, Lead Plaintiff having made a motion, pursuant to Federal Rule of Civil Procedure 23(e), for an order preliminarily approving the Settlement of this Litigation, in accordance with a Stipulation of Settlement, dated December 15, 2019 (the “Stipulation”), which, together with the Exhibits annexed thereto, sets forth the terms and conditions for a proposed Settlement of the Litigation between the Settling Parties and for dismissal of the Litigation with prejudice as to all Defendants except PriceWaterhouseCoopers LLP (“PwC”)¹ upon, and subject to, the terms and conditions set forth therein; and the Court having read and considered: (1) the motion for preliminary approval of the Settlement, and the papers filed and arguments made in connection therewith, and (2) the Stipulation and the exhibits annexed thereto;

¹ “Defendants” refers to Valeant Pharmaceuticals International, Inc. (“Valeant”) (n/k/a Bausch Health Companies Inc.); J. Michael Pearson; Howard B. Schiller; Robert L. Rosiello; Deborah Jorn; Ari S. Kellen; Tanya Carro; Jeffrey W. Ubben; Robert A. Ingram; Ronald H. Farmer; Colleen Goggins; Anders Lönner; Theo Melas-Kyriazi; Robert N. Power; Norma Provencio; Katharine B. Stevenson; Deutsche Bank Securities Inc.; HSBC Securities (USA) Inc.; MUFG Securities Americas Inc. f/k/a Mitsubishi UFJ Securities (USA) Inc.; DNB Markets, Inc.; Barclays Capital Inc.; Morgan Stanley & Co. LLC; RBC Capital Markets, LLC; Suntrust Robinson Humphrey, Inc.; ValueAct Capital Management, L.P.; VA Partners I, LLC; ValueAct Holdings, L.P.; ValueAct Capital Master Fund, L.P.; ValueAct Co-Invest Master Fund, L.P.

WHEREAS, the Settling Parties having consented to the entry of this Order;
and

WHEREAS, unless otherwise defined, all terms used herein have the same meanings as set forth in the Stipulation.

NOW, THEREFORE, IT IS HEREBY ORDERED:

1. The Court has reviewed the Stipulation and does hereby preliminarily approve the Stipulation and the Settlement set forth therein as fair, reasonable and adequate, subject to further consideration at the Final Approval Hearing (as defined in ¶6 below).

2. Pursuant to Rules 23(a) and (b)(3) of the Federal Rules of Civil Procedure, and for purposes of this Settlement only, the Litigation is hereby preliminarily certified as a class action on behalf of all Persons who purchased or otherwise acquired Valeant Securities² between January 4, 2013 and March 15, 2016,

² “Valeant Securities” means Valeant equity securities as defined in 15 U.S.C. §78c(11) and 17 C.F.R. §240.3a11-1, and Valeant debt securities, including Valeant common stock; options on Valeant common stock, defined to be the purchase or acquisition of call options and the sale of put options; and the following Valeant senior notes: (1) 5.375% senior notes due 2020; (2) 5.875% senior notes due 2023; (3) 6.125% senior notes due 2025; (4) 5.5% senior notes due 2023; (5) 5.625% senior notes due 2021; (6) 6.75% senior notes due 2018; (7) 7.5% senior notes due 2021; (8) 6.375% senior notes due 2020; (9) 7.25% senior notes due 2022; (10) 6.75% senior notes due 2021; or (11) 7.0% senior notes due 2020. This definition does not include securities at issue in the Canadian Actions.

inclusive. Excluded from the Class are Defendants and Former Defendants³, present and former executive officers of Defendants and Former Defendants, and members of their immediate families, present and former directors of Defendants and Former Defendants, and members of their immediate families, any entity in which a Defendant or current or former director of a Defendant has control and/or a majority ownership interest, and the legal representatives, heirs, successors or assigns of any such excluded party. For the avoidance of doubt, this exclusion does not extend to: (1) any investment company or pooled investment fund in which a Defendant or Former Defendant may have a direct or indirect interest, or as to which its affiliates may act as an advisor, but of which a Defendant or Former Defendant or its respective affiliates is not a majority owner or does not hold a majority beneficial interest; or (2) any employee benefit plan as to which a Defendant or Former Defendant or its affiliates acts as an investment advisor or otherwise may be a fiduciary; provided, however, that membership in the Class by such investment company, pooled investment fund or employee benefit plan is limited to transactions in Valeant Securities made on behalf of, or for the benefit of, persons other than persons that are excluded from the Class by definition. In other words, Defendants and Former

³ “Former Defendants” refers to Goldman Sachs & Co. LLC f/k/a Goldman Sachs & Co.; J.P. Morgan Securities LLC; Merrill Lynch, Pierce, Fenner & Smith Inc.; CIBC World Markets Inc.; Citigroup Global Markets Inc.; DBS Bank Ltd.; TD Securities (USA) LLC; BMO Capital Markets Corp.; and SMBC Nikko Securities America, Inc.

Defendants cannot make a claim on their own behalf for their ownership share in any of the above entities.

3. The Class also excludes: (1) any person or entity which during the Class Period purchased or otherwise acquired Valeant Securities and has been promised or received a payment from or on behalf of the Valeant Defendants related to or arising from litigation related to its Class Period transactions in Valeant Securities other than a payment of attorneys fees or costs to counsel for such person or entity; (2) any Class Member on Exhibit A to the Final Judgment that validly and timely requested exclusion in accordance with the requirements set by the Court in the Notice of Pendency and Proposed Settlement of Class Action; and (3) anyone on Exhibit B to the Final Judgment who has filed an individual action and not dismissed their claim and sought to be included in the Class.

4. Pursuant to Rule 23 of the Federal Rules of Civil Procedure, and for purposes of settlement only, Lead Plaintiff together with named plaintiffs City of Tucson together with and on behalf of Tucson Supplemental Retirement System (“Tucson”) and IBEW Local Union 481 Defined Contribution Plan and Trust (“IBEW”) are preliminarily certified as Class Representatives for the Class and Robbins Geller Rudman & Dowd LLP is preliminarily appointed as Class Counsel for the Class.

5. The Court preliminarily finds that the proposed Settlement should be approved as: (i) it is the result of extensive arm's-length and non-collusive negotiations; (ii) falling within a range of reasonableness warranting final approval; (iii) having no obvious deficiencies; and (iv) warranting notice of the proposed Settlement to Class Members and further consideration of the Settlement at the Final Approval Hearing described below.

6. A hearing shall be held before this Court on _____, 2020, at _____.m. [a date that is one hundred (100) calendar days or more from the date of this Order] (the "Final Approval Hearing"), at the Clarkson S. Fisher Building & U.S. Courthouse, 402 East State Street, Trenton, New Jersey 08608, to determine whether the proposed Settlement of the Litigation on the terms and conditions provided for in the Stipulation is fair, reasonable and adequate to the Class and should be approved by the Court; to determine whether a Judgment as provided in ¶1.13 of the Stipulation should be entered; to determine whether the proposed Plan of Allocation should be approved; to determine whether the Class should be finally certified for purposes of the Settlement only; to determine the amount of attorneys' fees, charges and expenses that should be awarded to Lead Counsel; to determine any award to Plaintiffs pursuant to 15 U.S.C. §78u-4(a)(4); to hear any objections by Class Members to: (i) the Settlement or Plan of Allocation; (ii) the award of attorneys' fees and expenses to Lead Counsel; and (iii) awards to Plaintiffs pursuant to 15 U.S.C. §78u-4(a)(4); and to

consider such other matters the Court deems appropriate. The Court may adjourn the Final Approval Hearing without further notice to the Class.

7. The Court approves the form, substance, and requirements of the Notice of Pendency and Proposed Settlement of Class Action (“Notice”) and Proof of Claim and Release, substantially in the forms annexed hereto as Exhibits A-1⁴ and A-2, respectively.

8. The Court approves the form of the Summary Notice of Pendency and Proposed Settlement of Class Action (“Summary Notice”), substantially in the form annexed hereto as Exhibit A-3.

9. The firm of Gilardi & Co. LLC (“Claims Administrator”) is hereby appointed to supervise and administer the notice procedure as well as the processing of claims as more fully set forth below.

10. To the extent they have not already done so, Valeant and its counsel shall provide or cause Valeant’s transfer agent to provide Lead Counsel and the Claims Administrator, without any charge to Plaintiffs or the Class, the last known names and addresses of all holders of record of Valeant common stock during the Class Period.

11. Not later than _____, 20__ [a date fourteen (14) calendar days after the Court signs and enters this Order] (the “Notice Date”), the Claims

⁴ The Tables set forth in the Notice (Exhibit A-1) may be posted on the settlement website for potential Class Members’ reference, rather than within the Notice.

Administrator shall commence mailing the Notice and Proof of Claim and Release, substantially in the forms annexed hereto, to be mailed by First-Class Mail to all Class Members who can be identified with reasonable effort and to be posted on the case-designated website, www.ValeantSecuritiesSettlement.com.

12. Not later than _____, 20__ [a date seven (7) calendar days after the Notice Date], the Claims Administrator shall cause the Summary Notice to be published once in *The Wall Street Journal*, and once over a national newswire service.

13. At least seven (7) calendar days prior to the Final Approval Hearing, Lead Counsel shall serve on Defendants' Counsel and file with the Court proof, by affidavit or declaration, of such mailing and publishing.

14. The Claims Administrator shall use reasonable efforts to give notice to nominee purchasers such as brokerage firms and other persons or entities who purchased or otherwise acquired Valeant Securities between January 4, 2013 and March 15, 2016, inclusive, as record owners but not as beneficial owners. Such nominee purchasers are directed, within fourteen (14) calendar days of their receipt of the Notice, to either forward copies of the Notice and Proof of Claim and Release to their beneficial owners or to provide the Claims Administrator with lists of the names and addresses of the beneficial owners, and the Claims Administrator is ordered to send the Notice and Proof of Claim and Release promptly to such identified beneficial owners. Nominee purchasers who elect to send the Notice and Proof of Claim and

Release to their beneficial owners shall send a statement to the Claims Administrator confirming that the mailing was made as directed. Additional copies of the Notice shall be made available to any record holder requesting such for the purpose of distribution to beneficial owners, and such record holders shall be reimbursed from the Settlement Fund, upon receipt by the Claims Administrator of proper documentation, for the reasonable expense of sending the Notice and Proof of Claim and Release to beneficial owners.

15. The form and content of the notice program described herein and the methods set forth herein for notifying the Class of the Settlement and its terms and conditions, the Fee and Expense Application, and the Plan of Allocation meet the requirements of Rule 23 of the Federal Rules of Civil Procedure, the Private Securities Litigation Reform Act of 1995 and due process, constitute the best notice practicable under the circumstances, and shall constitute due and sufficient notice to all Persons entitled thereto.

16. All fees and expenses incurred in identifying and notifying Members of the Class shall be paid from the Settlement Fund and in no event shall any of the Released Persons bear any responsibility or liability for such fees or expenses.

17. All Class Members shall be bound by all determinations and judgments in the Litigation concerning the Settlement, including, but not limited to, the releases provided for therein, whether favorable or unfavorable to the Class, regardless of

whether such Persons seek or obtain by any means, including, without limitation, by submitting a Proof of Claim and Release or any similar document, any distribution from the Settlement Fund or the Net Settlement Fund.

18. Valeant shall provide within 10 days of the entry of this Order: (a) to Lead Counsel the identity of any person or entity that is excluded pursuant to ¶3(1) above; (b) to Lead Counsel the scope of any release(s) provided by such excluded parties; and (c) to the Claims Administrator, to the extent that it is in Valeant's possession, the anonymized underlying trading data of such excluded parties. Valeant shall supplement this information within 5 business days of any person or entity being excluded pursuant to ¶3(1) above to the extent such exclusion occurs prior to the Final Approval Hearing.

19. Class Members who wish to participate in the Settlement shall complete and submit a Proof of Claim and Release in accordance with the instructions contained therein. Unless the Court orders otherwise, all Proofs of Claim and Release must be postmarked or submitted electronically no later than _____, 2020 [a date ninety (90) calendar days from the Notice Date]. Any Class Member who does not submit a Proof of Claim and Release within the time provided shall be barred from sharing in the distribution of the proceeds of the Net Settlement Fund, unless otherwise ordered by the Court, but shall nevertheless be bound by any final judgment entered by the Court. Notwithstanding the foregoing, Lead Counsel shall have the

discretion (but not the obligation) to accept late-submitted claims for processing by the Claims Administrator so long as distribution of the Net Settlement Fund is not materially delayed thereby. No person shall have any claim against any Plaintiff, Plaintiffs' Counsel or the Claims Administrator by reason of the decision to exercise such discretion whether to accept late-submitted claims.

20. Any Member of the Class may enter an appearance in the Litigation, at his, her, or its own expense, individually or through counsel of his, her, or its own choice. If they do not enter an appearance, they will be represented by Lead Counsel.

21. Any Person falling within the definition of the Class may, upon request, be excluded or "opt out" from the Class. Any such Person must submit to the Claims Administrator a request for exclusion ("Request for Exclusion"), by First-Class Mail such that it is postmarked no later than _____, 2020 [a date twenty-one (21) calendar days prior to the Final Approval Hearing]. A Request for Exclusion must be signed and state: (a) the name, address, and telephone number of the Person requesting exclusion; (b) the Person's purchases, acquisitions and sales of Valeant Securities between January 4, 2013 and March 15, 2016, inclusive (including the dates, the number of Valeant Securities purchased, acquired or sold, and price paid or received for each such purchase, acquisition or sale); and (c) that the Person wishes to be excluded from the Class. The Request for Exclusion shall not be effective unless it provides the required information and is made within the time stated above, or the exclusion is otherwise accepted by the Court. All Persons who submit valid and timely Requests for Exclusion in the manner set forth in this paragraph shall have no

rights under the Stipulation, shall not share in the distribution of the Net Settlement Fund, and shall not be bound by the Stipulation or any final judgment.

22. Any Person who is excluded from the Class by virtue of having submitted a valid and timely Request for Exclusion may, at any point up to seven (7) calendar days before the Final Approval Hearing, submit a written revocation of Request for Exclusion following the same instructions in ¶21 above.

23. Lead Counsel shall cause to be provided to Defendants' Counsel copies of all Requests for Exclusion and a list of all Class Members who have requested exclusion, and any written revocation of Requests for Exclusion, within five (5) business days of receipt thereof and in any event at least fifteen (15) calendar days prior to the Final Approval Hearing.

24. Any Member of the Class may appear at the Final Approval Hearing and object if he, she, or it has any reason why the proposed Settlement of the Litigation should not be approved as fair, reasonable and adequate, or why a judgment should not be entered thereon, why the Plan of Allocation should not be approved, or why attorneys' fees, together with charges and expenses, should not be awarded or amounts to Plaintiffs pursuant to 15 U.S.C. §78u-4(a)(4) should not be awarded; provided, however, that no Class Member or any other Person shall be heard at the Final Approval Hearing or entitled to contest the approval of the terms and conditions of the proposed Settlement, or, if approved, the Judgment to be entered thereon approving the same, or the order approving the Plan of Allocation, or any attorneys'

fees, together with charges and expenses, to be awarded to Lead Counsel or any award to Plaintiffs, unless the Person objecting has filed said written objections and copies of any papers and briefs with the Clerk of the United States District Court for the District of New Jersey and mailed copies thereof by First-Class Mail to Robbins Geller Rudman & Dowd LLP, Theodore J. Pintar, 655 West Broadway, Suite 1900, San Diego, CA 92101, and Simpson Thacher & Bartlett LLP, Craig S. Waldman, 425 Lexington Avenue, New York, NY 10017, no later than _____, 2020 [a date twenty-one (21) calendar days prior to the Final Approval Hearing]. Any Member of the Class who does not make his, her, or its objection in the manner provided shall be deemed to have waived such objection and shall forever be foreclosed from making any objection to the fairness, reasonableness or adequacy of the proposed Settlement as incorporated in the Stipulation, to the Plan of Allocation, or to the award of fees, charges and expenses to Lead Counsel or any award to Plaintiffs, unless otherwise ordered by the Court. Attendance at the Final Approval Hearing is not necessary. However, Persons wishing to be heard orally in opposition to the approval of the Settlement, the Plan of Allocation, and/or the application for an award of fees, charges and expenses are required to indicate in their written objection their intention to appear at the hearing and to include in their written objections the identity of any witnesses they may call to testify and copies of any exhibits they intend to introduce

into evidence at the Final Approval Hearing. Class Members do not need to appear at the Final Approval Hearing or take any other action to indicate their approval.

25. Any Class Member who does not object to the Settlement, the Plan of Allocation, or Lead Counsel's application for an award of attorneys' fees, charges and expenses in the manner prescribed herein and in the Notice shall be deemed to have waived such objection, and shall forever be foreclosed from making any objection to the fairness, adequacy or reasonableness of the proposed Settlement, this Order and the Judgment to be entered approving the Settlement, the Plan of Allocation and/or the application by Lead Counsel for an award of attorneys' fees together with charges and expenses or any award to Plaintiffs.

26. All funds held by the Escrow Agent shall be deemed and considered to be in *custodia legis*, and shall remain subject to the jurisdiction of the Court, until such time as such funds shall be distributed pursuant to the Stipulation and/or further order(s) of the Court.

27. All papers in support of the Settlement, Plan of Allocation, and any application by Lead Counsel for attorneys' fees, charges and expenses and awards to Plaintiffs shall be filed and served no later than _____, 2020 [a date thirty-five (35) calendar days prior to the Final Approval Hearing], and any reply papers shall be filed and served no later than _____, 2020 [a date seven (7) calendar days prior to the Final Approval Hearing].

28. The Released Persons shall have no responsibility for the Plan of Allocation or any application for attorneys' fees, charges or expenses submitted by Lead Counsel, and such matters will be considered by the Court separately from the fairness, reasonableness, and adequacy of the Settlement.

29. At or after the Final Approval Hearing, the Court shall determine whether the Plan of Allocation proposed by Lead Counsel, and any application for attorneys' fees, charges and expenses, should be approved. The Court reserves the right to enter the Order and Final Judgment approving the Settlement regardless of whether it has approved the Plan of Allocation or awarded attorneys' fees and/or charges and expenses.

30. All reasonable expenses incurred in identifying and notifying Class Members as well as administering the Settlement Fund shall be paid as set forth in the Stipulation. In the event the Court does not approve the Settlement, or it otherwise fails to become effective, neither Lead Plaintiff nor Lead Counsel nor the Claims Administrator shall have any obligation to repay any amounts actually and properly incurred or disbursed pursuant to ¶¶2.12 or 2.14 of the Stipulation.

31. Neither this Order nor the Stipulation, nor any of their respective terms or provisions, nor any of the negotiations, discussions, proceedings connected with them, nor any act performed or document executed pursuant to or in furtherance of the Stipulation or the Settlement or this Order may be construed as an admission or

concession by the Defendants or any other Released Persons of the truth of any of the allegations in the Litigation, or of any liability, fault, or wrongdoing of any kind, or offered or received in evidence, or otherwise used by any person in the Litigation, or in any other action or proceeding, whether civil, criminal, or administrative, in any court, administrative agency, or other tribunal, except in connection with any proceeding to enforce the terms of the Stipulation or this Order. The Released Persons, Lead Plaintiff, Class Members, and each of their counsel may file the Stipulation, and/or this Order and/or the Judgment in any action that may be brought against them in order to support a defense or counterclaim based on principles of *res judicata*, collateral estoppel, release, good faith settlement, judgment bar or reduction or any other theory of claim preclusion or issue preclusion or similar defense or counterclaim.

32. All proceedings in the Litigation against the Defendants are stayed until further order of this Court, except as may be necessary to implement the Settlement or comply with the terms of the Stipulation. The Litigation will continue as to PwC. Pending final determination of whether the Settlement should be approved, neither the Lead Plaintiff nor any Class Member, either directly, representatively, or in any other capacity shall commence or prosecute against any of the Released Persons any action or proceeding in any court or tribunal asserting any of the Released Claims.

33. The Court reserves the right to alter the time or the date of the Final Approval Hearing without further notice to Class Members, and retains jurisdiction to consider all further applications arising out of or connected with the proposed Settlement. The Court may approve the Settlement, with such modifications as may be agreed to by the Settling Parties, if appropriate, without further notice to the Class.

34. If the Settlement fails to become effective as defined in the Stipulation or is terminated, then, in any such event, the Stipulation, including any amendment(s) thereof, except as expressly provided in the Stipulation, and this Order shall be null and void, of no further force or effect, and without prejudice to any Settling Party, and may not be introduced as evidence or used in any actions or proceedings by any person or entity against the Settling Parties, and they shall be deemed to have reverted to their respective litigation positions as of November 21, 2019.

IT IS SO ORDERED.

DATED: _____

THE HONORABLE MICHAEL A. SHIPP
UNITED STATES DISTRICT JUDGE

EXHIBIT A-1

SEEGER WEISS LLP
CHRISTOPHER A. SEEGER
DAVID R. BUCHANAN
55 Challenger Road, 6th Floor
Ridgefield Park, NJ 07660
Telephone: 212/584-0700
212/584-0799 (fax)

Local Counsel

ROBBINS GELLER RUDMAN
& DOWD LLP
JAMES E. BARZ
FRANK A. RICHTER
200 South Wacker Drive, 31st Floor
Chicago, IL 60606
Telephone: 312/674-4674
312/674-4676 (fax)

Lead Counsel for Plaintiffs

UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY

In re VALEANT)	Master No. 3:15-cv-07658-MAS-LHG
PHARMACEUTICALS)	
INTERNATIONAL, INC.)	<u>CLASS ACTION</u>
SECURITIES LITIGATION)	
_____)	Judge Michael A. Shipp
)	Magistrate Judge Lois H. Goodman
This Document Relates To:)	Special Master Hon. Dennis M. Cavanaugh,
)	U.S.D.J. (Ret.)
Case No. 3:15-cv-07658-MAS-LHG.)	NOTICE OF PENDENCY AND
_____)	PROPOSED SETTLEMENT OF CLASS
)	ACTION

EXHIBIT A-1

TO: ALL PERSONS AND ENTITIES THAT PURCHASED OR OTHERWISE ACQUIRED VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (“VALEANT,” NOW KNOWN AS BAUSCH HEALTH COMPANIES INC.) COMMON STOCK, VALEANT DEBT SECURITIES, OR CALL OPTIONS ON VALEANT COMMON STOCK, OR SOLD PUT OPTIONS ON VALEANT COMMON STOCK, DURING THE PERIOD BETWEEN JANUARY 4, 2013 AND MARCH 15, 2016, INCLUSIVE (THE “CLASS PERIOD”)

NOTICE OF PENDENCY OF CLASS ACTION: Please be advised that your rights may be affected by the above-captioned class action lawsuit pending in this Court (the “Litigation”) if you purchased or otherwise acquired Valeant Securities¹ during the Class Period.²

NOTICE OF SETTLEMENT: Please also be advised that Lead Plaintiff TIAA, on behalf of the Class (as defined at page 5 below), has reached a proposed settlement of the Litigation for a total of \$1,210,000,000.00 in cash that will resolve all claims in the Litigation against the Released Persons (the “Settlement”).³

¹ “Valeant Securities” means Valeant equity securities as defined in 15 U.S.C. §78c(11) and 17 C.F.R. §240.3a11-1, and Valeant debt securities, including Valeant common stock; options on Valeant common stock, defined to be the purchase or acquisition of call options and the sale of put options; and the following Valeant senior notes: (1) 5.375% senior notes due 2020; (2) 5.875% senior notes due 2023; (3) 6.125% senior notes due 2025; (4) 5.5% senior notes due 2023; (5) 5.625% senior notes due 2021; (6) 6.75% senior notes due 2018; (7) 7.5% senior notes due 2021; (8) 6.375% senior notes due 2020; (9) 7.25% senior notes due 2022; (10) 6.75% senior notes due 2021; or (11) 7.0% senior notes due 2020. Valeant Securities does not include securities at issue in the Canadian Actions.

² All capitalized terms used in this Notice that are not otherwise defined herein shall have the meanings provided in the Stipulation of Settlement dated December 15, 2019 (the “Stipulation”), which is available on the website www.ValeantSecuritiesSettlement.com.

³ The Settlement does not include, and does not release, any claims against defendant PricewaterhouseCoopers LLP (“PwC”).

IN ORDER TO QUALIFY FOR A SETTLEMENT PAYMENT, YOU MUST TIMELY SUBMIT A PROOF OF CLAIM AND RELEASE FORM BY _____, 2020.

THIS NOTICE WAS AUTHORIZED BY THE COURT. IT IS NOT A LAWYER SOLICITATION. PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY.

WHY SHOULD I READ THIS NOTICE?

This Notice is given pursuant to an order issued by the United States District Court for the District of New Jersey (the “Court”). This Notice serves to inform you of the pendency and proposed settlement of the above-captioned class action lawsuit for \$1,210,000,000.00 in cash and the hearing (the “Final Approval Hearing”) to be held by the Court to consider the fairness, reasonableness, and adequacy of the Settlement, as set forth in the Stipulation, by and between Lead Plaintiff TIAA, on behalf of itself and the Class (as defined below), on the one hand, and Defendants Valeant, current and former officers and directors of Valeant,⁴ the Stock Underwriter Defendants,⁵ the ValueAct Defendants⁶ (collectively, “Defendants”), and the Former Defendants,⁷ on the other hand. Defendant PwC is not a party to the Settlement.

⁴ The current and former officer and director defendants include the following: J. Michael Pearson; Howard B. Schiller; Robert L. Rosiello; Deborah Jorn; Ari S. Kellen; Tanya Carro; Jeffrey W. Ubben; Robert A. Ingram; Ronald H. Farmer; Colleen Goggins; Anders Lönner; Theo Melas-Kyriazi; Robert N. Power; Norma Provencio; and Katharine B. Stevenson.

⁵ The “Stock Underwriter Defendants” include the following: Deutsche Bank Securities Inc.; HSBC Securities (USA) Inc.; MUFG Securities Americas Inc. f/k/a Mitsubishi UFJ Securities (USA) Inc.; DNB Markets, Inc.; Barclays Capital Inc.; Morgan Stanley & Co. LLC; RBC Capital Markets, LLC; and Suntrust Robinson Humphrey, Inc.

⁶ The “ValueAct Defendants” include the following: ValueAct Capital Management, L.P.; VA Partners I, LLC; ValueAct Holdings, L.P.; ValueAct Capital Master Fund, L.P.; ValueAct Co-Invest Master Fund, L.P.

⁷ The “Former Defendants” include the following: Goldman Sachs & Co. LLC f/k/a Goldman Sachs & Co.; J.P. Morgan Securities LLC; Merrill Lynch, Pierce, Fenner &

This Notice is intended to inform you how the pendency of this class action and the proposed Settlement may affect your rights and what steps you may take in relation to it. This Notice is NOT an expression of any opinion by the Court as to the merits of the claims or defenses asserted in the lawsuit or whether the Defendants and Former Defendants engaged in any wrongdoing.

YOUR LEGAL RIGHTS AND OPTIONS IN THIS SETTLEMENT	
SUBMIT A PROOF OF CLAIM AND RELEASE	The only way to be eligible to receive a payment from the Settlement. Proofs of Claim and Release must be postmarked (if mailed) or received (if submitted online) on or before _____, 2020.
EXCLUDE YOURSELF FROM THE SETTLEMENT	Receive no payment. This is the only option that potentially allows you to ever be part of any other lawsuit against the Defendants and Former Defendants or any other Released Persons about the legal claims related to the issues raised in this Litigation. A written request for exclusion must be postmarked on or before _____, 2020.
OBJECT TO THE SETTLEMENT BY SUBMITTING A WRITTEN OBJECTION	Write to the Court about why you do not like the Settlement, the Plan of Allocation and/or the request for attorneys' fees and expenses. Objections must be filed with the Court and served on the parties on or before _____, 2020.
GO TO THE HEARING ON _____, 2020, AND FILE A NOTICE OF INTENTION TO APPEAR	Ask to speak in Court about the fairness of the Settlement. Requests to speak must be filed with the Court and served on the parties on or before _____, 2020. If you submit a written objection, you may (but you do not have to) attend the hearing.
DO NOTHING	Receive no payment. You will, however, still be a Class Member, which means that you give up your right to ever be part of any other lawsuit against the Defendants and Former Defendants or any other Released Persons about

Smith Inc.; CIBC World Markets Inc.; Citigroup Global Markets Inc.; DBS Bank Ltd.; TD Securities (USA) LLC; BMO Capital Markets Corp.; SMBC Nikko Securities America, Inc.

	the legal claims being resolved by this Settlement and you will be bound by any judgments or orders entered by the Court in the Litigation.
--	---

SUMMARY OF THIS NOTICE

Description of the Litigation and the Class

This Notice relates to a proposed settlement of claims in a pending securities class action brought by Valeant investors alleging, among other things, that Defendants and Former Defendants violated the federal securities laws by making materially false and misleading statements or omitting to state facts necessary to make statements made not misleading in public filings and other public statements during the Class Period. A more detailed description of the Litigation is set forth on pages 7–8 below. The “Class” means all Persons who purchased or otherwise acquired Valeant Securities between January 4, 2013 and March 15, 2016, inclusive. Those excluded from the Class are described in pages 9–10 below. The proposed Settlement, if approved by the Court, will settle claims of the Class against the Released Persons, as defined on page 41 below.

Statement of Class Recovery

Pursuant to the Settlement described herein, a \$1,210,000,000.00 settlement fund has been established (the “Settlement Amount”). The Settlement Amount together with any interest earned thereon is the “Settlement Fund.” The Settlement Fund, less: (a) any taxes and tax expenses; (b) any Notice and Administration Expenses; and (c) any attorneys’ fees and litigation charges and expenses (including any awards to Plaintiffs pursuant to 15 U.S.C. §78u-4(a)(4) in connection with their representation of the Class) awarded by the Court, will be distributed to Class Members in accordance with a plan of allocation that is approved by the Court. The proposed plan of allocation (the “Plan of Allocation”) is set forth on pages 12–35 below. Based on Lead Plaintiff’s estimate of the number of Valeant Securities eligible to recover, the average distribution under the Plan of Allocation is roughly \$2.13 per common share, before deduction of any taxes on the income earned on the Settlement Fund, Notice and Administration Expenses, and attorneys’ fees and expenses (including any awards to Plaintiffs) as determined by the Court. **Class Members should note, however, that these are only estimates.** A Class Member’s actual recovery will be a proportion of the Net Settlement Fund determined by that claimant’s claims as compared to the total claims of all Class Members who submit acceptable Proofs of Claim. An individual Class Member may receive more or less

than these estimated average amounts. *See* Plan of Allocation set forth and discussed at pages 12–35 below for more information on the calculation of your claim.

Statement of Potential Outcome of Case

The Settling Parties disagree on both liability and damages and do not agree on the amount of damages per security, if any, that would be recoverable if the Class prevailed on each claim alleged. Defendants and Former Defendants deny that they are liable to the Class and deny that the Class has suffered any injury or damages. The issues on which the parties disagree are many, but include: (1) whether Defendants and Former Defendants engaged in conduct that would give rise to any liability to the Class under the federal securities laws; (2) whether Defendants and Former Defendants have valid defenses to any such claims of liability; (3) the appropriate economic model for determining the amount by which the prices of Valeant Securities were allegedly artificially inflated (if at all) during the Class Period; (4) the amount, if any, by which the prices of Valeant Securities were allegedly artificially inflated (if at all) during the Class Period; (5) the effect of various market forces on the prices of Valeant Securities at various times during the Class Period; (6) the extent to which external factors influenced the prices of Valeant Securities at various times during the Class Period; (7) the extent to which the various matters that Plaintiffs alleged were materially false or misleading influenced (if at all) the prices of Valeant Securities at various times during the Class Period; and (8) the extent to which the various allegedly adverse material facts that Lead Plaintiff alleged were omitted influenced (if at all) the prices of Valeant Securities during the Class Period.

Statement of Attorneys' Fees and Expenses Sought

Lead Counsel will apply to the Court on behalf of all Plaintiffs' Counsel for an award of attorneys' fees not to exceed thirteen percent of the Settlement Amount, plus charges and expenses not to exceed \$3 million, including award(s) to Plaintiffs of no more than \$175,000 in the aggregate pursuant to 15 U.S.C. §78u-4(a)(4) in connection with their representation of the Class, plus interest earned on these amounts at the same rate as earned by the Settlement Fund. Since the Litigation's inception, Lead Counsel have expended considerable time and effort in the prosecution of this Litigation on a wholly contingent basis and have advanced the expenses of the Litigation in the expectation that if they were successful in obtaining a recovery for the Class they would be paid from such recovery. The requested fee is the result of a negotiation between Lead Counsel and Lead Plaintiff that was designed to align the interests of Lead Counsel and the Class in maximizing the net recovery for the Class. The requested attorneys' fees, charges and expenses amount to an average cost of

approximately \$0.28 per common share. The average cost per damaged share will vary depending on the number of acceptable Proofs of Claim and Release submitted.

Further Information

For further information regarding the Litigation or this Notice or to review the Stipulation, please contact the Claims Administrator toll-free at _____, or visit the website www.ValeantSecuritiesSettlement.com.

You may also contact a representative of counsel for the Class: Rick Nelson, Shareholder Relations, Robbins Geller Rudman & Dowd LLP, 655 West Broadway, Suite 1900, San Diego, CA 92101, 1-800-449-4900, www.rgrdlaw.com.

Please Do Not Call the Court or Defendants or Former Defendants with Questions About the Settlement.

Reasons for the Settlement

Lead Plaintiff's principal reason for entering into the Settlement is the benefit to the Class now, without further risk or the delays inherent in continued litigation. The cash benefit under the Settlement must be considered against the significant risk that a smaller recovery – or, indeed, no recovery at all – might be achieved after trial, and likely appeals, a process that could last several years into the future.

Defendants and Former Defendants have denied and continue to deny each and all of the claims alleged by Lead Plaintiff in the Litigation. Defendants and Former Defendants expressly have denied and continue to deny all charges of wrongdoing or liability against them arising out of any of the conduct, statements, acts or omissions alleged, or that could have been alleged, in the Litigation. Defendants and Former Defendants also have denied and continue to deny, among other things, the allegations that Lead Plaintiff or the Class has suffered any damage, or that Lead Plaintiff or the Class was harmed by the conduct alleged in the Litigation. For Defendants and Former Defendants, the principal reason for entering into the Settlement is to eliminate the uncertainty, risk, costs, and burdens inherent in any litigation, especially in complex cases such as this Litigation. Defendants and Former Defendants have concluded that further conduct of this Litigation could be expensive, protracted and distracting.

WHAT IS THIS LAWSUIT ABOUT?

THE ALLEGATIONS

The Litigation is currently pending in the United States District Court for the District of New Jersey before the Honorable Michael A. Shipp (the “Court”). The Litigation was referred to Special Master Judge Dennis M. Cavanaugh, U.S.D.J. (ret), on September 10, 2019. The initial complaint in this action was filed on October 22, 2015. On May 31, 2016, the Court consolidated Civil Action Nos. 15-cv-07679, 15-cv-07746, and 15-cv-07809 with this action and appointed TIAA as Lead Plaintiff and Robbins Geller Rudman & Dowd LLP (“Robbins Geller”) as Lead Counsel.

Plaintiffs filed the Consolidated Complaint for Violations of the Federal Securities Laws (“Complaint”) on June 24, 2016. Plaintiffs later filed the First Amended Consolidated Complaint for Violations of the Federal Securities Laws (“Amended Complaint”) on September 20, 2018. The Complaint and Amended Complaint allege that certain Defendants and Former Defendants are liable for violations of the Securities Act of 1933 and/or the Securities Exchange Act of 1934 resulting from materially false and misleading statements or omissions of material facts necessary to make statements made by those Defendants and Former Defendants in public filings and other public statements not misleading. Among other things, Plaintiffs allege that those Defendants and Former Defendants are liable for false and misleading statements regarding Valeant’s business operations and financial performance. Plaintiffs further allege that when the truth regarding Valeant’s true business, operations, and prospects was revealed, artificial inflation was removed from the prices of Valeant Securities damaging members of the Class. The Amended Complaint also alleges that certain Defendants violated the Securities Exchange Act of 1934 by selling Valeant Securities while in possession of material, nonpublic information. Defendants and Former Defendants deny each and all of Plaintiffs’ allegations. Defendants and Former Defendants contend that they are not liable for any such alleged false or misleading statements and that all information required to be disclosed by the federal securities laws was so disclosed. Defendants also contend that their actions did not cause Plaintiffs’ alleged loss, and the Valeant Defendants contend that they did not act with scienter. Defendants and Former Defendants further deny that any Defendant sold Valeant Securities while in possession of material, nonpublic information or that they sold such Valeant Securities on the basis of material, nonpublic information.

THE COURT HAS NOT RULED AS TO WHETHER DEFENDANTS ARE LIABLE TO LEAD PLAINTIFF OR TO THE CLASS. THIS NOTICE IS NOT INTENDED TO BE AN EXPRESSION OF ANY OPINION BY THE

COURT WITH RESPECT TO THE TRUTH OF THE ALLEGATIONS IN THIS LITIGATION OR THE MERITS OF THE CLAIMS OR DEFENSES ASSERTED. THIS NOTICE IS SOLELY TO ADVISE YOU OF THE PENDENCY AND PROPOSED SETTLEMENT OF THIS ACTION AND YOUR RIGHTS IN CONNECTION WITH THAT SETTLEMENT.

PROCEDURAL HISTORY

The parties vigorously litigated this case for four years. The parties submitted extensive briefing regarding a motion to lift the discovery stay and after the nearly 300-page consolidated Complaint was filed, the parties briefed and argued six initial motions to dismiss filed by 34 Defendants and Former Defendants. After nearly 400 pages of briefing and a lengthy hearing, the Court denied the motions to dismiss in substantial part, and dismissed all claims against the Former Defendants. The parties then engaged in extensive fact and class-related discovery involving Class Representatives, Defendants and Former Defendants, and approximately 150 non-parties, which included the exchange of over 13 million pages of documents. Plaintiffs also conducted interviews of former Valeant employees and certain third parties and reviewed the public record, including statements submitted as part of Congressional hearings. Plaintiffs moved for class certification on September 28, 2018. Defendants' time to respond to Plaintiffs' motion for class certification has not yet elapsed, and the Court has not ruled on Plaintiffs' motion. Plaintiffs amended the Complaint to add insider trading claims against the ValueAct Defendants and Defendant Ubben. The ValueAct Defendants and Defendant Ubben moved to dismiss the insider trading claims and after the parties exchanged 70 additional pages of briefing, the Court denied the ValueAct Defendants' motion to dismiss. The ValueAct Defendants and Defendant Ubben continue to deny the insider trading allegations.

During the course of the Litigation, the parties engaged an experienced and neutral third-party mediator, Eric D. Green, and held direct settlement discussions. The parties exchanged lengthy and detailed briefs and Lead Counsel met in person with the mediator and counsel for the Valeant Defendants on September 17, 2018, but were unable to reach an agreement. During the following year counsel for the parties engaged in numerous teleconferences with the mediator. On November 6, 2019, the parties attended another in person mediation after exchanging supplemental mediation briefs. Once again the parties were unable to reach an agreement. Then, in response to a mediator's proposal, on November 22, 2019, the Settling Parties agreed to settle the Litigation with all Defendants and Former Defendants, except PwC, in return for a cash payment of \$1,210,000,000 for the benefit of the Class.

HOW DO I KNOW IF I AM A CLASS MEMBER?

If you purchased or otherwise acquired Valeant Securities during the period between January 4, 2013 and March 15, 2016, inclusive, and are not otherwise excluded, you are a Class Member. As set forth in the Stipulation, excluded from the Class are: Defendants and Former Defendants, present and former executive officers of Defendants and Former Defendants, and members of their immediate families, present and former directors of Defendants and Former Defendants, and members of their immediate families, any entity in which a Defendant or current or former director of a Defendant has control and/or a majority ownership interest, and the legal representatives, heirs, successors or assigns of any such excluded party. For the avoidance of doubt, this exclusion does not extend to: (1) any investment company or pooled investment fund in which a Defendant or Former Defendant may have a direct or indirect interest, or as to which its affiliates may act as an advisor, but of which a Defendant or Former Defendant or its respective affiliates is not a majority owner or does not hold a majority beneficial interest; or (2) any employee benefit plan as to which a Defendant or Former Defendant or its affiliates acts as an investment advisor or otherwise may be a fiduciary; provided, however, that membership in the Class by such investment company, pooled investment fund or employee benefit plan is limited to transactions in Valeant Securities made on behalf of, or for the benefit of, persons other than persons that are excluded from the Class by definition. In other words, Defendants and Former Defendants cannot make a claim on their own behalf for their ownership share in any of the above entities. The Class also excludes: (1) any person or entity which during the Class Period purchased or otherwise acquired Valeant Securities and has been promised or received a payment from or on behalf of the Valeant Defendants related to or arising from litigation related to its Class Period transactions in Valeant Securities other than a payment of attorneys fees or costs to counsel for such person or entity; (2) any Class Member on Exhibit A to the Final Judgment that validly and timely requested exclusion in accordance with the requirements set by the Court in this Notice; and (3) anyone on Exhibit B to the Final Judgment who has filed an individual action and not dismissed their claim and sought to be included in the Class.

PLEASE NOTE: Receipt of this Notice does not mean that you are a Class Member or that you will be entitled to receive a payment from the Settlement. If you are a Class Member and you wish to be eligible to participate in the distribution of proceeds from the Settlement, you are required to submit the Proof of Claim and Release that is being distributed with this Notice and the required supporting documentation as set forth therein postmarked or submitted online on or before _____, 2020.

WHAT IS THE MONETARY VALUE OF THE PROPOSED SETTLEMENT?

The Settlement, if approved, will result in the creation of a cash settlement fund of \$1,210,000,000.00. This fund, plus accrued interest and minus the costs of this Notice and all costs associated with the administration of the Settlement, any taxes and tax expenses, as well as attorneys' fees and expenses, and any award to Plaintiffs pursuant to 15 U.S.C. §78u-4(a)(4) in connection with their representation of the Class, as approved by the Court (the "Net Settlement Fund"), will be distributed to eligible Class Members pursuant to the Plan of Allocation that is described in the next section of this Notice.

WHAT IS THE PROPOSED PLAN OF ALLOCATION?

If the Settlement is approved by the Court, the Net Settlement Fund will be distributed to eligible Authorized Claimants – *i.e.*, members of the Class who timely submit valid Claim Forms that are accepted for payment by the Court – in accordance with this proposed Plan of Allocation ("Plan of Allocation" or "Plan") or such other plan of allocation as the Court may approve. Class Members who do not timely submit valid Claim Forms will not share in the Net Settlement Fund, but will otherwise be bound by the Settlement. The Court may approve this proposed Plan of Allocation, or modify it, without additional notice to the Class. Any order modifying the Plan of Allocation will be posted on the settlement website, www.ValeantSecuritiesSettlement.com.

The Plan of Allocation is intended to compensate Class Members who purchased or acquired Valeant common stock, call options, and/or certain bonds⁸,

⁸ There are eleven (11) bonds eligible for Exchange Act claims: (i) the 5.375% senior notes due 2020, CUSIP 91831AAA (the "AAA Notes"); (ii) the 5.875% senior notes due 2023, CUSIP 91831AAB (the "AAB Notes"); (iii) the 6.125% senior notes due 2025, CUSIP 91831AAC (the "AAC Notes"); (iv) the 7.5% senior notes due 2021, CUSIP 92912EAA (the "EAA Notes"); (v) the 6.75% senior notes due 2018, CUSIP 92912EAC (the "EAC Notes"); (vi) the 6.375% senior notes due 2020, CUSIP 91829KAA (the "KAA Notes"); (vii) the 5.625% senior notes due 2021, CUSIP 91911KAD (the "KAD Notes"); (viii) the 5.5% senior notes due 2023, CUSIP 91911KAE (the "KAE Notes"); (ix) the 7.0% senior notes due 2020, CUSIP 91911XAM (the "XAM Notes"); (x) the 6.75% senior notes due 2021, CUSIP 91911XAQ (the "XAQ Notes"); and (xi) the 7.25% senior notes due 2022, CUSIP 91911XAS (the "XAS Notes").

and/or sold put options during the Class Period and were damaged thereby under the Securities Exchange Act of 1934 (“Exchange Act”) and Class Members who purchased or acquired Valeant common stock⁹ pursuant to certain registration statements or offering materials¹⁰ and were damaged thereby under the Securities Act of 1933 (“Securities Act”). Collectively, the Valeant common stock, call options, put options, and bonds that were damaged under the Exchange Act are referred to as the “Exchange Act Securities.” Shares of Valeant common stock that were damaged under the Securities Act are referred to as the “Securities Act Securities.” No other securities other than the Exchange Act Securities and Securities Act Securities are eligible for compensation under the Settlement.¹¹

In this case, Plaintiffs allege that Defendants made false statements and omitted material facts during the Class Period, which had the effect of artificially inflating the prices of the Valeant Securities. As the result of the alleged corrective disclosures, artificial inflation was removed from the prices of Valeant Securities on September 28, 2015, September 29, 2015, October 5, 2015, October 15, 2015, October 19, 2015, October 20, 2015, October 21, 2015, October 22, 2015, October 26, 2015, October 29, 2015, October 30, 2015, November 4, 2015, November 5, 2015, February 19, 2016, February 22, 2016, February 29, 2016, March 15, 2016, and June 7, 2016.

ALLOCATION OF THE NET SETTLEMENT FUND

As detailed below, the Net Settlement Fund will be allocated on a *pro rata* basis according to recognized claims for Class Member’s Exchange Act damages (which will be calculated based on the claimant’s purchases of Valeant Exchange Act Securities during the Class Period) and Class Member’s Securities Act damages

⁹ Bonds are not eligible for Securities Act claims under this Plan of Allocation. Neither call options purchased nor put options sold are eligible for Securities Act claims under this Plan of Allocation.

¹⁰ These registration statements were: the March 16, 2015 Form 424(b)5 Prospectus Supplement (to the shelf registration and prospectus dated June 10, 2013), and the March 18, 2015 Form 424(b)5 Prospectus Supplement (to the prospectus dated June 10, 2013). Collectively, the “March 2015 Offering Materials.”

¹¹ The Exchange Act Securities and the Securities Act Securities are referred to collectively as the “Valeant Securities” or as a “Valeant Security.”

(which will be calculated based on the claimant's purchases of Valeant Securities Act Securities pursuant to a Registration Statement).¹²

The Net Settlement Fund will be allocated to Authorized Claimants as follows: (a) at least 95% of the Net Settlement Fund will be allocated collectively to Valeant common stock and the specified Valeant debt securities; and (b) no more than 5% of the Net Settlement Fund will be allocated to options on Valeant common stock.

CALCULATION OF RECOGNIZED LOSS AMOUNTS

For each Class Period purchase of a Valeant Security that is properly documented, a "Recognized Loss Amount" will be calculated for that security according to the formulas described below. Such Recognized Loss Amounts will be aggregated across all Valeant Securities to determine the "Overall Recognized Loss Amounts" for each Class Member.

The calculations made pursuant to the Plan of Allocation are not intended to be estimates of, nor indicative of, the amounts that Class Members might have been able to recover after a trial. Nor are the calculations pursuant to the Plan of Allocation intended to be estimates of the amounts that will be paid to Authorized Claimants pursuant to the Settlement. The computations under the Plan of Allocation are only a method to weigh the claims of claimants against one another for the purposes of making *pro rata* allocations of the Net Settlement Fund.

I. EXCHANGE ACT RECOGNIZED LOSS AMOUNTS

For the Exchange Act Securities, estimated damages and the Plan were developed based on event study analysis, which determines how much artificial inflation was in the prices of such securities on each day during the Class Period by measuring how much the prices declined as a result of disclosures that corrected the alleged misrepresentations and omissions. An Exchange Act Recognized Loss Amount is calculated for each Class Member who purchased Exchange Act Securities during the Class Period based on when that claimant purchased and sold the securities, or retained the securities beyond the end of the Class Period.

¹² Unless otherwise indicated, any transactions in Valeant Exchange Act Securities or Securities Act Securities executed outside of regular trading hours for the U.S. financial markets shall be deemed to have occurred during the next regular trading session.

Based on the formulas presented below, an “Exchange Act Recognized Loss Amount” will be calculated for each purchase or acquisition of Valeant Exchange Act Securities during the Class Period that is listed on the Claim Form and for which adequate documentation is provided. If a Recognized Loss Amount calculates to a negative number or zero under the formula below, that Recognized Loss Amount will be zero.

A. Calculation of Exchange Act Recognized Loss Amount for Class Members with 10(b) Claims

1. Valeant Common Stock

1. For each share of Valeant common stock purchased or otherwise acquired during the Class Period, the claim per share shall be as follows:

(a) Sold with an equal, or greater, level of percent inflation (see Table-A), the Exchange Act Recognized Loss Amount is zero.

(b) Sold prior to September 28, 2015, the Exchange Act Recognized Loss Amount per share is zero.

(c) Sold on or after September 28, 2015 and prior to the close of trading on June 7, 2016, the Exchange Act Recognized Loss Amount per share is equal to the *lesser* of:

(i) the purchase price multiplied by the percent inflation at the time of purchase (see Table-A) less the sales price multiplied by the percent inflation at the time of sale (see Table-A); and

(ii) the difference between the purchase price and the sales price.

(d) Retained at the end of June 7, 2016, and sold on or before September 2, 2016, the Exchange Act Recognized Loss Amount per share is equal to the *least* of:

(i) the purchase price multiplied by the percent inflation at the time of purchase (see Table-A);

(ii) the difference between the purchase price and the sales price; and

(iii) the difference between the purchase price and the average closing price up to the date of sale as set forth in Table-C below.

(e) Held as of the close of trading on September 2, 2016, or sold thereafter, the Exchange Act Recognized Loss Amount per share is equal to the *lesser* of:

(i) the purchase price multiplied by the percent inflation at the time of purchase (see Table-A); and

(ii) the difference between the purchase price and \$24.43 per share.¹³

2. Valeant AAA Note

For each \$100 of par of Valeant AAA Notes purchased or otherwise acquired during any of the periods shown below in Table-B, and:

(a) Sold within the same period, the Exchange Act Recognized Loss Amount is zero.

(b) Sold prior to September 28, 2015, the Exchange Act Recognized Loss Amount per share is zero.

(c) Sold on or after September 28, 2015 and prior to the close of trading on June 7, 2016, the Exchange Act Recognized Loss Amount per share is equal to the *lesser* of: (i) the inflation at purchase per \$100 of par less the

¹³ Under Section 21(D)(e)(1) of the Exchange Act, “in any private action arising under this Act in which the plaintiff seeks to establish damages by reference to the market price of a security, the award of damages to the plaintiff shall not exceed the difference between the purchase or sale price paid or received, as appropriate, by the plaintiff for the subject security and the mean trading price of that security during the 90-day period beginning on the date on which the information correcting the misstatement or omission that is the basis for the action is disseminated to the market.” Consistent with the requirements of the statute, Exchange Act Recognized Loss Amounts for Valeant common stock are reduced to an appropriate extent by taking into account the closing prices of Valeant common stock during the 90-day look-back period. The mean (average) closing price for Valeant common stock during this 90-day look-back period was \$24.43 per share as shown in Table-C.

inflation at sale per \$100 of par (see Table-B); and (ii) the purchase price less the sales price.

(d) Retained at the end of June 7, 2016, and sold on or before September 2, 2016, the Exchange Act Recognized Loss Amount per \$100 of par is equal to the *least* of: (i) the inflation at purchase per \$100 of par less the inflation at sale per \$100 of par (see Table-B); (ii) the purchase price less the sales price; and (iii) the difference between the purchase price and the average price up to the date of sale as set forth in Table-C below.

(e) Held as of the close of trading on September 2, 2016, or sold thereafter, the Exchange Act Recognized Loss Amount per \$100 of par is equal to the *lesser* of: (i) the inflation at purchase per \$100 of par less the inflation at sale per \$100 of par (see Table-B); and (ii) the difference between the purchase price and \$89.74 per \$100 of par.¹⁴

3. Valeant AAB Note

For each \$100 of par of Valeant AAB Notes purchased or otherwise acquired during any of the periods shown below in Table-B, and:

(a) Sold within the same period, the Exchange Act Recognized Loss Amount is zero.

(b) Sold prior to September 28, 2015, the Exchange Act Recognized Loss Amount per share is zero.

(c) Sold on or after September 28, 2015 and prior to the close of trading on June 7, 2016, the Exchange Act Recognized Loss Amount per share is equal to the *lesser* of: (i) the inflation at purchase per \$100 of par less the inflation at sale per \$100 of par (see Table-B); and (ii) the purchase price less the sales price.

¹⁴ Consistent with the requirements of Section 21(D)(e)(1) of the Exchange Act, Exchange Act Recognized Loss Amounts for Valeant AAA Notes are reduced to an appropriate extent by taking into account the closing prices for Valeant AAA Notes during the 90-day look-back period. The mean (average) price for Valeant AAA Notes during this 90-day look-back period was \$89.74 per \$100 of par as shown in Table-C.

(d) Retained at the end of June 7, 2016, and sold on or before September 2, 2016, the Exchange Act Recognized Loss Amount per \$100 of par is equal to the *least* of: (i) the inflation at purchase per \$100 of par less the inflation at sale per \$100 of par (see Table-B); (ii) the purchase price less the sales price; and (iii) the difference between the purchase price and the average price up to the date of sale as set forth in Table-C below.

(e) Held as of the close of trading on September 2, 2016, or sold thereafter, the Exchange Act Recognized Loss Amount per \$100 of par is equal to the *lesser* of: (i) the inflation at purchase per \$100 of par less the inflation at sale per \$100 of par (see Table-B); and (ii) the difference between the purchase price and \$84.32 per \$100 of par.¹⁵

4. Valeant AAC Note

For each \$100 of par of Valeant AAC Notes purchased or otherwise acquired during any of the periods shown below in Table-B, and:

(a) Sold within the same period, the Exchange Act Recognized Loss Amount is zero.

(b) Sold prior to September 28, 2015, the Exchange Act Recognized Loss Amount per share is zero.

(c) Sold on or after September 28, 2015 and prior to the close of trading on June 7, 2016, the Exchange Act Recognized Loss Amount per share is equal to the *lesser* of: (i) the inflation at purchase per \$100 of par less the inflation at sale per \$100 of par (see Table-B); and (ii) the purchase price less the sales price.

(d) Retained at the end of June 7, 2016, and sold on or before September 2, 2016, the Exchange Act Recognized Loss Amount per \$100 of par is equal to the *least* of: (i) the inflation at purchase per \$100 of par less the

¹⁵ Consistent with the requirements of Section 21(D)(e)(1) of the Exchange Act, Exchange Act Recognized Loss Amounts for Valeant AAB Notes are reduced to an appropriate extent by taking into account the closing prices for Valeant AAB Notes during the 90-day look-back period. The mean (average) price for Valeant AAB Notes during this 90-day look-back period was \$84.32 per \$100 of par as shown in Table-C.

inflation at sale per \$100 of par (see Table-B); (ii) the purchase price less the sales price; and (iii) the difference between the purchase price and the average price up to the date of sale as set forth in Table-C below.

(e) Held as of the close of trading on September 2, 2016, or sold thereafter, the Exchange Act Recognized Loss Amount per \$100 of par is equal to the *lesser* of: (i) the inflation at purchase per \$100 of par less the inflation at sale per \$100 of par (see Table-B); and (ii) the difference between the purchase price and \$83.72 per \$100 of par.¹⁶

5. Valeant EAA Note

For each \$100 of par of Valeant EAA Notes purchased or otherwise acquired during any of the periods shown below in Table-B, and:

(a) Sold within the same period, the Exchange Act Recognized Loss Amount is zero.

(b) Sold prior to September 28, 2015, the Exchange Act Recognized Loss Amount per share is zero.

(c) Sold on or after September 28, 2015 and prior to the close of trading on June 7, 2016, the Exchange Act Recognized Loss Amount per share is equal to the *lesser* of: (i) the inflation at purchase per \$100 of par less the inflation at sale per \$100 of par (see Table-B); and (ii) the purchase price less the sales price.

(d) Retained at the end of June 7, 2016, and sold on or before September 2, 2016, the Exchange Act Recognized Loss Amount per \$100 of par is equal to the *least* of: (i) the inflation at purchase per \$100 of par less the inflation at sale per \$100 of par (see Table-B); (ii) the purchase price less the sales price; and (iii) the difference between the purchase price and the average price up to the date of sale as set forth in Table-C below.

¹⁶ Consistent with the requirements of Section 21(D)(e)(1) of the Exchange Act, Exchange Act Recognized Loss Amounts for Valeant AAC Notes are reduced to an appropriate extent by taking into account the closing prices of Valeant AAC Notes during the 90-day look-back period. The mean (average) price for Valeant AAC Notes during this 90-day look-back period was \$83.72 per \$100 of par as shown in Table-C.

(e) Held as of the close of trading on September 2, 2016, or sold thereafter, the Exchange Act Recognized Loss Amount per \$100 of par is equal to the *lesser* of: (i) the inflation at purchase per \$100 of par less the inflation at sale per \$100 of par (see Table-B); and (ii) the difference between the purchase price and \$92.70 per \$100 of par.¹⁷

6. Valeant EAC Note

For each \$100 of par of Valeant EAC Notes purchased or otherwise acquired during any of the periods shown below in Table-B, and:

(a) Sold within the same period, the Exchange Act Recognized Loss Amount is zero.

(b) Sold prior to September 28, 2015, the Exchange Act Recognized Loss Amount per share is zero.

(c) Sold on or after September 28, 2015 and prior to the close of trading on June 7, 2016, the Exchange Act Recognized Loss Amount per share is equal to the *lesser* of: (i) the inflation at purchase per \$100 of par less the inflation at sale per \$100 of par (see Table-B); and (ii) the purchase price less the sales price.

(d) Retained at the end of June 7, 2016, and sold on or before September 2, 2016, the Exchange Act Recognized Loss Amount per \$100 of par is equal to the *least* of: (i) the inflation at purchase per \$100 of par less the inflation at sale per \$100 of par (see Table-B); (ii) the purchase price less the sales price; and (iii) the difference between the purchase price and the average price up to the date of sale as set forth in Table-C below.

(e) Held as of the close of trading on September 2, 2016, or sold thereafter, the Exchange Act Recognized Loss Amount per \$100 of par is equal to the *lesser* of: (i) the inflation at purchase per \$100 of par less the inflation at

¹⁷ Consistent with the requirements of Section 21(D)(e)(1) of the Exchange Act, Exchange Act Recognized Loss Amounts for Valeant EAA Notes are reduced to an appropriate extent by taking into account the closing prices of Valeant EAA Notes during the 90-day look-back period. The mean (average) price for Valeant EAA Notes during this 90-day look-back period was \$92.70 per \$100 of par as shown in Table-C.

sale per \$100 of par (see Table-B); and (ii) the difference between the purchase price and \$98.55 per \$100 of par.¹⁸

7. Valeant KAA Note

For each \$100 of par of Valeant KAA Notes purchased or otherwise acquired during any of the periods shown below in Table-B, and:

(a) Sold within the same period, the Exchange Act Recognized Loss Amount is zero.

(b) Sold prior to September 28, 2015, the Exchange Act Recognized Loss Amount per share is zero.

(c) Sold on or after September 28, 2015 and prior to the close of trading on June 7, 2016, the Exchange Act Recognized Loss Amount per share is equal to the *lesser* of: (i) the inflation at purchase per \$100 of par less the inflation at sale per \$100 of par (see Table-B); and (ii) the purchase price less the sales price.

(d) Retained at the end of June 7, 2016, and sold on or before September 2, 2016, the Exchange Act Recognized Loss Amount per \$100 of par is equal to the *least* of: (i) the inflation at purchase per \$100 of par less the inflation at sale per \$100 of par (see Table-B); (ii) the purchase price less the sales price; and (iii) the difference between the purchase price and the average price up to the date of sale as set forth in Table-C below.

(e) Held as of the close of trading on September 2, 2016, or sold thereafter, the Exchange Act Recognized Loss Amount per \$100 of par is equal to the *lesser* of: (i) the inflation at purchase per \$100 of par less the inflation at

¹⁸ Consistent with the requirements of Section 21(D)(e)(1) of the Exchange Act, Exchange Act Recognized Loss Amounts for Valeant EAC Notes are reduced to an appropriate extent by taking into account the closing prices of Valeant EAC Notes during the 90-day look-back period. The mean (average) price for Valeant EAC Notes during this 90-day look-back period was \$98.55 per \$100 of par as shown in Table-C.

sale per \$100 of par (see Table-B); and (ii) the difference between the purchase price and \$90.45 per \$100 of par.¹⁹

8. Valeant KAD Note

For each \$100 of par of Valeant KAD Notes purchased or otherwise acquired during any of the periods shown below in Table-B, and:

(a) Sold within the same period, the Exchange Act Recognized Loss Amount is zero.

(b) Sold prior to September 28, 2015, the Exchange Act Recognized Loss Amount per share is zero.

(c) Sold on or after September 28, 2015 and prior to the close of trading on June 7, 2016, the Exchange Act Recognized Loss Amount per share is equal to the *lesser* of: (i) the inflation at purchase per \$100 of par less the inflation at sale per \$100 of par (see Table-B); and (ii) the purchase price less the sales price.

(d) Retained at the end of June 7, 2016, and sold on or before September 2, 2016, the Exchange Act Recognized Loss Amount per \$100 of par is equal to the *least* of: (i) the inflation at purchase per \$100 of par less the inflation at sale per \$100 of par (see Table-B); (ii) the purchase price less the sales price; and (iii) the difference between the purchase price and the average price up to the date of sale as set forth in Table-C below.

(e) Held as of the close of trading on September 2, 2016, or sold thereafter, the Exchange Act Recognized Loss Amount per \$100 of par is equal to the *lesser* of: (i) the inflation at purchase per \$100 of par less the inflation at

¹⁹ Consistent with the requirements of Section 21(D)(e)(1) of the Exchange Act, Exchange Act Recognized Loss Amounts for Valeant KAA Notes are reduced to an appropriate extent by taking into account the closing prices of Valeant KAA Notes during the 90-day look-back period. The mean (average) price for Valeant KAA Notes during this 90-day look-back period was \$90.45 per \$100 of par as shown in Table-C.

sale per \$100 of par (see Table-B); and (ii) the difference between the purchase price and \$85.97 per \$100 of par.²⁰

9. Valeant KAE Note

For each \$100 of par of Valeant KAE Notes purchased or otherwise acquired during any of the periods shown below in Table-B, and:

(a) Sold within the same period, the Exchange Act Recognized Loss Amount is zero.

(b) Sold prior to September 28, 2015, the Exchange Act Recognized Loss Amount per share is zero.

(c) Sold on or after September 28, 2015 and prior to the close of trading on June 7, 2016, the Exchange Act Recognized Loss Amount per share is equal to the *lesser* of: (i) the inflation at purchase per \$100 of par less the inflation at sale per \$100 of par (see Table-B); and (ii) the purchase price less the sales price.

(d) Retained at the end of June 7, 2016, and sold on or before September 2, 2016, the Exchange Act Recognized Loss Amount per \$100 of par is equal to the *least* of: (i) the inflation at purchase per \$100 of par less the inflation at sale per \$100 of par (see Table-B); (ii) the purchase price less the sales price; and (iii) the difference between the purchase price and the average price up to the date of sale as set forth in Table-C below.

(e) Held as of the close of trading on September 2, 2016, or sold thereafter, the Exchange Act Recognized Loss Amount per \$100 of par is equal to the *lesser* of: (i) the inflation at purchase per \$100 of par less the inflation at

²⁰ Consistent with the requirements of Section 21(D)(e)(1) of the Exchange Act, Exchange Act Recognized Loss Amounts for Valeant KAD Notes are reduced to an appropriate extent by taking into account the closing prices of Valeant KAD Notes during the 90-day look-back period. The mean (average) price for Valeant KAD Notes during this 90-day look-back period was \$85.97 per \$100 of par as shown in Table-C.

sale per \$100 of par (see Table-B); and (ii) the difference between the purchase price and \$83.15 per \$100 of par.²¹

10. Valeant XAM Note

For each \$100 of par of Valeant XAM Notes purchased or otherwise acquired during any of the periods shown below in Table-B, and:

(a) Sold within the same period, the Exchange Act Recognized Loss Amount is zero.

(b) Sold prior to September 28, 2015, the Exchange Act Recognized Loss Amount per share is zero.

(c) Sold on or after September 28, 2015 and prior to the close of trading on June 7, 2016, the Exchange Act Recognized Loss Amount per share is equal to the *lesser* of: (i) the inflation at purchase per \$100 of par less the inflation at sale per \$100 of par (see Table-B); and (ii) the purchase price less the sales price.

(d) Retained at the end of June 7, 2016, and sold on or before September 2, 2016, the Exchange Act Recognized Loss Amount per \$100 of par is equal to the *least* of: (i) the inflation at purchase per \$100 of par less the inflation at sale per \$100 of par (see Table-B); (ii) the purchase price less the sales price; and (iii) the difference between the purchase price and the average price up to the date of sale as set forth in Table-C below.

(e) Held as of the close of trading on September 2, 2016, or sold thereafter, the Exchange Act Recognized Loss Amount per \$100 of par is equal to the *lesser* of: (i) the inflation at purchase per \$100 of par less the inflation at

²¹ Consistent with the requirements of Section 21(D)(e)(1) of the Exchange Act, Exchange Act Recognized Loss Amounts for Valeant KAE Notes are reduced to an appropriate extent by taking into account the closing prices of Valeant KAE Notes during the 90-day look-back period. The mean (average) price for Valeant KAE Notes during this 90-day look-back period was \$83.15 per \$100 of par as shown in Table-C.

sale per \$100 of par (see Table-B); and (ii) the difference between the purchase price and \$93.37 per \$100 of par.²²

11. Valeant XAQ Note

For each \$100 of par of Valeant XAQ Notes purchased or otherwise acquired during any of the periods shown below in Table-B, and:

(a) Sold within the same period, the Exchange Act Recognized Loss Amount is zero.

(b) Sold prior to September 28, 2015, the Exchange Act Recognized Loss Amount per share is zero.

(c) Sold on or after September 28, 2015 and prior to the close of trading on June 7, 2016, the Exchange Act Recognized Loss Amount per share is equal to the *lesser* of: (i) the inflation at purchase per \$100 of par less the inflation at sale per \$100 of par (see Table-B); and (ii) the purchase price less the sales price.

(d) Retained at the end of June 7, 2016, and sold on or before September 2, 2016, the Exchange Act Recognized Loss Amount per \$100 of par is equal to the *least* of: (i) the inflation at purchase per \$100 of par less the inflation at sale per \$100 of par (see Table-B); (ii) the purchase price less the sales price; and (iii) the difference between the purchase price and the average price up to the date of sale as set forth in Table-C below.

(e) Held as of the close of trading on September 2, 2016, or sold thereafter, the Exchange Act Recognized Loss Amount per \$100 of par is equal to the *lesser* of: (i) the inflation at purchase per \$100 of par less the inflation at

²² Consistent with the requirements of Section 21(D)(e)(1) of the Exchange Act, Exchange Act Recognized Loss Amounts for Valeant XAM Notes are reduced to an appropriate extent by taking into account the closing prices of Valeant XAM Notes during the 90-day look-back period. The mean (average) price for Valeant XAM Notes during this 90-day look-back period was \$93.37 per \$100 of par as shown in Table-C.

sale per \$100 of par (see Table-B); and (ii) the difference between the purchase price and \$90.19 per \$100 of par.²³

12. Valeant XAS Note

For each \$100 of par of Valeant XAS Notes purchased or otherwise acquired during any of the periods shown below in Table-B, and:

(a) Sold within the same period, the Exchange Act Recognized Loss Amount is zero.

(b) Sold prior to September 28, 2015, the Exchange Act Recognized Loss Amount per share is zero.

(c) Sold on or after September 28, 2015 and prior to the close of trading on June 7, 2016, the Exchange Act Recognized Loss Amount per share is equal to the *lesser* of: (i) the inflation at purchase per \$100 of par less the inflation at sale per \$100 of par (see Table-B); and (ii) the purchase price less the sales price.

(d) Retained at the end of June 7, 2016, and sold on or before September 2, 2016, the Exchange Act Recognized Loss Amount per \$100 of par is equal to the *least* of: (i) the inflation at purchase per \$100 of par less the inflation at sale per \$100 of par (see Table-B); (ii) the purchase price less the sales price; and (iii) the difference between the purchase price and the average price up to the date of sale as set forth in Table-C below.

(e) Held as of the close of trading on September 2, 2016, or sold thereafter, the Exchange Act Recognized Loss Amount per \$100 of par is equal to the *lesser* of: (i) the inflation at purchase per \$100 of par less the inflation at

²³ Consistent with the requirements of Section 21(D)(e)(1) of the Exchange Act, Exchange Act Recognized Loss Amounts for Valeant XAQ Notes are reduced to an appropriate extent by taking into account the closing prices of Valeant XAQ Notes during the 90-day look-back period. The mean (average) price for Valeant XAQ Notes during this 90-day look-back period was \$90.19 per \$100 of par as shown in Table-C.

sale per \$100 of par (see Table-B); and (ii) the difference between the purchase price and \$89.85 per \$100 of par.²⁴

13. Options

In order to have an Exchange Act Recognized Loss Amount for options on Valeant common stock, the option contract must have been purchased or written (sold) *and* the position remained open through at least one of the following dates: September 28, 2015, September 29, 2015, October 5, 2015, October 15, 2015, October 19, 2015, October 20, 2015, October 21, 2015, October 22, 2015, October 26, 2015, October 29, 2015, October 30, 2015, November 4, 2015, November 5, 2015, February 19, 2016, February 22, 2016, February 29, 2016, March 15, 2016, and/or June 7, 2016.²⁵

1. For call options on Valeant common stock purchased or otherwise acquired during the Class Period, and:

(a) Closed (through sale, exercise or expiration) before September 28, 2015, the Exchange Act Recognized Loss Amount is zero.

(b) Closed (through sale, exercise or expiration) without being held through at least one of the above-mentioned disclosures (*see* page 26), the Exchange Act Recognized Loss Amount is zero.

²⁴ Consistent with the requirements of Section 21(D)(e)(1) of the Exchange Act, Exchange Act Recognized Loss Amounts for Valeant XAS Notes are reduced to an appropriate extent by taking into account the closing prices of Valeant XAS Notes during the 90-day look-back period. The mean (average) price for Valeant XAS Notes during this 90-day look-back period was \$89.85 per \$100 of par as shown in Table-C.

²⁵ To participate in the Settlement, claimants must provide adequate documentation to establish that each call option and put option purchased or sold remained open through at least one of the disclosures identified above. With respect to shares of Valeant common stock purchased or sold through the exercise of an option, the purchase/sale date of the Valeant common stock is the exercise date of the option, and the purchase/sale price of the Valeant common stock is the exercise price of the option.

(c) Held though at least one of the above-mentioned disclosures (*see* page 26), the Exchange Act Recognized Loss Amount is the difference between the price paid for the call option less the proceeds received upon settlement of the call option contract.

2. For call options on Valeant common stock written or otherwise sold, the Exchange Act Recognized Loss Amount is zero.

3. For put options on Valeant common stock written or otherwise sold during the Class Period, and:

(a) Closed (through purchase, exercise or expiration) before September 28, 2015, the Exchange Act Recognized Loss Amount is zero.

(b) Closed (through purchase, exercise or expiration) without being held through at least one of the above-mentioned disclosures (*see* page 26), the Exchange Act Recognized Loss Amount is zero.

(c) Held though at least one of the above-mentioned disclosures (*see* page 26), the Exchange Act Recognized Loss Amount is the difference between the amount(s) paid upon settlement of the put option contract less the initial proceeds received upon the sale of the put option contract.

4. For put options on Valeant common stock purchased or otherwise acquired, the Exchange Act Recognized Loss Amount is zero.

B. Calculation of Exchange Act Recognized Loss Amount for Class Members with 20A Claims

1. Valeant Common Stock

Based on the formulas stated below, an “Exchange Act Recognized Loss Amount” will be calculated for each purchase or acquisition of Valeant common stock between June 10, 2015 and June 15, 2015, inclusive, that is listed on the Claim Form and for which adequate documentation is provided.

For each share of Valeant common stock purchased or otherwise acquired between June 10, 2015 and June 15, 2015, inclusive, and:

(a) Sold prior to September 28, 2015, the Recognized Loss Amount per share is zero.

(b) Sold on or after September 28, 2015 and prior to the close of trading on June 7, 2016, the Recognized Loss Amount per share is the difference between the purchase price and the sale price.

(c) Retained at the end of June 7, 2016, the Recognized Loss Amount per share is the difference between the purchase price and \$24.64.

Class Members who did not purchase or otherwise acquire Valeant common stock between June 10, 2015 and June 15, 2015, inclusive, do not have a valid Section 20A Claim under this Plan of Allocation. Class Members with Section 20A Claims in connection with their purchases or acquisitions of Valeant common stock between June 10, 2015 and June 15, 2015, inclusive, shall forfeit their Section 10(b) Claims in connection with those purchases.

II. SECURITIES ACT RECOGNIZED LOSS AMOUNTS

Securities Act claims were asserted with respect to Valeant Securities Act Securities purchased or otherwise acquired pursuant or traceable to the March 2015 Offering Materials. The Section 11 Securities Act claims asserted in the Litigation serve as the basis for the calculation of Securities Act Recognized Loss Amounts. Section 11 provides a statutory formula for the calculation of damages under that provision. The formula set forth below, developed by Plaintiffs' damages expert generally tracks the statutory scheme for causation and damages. For purposes of the calculations, June 24, 2016 is the date of suit, and is the proxy for the date of judgment.

Based on the formulas stated below, a "Securities Act Recognized Loss Amount" will be calculated for each purchase/acquisition of Valeant Securities Act Securities. If a Securities Act Recognized Loss Amount calculates to a negative number or zero under the formula below, that number will be zero.

For the Securities Act Securities, a Securities Act Recognized Loss Amount will be calculated as set forth below for each purchase or other acquisition of a security pursuant or traceable to a Registration Statement. The calculation of a Securities Act Recognized Loss Amount will depend upon several factors, including (i) when the security was purchased or otherwise acquired; and (ii) whether the security was sold, and if so, when it was sold, and for what amount. The "value" of a security on the date on which a complaint was first filed alleging claims under Section 11 of the Securities Act is relevant for purposes of calculating damages for securities still held as of that date under Section 11(e). This "value" is measured by the closing price on June 24, 2016, which is the date the complaint was filed.

A. Valeant's March 2015 Secondary Stock Offering

For each share of Valeant common stock purchased or acquired pursuant to the Company's March 2015 Offering Materials, and

(a) Sold prior to September 28, 2015, the Securities Act Recognized Loss Amount per share is zero.

(b) Sold on or after September 28, 2015, and prior to the close of trading on June 24, 2016, the Securities Act Recognized Loss Amount per share is equal to the *lesser* of:

(i) the purchase/acquisition price per share (not to exceed \$199.00, the issue price of the March Offering) multiplied by the percent inflation at the time of purchase (see Table A) less the sales price multiplied by the percent inflation at the time of sale (see Table A); and

(ii) the purchase/acquisition price per share (not to exceed \$199.00, the issue price of the March Offering) less the sales price per share.

(c) Retained as of the close of trading on June 24, 2016, or, sold on or after June 25, 2016, the Recognized Loss Amount for each share shall be the *lesser* of:

(i) the purchase/acquisition price per share (not to exceed \$199.00, the issue price of the March Offering) multiplied by the percent inflation at the time of purchase (see Table A); and

(ii) \$178.73 per share (equal to \$199.00 less \$20.27).

Class Members with Section 11 Claims in connection with their purchases or acquisitions of Valeant common stock pursuant to the March 2015 Offering Materials will receive either Recognized Loss Amounts under their Section 11 Claims or their Section 10(b) Claims in connection with those purchases, whichever results in the larger Recognized Loss Amount, but not both.

ADDITIONAL PROVISIONS

If a Class Member held Valeant Securities at the beginning of the Class Period or made multiple purchases, acquisitions or sales of Valeant Securities during or after the Class Period, the starting point for calculating a claimant's Recognized Loss is to match the claimant's holdings, purchases and acquisitions to their sales using the

FIFO (*i.e.*, first-in-first-out) method. Under the FIFO method, Valeant Securities sold during the Class Period will be matched, in chronological order, first against the respective securities held at the beginning of the Class Period. The remaining sales of Valeant Securities during the Class Period will then be matched, in chronological order against the respective security purchased or acquired during the Class Period.

Purchases or acquisitions and sales of Valeant Securities shall be deemed to have occurred on the “contract” or “trade” date as opposed to the “settlement” or “payment” date. The receipt or grant by gift, inheritance or operation of law of Valeant Securities during the Class Period shall not be deemed a purchase, acquisition or sale of Valeant Securities for the calculation of Recognized Loss, unless (i) the donor or decedent purchased or otherwise acquired such Valeant Securities during the Class Period; (ii) no Proof of Claim was submitted by or on behalf of the donor, on behalf of the decedent, or by anyone else with respect to such Valeant Securities; and (iii) it is specifically so provided in the instrument of gift or assignment.

With respect to all of a Claimant’s transactions in Valeant Securities during the Class Period, the Claims Administrator will determine if each Claimant had a “market gain” or “market loss.” If a Claimant had an overall market gain, the value of the Claimant’s “Recognized Claim” shall be zero and such Claimants shall be bound by the Settlement. If the Claimant had an overall market loss, the value of the Claimant’s Recognized Claim shall be the *lesser* of the (a) overall market loss; and (b) the Overall Recognized Loss Amounts as calculated above.

An Authorized Claimant’s Recognized Claim shall be the amount used to calculate the Authorized Claimant’s *pro rata* share of the Net Settlement Fund. If the sum total of Recognized Claims of all Authorized Claimants who are entitled to receive payment out of the Net Settlement Fund is greater than the Net Settlement Fund, each Authorized Claimant shall receive his, her, or its *pro rata* share of the Net Settlement Fund. The *pro rata* share shall be the Authorized Claimant’s Recognized Claim divided by the total of the Recognized Claim of all Authorized Claimants, multiplied by the total amount in the Net Settlement Fund. Given the costs of distribution, the Net Settlement Fund will be allocated among all Authorized Claimants whose distribution amount is \$10.00 or greater.

Distributions will be made to Authorized Claimants after all claims have been processed, after the Court has finally approved the Settlement, and after any appeals are resolved. If there is any balance remaining in the Net Settlement Fund after a reasonable amount of time from the initial date of distribution of the Net Settlement Fund (whether by reason of tax refunds, uncashed checks, or otherwise), the Claims Administrator shall, if feasible, reallocate such balance among Authorized Claimants

in an equitable and economic fashion. These redistributions shall be repeated until the balance remaining in the Net Settlement Fund is no longer economically feasible to distribute to Class Members. Thereafter, any balance that still remains in the Net Settlement Fund shall be donated to an appropriate non-profit charitable organization(s) unaffiliated with any party or their counsel serving the public interest.

Please contact the Claims Administrator or Lead Counsel if you disagree with any determinations made by the Claims Administrator regarding your Proof of Claim and Release. If you are dissatisfied with the determinations, you may ask the Court, which retains jurisdiction over all Class Members and the claims administration process, to decide the issue by submitting a written request.

The Court has reserved jurisdiction to allow, disallow, or adjust the claim of any Class Member on equitable grounds.

Payment pursuant to the Plan of Allocation set forth above shall be conclusive against all Authorized Claimants. No Person shall have any claim against Lead Plaintiff, Lead Counsel, any Claims Administrator, any other Person designated by Lead Plaintiff's counsel, or any of the Released Persons, based on the distributions made substantially in accordance with the Stipulation and the Settlement contained therein, the Plan of Allocation, or further orders of the Court. All Class Members who fail to complete and submit a valid and timely Proof of Claim and Release shall be barred from participating in distributions from the Net Settlement Fund (unless otherwise ordered by the Court), but otherwise shall be bound by all of the terms of the Settlement, including the terms of any judgment entered and the releases given.

TABLE-A
Valeant Common Stock Inflation

Date Range		Inflation as Percent of Purchase Price
1/4/2013	3/27/2013	56.98%
3/28/2013	6/27/2013	58.43%
6/28/2013	9/29/2013	59.92%
9/30/2013	12/30/2013	62.02%
12/31/2013	3/30/2014	64.83%
3/31/2014	6/29/2014	67.40%
6/30/2014	9/29/2014	70.18%
9/30/2014	12/30/2014	72.98%
12/31/2014	3/30/2015	82.64%
3/31/2015	6/29/2015	87.77%
6/30/2015	9/27/2015	91.49%
9/28/2015	9/28/2015	90.29%
9/29/2015	10/4/2015	89.71%
10/5/2015	10/14/2015	88.50%
10/15/2015	10/18/2015	87.64%
10/19/2015	10/19/2015	86.57%
10/20/2015	10/20/2015	85.36%
10/21/2015	10/21/2015	82.04%
10/22/2015	10/25/2015	80.37%
10/26/2015	10/28/2015	79.16%
10/29/2015	10/29/2015	78.05%
10/30/2015	11/3/2015	74.19%
11/4/2015	11/4/2015	72.69%
11/5/2015	2/18/2016	70.76%
2/19/2016	2/21/2016	67.76%
2/22/2016	2/28/2016	63.67%
2/29/2016	3/14/2016	56.63%
3/15/2016	6/6/2016	12.85%
On and after 6/7/2016		0.00%

TABLE-B
Inflation Per \$100 Par Value

Date Range		AAA Note	AAB Note	AAC Note	EAA Note	EAC Note	KAA Note	KAD Note	KAE Note	XAM Note	XAQ Note	XAS Note
Start Date	End Date											
1/4/2013	3/27/2013						\$2.29			\$1.93	\$2.87	\$3.08
3/28/2013	6/27/2013						\$3.24			\$2.55	\$3.79	\$3.74
6/28/2013	9/29/2013				\$4.81	\$4.77	\$4.22			\$3.19	\$4.73	\$4.42
9/30/2013	11/14/2013				\$6.04	\$5.99	\$5.59			\$4.08	\$6.05	\$5.38
11/15/2013	12/30/2013				\$6.04	\$5.99	\$5.59	\$7.16		\$4.08	\$6.05	\$5.38
12/31/2013	3/30/2014				\$7.69	\$7.61	\$7.43	\$8.91		\$5.28	\$7.82	\$6.66
3/31/2014	6/29/2014				\$9.21	\$9.10	\$9.11	\$10.51		\$6.37	\$9.44	\$7.83
6/30/2014	9/29/2014				\$10.84	\$10.70	\$10.93	\$12.24		\$7.55	\$11.19	\$9.09
9/30/2014	12/30/2014				\$12.49	\$12.32	\$12.76	\$13.99		\$8.74	\$12.95	\$10.37
12/31/2014	1/14/2015				\$22.88	\$22.53	\$22.83	\$25.84		\$19.59	\$21.40	\$16.85
1/15/2015	3/12/2015				\$22.88	\$22.53	\$22.83	\$25.84	\$28.91	\$19.59	\$21.40	\$16.85
3/13/2015	3/30/2015	\$23.36	\$28.97	\$30.08	\$22.88	\$22.53	\$22.83	\$25.84	\$28.91	\$19.59	\$21.40	\$16.85
3/31/2015	6/29/2015	\$28.15	\$34.42	\$36.44	\$27.44	\$27.01	\$27.42	\$30.94	\$34.41	\$23.98	\$25.41	\$19.87
6/30/2015	9/27/2015	\$30.53	\$37.10	\$39.32	\$29.63	\$29.16	\$29.85	\$33.26	\$37.12	\$25.56	\$27.75	\$21.56
9/28/2015	9/28/2015	\$29.52	\$34.71	\$36.88	\$28.02	\$27.51	\$29.85	\$30.40	\$37.12	\$24.54	\$27.75	\$21.56
9/29/2015	10/4/2015	\$29.52	\$34.71	\$36.88	\$28.02	\$27.51	\$28.88	\$30.40	\$33.67	\$24.54	\$26.32	\$20.92
10/5/2015	10/14/2015	\$28.35	\$32.90	\$34.92	\$28.02	\$27.51	\$27.96	\$30.40	\$31.82	\$24.54	\$26.32	\$20.92
10/15/2015	10/19/2015	\$27.25	\$31.61	\$33.51	\$26.76	\$26.23	\$27.05	\$29.28	\$30.35	\$24.54	\$25.44	\$19.75
10/20/2015	10/20/2015	\$27.25	\$30.72	\$33.51	\$26.76	\$26.23	\$26.35	\$29.28	\$30.35	\$24.54	\$25.44	\$19.75
10/21/2015	10/21/2015	\$21.81	\$25.13	\$28.10	\$19.97	\$19.37	\$21.78	\$23.07	\$23.82	\$18.25	\$18.87	\$12.59
10/22/2015	10/25/2015	\$21.81	\$23.30	\$28.10	\$19.97	\$19.37	\$18.16	\$21.43	\$23.82	\$16.73	\$16.08	\$9.91
10/26/2015	10/28/2015	\$18.61	\$21.66	\$26.06	\$19.97	\$19.37	\$16.54	\$19.60	\$21.07	\$16.73	\$12.20	\$8.22
10/29/2015	10/29/2015	\$18.61	\$21.66	\$23.54	\$19.97	\$19.37	\$16.54	\$17.81	\$21.07	\$16.73	\$12.20	\$8.22
10/30/2015	11/3/2015	\$17.00	\$21.66	\$23.54	\$18.01	\$17.45	\$15.11	\$17.81	\$21.07	\$16.73	\$9.50	\$5.61
11/4/2015	11/4/2015	\$17.00	\$19.41	\$23.54	\$18.01	\$17.45	\$15.11	\$17.81	\$21.07	\$16.73	\$9.50	\$5.61
11/5/2015	2/20/2016	\$16.11	\$19.41	\$23.54	\$17.12	\$16.57	\$14.18	\$16.66	\$19.87	\$15.60	\$8.18	\$3.57
2/22/2016	2/28/2016	\$13.31	\$16.84	\$16.89	\$17.12	\$16.57	\$14.18	\$13.18	\$16.62	\$13.35	\$8.18	\$3.57
2/29/2016	3/14/2016	\$9.62	\$10.14	\$10.87	\$11.00	\$10.49	\$10.11	\$10.48	\$9.79	\$8.75	\$5.25	\$3.57
3/15/2016	thereafter	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00

TABLE-C
Valeant Securities Average Closing Prices
June 7, 2016 – September 2, 2016

Date	Common Stock	AAA Note	AAB Note	AAC Note	EAA Note	EAC Note	KAA Note	KAD Note	KAE Note	XAM Note	XAQ Note	XAS Note
6/7/2016	\$24.64	\$87.25	\$82.63	\$82.00	\$90.25	\$96.75	\$88.00	\$84.00	\$82.06	\$91.00	\$87.50	\$86.56
6/8/2016	\$24.28	\$87.53	\$82.81	\$82.25	\$90.26	\$97.06	\$88.38	\$84.00	\$82.16	\$91.13	\$87.75	\$86.66
6/9/2016	\$24.68	\$87.75	\$83.21	\$82.65	\$90.59	\$97.38	\$88.52	\$84.00	\$82.44	\$91.13	\$87.80	\$87.27
6/10/2016	\$24.55	\$87.38	\$82.82	\$82.48	\$90.57	\$97.39	\$88.21	\$83.75	\$81.99	\$91.13	\$87.56	\$87.27
6/13/2016	\$24.39	\$87.32	\$82.70	\$82.22	\$90.50	\$97.41	\$88.17	\$83.75	\$81.94	\$91.17	\$87.38	\$86.96
6/14/2016	\$24.35	\$87.23	\$82.67	\$82.41	\$90.38	\$97.55	\$88.18	\$83.57	\$81.99	\$91.13	\$87.36	\$86.91
6/15/2016	\$24.25	\$87.20	\$82.65	\$82.37	\$90.39	\$97.65	\$88.15	\$83.51	\$82.07	\$91.15	\$87.30	\$86.91
6/16/2016	\$24.02	\$87.17	\$82.60	\$82.17	\$90.26	\$97.69	\$88.17	\$83.43	\$81.84	\$90.92	\$87.30	\$86.80
6/17/2016	\$23.80	\$87.15	\$82.60	\$82.09	\$90.26	\$97.67	\$88.11	\$83.43	\$81.84	\$90.92	\$87.30	\$86.72
6/20/2016	\$23.67	\$87.16	\$82.54	\$82.03	\$90.25	\$97.70	\$88.11	\$83.44	\$81.86	\$90.92	\$87.30	\$86.75
6/21/2016	\$23.49	\$87.14	\$82.43	\$81.96	\$90.27	\$97.68	\$88.12	\$83.20	\$81.86	\$90.85	\$87.31	\$86.78
6/22/2016	\$23.34	\$87.13	\$82.38	\$81.88	\$90.24	\$97.65	\$88.13	\$83.23	\$81.82	\$90.81	\$87.28	\$86.80
6/23/2016	\$23.25	\$87.16	\$82.32	\$81.84	\$90.14	\$97.62	\$88.10	\$83.23	\$81.76	\$90.78	\$87.28	\$86.80
6/24/2016	\$23.04	\$87.04	\$82.22	\$81.73	\$90.14	\$97.56	\$88.01	\$83.14	\$81.76	\$90.57	\$87.28	\$86.80
6/27/2016	\$22.75	\$86.87	\$82.01	\$81.55	\$89.94	\$97.46	\$87.81	\$82.85	\$81.45	\$90.57	\$87.28	\$86.80
6/28/2016	\$22.58	\$86.75	\$81.87	\$81.40	\$89.76	\$97.36	\$87.67	\$82.70	\$81.29	\$90.57	\$87.28	\$86.59
6/29/2016	\$22.44	\$86.69	\$81.78	\$81.38	\$89.67	\$97.31	\$87.60	\$82.68	\$81.21	\$90.39	\$87.12	\$86.54
6/30/2016	\$22.32	\$86.63	\$81.72	\$81.34	\$89.60	\$97.27	\$87.51	\$82.67	\$81.15	\$90.27	\$87.00	\$86.50
7/1/2016	\$22.22	\$86.62	\$81.72	\$81.32	\$89.60	\$97.25	\$87.57	\$82.67	\$81.15	\$90.25	\$86.95	\$86.50
7/5/2016	\$22.10	\$86.64	\$81.73	\$81.32	\$89.60	\$97.25	\$87.59	\$82.72	\$81.12	\$90.23	\$86.95	\$86.47
7/6/2016	\$22.15	\$86.78	\$81.81	\$81.38	\$89.62	\$97.28	\$87.72	\$82.85	\$81.16	\$90.31	\$86.92	\$86.54
7/7/2016	\$22.21	\$86.90	\$81.89	\$81.46	\$89.70	\$97.33	\$87.85	\$82.96	\$81.23	\$90.45	\$86.92	\$86.63
7/8/2016	\$22.26	\$87.06	\$82.02	\$81.58	\$89.82	\$97.42	\$88.03	\$83.11	\$81.34	\$90.63	\$87.09	\$86.80
7/11/2016	\$22.29	\$87.23	\$82.19	\$81.72	\$89.99	\$97.50	\$88.21	\$83.32	\$81.50	\$90.86	\$87.30	\$87.06
7/12/2016	\$22.33	\$87.40	\$82.34	\$81.85	\$90.18	\$97.59	\$88.37	\$83.53	\$81.64	\$91.10	\$87.53	\$87.29
7/13/2016	\$22.30	\$87.50	\$82.41	\$81.90	\$90.28	\$97.61	\$88.49	\$83.69	\$81.69	\$91.30	\$87.68	\$87.43
7/14/2016	\$22.33	\$87.60	\$82.48	\$81.97	\$90.39	\$97.63	\$88.60	\$83.81	\$81.75	\$91.30	\$87.80	\$87.55
7/15/2016	\$22.35	\$87.69	\$82.53	\$82.01	\$90.47	\$97.63	\$88.67	\$83.88	\$81.77	\$91.39	\$87.88	\$87.63
7/18/2016	\$22.39	\$87.76	\$82.56	\$82.03	\$90.53	\$97.63	\$88.74	\$83.93	\$81.80	\$91.46	\$87.93	\$87.63
7/19/2016	\$22.42	\$87.81	\$82.57	\$82.07	\$90.58	\$97.63	\$88.79	\$83.93	\$81.80	\$91.53	\$87.93	\$87.70
7/20/2016	\$22.49	\$87.86	\$82.61	\$82.11	\$90.64	\$97.65	\$88.86	\$84.00	\$81.86	\$91.61	\$87.93	\$87.78
7/21/2016	\$22.56	\$87.92	\$82.67	\$82.15	\$90.67	\$97.67	\$88.93	\$84.06	\$81.92	\$91.69	\$87.93	\$87.88
7/22/2016	\$22.56	\$87.96	\$82.72	\$82.18	\$90.72	\$97.68	\$88.97	\$84.06	\$81.92	\$91.76	\$87.93	\$87.98
7/25/2016	\$22.57	\$87.99	\$82.74	\$82.20	\$90.76	\$97.67	\$89.01	\$84.13	\$81.92	\$91.76	\$87.98	\$88.06
7/26/2016	\$22.59	\$88.00	\$82.74	\$82.20	\$90.79	\$97.67	\$89.04	\$84.13	\$81.91	\$91.79	\$87.98	\$88.06
7/27/2016	\$22.61	\$88.03	\$82.75	\$82.22	\$90.81	\$97.69	\$89.07	\$84.17	\$81.92	\$91.84	\$88.02	\$88.13

Date	Common Stock	AAA Note	AAB Note	AAC Note	EAA Note	EAC Note	KAA Note	KAD Note	KAE Note	XAM Note	XAQ Note	XAS Note
7/28/2016	\$22.62	\$88.06	\$82.77	\$82.26	\$90.86	\$97.70	\$89.10	\$84.20	\$81.94	\$91.88	\$88.06	\$88.20
7/29/2016	\$22.62	\$88.10	\$82.79	\$82.28	\$90.92	\$97.71	\$89.13	\$84.26	\$81.96	\$91.95	\$88.06	\$88.20
8/1/2016	\$22.57	\$88.12	\$82.80	\$82.29	\$90.96	\$97.72	\$89.17	\$84.26	\$81.95	\$91.95	\$88.12	\$88.28
8/2/2016	\$22.54	\$88.14	\$82.78	\$82.28	\$90.96	\$97.73	\$89.18	\$84.26	\$81.94	\$91.97	\$88.14	\$88.29
8/3/2016	\$22.53	\$88.15	\$82.78	\$82.27	\$90.93	\$97.74	\$89.17	\$84.26	\$81.93	\$91.99	\$88.18	\$88.29
8/4/2016	\$22.53	\$88.15	\$82.77	\$82.27	\$90.93	\$97.75	\$89.18	\$84.26	\$81.93	\$92.01	\$88.21	\$88.29
8/5/2016	\$22.51	\$88.15	\$82.77	\$82.26	\$90.92	\$97.77	\$89.18	\$84.26	\$81.93	\$92.01	\$88.21	\$88.30
8/8/2016	\$22.51	\$88.14	\$82.77	\$82.26	\$90.91	\$97.78	\$89.20	\$84.27	\$81.93	\$92.02	\$88.21	\$88.31
8/9/2016	\$22.64	\$88.25	\$82.87	\$82.37	\$91.01	\$97.84	\$89.29	\$84.41	\$82.05	\$92.14	\$88.37	\$88.46
8/10/2016	\$22.74	\$88.37	\$82.99	\$82.49	\$91.14	\$97.91	\$89.41	\$84.56	\$82.19	\$92.26	\$88.55	\$88.62
8/11/2016	\$22.78	\$88.45	\$83.09	\$82.56	\$91.24	\$97.96	\$89.48	\$84.66	\$82.26	\$92.33	\$88.68	\$88.75
8/12/2016	\$22.82	\$88.52	\$83.16	\$82.63	\$91.33	\$98.00	\$89.48	\$84.75	\$82.26	\$92.40	\$88.68	\$88.85
8/15/2016	\$22.90	\$88.60	\$83.24	\$82.71	\$91.42	\$98.03	\$89.57	\$84.83	\$82.35	\$92.48	\$88.78	\$88.96
8/16/2016	\$22.97	\$88.67	\$83.32	\$82.79	\$91.50	\$98.06	\$89.65	\$84.83	\$82.35	\$92.55	\$88.91	\$89.07
8/17/2016	\$23.11	\$88.76	\$83.41	\$82.88	\$91.62	\$98.10	\$89.76	\$84.96	\$82.47	\$92.64	\$89.06	\$89.22
8/18/2016	\$23.23	\$88.83	\$83.49	\$82.97	\$91.73	\$98.13	\$89.84	\$85.08	\$82.56	\$92.75	\$89.19	\$89.35
8/19/2016	\$23.33	\$88.90	\$83.56	\$83.06	\$91.83	\$98.16	\$89.84	\$85.19	\$82.56	\$92.84	\$89.19	\$89.46
8/22/2016	\$23.48	\$88.98	\$83.64	\$83.15	\$91.95	\$98.20	\$89.94	\$85.30	\$82.67	\$92.84	\$89.32	\$89.46
8/23/2016	\$23.62	\$89.06	\$83.73	\$83.24	\$92.06	\$98.25	\$89.94	\$85.43	\$82.77	\$92.94	\$89.49	\$89.59
8/24/2016	\$23.74	\$89.15	\$83.82	\$83.34	\$92.18	\$98.31	\$90.04	\$85.54	\$82.88	\$93.05	\$89.49	\$89.73
8/25/2016	\$23.87	\$89.24	\$83.91	\$83.42	\$92.29	\$98.35	\$90.13	\$85.66	\$82.97	\$93.16	\$89.63	\$89.73
8/26/2016	\$23.99	\$89.33	\$83.98	\$83.50	\$92.29	\$98.35	\$90.22	\$85.77	\$82.97	\$93.16	\$89.63	\$89.73
8/29/2016	\$24.10	\$89.41	\$84.06	\$83.50	\$92.29	\$98.40	\$90.22	\$85.77	\$82.97	\$93.27	\$89.79	\$89.73
8/30/2016	\$24.20	\$89.50	\$84.13	\$83.59	\$92.40	\$98.44	\$90.27	\$85.88	\$82.97	\$93.27	\$89.93	\$89.85
8/31/2016	\$24.28	\$89.58	\$84.20	\$83.66	\$92.51	\$98.48	\$90.36	\$85.97	\$83.07	\$93.27	\$90.07	\$89.85
9/1/2016	\$24.36	\$89.66	\$84.26	\$83.72	\$92.61	\$98.51	\$90.36	\$85.97	\$83.15	\$93.37	\$90.07	\$89.85
9/2/2016	\$24.43	\$89.74	\$84.32	\$83.72	\$92.70	\$98.55	\$90.45	\$85.97	\$83.15	\$93.37	\$90.19	\$89.85

**DO I NEED TO CONTACT LEAD COUNSEL IN ORDER TO
PARTICIPATE IN DISTRIBUTION OF THE SETTLEMENT FUND?**

No. If you have received this Notice and timely submit your Proof of Claim and Release to the designated address, you need not contact Lead Counsel. If your address changes, please contact the Claims Administrator at:

Valeant Securities Settlement
c/o Gilardi & Co. LLC
P.O. Box 43337
Providence, RI 02940-3337
Telephone: 1-866-524-0721
www.ValeantSecuritiesSettlement.com

**THERE WILL BE NO PAYMENTS IF THE STIPULATION IS
TERMINATED**

The Stipulation may be terminated under several circumstances outlined in it. If the Stipulation is terminated, the Litigation will proceed as if the Stipulation had not been entered into.

WHAT ARE THE REASONS FOR SETTLEMENT?

The Settlement was reached after contested motion practice directed to the sufficiency of Lead Plaintiff's claims. The parties also completed certain document discovery. Nevertheless, the Court has not reached any final decisions in connection with Lead Plaintiff's claims against Defendants. Instead, Lead Plaintiff and Defendants, along with the Former Defendants, have agreed to this Settlement, which was reached with the substantial assistance of a highly respected mediator. In reaching the Settlement, the parties have avoided the cost, delay and uncertainty of further litigation.

As in any litigation, Lead Plaintiff and the Class would face an uncertain outcome if they did not agree to the Settlement. If Lead Plaintiff succeeded at trial, Defendants would likely file appeals that would postpone final resolution of the case. Continuation of the Litigation against Defendants could result in a judgment greater than this Settlement. Conversely, continuing the case could result in no recovery at all or a recovery that is less than the amount of the Settlement.

Lead Plaintiff and Lead Counsel believe that this Settlement is fair and reasonable to the Members of the Class. They have reached this conclusion for several reasons. Specifically, if the Settlement is approved, the Class will receive a certain and immediate monetary recovery. Additionally, Lead Counsel believes that the significant and immediate benefits of the Settlement, when weighed against the significant risk, delay and uncertainty of continued litigation, are a very favorable result for the Class.

Defendants and Former Defendants are entering into this Settlement because it would be beneficial to avoid the burden, inconvenience, and expense associated with continuing the Litigation, and the uncertainty and risks inherent in any litigation. Defendants and Former Defendants have determined that it is desirable and beneficial to them that the Litigation be settled in the manner and upon the terms and conditions set forth in the Stipulation.

WHO REPRESENTS THE CLASS?

The following attorneys are counsel for the Class:

Theodore J. Pintar
ROBBINS GELLER RUDMAN & DOWD LLP
655 West Broadway, Suite 1900
San Diego, CA 92101
Telephone: 800/449-4900

If you have any questions about the Litigation, or the Settlement, you are entitled to consult with Lead Counsel by contacting counsel at the phone number listed above.

You may obtain a copy of the Stipulation by contacting the Claims Administrator at:

Valeant Securities Settlement
c/o Gilardi & Co. LLC
P.O. Box 43337
Providence, RI 02940-3337
Telephone: 1-866-824-0721
www.ValeantSecuritiesSettlement.com

HOW WILL THE LEAD PLAINTIFF'S LAWYERS BE PAID?

Lead Counsel will file a motion for an award of attorneys' fees and expenses that will be considered at the Final Approval Hearing. Lead Counsel will apply for an attorneys' fee award for Plaintiffs' Counsel in the amount of up to thirteen percent of the Settlement Amount, plus payment of Plaintiffs' Counsel's charges and expenses incurred in connection with this Litigation in an amount not to exceed \$3 million, including any award(s) to Plaintiffs of no more than \$175,000 in the aggregate pursuant to 15 U.S.C. §78u-4(a)(4) in connection with their representation of the Class. Such sums as may be approved by the Court will be paid from the Settlement Fund. Class Members are not personally liable for any such fees or expenses.

The attorneys' fees and charges and expenses requested will be the only payment to Plaintiffs' Counsel for their efforts in achieving this outstanding Settlement and for their risk in undertaking this representation on a wholly contingent basis. The fees requested will compensate Plaintiffs' Counsel for their work in achieving the Settlement. The Court will decide what constitutes a reasonable fee award and may award less than the amount requested by Lead Counsel.

HOW DO I EXCLUDE MYSELF FROM THE SETTLEMENT?

You may request to be excluded from the Class. To do so, you must mail a written request stating that you wish to be excluded from the Class to:

Valeant Securities Settlement
Claims Administrator
c/o Gilardi & Co. LLC
EXCLUSIONS
3301 Kerner Blvd.
San Rafael, CA 94901

The request for exclusion must state: (1) your name, address, and telephone number; (2) all purchases, acquisitions and sales of Valeant Securities made from January 4, 2013 through March 15, 2016, inclusive, including the dates and prices of each purchase, acquisition or sale, and the amount of Valeant Securities purchased, otherwise acquired or sold; and (3) that you wish to be excluded from the Class. ***YOUR EXCLUSION REQUEST MUST BE POSTMARKED ON OR BEFORE _____, 2020.*** If you submit a valid and timely request for exclusion, you shall have no rights under the Settlement, shall not share in the distribution of the Net Settlement Fund, and shall not be bound by the Stipulation or the Judgment.

If you exclude yourself from the Class, you should understand that Defendants and Former Defendants and the other Released Persons will have the right to assert any and all defenses they may have to any claims that you may seek to assert, including, without limitation, the defense that any such claims are untimely under the applicable statutes of limitations or statutes of repose.

Excluding yourself from the Class is the only option that allows you to be part of any other current or future lawsuit against Defendants and Former Defendants or any of the other Released Persons concerning the Released Claims. Please note, however, that if you decide to exclude yourself from the Class, you may be time-barred from asserting the claims covered by the Litigation by applicable statutes of limitations or statutes of repose.

**CAN I OBJECT TO THE SETTLEMENT, THE REQUESTED
ATTORNEYS' FEES, THE REQUESTED PAYMENT OF EXPENSES
AND/OR THE PLAN OF ALLOCATION?**

Yes. If you are a Class Member and do not exclude yourself from the Class, you may object to the terms of the Settlement. Whether or not you object to the terms of the Settlement, you may also object to the requested attorneys' fees, charges and expenses, Plaintiffs' request for awards for representing the Class and/or the Plan of Allocation. In order for any objection to be considered, you must file a written statement, accompanied by proof of Class membership, with the Court and send a copy to Lead Counsel and Valeant's Counsel, at the addresses listed below **by _____, 2020**. The objection must state whether it applies only to the objector, to a specific subset of the Class, or to the entire Class. The objection must also state with specificity the grounds for the objection. The Court's address is Clarkson S. Fisher Building & U.S. Courthouse, 402 East State Street, Trenton, New Jersey 08608; Lead Counsel's address is Robbins Geller Rudman & Dowd LLP, 655 West Broadway, Suite 1900, San Diego, CA 92101, c/o Theodore J. Pinar; Valeant's Counsel's address is Simpson Thacher & Bartlett LLP, 425 Lexington Avenue, New York, NY 10017, c/o Craig S. Waldman. Attendance at the Final Approval Hearing is not necessary; however, persons wishing to be heard orally at the Final Approval Hearing are required to indicate in their written objection their intention to appear at the hearing and identify any witnesses they may call to testify and exhibits, if any, they intend to introduce into evidence.

WHAT ARE MY RIGHTS AND OBLIGATIONS UNDER THE SETTLEMENT?

If you are a Class Member and you do not exclude yourself from the Class, you may receive the benefit of, and you will be bound by, the terms of the Settlement described in this Notice, upon approval by the Court.

HOW CAN I GET A PAYMENT?

In order to qualify for a payment, you must timely complete and return the Proof of Claim and Release that accompanies this Notice. A Proof of Claim and Release is enclosed with this Notice and also may be downloaded at www.ValeantSecuritiesSettlement.com. Read the instructions carefully; fill out the Proof of Claim and Release; sign it; and mail or submit it online so that it is **postmarked (if mailed) or received (if submitted online) no later than _____, 2020**. The Proof of Claim and Release may be submitted online at www.ValeantSecuritiesSettlement.com. If you do not submit a timely Proof of Claim and Release with all of the required information, you will not receive a payment from the Settlement Fund; however, unless you expressly exclude yourself from the Class as described above, you will still be bound in all other respects by the Settlement, the Judgment, and the release contained in them.

WHAT CLAIMS WILL BE RELEASED BY THE SETTLEMENT?

If the Settlement is approved by the Court, the Court will enter a Judgment. If the Judgment becomes final pursuant to the terms of the Stipulation, all Class Members shall be deemed to have, and by operation of the Final Judgment shall have, fully, finally, and forever released, relinquished, and discharged any and all of the Released Persons from all Released Claims.

- “Released Claims” means any and all rights, liabilities, suits, debts, obligations, demands, damages, losses, judgment matters, issues, claims (including Unknown Claims), and causes of action of every nature and description whatsoever, in law, equity, or otherwise, whether accrued or unaccrued, fixed or contingent, liquidated or unliquidated, whether arising under federal, state, local, statutory, common law, foreign law, or any other law, rule, or regulation, and whether class and/or individual in nature, concerning, based on, arising out of, or in connection with both: (i) the purchase or other acquisition of Valeant Securities by Lead Plaintiff or any other Class Member between January 4, 2013 and March 15, 2016, inclusive; and (ii) the allegations, transactions, acts,

facts, matters, occurrences, disclosures, statements, filings, representations, omissions, or events that were or could have been alleged or asserted in the Litigation. Released Claims do not include claims to enforce the Settlement, shareholder derivative claims on behalf of Valeant, governmental agency actions against the Released Persons, claims asserted in the RICO Class Action, the Canadian Actions, or the claims that are or could be asserted in this Litigation against PwC.

- “Related Parties” means each Defendant and Former Defendants’ respective present and former parents, subsidiaries, divisions, controlling persons, associates, entities and affiliates and each and all of their respective present and former employees, members, partners, principals, officers, directors, controlling shareholders, agents, attorneys, advisors (including financial or investment advisors), consultants, underwriters, investment bankers, commercial bankers, general or limited partners or partnerships, limited liability companies, members, joint ventures and insurers and reinsurers of each of them; as well as the predecessors, successors, estates, immediate family members, spouses, heirs, executors, trusts, trustees, administrators, agents, legal or personal representatives, assigns, and assignees of each of them, in their capacity as such. Related Parties does not include PwC.
- “Released Persons” means each and all of the Defendants, Former Defendants and their Related Parties. Released Persons does not include PwC.
- “Unknown Claims” means: (a) any and all Released Claims which the Releasing Plaintiff Parties do not know or suspect to exist in his, her, or its favor at the time of the release of the Released Persons, which, if known by him, her, or it, might have affected his, her, or its settlement with and release of the Released Persons, or might have affected his, her, or its decision(s) with respect to the Settlement, including, but not limited to, whether or not to object to this Settlement or seek exclusion from the Class; and (b) any and all Released Defendants’ Claims that the Released Persons do not know or suspect to exist in his, her, or its favor at the time of the release of the Plaintiffs, the Class and Plaintiffs’ Counsel, which, if known by him, her, or it, might have affected his, her, or its settlement and release of Plaintiffs, the Class and Plaintiffs’ Counsel. With respect to (a) any and all Released Claims against the Released Persons, and (b) any and all Released Defendants’ Claims

against Plaintiffs, the Class and Plaintiffs' Counsel, the Settling Parties stipulate and agree that, upon the Effective Date, the Settling Parties shall expressly waive and each Releasing Plaintiff Party and Released Person shall be deemed to have, and by operation of the Judgment shall have expressly waived, the provisions, rights, and benefits of California Civil Code §1542, which provides:

A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.

The Settling Parties shall expressly waive and each Releasing Plaintiff Party and Released Person shall be deemed to have, and by operation of the Judgment shall have, expressly waived any and all provisions, rights, and benefits conferred by any law of any state or territory of the United States, or principle of common law, which is similar, comparable, or equivalent to California Civil Code §1542. The Releasing Plaintiff Parties and Released Persons acknowledge that they may hereafter discover facts in addition to or different from those which he, she, it or their counsel now knows or believes to be true with respect to the subject matter of the Released Claims or Released Defendants' Claims, but: (a) the Releasing Plaintiff Parties shall expressly fully, finally, and forever waive, compromise, settle, discharge, extinguish, and release, and each Releasing Plaintiff Party shall be deemed to have waived, compromised, settled, discharged, extinguished, and released, and upon the Effective Date, and by operation of the Judgment shall have waived, compromised, settled, discharged, extinguished, and released, fully, finally, and forever, any and all Released Claims against the Released Persons, known or unknown, suspected or unsuspected, contingent or non-contingent, whether or not concealed or hidden, which now exist, or heretofore have existed, upon any theory of law or equity now existing or coming into existence in the future, including, but not limited to, conduct which is negligent, intentional, with or without malice, or a breach of any duty, law or rule, without regard to the subsequent discovery or existence of such different or additional facts, legal theories, or authorities; and (b) the Released Persons shall expressly fully, finally, and forever waive, compromise, settle, discharge, extinguish, and

release, and upon the Effective Date, and by operation of the Judgment shall have waived, compromised, settled, discharged, extinguished, and released, fully, finally, and forever, any and all Released Defendants' Claims against the Plaintiffs, the Class and Plaintiffs' Counsel, known or unknown, suspected or unsuspected, contingent or non-contingent, whether or not concealed or hidden, which now exist, or heretofore have existed, upon any theory of law or equity now existing or coming into existence in the future, including, but not limited to, conduct which is negligent, intentional, with or without malice, or a breach of any duty, law or rule, without regard to the subsequent discovery or existence of such different or additional facts, legal theories, or authorities. This paragraph does not affect any claims for contractual or other indemnification rights between or among the Defendants and Former Defendants. The Settling Parties acknowledge, and the Releasing Plaintiff Parties and Released Persons shall be deemed by operation of the Judgment to have acknowledged, that the foregoing waiver was separately bargained for and is an essential element of the Settlement of which this release is a part.

THE FINAL APPROVAL HEARING

The Court will hold a Final Approval Hearing on _____, 2020, at _____ .m., before the Honorable Michael A. Shipp at the United States District Court for the District of New Jersey, Clarkson S. Fisher Building & U.S. Courthouse, 402 East State Street, Trenton, New Jersey 08608, for the purpose of determining whether: (1) the Settlement as set forth in the Stipulation for \$1,210,000,000.00 in cash should be approved by the Court as fair, reasonable and adequate; (2) the Class should be finally certified pursuant to Rules 23(a) and (b)(3) of the Federal Rules of Civil Procedure for purposes of settlement only; (3) Judgment as provided under the Stipulation should be entered; (4) to award Lead Counsel attorneys' fees and expenses out of the Settlement Fund and, if so, in what amount; (5) to award Plaintiffs an amount pursuant to 15 U.S.C. §78u-4(a)(4) in connection with their representation of the Class out of the Settlement Fund and, if so, in what amount; and (6) the Plan of Allocation should be approved by the Court. The Court may adjourn or continue the Final Approval Hearing without further notice to Members of the Class.

Any Class Member may appear at the Final Approval Hearing and be heard on any of the foregoing matters; provided, however, that no such person shall be heard unless his, her, or its objection is made in writing and is filed, together with proof of membership in the Class and with copies of all other papers and briefs to be submitted

by him, her, or it to the Court at the Final Approval Hearing, with the Court no later than _____, 2020, and showing proof of service on the following counsel:

Theodore J. Pintar
ROBBINS GELLER RUDMAN
& DOWD LLP
655 West Broadway, Suite 1900
San Diego, CA 92101

Craig S. Waldman
SIMPSON THACHER &
BARTLETT LLP
425 Lexington Avenue
New York, NY 10017

Attorneys for Lead Plaintiff

Attorneys for Valeant

Unless otherwise directed by the Court, any Class Member who does not make his, her or its objection in the manner provided shall be deemed to have waived all objections to this Settlement and shall be foreclosed from raising (in this or any other proceeding or on any appeal) any objection and any untimely objection shall be barred.

If you hire an attorney (at your own expense) to represent you for purposes of objecting, your attorney must serve a notice of appearance on counsel listed above and file it with the Court (at the address set out above) by no later than _____, 2020.

INJUNCTION

The Court has issued an order enjoining all Class Members from instituting, commencing, maintaining or prosecuting any action in any court or tribunal that asserts Released Claims against any Released Persons, pending final determination by the Court of whether the Settlement should be approved.

HOW DO I OBTAIN ADDITIONAL INFORMATION?

This Notice contains only a summary of the terms of the proposed Settlement. The records in this Litigation may be examined and copied at any time during regular office hours, and subject to customary copying fees, at the Clerk of the United States District Court for the District of New Jersey. For a fee, all papers filed in this Litigation are available at www.pacer.gov. In addition, all of the Settlement documents, including the Stipulation, this Notice, the Proof of Claim and Release and proposed Judgment may be obtained by contacting the Claims Administrator at:

Valeant Securities Settlement
c/o Gilardi & Co. LLC
P.O. Box 43337
Providence, RI 02940-3337
Email: info@ValeantSecuritiesSettlement.com
Telephone: 1-866-524-0721
www.ValeantSecuritiesSettlement.com

In addition, you may contact Rick Nelson, Shareholder Relations, Robbins Geller Rudman & Dowd LLP, 655 West Broadway, Suite 1900, San Diego, CA 92101, 1(800)449-4900, if you have any questions about the Litigation or the Settlement.

**DO NOT WRITE TO OR TELEPHONE THE COURT FOR
INFORMATION**

SPECIAL NOTICE TO BANKS, BROKERS, AND OTHER NOMINEES

If you hold any Valeant Securities purchased or acquired during the Class Period, as a nominee for a beneficial owner, then, within fourteen (14) calendar days after you receive this Notice, you must either: (1) send a copy of this Notice by First-Class Mail to all such Persons; or (2) provide a list of the names and addresses of such Persons to the Claims Administrator:

Valeant Securities Litigation
c/o Gilardi & Co. LLC
P.O. Box 43337
Providence, RI 02940-3337
E-mail: info@ValeantSecuritiesSettlement.com
Telephone: 1-866-524-0721
www.ValeantSecuritiesSettlement.com

If you choose to mail the Notice and Proof of Claim and Release yourself, you may obtain from the Claims Administrator (without cost to you) as many additional copies of these documents as you will need to complete the mailing.

Regardless of whether you choose to complete the mailing yourself or elect to have the mailing performed for you, you may obtain reimbursement for or advancement of reasonable administrative costs actually incurred or expected to be incurred in connection with forwarding the Notice and which would not have been

incurred but for the obligation to forward the Notice, upon submission of appropriate documentation to the Claims Administrator.

DATED:

BY ORDER OF THE
UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY

EXHIBIT A-2

SEEGER WEISS LLP
CHRISTOPHER A. SEEGER
DAVID R. BUCHANAN
55 Challenger Road, 6th Floor
Ridgefield Park, NJ 07660
Telephone: 212/584-0700
212/584-0799 (fax)

Local Counsel

ROBBINS GELLER RUDMAN
& DOWD LLP
JAMES E. BARZ
FRANK A. RICHTER
200 South Wacker Drive, 31st Floor
Chicago, IL 60606
Telephone: 312/674-4674
312/674-4676 (fax)

Lead Counsel for Plaintiffs

UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY

In re VALEANT)	Master No. 3:15-cv-07658-MAS-LHG
PHARMACEUTICALS)	
INTERNATIONAL, INC.)	<u>CLASS ACTION</u>
SECURITIES LITIGATION)	
_____)	Judge Michael A. Shipp
This Document Relates To:)	Magistrate Judge Lois H. Goodman
)	Special Master Hon. Dennis M. Cavanaugh,
)	U.S.D.J. (Ret.)
Case No. 3:15-cv-07658-MAS-LHG.)	
_____)	PROOF OF CLAIM AND RELEASE

EXHIBIT A-2

I. GENERAL INSTRUCTIONS

1. To recover as a member of the Class based on your claims in the action entitled *In re Valeant Pharmaceuticals International, Inc. Securities Litigation*, No. 3:15-cv-07658-MAS-LHG (the “Litigation”), you must complete and, on page 20 hereof, sign this Proof of Claim and Release. If you fail to submit a properly addressed (as set forth in paragraph 3 below) Proof of Claim and Release form, postmarked or received by the date shown below, your claim may be rejected and you may be precluded from any recovery from the Net Settlement Fund created in connection with the proposed settlement of the Litigation (the “Settlement”).¹

2. Submission of this Proof of Claim and Release form, however, does not assure that you will share in the proceeds of the Settlement.

3. YOU MUST MAIL OR SUBMIT ONLINE YOUR COMPLETED AND SIGNED PROOF OF CLAIM AND RELEASE FORM, ACCOMPANIED BY COPIES OF THE DOCUMENTS REQUESTED HEREIN, NO LATER THAN _____, 2020, TO THE COURT-APPOINTED CLAIMS ADMINISTRATOR IN THIS CASE, AT THE FOLLOWING ADDRESS:

Valeant Securities Settlement
Claims Administrator
c/o Gilardi & Co. LLC
P.O. Box _____
Providence, RI 02940-_____
Online Submissions: www.ValeantSecuritiesSettlement.com

¹ This Proof of Claim and Release incorporates by reference the definitions in the Stipulation of Settlement (“Stipulation”), which can be obtained at www.ValeantSecuritiesSettlement.com.

If you are NOT a member of the Class (as defined in the Notice of Pendency and Proposed Settlement of Class Action (the “Notice”)), DO NOT submit a Proof of Claim and Release form.

4. If you are a member of the Class and you did not timely request exclusion from the Class, you will be bound by the terms of any judgment entered in the Litigation, including the releases provided therein, WHETHER OR NOT YOU SUBMIT A PROOF OF CLAIM AND RELEASE FORM.

II. CLAIMANT IDENTIFICATION

You are a member of the Class if you purchased or otherwise acquired Valeant Pharmaceuticals International, Inc. (“Valeant” n/k/a Bausch Health Companies Inc.) common stock, stock options or debt securities between January 4, 2013 and March 15, 2016, inclusive (“Valeant Securities”²). Excluded from the Class are Defendants and Former Defendants, present and former executive officers of Defendants and Former Defendants, and members of their immediate families, present and former directors of Defendants and Former Defendants, and members of their immediate families, any

² “Valeant Securities” means Valeant equity securities as defined in 15 U.S.C. §78c(11) and 17 C.F.R. §240.3a11-1, and Valeant debt securities, including Valeant common stock; options on Valeant common stock, defined to be the purchase or acquisition of call options and the sale of put options; and the following Valeant senior notes: (1) 5.375% senior notes due 2020; (2) 5.875% senior notes due 2023; (3) 6.125% senior notes due 2025; (4) 5.5% senior notes due 2023; (5) 5.625% senior notes due 2021; (6) 6.75% senior notes due 2018; (7) 7.5% senior notes due 2021; (8) 6.375% senior notes due 2020; (9) 7.25% senior notes due 2022; (10) 6.75% senior notes due 2021; or (11) 7.0% senior notes due 2020. Valeant Securities does not include securities at issue in the Canadian Actions.

entity in which a Defendant or current or former director of a Defendant has control and/or a majority ownership interest, and the legal representatives, heirs, successors or assigns of any such excluded party. For the avoidance of doubt, this exclusion does not extend to: (1) any investment company or pooled investment fund in which a Defendant or Former Defendant may have a direct or indirect interest, or as to which its affiliates may act as an advisor, but of which a Defendant or Former Defendant or its respective affiliates is not a majority owner or does not hold a majority beneficial interest; or (2) any employee benefit plan as to which a Defendant or Former Defendant or its affiliates acts as an investment advisor or otherwise may be a fiduciary; provided, however, that membership in the Class by such investment company, pooled investment fund or employee benefit plan is limited to transactions in Valeant Securities made on behalf of, or for the benefit of, persons other than persons that are excluded from the Class by definition. In other words, Defendants and Former Defendants cannot make a claim on their own behalf for their ownership share in any of the above entities. The Class also excludes: (1) any person or entity which during the Class Period purchased or otherwise acquired Valeant Securities and has been promised or received a payment from or on behalf of the Valeant Defendants related to or arising from litigation related to its Class Period transactions in Valeant Securities other than a payment of attorneys fees or costs to counsel for such person or entity; (2) any Class Member on Exhibit A to the Final Judgment that validly and

timely requested exclusion in accordance with the requirements set by the Court in the Notice of Pendency and Proposed Settlement of Class Action; and (3) anyone on Exhibit B to the Final Judgment who has filed an individual action and not dismissed their claim and sought to be included in the Class.

Use Part I of this form entitled “Claimant Identification” to identify each purchaser or acquirer of record (“nominee”), if different from the beneficial purchaser or acquirer of the securities which form the basis of this claim. **THIS CLAIM MUST BE FILED BY THE ACTUAL BENEFICIAL PURCHASER(S) OR ACQUIRER(S) OR THE LEGAL REPRESENTATIVE OF SUCH PURCHASER(S) OR ACQUIRER(S) OF THE VALEANT SECURITIES UPON WHICH THIS CLAIM IS BASED.**

All joint purchasers or acquirers must sign this claim. Executors, administrators, guardians, conservators and trustees must complete and sign this claim on behalf of persons represented by them and their authority must accompany this claim and their titles or capacities must be stated. The Social Security (or taxpayer identification) number and telephone number of the beneficial owner may be used in verifying the claim. Failure to provide the foregoing information could delay verification of your claim or result in rejection of the claim.

If you are acting in a representative capacity on behalf of a Class Member (for example, as an executor, administrator, trustee, or other representative), you must submit evidence of your current authority to act on behalf of that Class Member. Such

evidence would include, for example, letters testamentary, letters of administration, or a copy of the trust documents.

NOTICE REGARDING ELECTRONIC FILES: Certain claimants with large numbers of transactions may request to, or may be requested to, submit information regarding their transactions in electronic files. All claimants **MUST** submit a manually signed paper Proof of Claim and Release form listing all their transactions whether or not they also submit electronic copies. If you wish to file your claim electronically, you must contact the Claims Administrator at edata@gilardi.com to obtain the required file layout. No electronic files will be considered to have been properly submitted unless the Claims Administrator issues to the claimant a written acknowledgement of receipt and acceptance of electronically submitted data.

III. CLAIM FORM

Use Part II of this form entitled “Schedule of Transactions in Valeant Common Stock,” Part III of this form entitled “Schedule of Transactions in Valeant Debt Securities” and Part IV of this form entitled “Schedule of Transactions in Valeant Stock Options” to supply all required details of your transaction(s) in Valeant Securities. If you need more space or additional schedules, attach separate sheets giving all of the required information in substantially the same form. Sign and print or type your name on each additional sheet.

On the schedules, provide all of the requested information with respect to *all* of your purchases and acquisitions and *all* of your sales of Valeant common stock, debt securities and stock options on Valeant common stock between January 4, 2013 and September 2, 2016, inclusive, whether such transactions resulted in a profit or a loss. You must also provide all of the requested information with respect to *all* of the Valeant common stock and debt securities you held at the close of trading on January 3, 2013, March 15, 2016, and September 2, 2016. Failure to report all such transactions may result in the rejection of your claim.

If your claim includes transactions in Valeant debt securities, you must include the 3-letter type of the Valeant Note which you purchased in the space provided in the column labeled “Valeant Note Identifier.” This three letter code is included in the CUSIP for each note; for example, CUSIP 91831AAA is referred to as the Valeant AAA Note. As stated in the Plan of Allocation, the Valeant debt securities are as follows, with the correct 3-letter identifier from the CUSIP listed in parentheses for each: Valeant AAA Notes (AAA); Valeant AAB Notes (AAB); Valeant AAC Notes (AAC); Valeant EAA Notes (EAA); Valeant EAC Notes (EAC); Valeant KAA Notes (KAA); Valeant KAD Notes (KAD); Valeant KAE Notes (KAE); Valeant XAM Notes (XAM); Valeant XAQ Notes (XAQ); and Valeant XAS Notes (XAS).

List these transactions separately and in chronological order, by trade date, beginning with the earliest. You must accurately provide the month, day and year of each transaction you list.

For short-sale transactions, the date of covering a “short sale” is deemed to be the date of purchase of Valeant common stock, and the date of a “short sale” is deemed to be the date of sale of Valeant common stock.

For each transaction, you must provide, together with this claim form, copies of stockbroker confirmation slips, stockbroker statements, or other documents adequately evidencing your transactions in Valeant Securities. If any such documents are not in your possession, please obtain a copy or equivalent documents from your broker because these documents are necessary to prove and process your claim. Failure to provide this documentation could delay verification of your claim or result in rejection of your claim.

UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY

In re Valeant Pharmaceuticals International, Inc. Securities Litigation

No. 3:15-cv-07658-MAS-LHG

PROOF OF CLAIM AND RELEASE

Must Be Postmarked (if mailed) or Received (if submitted online)
No Later Than:

_____, 2020

Please Type or Print

**REMEMBER TO ATTACH COPIES OF BROKER CONFIRMATIONS
OR OTHER DOCUMENTATION OF YOUR TRANSACTIONS IN VALEANT
SECURITIES. FAILURE TO PROVIDE THIS DOCUMENTATION COULD
DELAY VERIFICATION OF YOUR CLAIM OR RESULT IN REJECTION
OF YOUR CLAIM.**

If you require additional space, attach extra schedules in the same format as above. Sign and print your name on each additional page.

YOU MUST READ AND SIGN THE RELEASE ON PAGE 20. FAILURE TO SIGN THE RELEASE MAY RESULT IN A DELAY IN PROCESSING OR THE REJECTION OF YOUR CLAIM.

PART III: SCHEDULE OF TRANSACTIONS IN VALEANT DEBT SECURITIES

A. Holdings as of January 3, 2013 of Valeant Debt Securities.

Note Identifier	Number of Units Held

B. Purchases or Acquisitions of Valeant Debt Securities between January 4, 2013 and September 2, 2016, inclusive:

Trade Date Month Day Year	Note Identifier	Number of Units Purchased or Acquired	Total Purchase or Acquisition Price

C. Sales of Valeant Debt Securities between January 4, 2013 and September 2, 2016, inclusive:

Trade Date Month Day Year	Note Identifier	Number of Units Sold	Total Sales Price

C. Face value of Valeant Debt Securities held at the close of trading on March 15, 2016: _____

D. Face value of Valeant Debt Securities held at the close of trading on September 2, 2016: _____

If you require additional space, attach extra schedules in the same format as above. Sign and print your name on each additional page.

YOU MUST READ AND SIGN THE RELEASE ON PAGE 20. FAILURE TO SIGN THE RELEASE MAY RESULT IN A DELAY IN PROCESSING OR THE REJECTION OF YOUR CLAIM.

IV. SUBMISSION TO JURISDICTION OF COURT AND ACKNOWLEDGMENTS

I (We) submit this Proof of Claim and Release under the terms of the Stipulation described in the Notice. I (We) also submit to the jurisdiction of the United States District Court for the District of New Jersey with respect to my (our) claim as a Class Member and for purposes of enforcing the releases set forth herein. I (We) further acknowledge that I am (we are) bound by and subject to the terms of the Stipulation and any judgment that may be entered in the Litigation, including the releases and the covenants set forth herein. I (We) agree to furnish additional information to the Claims Administrator to support this claim if requested to do so. I (We) have not submitted any other claim in connection with transactions in Valeant Securities during the Class Period and know of no other person having done so on my (our) behalf.

V. RELEASES

1. I (We) hereby acknowledge full and complete satisfaction of, and do hereby fully, finally, and forever settle, release, and discharge from the Released Claims each and all of the Released Persons.

2. “Released Persons” means each and all of the Defendants, Former Defendants and their Related Parties. Released Persons does not include PwC.

3. “Released Claims” means any and all rights, liabilities, suits, debts, obligations, demands, damages, losses, judgment matters, issues, claims (including Unknown Claims), and causes of action of every nature and description whatsoever, in

law, equity, or otherwise, whether accrued or unaccrued, fixed or contingent, liquidated or unliquidated, whether arising under federal, state, local, statutory, common law, foreign law, or any other law, rule, or regulation, and whether class and/or individual in nature, concerning, based on, arising out of, or in connection with both: (i) the purchase or other acquisition of Valeant Securities by Lead Plaintiff or any other Class Member between January 4, 2013 and March 15, 2016, inclusive; and (ii) the allegations, transactions, acts, facts, matters, occurrences, disclosures, statements, filings, representations, omissions, or events that were or could have been alleged or asserted in the Litigation. Released Claims do not include claims to enforce the Settlement, shareholder derivative claims on behalf of Valeant, governmental agency actions against the Released Persons, claims asserted in the RICO Class Action, the Canadian Actions, or the claims that are or could be asserted in this Litigation against PwC.

4. “Released Defendants’ Claims” means any and all claims and causes of action of every nature and description whatsoever, including both known claims and Unknown Claims, that arise out of, are based upon, or relate in any way to the institution, prosecution, or settlement of the claims against Defendants or Former Defendants in the Litigation, except for claims relating to the enforcement of the Settlement or contractual or other indemnification rights.

5. “Unknown Claims” means: (a) any and all Released Claims which the Releasing Plaintiff Parties do not know or suspect to exist in his, her, or its favor at the time of the release of the Released Persons, which, if known by him, her, or it, might have affected his, her, or its settlement with and release of the Released Persons, or

might have affected his, her, or its decision(s) with respect to the Settlement, including, but not limited to, whether or not to object to this Settlement or seek exclusion from the Class; and (b) any and all Released Defendants' Claims that the Released Persons do not know or suspect to exist in his, her, or its favor at the time of the release of the Plaintiffs, the Class and Plaintiffs' Counsel, which, if known by him, her, or it, might have affected his, her, or its settlement and release of Plaintiffs, the Class and Plaintiffs' Counsel. With respect to (a) any and all Released Claims against the Released Persons, and (b) any and all Released Defendants' Claims against Plaintiffs, the Class and Plaintiffs' Counsel, the Settling Parties stipulate and agree that, upon the Effective Date, the Settling Parties shall expressly waive and each Releasing Plaintiff Party and Released Person shall be deemed to have, and by operation of the Judgment shall have expressly waived, the provisions, rights, and benefits of California Civil Code §1542, which provides:

A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.

The Settling Parties shall expressly waive and each Releasing Plaintiff Party and Released Person shall be deemed to have, and by operation of the Judgment shall have, expressly waived any and all provisions, rights, and benefits conferred by any law of any state or territory of the United States, or principle of common law, which is similar, comparable, or equivalent to California Civil Code §1542. The Releasing Plaintiff Parties and Released Persons acknowledge that they may hereafter discover

facts in addition to or different from those which he, she, it or their counsel now knows or believes to be true with respect to the subject matter of the Released Claims or Released Defendants' Claims, but: (a) the Releasing Plaintiff Parties shall expressly fully, finally, and forever waive, compromise, settle, discharge, extinguish, and release, and each Releasing Plaintiff Party shall be deemed to have waived, compromised, settled, discharged, extinguished, and released, and upon the Effective Date, and by operation of the Judgment shall have waived, compromised, settled, discharged, extinguished, and released, fully, finally, and forever, any and all Released Claims against the Released Persons, known or unknown, suspected or unsuspected, contingent or non-contingent, whether or not concealed or hidden, which now exist, or heretofore have existed, upon any theory of law or equity now existing or coming into existence in the future, including, but not limited to, conduct which is negligent, intentional, with or without malice, or a breach of any duty, law or rule, without regard to the subsequent discovery or existence of such different or additional facts, legal theories, or authorities; and (b) the Released Persons shall expressly fully, finally, and forever waive, compromise, settle, discharge, extinguish, and release, and upon the Effective Date, and by operation of the Judgment shall have waived, compromised, settled, discharged, extinguished, and released, fully, finally, and forever, any and all Released Defendants' Claims against the Plaintiffs, the Class and Plaintiffs' Counsel, known or unknown, suspected or unsuspected, contingent or non-

contingent, whether or not concealed or hidden, which now exist, or heretofore have existed, upon any theory of law or equity now existing or coming into existence in the future, including, but not limited to, conduct which is negligent, intentional, with or without malice, or a breach of any duty, law or rule, without regard to the subsequent discovery or existence of such different or additional facts, legal theories, or authorities. This paragraph does not affect any claims for contractual or other indemnification rights between or among the Defendants and Former Defendants. The Settling Parties acknowledge, and the Releasing Plaintiff Parties and Released Persons shall be deemed by operation of the Judgment to have acknowledged, that the foregoing waiver was separately bargained for and is an essential element of the Settlement of which this release is a part.

6. These releases shall be of no force or effect unless and until the Court approves the Stipulation and the Settlement becomes effective on the Effective Date.

7. I (We) hereby warrant and represent that I (we) have not assigned or transferred or purported to assign or transfer, voluntarily or involuntarily, any claim or matter released pursuant to this release or any other part or portion thereof.

8. I (We) hereby warrant and represent that I (we) have included information about all of my (our) purchases, acquisitions and sales of Valeant Securities during the Class Period and the number of shares of Valeant common stock and face value of debt securities held by me (us) at the close of trading on January 3, 2013, March 15, 2016, and September 2, 2016.

I (We) declare under penalty of perjury under the laws of the United States of America that the foregoing information supplied by the undersigned is true and correct and that the claimant has not previously received or been promised a payment from or on behalf of the Valeant Defendants, other than a payment of attorneys fees or costs to counsel, related to or arising from litigation related to Class Period transactions in Valeant Securities.

Executed this _____ day of _____ in _____
(Month/Year) (City/State/Country)

(Sign your name here)

(Sign your name here)

(Type or print your name here)

(Type or print your name here)

(Capacity of person(s) signing, e.g.,
Beneficial Purchaser, Executor or Administrator)

(Capacity of person(s) signing, e.g.,
Beneficial Purchaser, Executor or Administrator)

**ACCURATE CLAIMS PROCESSING TAKES A SIGNIFICANT AMOUNT OF TIME.
THANK YOU FOR YOUR PATIENCE.**

Reminder Checklist:

- 1. Please sign the above release and declaration.
- 2. If this Claim is being made on behalf of Joint Claimants, then both must sign.
- 3. Remember to attach copies of supporting documentation, if available.
- 4. Do not send originals of certificates.
- 5. Keep a copy of your claim form and all supporting documentation for your records.
- 6. If you desire an acknowledgment of receipt of your claim form please send it Certified Mail, Return Receipt Requested.
- 7. If you move, please send your new address to the address below.
- 8. Do not use red pen or highlighter on the Proof of Claim and Release form or supporting documentation.

THIS PROOF OF CLAIM AND RELEASE FORM MUST BE SUBMITTED ONLINE OR MAILED NO LATER THAN _____, 2020, ADDRESSED AS FOLLOWS:

Valeant Securities Settlement
Claims Administrator
c/o Gilardi & Co. LLC
P.O. Box _____
Providence, RI 02940-_____
www.ValeantSecuritiesSettlement.com

EXHIBIT A-3

SEEGER WEISS LLP
CHRISTOPHER A. SEEGER
DAVID R. BUCHANAN
55 Challenger Road, 6th Floor
Ridgefield Park, NJ 07660
Telephone: 212/584-0700
212/584-0799 (fax)

Local Counsel

ROBBINS GELLER RUDMAN
& DOWD LLP
JAMES E. BARZ
FRANK A. RICHTER
200 South Wacker Drive, 31st Floor
Chicago, IL 60606
Telephone: 312/674-4674
312/674-4676 (fax)

Lead Counsel for Plaintiffs

UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY

In re VALEANT)	Master No. 3:15-cv-07658-MAS-LHG
PHARMACEUTICALS)	
INTERNATIONAL, INC.)	<u>CLASS ACTION</u>
SECURITIES LITIGATION)	Judge Michael A. Shipp
_____)	Magistrate Judge Lois H. Goodman
This Document Relates To:)	Special Master Hon. Dennis M. Cavanaugh,
)	U.S.D.J. (Ret.)
Case No. 3:15-cv-07658-MAS-LHG.)	SUMMARY NOTICE OF PENDENCY
_____)	AND PROPOSED SETTLEMENT OF
)	CLASS ACTION
		EXHIBIT A-3

TO: ALL PERSONS AND ENTITIES THAT PURCHASED OR OTHERWISE ACQUIRED VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (“VALEANT,” NOW KNOWN AS BAUSCH HEALTH COMPANIES INC.) COMMON STOCK, VALEANT DEBT SECURITIES, OR CALL OPTIONS ON VALEANT COMMON STOCK, OR SOLD PUT OPTIONS ON VALEANT COMMON STOCK, DURING THE PERIOD BETWEEN JANUARY 4, 2013 AND MARCH 15, 2016, INCLUSIVE (THE “CLASS PERIOD”)

THIS NOTICE WAS AUTHORIZED BY THE COURT. IT IS NOT A LAWYER SOLICITATION. PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY.

YOU ARE HEREBY NOTIFIED that a hearing will be held on _____, 2020, at ___ .m., before the Honorable Michael A. Shipp at the Clarkson S. Fisher Building & U.S. Courthouse, 402 East State Street, Trenton, New Jersey 08608, to determine whether: (1) the proposed settlement (the “Settlement”) of the above-captioned action as set forth in the Stipulation of Settlement (“Stipulation”)¹ for \$1,210,000,000.00 in cash should be approved by the Court as fair, reasonable and adequate; (2) the Judgment as provided under the Stipulation should be entered dismissing the Litigation against all Defendants with prejudice except PriceWaterhouseCoopers LLP (“PwC”); (3) the Class should be finally certified for purposes of the Settlement only; (4) to award Lead Counsel attorneys’ fees and charges and expenses out of the Settlement Fund (as defined in the Notice of Pendency and Proposed Settlement of Class Action (“Notice”), which is discussed

¹ The Stipulation can be viewed and/or obtained at www.ValeantSecuritiesSettlement.com. Capitalized terms not otherwise defined herein have the meaning given to them in the Stipulation.

below) and, if so, in what amount; (5) to award Plaintiffs out of the Settlement Fund pursuant to 15 U.S.C. §78u-4(a)(4) in connection with their representation of the Class and, if so, in what amount; and (6) the Plan of Allocation should be approved by the Court as fair, reasonable and adequate.

IF YOU PURCHASED OR OTHERWISE ACQUIRED VALEANT SECURITIES² BETWEEN JANUARY 4, 2013 AND MARCH 15, 2016, INCLUSIVE, YOUR RIGHTS MAY BE AFFECTED BY THE SETTLEMENT OF THIS LITIGATION.

To share in the distribution of the Settlement Fund, you must establish your rights by submitting a Proof of Claim and Release form by mail (**postmarked no later than _____, 2020**) or electronically (**no later than _____, 2020**). Your failure to submit your Proof of Claim and Release by _____, 2020, will subject your claim to rejection and preclude your receiving any of the recovery in connection with the Settlement of this Litigation. To exclude yourself from the Class,

² “Valeant Securities” means Valeant equity securities as defined in 15 U.S.C. §78c(11) and 17 C.F.R. §240.3a11-1, and Valeant debt securities, including Valeant common stock; options on Valeant common stock, defined to be the purchase or acquisition of call options and the sale of put options; and the following Valeant senior notes: (1) 5.375% senior notes due 2020; (2) 5.875% senior notes due 2023; (3) 6.125% senior notes due 2025; (4) 5.5% senior notes due 2023; (5) 5.625% senior notes due 2021; (6) 6.75% senior notes due 2018; (7) 7.5% senior notes due 2021; (8) 6.375% senior notes due 2020; (9) 7.25% senior notes due 2022; (10) 6.75% senior notes due 2021; or (11) 7.0% senior notes due 2020. This definition does not include securities at issue in the Canadian Actions.

you must submit a written request for exclusion so that it is postmarked no later than _____, 2020, in accordance with the instructions set forth in the Notice. If you request exclusion, you will not recover money pursuant to the Settlement.

If you have not received a copy of the Notice, which more completely describes the Settlement and your rights thereunder (including your right to exclude yourself from the Class or to object to the Settlement), and a Proof of Claim and Release, you may obtain these documents, as well as a copy of the Stipulation and other settlement documents, online at www.ValeantSecuritiesSettlement.com, or by writing to:

Valeant Securities Settlement
c/o Gilardi & Co. LLC
P.O. Box _____
Providence, RI 02940

Inquiries should NOT be directed to Defendants, the Court, or the Clerk of the Court.

Inquiries, other than requests for the Notice or for a Proof of Claim and Release, may be made to a representative of Lead Counsel:

ROBBINS GELLER RUDMAN & DOWD LLP
Rick Nelson
c/o Shareholder Relations
655 West Broadway, Suite 1900
San Diego, CA 92101
Telephone: 800/449-4900

IF YOU ARE A CLASS MEMBER, YOU HAVE THE RIGHT TO OBJECT TO THE SETTLEMENT, THE PLAN OF ALLOCATION, THE REQUEST BY

LEAD COUNSEL FOR AN AWARD OF ATTORNEYS' FEES AND EXPENSES
AND/OR THE AWARDS TO PLAINTIFFS PURSUANT TO 15 U.S.C. §78u-4(a)(4)
IN CONNECTION WITH THEIR REPRESENTATION OF THE CLASS. ANY
OBJECTIONS MUST BE FILED WITH THE COURT AND MAILED TO LEAD
COUNSEL AND VALEANT'S COUNSEL **BY** _____, **2020**, IN THE
MANNER AND FORM EXPLAINED IN THE NOTICE.

DATED: _____

BY ORDER OF THE
UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY

EXHIBIT B

SEEGER WEISS LLP
CHRISTOPHER A. SEEGER
DAVID R. BUCHANAN
55 Challenger Road, 6th Floor
Ridgefield Park, NJ 07660
Telephone: 212/584-0700
212/584-0799 (fax)

Local Counsel

ROBBINS GELLER RUDMAN
& DOWD LLP
JAMES E. BARZ
FRANK A. RICHTER
200 South Wacker Drive, 31st Floor
Chicago, IL 60606
Telephone: 312/674-4674
312/674-4676 (fax)

Lead Counsel for Plaintiffs

UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY

In re VALEANT)	Master No. 3:15-cv-07658-MAS-LHG
PHARMACEUTICALS)	
INTERNATIONAL, INC.)	<u>CLASS ACTION</u>
SECURITIES LITIGATION)	Judge Michael A. Shipp
_____)	Magistrate Judge Lois H. Goodman
This Document Relates To:)	Special Master Hon. Dennis M. Cavanaugh,
)	U.S.D.J. (Ret.)
Case No. 3:15-cv-07658-MAS-LHG.)	[PROPOSED] ORDER AND FINAL
_____)	JUDGMENT

EXHIBIT B

On the ____ day of _____, 2020, a hearing having been held before this Court to determine: (1) whether the terms and conditions of the Stipulation of Settlement dated December 15, 2019 (the “Stipulation”) are fair, reasonable and adequate for the settlement of all claims asserted by the Class against the Defendants¹ in the complaint now pending in this Court in the above-captioned action (the “Litigation”) and the Former Defendants², including the release of the Released Persons, but not as to defendant PricewaterhouseCoopers LLP (“PwC”) against whom the Litigation continues, and should be approved; (2) whether judgment should be entered dismissing the Complaint on the merits and with prejudice in favor of the Defendants (which does not include PwC) and Former Defendants herein and as against all persons or entities who are Members of the Class herein who have not

¹ “Defendants” refers to Valeant Pharmaceuticals International, Inc. (“Valeant”) (n/k/a Bausch Health Companies Inc.); J. Michael Pearson; Howard B. Schiller; Robert L. Rosiello; Deborah Jorn; Ari S. Kellen; Tanya Carro; Jeffrey W. Ubben; Robert A. Ingram; Ronald H. Farmer; Colleen Goggins; Anders Lönner; Theo Melas-Kyriazi; Robert N. Power; Norma Provencio; Katharine B. Stevenson; Deutsche Bank Securities Inc.; HSBC Securities (USA) Inc.; MUFG Securities Americas Inc. f/k/a Mitsubishi UFJ Securities (USA) Inc.; DNB Markets, Inc.; Barclays Capital Inc.; Morgan Stanley & Co. LLC; RBC Capital Markets, LLC; Suntrust Robinson Humphrey, Inc.; ValueAct Capital Management, L.P.; VA Partners I, LLC; ValueAct Holdings, L.P.; ValueAct Capital Master Fund, L.P.; and ValueAct Co-Invest Master Fund, L.P.

² “Former Defendants” refers to Goldman Sachs & Co. LLC f/k/a Goldman Sachs & Co.; J.P. Morgan Securities LLC; Merrill Lynch, Pierce, Fenner & Smith Inc.; CIBC World Markets Inc.; Citigroup Global Markets Inc.; DBS Bank Ltd.; TD Securities (USA) LLC; BMO Capital Markets Corp.; and SMBC Nikko Securities America, Inc.

timely and validly requested exclusion therefrom; (3) whether the Class should be finally certified for purposes of settlement; (4) whether to approve the Plan of Allocation as a fair and reasonable method to allocate the settlement proceeds among the Members of the Class; (5) whether and in what amount to award Lead Counsel fees and charges and expenses; and (6) whether and in what amount to award Plaintiffs pursuant to 15 U.S.C. §78u-4(a)(4) in connection with their representation of the Class; the Court having considered all matters submitted to it at the hearing and otherwise; it appearing that a notice of the hearing substantially in the form approved by the Court was provided to all individuals and entities, reasonably identifiable, who purchased or otherwise acquired Valeant Securities between January 4, 2013 and March 15, 2016, inclusive, as shown by the records compiled by the Claims Administrator in connection with its providing of the Notice, at the respective addresses set forth in such records, and that a summary notice of the hearing substantially in the form approved by the Court was published pursuant to the Order Granting Preliminary Approval Pursuant to Fed. R. Civ. P. 23(e)(1) and Permitting Notice to the Class (the “Order”) as set forth in the Declaration of _____, and the Supplemental Declaration of _____; the Court having considered and determined the fairness and reasonableness of the award of attorneys’ fees and charges and expenses requested by Lead Counsel and the request for awards to

Plaintiffs pursuant to 15 U.S.C. §78u-4(a)(4); and all capitalized terms not otherwise defined herein having the meanings set forth and defined in the Stipulation.

NOW, THEREFORE, IT IS HEREBY ORDERED THAT:

1. This Judgment incorporates by reference the definitions in the Stipulation, and all terms used herein shall have the same meanings as set forth in the Stipulation, unless otherwise set forth herein.

2. The Court has jurisdiction over the subject matter of this Litigation, the Lead Plaintiff, all Class Members, and Defendants.

3. Pursuant to Rule 23 of the Federal Rules of Civil Procedure, this Court hereby affirms its determinations in the Order and finally certifies for purposes of settlement only a Class defined as all Persons who purchased or otherwise acquired Valeant Securities between January 4, 2013 and March 15, 2016, inclusive. Excluded from the Class are Defendants and Former Defendants, present and former executive officers of Defendants and Former Defendants, and members of their immediate families, present and former directors of Defendants and Former Defendants, and members of their immediate families, any entity in which a Defendant or current or former director of a Defendant has control and/or a majority ownership interest, and the legal representatives, heirs, successors or assigns of any such excluded party. For the avoidance of doubt, this exclusion does not extend to: (1) any investment company or pooled investment fund in which a Defendant or Former Defendant may have a direct or indirect interest, or as to which its affiliates may act as an advisor, but of which a Defendant or Former Defendant or its respective affiliates is not a majority

owner or does not hold a majority beneficial interest; or (2) any employee benefit plan as to which a Defendant or Former Defendant or its affiliates acts as an investment advisor or otherwise may be a fiduciary; provided, however, that membership in the Class by such investment company, pooled investment fund or employee benefit plan is limited to transactions in Valeant Securities made on behalf of, or for the benefit of, persons other than persons that are excluded from the Class by definition. In other words, Defendants and Former Defendants cannot make a claim on their own behalf for their ownership share in any of the above entities. The Class also excludes: (1) any person or entity which during the Class Period purchased or otherwise acquired Valeant Securities and has been promised or received a payment from or on behalf of the Valeant Defendants related to or arising from litigation related to its Class Period transactions in Valeant Securities other than a payment of attorneys fees or costs to counsel for such person or entity; (2) any Class Member on Exhibit A hereto that validly and timely requested exclusion in accordance with the requirements set by the Court in the Notice of Pendency and Proposed Settlement of Class Action; and (3) anyone on Exhibit B hereto who has filed an individual action and not dismissed their claim and sought to be included in the Class.

4. This Court hereby affirms its determinations in the Order and finds, for the purposes of the Settlement only, that the prerequisites for a class action under Rules 23(a) and (b)(3) of the Federal Rules of Civil Procedure have been satisfied in that: (a) the number of Class Members is so numerous that joinder of all members is impracticable; (b) there are questions of law and fact common to the Class; (c) the

claims of the Class Representatives are typical of the claims of the Class they seek to represent; (d) Class Representatives and Lead Counsel have and will fairly and adequately represent the interests of the Class; (e) the questions of law and fact common to the Members of the Class predominate over any questions affecting only individual Class Members; and (f) a class action is superior to other available methods for the fair and efficient adjudication of the controversy.

5. Pursuant to Rule 23 of the Federal Rules of Civil Procedure, and for purposes of settlement only, the Court hereby affirms its determinations in the Order and finally appoints Lead Plaintiff TIAA together with named plaintiffs City of Tucson together with and on behalf of Tucson Supplemental Retirement System (“Tucson”) and IBEW Local Union 481 Defined Contribution Plan and Trust (“IBEW”) as Class Representatives for the Class and Robbins Geller Rudman & Dowd LLP as Class Counsel for the Class.

6. Notice of the pendency of this Litigation and the proposed Settlement was given to all Class Members who could be identified with reasonable effort. The form and method of notifying the Class of the pendency of the Litigation and the terms and conditions of the proposed Settlement met the requirements of Rule 23 of the Federal Rules of Civil Procedure, the Private Securities Litigation Reform Act of 1995 (the “PSLRA”), due process, and any other applicable law, constituted the best

notice practicable under the circumstances, and constituted due and sufficient notice to all individuals and entities entitled thereto.

7. Pursuant to Federal Rule of Civil Procedure 23(e)(2), the Court hereby approves the Settlement set forth in the Stipulation and finds that in light of the benefits to the Class, the complexity and expense of further litigation, and the costs of continued litigation, the Settlement is, in all respects, fair, reasonable, and adequate having considered and found that: (a) Lead Plaintiff and Lead Counsel have adequately represented the Class; (b) the proposal was negotiated at arm's length; (c) the relief provided for the Class is adequate, having taken into account (i) the costs, risks, and delay of trial and appeal; (ii) the effectiveness of any proposed method of distributing relief to the Class, including the method of processing Class Members' claims; (iii) the terms of any proposed award of attorneys' fees, including timing of payment; and (iv) any agreement required to be identified under Rule 23(e)(2); and (d) the proposed Plan of Allocation treats Class Members equitably relative to each other.

8. Accordingly, the Court authorizes and directs implementation and performance of all the terms and provisions of the Stipulation, as well as the terms and provisions hereof. Except as to any individual claim of those Persons who (1) during the Class Period purchased or otherwise acquired Valeant Securities and have been promised or received a payment from or on behalf of the Valeant Defendants related to or arising from litigation related to their Class Period transactions in Valeant

Securities other than a payment of attorneys fees or costs to counsel for such Persons; (2) who have validly and timely requested exclusion from the Class (identified in Exhibit A attached hereto); or (3) filed an individual action and has not dismissed their claim and sought to be included in the Class (identified in Exhibit B attached hereto), the Court hereby dismisses all Released Claims of the Class, as against the Released Persons, with prejudice. The Settling Parties are to bear their own costs, except as to and to the extent provided in the Stipulation and herein.

9. The releases as set forth in ¶¶4.1-4.5 of the Stipulation (the “Releases”), together with the definitions contained in ¶¶1.1-1.41 relating thereto, are expressly incorporated herein in all respects. The Releases are effective as of the Effective Date.

10. Upon the Effective Date, each of the Releasing Plaintiff Parties will be forever barred and enjoined from commencing, instituting, prosecuting, or continuing to prosecute any action or other proceeding in any court of law or equity, arbitration tribunal, or administrative forum, asserting the Released Claims against any of the Released Persons. Claims to enforce the terms of the Stipulation are not released.

11. Upon the Effective Date, Lead Plaintiff shall, and each and every Releasing Plaintiff Party shall be deemed to have, and by operation of this Judgment shall have, fully, finally, and forever waived, released, relinquished, discharged and dismissed each and every one of the Released Claims (including Unknown Claims)

against each and every one of the Released Persons and shall forever be barred and enjoined from commencing, instituting, prosecuting, or maintaining any and all of the Released Claims against any and all of the Released Persons, whether or not such Releasing Plaintiff Party executes and delivers the Proof of Claim and Release or shares in the Net Settlement Fund. Lead Plaintiff and each Releasing Plaintiff Party are bound by this Judgment, including, without limitation, the release of claims as set forth in the Stipulation. The Released Claims are hereby compromised, settled, released, discharged, and dismissed as against the Released Persons on the merits and with prejudice by virtue of the proceedings herein and this Order and Final Judgment. Claims to enforce the terms of the Settlement are not released.

12. Upon the Effective Date, each of the Released Persons shall be deemed to have, and by operation of this Judgment shall have, fully, finally, and forever released, relinquished, and discharged Plaintiffs, the Class and Plaintiffs' Counsel from all Released Defendants' Claims (including Unknown Claims). Claims to enforce the terms of the Stipulation are not released.

13. Upon the Effective Date, to the fullest extent permitted by law, (i) all Persons shall be permanently enjoined, barred and restrained from commencing, instituting, prosecuting, or maintaining any claims, actions, or causes of action for contribution, indemnity or otherwise against any of the Released Persons seeking as damages or otherwise the recovery of all or part of any liability, judgment or

settlement which they pay or are obligated to pay or agree to pay to the Releasing Plaintiff Parties arising out of, relating to or concerning any acts, facts, statements or omissions that were or could have been alleged in the Litigation, both known and Unknown Claims, whether arising under state, federal or foreign law, as claims, cross-claims, counterclaims, third-party claims or otherwise, in the Court or any other federal, state, or foreign court, or in any arbitration proceeding, administrative agency proceeding, tribunal, or any other proceeding or forum; and (ii) all Released Persons shall be permanently enjoined, barred and restrained from commencing, instituting, prosecuting, or maintaining any claims, actions, or causes of action for contribution, indemnity or otherwise against any Persons seeking as damages or otherwise the recovery of all or part of any liability, judgment or settlement which they pay or are obligated to pay or agree to pay to the Releasing Plaintiff Parties arising out of, relating to, or concerning any acts, facts, statements or omissions that were or could have been alleged in the Litigation, both known and Unknown Claims, whether arising under state, federal or foreign law, as claims, cross-claims, counterclaims, third-party claims or otherwise, in the Court or any other federal, state, or foreign court, or in any arbitration proceeding, administrative agency proceeding, tribunal, or any other proceeding or forum; *provided that* clauses (i) and (ii) of this Paragraph shall not be construed to modify, amend, or supersede any agreements between or among the Released Persons with respect to claims between or among those Released

Persons, including, without limitation, any claims for contractual or other indemnification rights, nor limit the Valeant Defendants' ability to pursue insurance recoveries against their insurers for claims relating to this Litigation, including the Settlement Amount and legal fees and costs incurred in connection with the Litigation.

14. Any final verdict or judgment that may be obtained by or on behalf of the Class against any person or entity subject to the bar order set forth in paragraph 13 above shall, pursuant to 15 U.S.C. §78u-4(f)(7)(B), be reduced by the greater of (a) an amount that corresponds to the percentage of responsibility of the Defendants for common damages; or (b) the amount paid by or on behalf of Defendants and Former Defendants to the Class or a Class Member for common damages.

15. Defendants and Former Defendants have denied, and continue to deny, any and all allegations and claims asserted in the Litigation, and Defendants and Former Defendants have represented that they entered into the Settlement because it would be beneficial to avoid the burden, inconvenience, and expense associated with continuing the Litigation and the uncertainty and risks inherent in any litigation. Neither this Order and Final Judgment, the Stipulation, nor any of their respective terms and provisions, nor any of the negotiations, discussions, or proceedings connected with them, nor any act performed or document executed pursuant to or in furtherance of the Stipulation or the Settlement, nor any of the documents or

statements referred to therein, nor any payment or consideration provided for therein, shall be:

(a) offered or received against any of the Released Persons as evidence of, or construed as evidence of, any presumption, concession, or admission by any of the Released Persons with respect to the truth of any of the allegations in the Litigation or the validity of any claim that has been or could have been asserted against any of the Released Persons in the Litigation or in any other litigation, action, or proceeding, whether civil, criminal, or administrative, in any court, administrative agency, or other tribunal, or the deficiency of any defense that has been or could have been asserted in the Litigation or in any other litigation, action, or proceeding, whether civil, criminal, or administrative in any court, administrative agency, or other tribunal, or of any liability, negligence, fault, or other wrongdoing of any kind by any of the Released Persons;

(b) offered or received against any of the Released Persons as evidence of, or construed as evidence of, any presumption, concession, or admission of any fault, misrepresentation, or omission with respect to any statement or written document approved or made by any of the Released Persons, or against Lead Plaintiff or any Member of the Class as evidence of, or construed as evidence of, any infirmity of the claims alleged by Lead Plaintiff;

(c) offered or received against the Released Persons, Lead Plaintiff, or any Member of the Class as evidence of, or construed as evidence of, any presumption, concession, or admission by any of the Released Persons, Lead Plaintiff, or any Member of the Class with respect to any liability, negligence, fault, or wrongdoing as against any of the Released Persons, Lead Plaintiff, or any Member of the Class in any other litigation, action, or proceeding, whether civil, criminal, or administrative, in any court, administrative agency, or other tribunal, other than such proceedings as may be necessary to effectuate the provisions of the Stipulation or this Order and Final Judgment; provided, however, that the Released Persons, Lead Plaintiff, and any Member of the Class may refer to them to effectuate the liability protection granted them hereunder;

(d) offered or received against any Defendant or Former Defendant as evidence of a presumption, concession, or admission that any class, however defined or constituted and whether under Rule 23 of the Federal Rules of Civil Procedure or otherwise, should be certified in the Litigation or in any other civil action or proceeding, except with respect to the certification of the Class for purposes of the Settlement only; or

(e) offered or received against any of the Released Persons as evidence of, or construed as evidence of, any presumption, concession, or admission

by any of the Released Persons that the Settlement Amount represents the amount which could or would have been recovered after trial; or

(f) offered or received against Lead Plaintiff or any Member of the Class as evidence of, or construed as evidence of, any presumption, concession, or admission by Lead Plaintiff or any Member of the Class that any of their claims are without merit, or that any defenses asserted by the Defendants or Former Defendants in the Litigation have any merit, or that damages recoverable in the Litigation would not have exceeded the Settlement Fund.

16. The Released Persons may file the Stipulation and/or this Judgment in any action in order to support a defense, claim, or counterclaim based on principles of *res judicata*, collateral estoppel, release, good faith settlement, judgment bar or reduction, or any other theory of claim preclusion or issue preclusion or similar defense or counterclaim.

17. The Court finds that Defendant Valeant has satisfied or will satisfy its financial obligations under the Stipulation by paying or causing to be paid \$1,210,000,000.00 plus any accrued interest from January 10, 2020 until deposited with the Escrow Agent to the Settlement Fund, in accordance with ¶¶2.2 and 2.3 of the Stipulation.

18. The Court finds and concludes that the Lead Plaintiff, Plaintiffs' Counsel, Defendants, Former Defendants and Defendants' and Former Defendants' Counsel

have complied with each requirement of Rule 11(b) of the Federal Rules of Civil Procedure as to any complaint, responsive pleading, dispositive motion, or other filing.

19. Any Plan of Allocation submitted by Lead Counsel or any order entered regarding any attorneys' fee and expense application or awards to Plaintiffs shall in no way disturb or affect this Judgment and shall be considered separate from this Judgment. Separate orders shall be entered regarding approval of a plan of allocation and Lead Counsel's application for an award of attorneys' fees and expenses, and awards to Plaintiffs.

20. The Settling Parties are hereby authorized, without further approval of the Court, to unanimously agree to and adopt in writing amendments, modifications, and expansions of the Stipulation, provided that such amendments, modifications, and expansions of the Stipulation are not materially inconsistent with this Judgment, and do not materially limit the rights of the Members of the Class under the Stipulation.

21. Any appeal or any challenge affecting the approval of (a) the Plan of Allocation submitted by Lead Counsel and/or (b) this Court's approval regarding any attorneys' fee and expense applications, including any awards to Plaintiffs, shall in no way disturb or affect the finality of the other provisions of this Order and Final Judgment nor the Effective Date of the Settlement.

22. Without affecting the finality of this Judgment in any way, jurisdiction is hereby retained over Defendants, Plaintiffs and Class Members for all matters relating to the administration, interpretation, effectuation or enforcement of the Stipulation and this Order and Final Judgment, including administering and distributing the settlement proceeds to the Members of the Class.

23. In the event that the Effective Date does not occur in accordance with the terms of the Stipulation, or the Settlement is terminated pursuant to ¶2.17 of the Stipulation, ¶¶7.4, 7.5 and 7.6 of the Stipulation shall apply and this Order and Final Judgment shall be rendered null and void to the extent provided by and in accordance with the Stipulation and shall be vacated and may not be introduced as evidence or reflected in any action or proceeding by any person or entity, and each party shall be restored to his, her or its respective position as it existed prior to November 21, 2019.

24. Without further order of the Court, the parties may agree to reasonable extensions of time to carry out any of the provisions of the Stipulation.

25. Defendants have provided notification to all appropriate federal and state officials regarding the Settlement as required by 28 U.S.C. §1715.

26. The Litigation shall continue as to PwC, but the Litigation and all Released Claims against the Released Persons are dismissed with prejudice. The parties are to bear their own costs, except as otherwise agreed to in writing by the

Settling Parties or as otherwise provided in the Stipulation or this Order and Final Judgment.

27. There is no just reason for delay in the entry of this Order and Final Judgment and immediate entry by the Clerk of the Court is expressly directed.

DATED: _____

THE HONORABLE MICHAEL A. SHIPP
UNITED STATES DISTRICT JUDGE

EXHIBIT B



THE TOP 100

U.S. Class Action Settlements of All Time

AS OF
DECEMBER 31, 2018

EXECUTIVE SUMMARY

For calendar 2018, ISS Securities Class Action Services LLC (“SCAS”) recorded 126 approved securities class action settlements, four (4) of which are included in SCAS’ Top 100, which charts the largest U.S. class action settlements since passage of the Private Securities Litigation Reform Act of 1995. The four new entrants into the Top 100 are:

- Petroleo Brasileiro S.A. (Petrobras) – \$3 billion;
- Wells Fargo & Company – \$480 million;
- Allergan, Inc – \$250 million; and
- Wilmington Trust Corp – \$210 million.

Collectively, in calendar year 2018 \$5.84 billion in settlement funds were approved for distribution. While the count of settlements dropped by 23 percent to 126 from 163 in 2017, total settlement dollars were 164 percent higher than the prior year. Of the 126 settlements, 94 occurred in Federal Court while 32 occurred in a state court. Not surprisingly, the most frequent Federal Court was the U.S. District Court for the Southern District of New York (“USDC - New York (Southern)”) with 20 settlements totalling \$3.35 billion, while the most frequent State Court was the Delaware Court of Chancery with 13 settlements totalling \$231.3 million.

The allegations of the four newly added settlements in the Top 100 were as follows¹:

- Three were related to violations of Employment of Manipulative and Deceptive Practices of the Securities and Exchange Act of 1934 (“Rule 10b-5”);
- Two were related to violations of Civil Liabilities on Account of False Registration Statement of the Securities Act of 1933 (“Section 11”);
- Two were alleged violations of Generally Accepted Accounting Principles (“GAAP”) which stemmed from financial restatements;
- Two were related to insider trading; and
- One was related to M&A transactions.

Interestingly, Petrobras, the largest settlement of 2018, becomes the largest non-U.S. company to settle within the U.S. court system (eligible shareholders were holders of the company’s ADRs). Lead plaintiffs for this case included the Employees' Retirement System of the State of Hawaii; Universities Superannuation Scheme, Ltd; and the North Carolina Department of State Treasurer. Pomerantz LLP, now with two cases within the Top 100, was sole lead counsel. In January 2018, parties in the Petrobras case entered an agreement to settle, which was later finalized in USDC – New York (Southern) in July 2018. At \$3 billion, the Petrobras settlement now stands as the fifth highest within the Top 100. Lead counsel (or co-lead counsel) for the three other new entrants into the Top 100 (Wells Fargo, Allergan, and Wilmington Trust) was Bernstein Litowitz Berger & Grossmann.

Not included within the Top 100 Report are antitrust cases; however, in 2018, investors were able to participate in a handful of key settlements totaling \$4 billion, including the Foreign Exchange Benchmark Rates, Relevant LIBOR-Based Financial Instruments, ISDAfix Transactions, Euro Interbank Offered Rate, State AG LIBOR/Euribor, and Euroyen-Based Derivatives.

¹ The totals are greater than four as multiple allegations within one case (and settlement) are common.

TABLE OF CONTENTS

EXECUTIVE SUMMARY	2
METHODOLOGY	3
SETTLEMENT CATEGORIZATION	4
NUMBER OF SETTLEMENTS ADDED TO THE TOP 100	5
TOP 100 SETTLEMENTS	5
SETTLEMENTS REPRESENTED BY INSTITUTIONAL LEAD PLAINTIFF IN THE TOP 100	9
INSTITUTIONAL LEAD PLAINTIFFS PARTICIPATION	10
MOST FREQUENT LEAD COUNSEL IN THE TOP 100	11
LEAD COUNSEL PARTICIPATION	12
MOST FREQUENT CLAIMS ADMINISTRATOR IN THE TOP 100	20
CASES INVOLVING ACCOUNTING RESTATEMENTS IN THE TOP 100 SETTLEMENTS	25
RESTATEMENTS IN THE TOP 100	25
NUMBER OF SETTLEMENTS ADDED TO TOP 50 SEC DISGORGEMENTS	27
TOP 50 SEC DISGORGEMENTS	27
GLOSSARY	30

METHODOLOGY

This report provides the complete list of the Top 100 U.S. Securities Class Action settlements, ranked per the total settlement amount, and provides information on the filing court, settlement year and settlement fund. The Top 100 Report does not include non-U.S. cases and SEC disgorgements (data on these latter cases are compiled within its own Top 50 category). Cases with the same settlement amount are given the same ranking.

For cases with multiple partial settlements, the amount indicated in the total settlement amount is computed by combining all partial settlements. The settlement year reflects the year the most recent settlement received final approval from the court. Cases in the Top 100 are limited to those that have been filed on or after January 1, 1996. Only court approved final settlements are included.

SETTLEMENT CATEGORIZATION

The Top 100 U.S. Class Action Settlements of All Time provides a wealth of information, including the settlement year, filing court, settlement fund, and identifies the key players for each settlement. The report is broken down into following categories:

Institutional Lead Plaintiff Participation

This section displays the most frequent institutional lead plaintiffs in the Top 100 settlements. It also identifies the specific cases they served as lead plaintiff.

Lead Counsel Participation

This section lists the law firms that served as lead or co-lead counsel for each litigation in the Top 100 Settlements and identifies the most frequent lead or co-lead counsel in the Top 100 Settlements. Counsels with the same participation are given the same ranking. In addition, the list includes participation in cases where they were litigated under a previous name.

Claims Administration Participation

This section lists the claims administrators who handled the Top 100 Settlements and identifies the most frequent claims administrators. It includes settlements administered from old entities.


Restatements

This section identifies the cases in the Top 100 Settlements involving accounting restatements and shows the number of restatement cases versus non-restatement cases.

Top 50 SEC Disgorgements

This section provides a list of the largest SEC settlements, ranked according to the Total Settlement Amount. The Total Settlement Amount reflects the sum of disgorgement and civil penalties in settlements reached with the Securities and Exchange Commission. The Top 50 SEC Disgorgements includes only those where the distribution plan has received final approval from the SEC. Cases with the same settlement amount are given the same ranking.

NUMBER OF SETTLEMENTS ADDED TO THE TOP 100



TOP 100 SETTLEMENTS

RANK	COMPANY NAME	COURT	SETTLEMENT YEAR	TOTAL SETTLEMENT AMOUNT
1	Enron Corp.	S.D. Tex.	2010	\$7,242,000,000
2	WorldCom, Inc.	S.D.N.Y.	2012	\$6,194,100,714
3	Cendant Corp.	D. N.J.	2000	\$3,319,350,000
4	Tyco International, Ltd.	D. N.H.	2007	\$3,200,000,000
5	Petroleo Brasileiro S.A. - Petrobras	S.D.N.Y.	2018	\$3,000,000,000
6	AOL Time Warner, Inc.	S.D.N.Y.	2006	\$2,500,000,000
7	Bank of America Corporation	S.D.N.Y.	2013	\$2,425,000,000
8	Household International, Inc.	N.D. Ill.	2016	\$1,575,000,000
9	Nortel Networks Corp. I	S.D.N.Y.	2006	\$1,142,775,308
10	Royal Ahold, N.V.	D. Md.	2006	\$1,100,000,000


RANK	COMPANY NAME	COURT	SETTLEMENT YEAR	TOTAL SETTLEMENT AMOUNT
11	Nortel Networks Corp. II	S.D.N.Y.	2006	\$1,074,265,298
12	Merck & Co., Inc.	D. N.J.	2016	\$1,062,000,000
13	McKesson HBOC Inc.	N.D. Cal.	2013	\$1,052,000,000
14	American International Group, Inc.	S.D.N.Y.	2013	\$1,009,500,000
15	American International Group, Inc.	S.D.N.Y.	2015	\$970,500,000
16	UnitedHealth Group, Inc.	D. Minn.	2009	\$925,500,000
17	HealthSouth Corp.	N.D. Ala.	2010	\$804,500,000
18	Xerox Corp.	D. Conn.	2009	\$750,000,000
19	Lehman Brothers Holdings, Inc.	S.D.N.Y.	2014	\$735,218,000
20	Citigroup Bonds	S.D.N.Y.	2013	\$730,000,000
21	Lucent Technologies, Inc.	D. N.J.	2003	\$667,000,000
22	Wachovia Preferred Securities and Bond/Notes	S.D.N.Y.	2011	\$627,000,000
23	Countrywide Financial Corp.	C.D. Cal.	2011	\$624,000,000
24	Cardinal Health, Inc.	S.D. Ohio	2007	\$600,000,000
25	Citigroup, Inc.	S.D.N.Y.	2013	\$590,000,000
26	IPO Securities Litigation (Master Case)	S.D.N.Y.	2012	\$585,999,996
27	Bear Stearns Mortgage Pass-Through Certificates	S.D.N.Y.	2015	\$500,000,000
27	Countrywide Financial Corp.	C.D. Cal.	2013	\$500,000,000
29	BankAmerica Corp.	E.D. Mo.	2004	\$490,000,000
30	Pfizer, Inc.	S.D.N.Y.	2016	\$486,000,000
31	Wells Fargo & Company	N.D. Cal.	2018	\$480,000,000
32	Adelphia Communications Corp.	S.D.N.Y.	2013	\$478,725,000
33	Merrill Lynch & Co., Inc.	S.D.N.Y.	2009	\$475,000,000
34	Dynegy Inc.	S.D. Tex.	2005	\$474,050,000
35	Schering-Plough Corp.	D. N.J.	2013	\$473,000,000
36	Raytheon Company	D. Mass.	2004	\$460,000,000
37	Waste Management Inc.	S.D. Tex.	2003	\$457,000,000
38	Global Crossing, Ltd.	S.D.N.Y.	2007	\$447,800,000

RANK	COMPANY NAME	COURT	SETTLEMENT YEAR	TOTAL SETTLEMENT AMOUNT
39	Qwest Communications International, Inc.	D.D.C.	2009	\$445,000,000
40	Federal Home Loan Mortgage Corp. (Freddie Mac)	S.D.N.Y.	2006	\$410,000,000
41	Marsh & McLennan Companies, Inc.	S.D.N.Y.	2009	\$400,000,000
41	Pfizer, Inc.	S.D.N.Y.	2015	\$400,000,000
43	J.P. Morgan Acceptance Corp. I	S.D.N.Y.	2015	\$388,000,000
44	Cendant Corp. II	D. N.J.	2006	\$374,000,000
45	Refco, Inc.	S.D.N.Y.	2011	\$358,300,000
46	IndyMac Mortgage Pass-Through Certificates	S.D.N.Y.	2015	\$346,000,000
47	RALI Mortgage (Asset-Backed Pass-Through Certificates)	S.D.N.Y.	2015	\$335,000,000
47	Bank of America Corporation	S.D.N.Y.	2016	\$335,000,000
49	Rite Aid Corp.	E.D.Pa.	2003	\$319,580,000
50	Merrill Lynch Mortgage Investors, Inc.	S.D.N.Y.	2012	\$315,000,000
51	Williams Companies, Inc.	N.D. Ok.	2007	\$311,000,000
52	Caremark, Rx, Inc. f/k/a MedPartners, Inc.	Alabama Circuit	2016	\$310,000,000
53	General Motors Corp.	E.D. Mich.	2009	\$303,000,000
54	Oxford Health Plans Inc.	S.D.N.Y.	2003	\$300,000,000
54	DaimlerChrysler AG	D. Del.	2004	\$300,000,000
54	Bristol-Myers Squibb Co.	S.D.N.Y.	2004	\$300,000,000
54	General Motors Company	E.D. Mich.	2016	\$300,000,000
58	Bear Stearns Companies, Inc.	S.D.N.Y.	2012	\$294,900,000
59	El Paso Corporation	S.D. Tex.	2007	\$285,000,000
60	Tenet Healthcare Corp.	C.D. Cal.	2008	\$281,500,000
61	J.P. Morgan Acceptance Corp. I	E.D.N.Y.	2014	\$280,000,000
61	BNY Mellon, N.A.	E.D. OK.	2012	\$280,000,000
63	HarborView Mortgage Loan Trust	S.D.N.Y.	2014	\$275,000,000
63	Activision Blizzard, Inc.	Delaware Chancery	2015	\$275,000,000

RANK	COMPANY NAME	COURT	SETTLEMENT YEAR	TOTAL SETTLEMENT AMOUNT
65	GS Mortgage Securities Corp.	S.D.N.Y.	2016	\$272,000,000
66	Massey Energy Company	W.D. Va.	2014	\$265,000,000
67	3Com Corp.	N.D. Cal.	2001	\$259,000,000
68	Allergan, Inc.	C.D. Cal.	2018	\$250,000,000
69	Bernard L. Madoff Investment Securities LLC	S.D.N.Y.	2016	\$235,250,000
70	Charles Schwab & Co., Inc.	N.D. Cal.	2011	\$235,000,000
71	MF Global Holdings Ltd.	S.D.N.Y.	2016	\$234,257,828
72	Comverse Technology, Inc.	E.D.N.Y.	2010	\$225,000,000
73	Waste Management Inc.	N.D. Ill.	1999	\$220,000,000
74	Bernard L. Madoff Investment Securities LLC	S.D.N.Y.	2013	\$219,857,694
75	Genworth Financial, Inc.	E.D. Va.	2016	\$219,000,000
76	Washington Mutual, Inc.	W.D. Wash.	2016	\$216,750,000
77	Sears, Roebuck & Co.	N.D. Ill.	2006	\$215,000,000
77	Merck & Co., Inc.	D. N.J.	2013	\$215,000,000
77	HCA Holdings, Inc.	M.D. Tenn.	2016	\$215,000,000
80	Salix Pharmaceuticals, Ltd.	S.D.N.Y.	2017	\$210,000,000
80	Wilmington Trust Corporation	D. Del.	2018	\$210,000,000
82	The Mills Corp.	E.D. Va.	2009	\$202,750,000
83	CMS Energy Corp.	E.D. Mich.	2007	\$200,000,000
83	Kinder Morgan, Inc.	Kansas District	2010	\$200,000,000
83	Motorola, Inc.	N.D. Ill.	2012	\$200,000,000
83	WellCare Health Plans, Inc.	M.D. Fla.	2011	\$200,000,000
87	Safety-Kleen Corp.	D. S.C.	2006	\$197,622,944
88	MicroStrategy Inc.	E.D. Va.	2001	\$192,500,000
89	Motorola, Inc.	N.D. Ill.	2007	\$190,000,000
90	Bristol-Myers Squibb Co.	D. N.J.	2006	\$185,000,000
91	The Bank of New York Mellon Corporation	S.D.N.Y.	2015	\$180,000,000

RANK	COMPANY NAME	COURT	SETTLEMENT YEAR	TOTAL SETTLEMENT AMOUNT
92	BP p.l.c.	S.D. Tex.	2017	\$175,000,000
93	Broadcom Corp.	C.D. Cal.	2012	\$173,500,000
94	Maxim Integrated Products, Inc.	N.D. Cal.	2010	\$173,000,000
95	Federal National Mortgage Association (Fannie Mae)	S.D.N.Y.	2015	\$170,000,000
96	Juniper Networks, Inc.	N.D. Cal.	2010	\$169,500,000
97	National City Corp.	N.D. Ohio	2012	\$168,000,000
98	Digex, Inc.	Delaware Chancery	2001	\$165,000,000
98	Schering-Plough Corp.	D. N.J.	2009	\$165,000,000
100	Pharmacia Corp.	D. N.J.	2013	\$164,000,000

SETTLEMENTS REPRESENTED BY INSTITUTIONAL LEAD PLAINTIFF IN THE TOP 100




INSTITUTIONAL LEAD PLAINTIFFS PARTICIPATION

Most Frequent Institutional Lead Plaintiff in Top 100 Settlements

INSTITUTIONAL LEAD PLAINTIFF CASE NAME	RANK	TOTAL SETTLEMENT AMOUNT	NUMBER OF SETTLEMENTS
State Teachers Retirement System of Ohio		\$5,592,300,000	8
Bank of America Corporation	7	\$2,425,000,000	
American International Group, Inc.	14	\$1,009,500,000	
Merrill Lynch & Co., Inc.	33	\$475,000,000	
Global Crossing, Ltd.	38	\$447,800,000	
Federal Home Loan Mortgage Corp. (Freddie Mac)	40	\$410,000,000	
Marsh & McLennan Companies, Inc.	41	\$400,000,000	
Allergan, Inc.	68	\$250,000,000	
BP p.l.c.	92	\$175,000,000	
New York State Common Retirement Fund		\$11,368,450,714	6
WorldCom, Inc.	2	\$6,194,100,714	
Cendant Corp.	3	\$3,319,350,000	
McKesson HBOC Inc.	13	\$1,052,000,000	
Raytheon Company	36	\$460,000,000	
BP p.l.c.	92	\$175,000,000	
National City Corp.	97	\$168,000,000	
Public Employees' Retirement System of Mississippi		\$2,332,750,000	5
Merck & Co., Inc.	12	\$1,062,000,000	
Schering-Plough Corp.	35	\$473,000,000	
Merrill Lynch Mortgage Investors, Inc.	50	\$315,000,000	
J.P. Morgan Acceptance Corp. I	61	\$280,000,000	
The Mills Corp.	82	\$202,750,000	
Ohio Public Employees Retirement System		\$4,467,300,000	5
Bank of America Corporation	7	\$2,425,000,000	
American International Group, Inc.	14	\$1,009,500,000	
Global Crossing, Ltd.	38	\$447,800,000	
Federal Home Loan Mortgage Corp. (Freddie Mac)	40	\$410,000,000	
BP p.l.c.	92	\$175,000,000	
Teachers' Retirement System of Louisiana		\$4,186,000,000	4

INSTITUTIONAL LEAD PLAINTIFF CASE NAME	RANK	TOTAL SETTLEMENT AMOUNT	NUMBER OF SETTLEMENTS
Tyco International, Ltd.	4	\$3,200,000,000	
Pfizer, Inc.	30	\$486,000,000	
Bristol-Myers Squibb Co.	54	\$300,000,000	
WellCare Health Plans, Inc.	83	\$200,000,000	
New Mexico State Investment Council		\$1,778,000,000	4
HealthSouth Corp.	17	\$804,500,000	
Cardinal Health, Inc.	24	\$600,000,000	
WellCare Health Plans, Inc.	83	\$200,000,000	
Broadcom Corp.	93	\$173,500,000	

MOST FREQUENT LEAD COUNSEL IN THE TOP 100²



² Totals exceed 100 as a number of Top 100 settlements include more than one law firm as lead counsel.

LEAD COUNSEL PARTICIPATION

Most Frequent Lead/Co-Lead Counsel in Top 100 Settlements

LEAD / CO-LEAD COUNSEL CASE NAME	RANK	TOTAL SETTLEMENT AMOUNT
Bernstein Litowitz Berger & Grossmann		\$25,572,491,840
WorldCom, Inc.	2	\$6,194,100,714
Cendant Corp.	3	\$3,319,350,000
Bank of America Corporation	7	\$2,425,000,000
Nortel Networks Corp. (II)	11	\$1,074,265,298
Merck & Co., Inc.	12	\$1,062,000,000
McKesson HBOC Inc.	13	\$1,052,000,000
HealthSouth Corp.	17	\$804,500,000
Lehman Brothers Holdings, Inc.	19	\$735,218,000
Citigroup Bonds	20	\$730,000,000
Lucent Technologies, Inc.	21	\$667,000,000
Wachovia Preferred Securities and Bond/Notes	22	\$627,000,000
Bear Stearns Mortgage Pass-Through Certificates	27	\$500,000,000
Wells Fargo & Company	31	\$480,000,000
Schering-Plough Corp.	35	\$473,000,000
Federal Home Loan Mortgage Corp. (Freddie Mac)	40	\$410,000,000
Refco, Inc.	45	\$358,300,000
Merrill Lynch Mortgage Investors, Inc.	50	\$315,000,000
Williams Companies, Inc.	51	\$311,000,000
General Motors Company	54	\$300,000,000
Bristol-Myers Squibb Co.	54	\$300,000,000
DaimlerChrysler AG	54	\$300,000,000
El Paso Corporation	59	\$285,000,000
J.P. Morgan Acceptance Corp. I	61	\$280,000,000
3Com Corp.	67	\$259,000,000

LEAD / CO-LEAD COUNSEL CASE NAME	RANK	TOTAL SETTLEMENT AMOUNT
Allergan, Inc.	68	\$250,000,000
MF Global Holdings Ltd.	71	\$234,257,828
Genworth Financial, Inc.	75	\$219,000,000
Washington Mutual, Inc.	76	\$216,750,000
Merck & Co., Inc.	77	\$215,000,000
Wilmington Trust Corporation	80	\$210,000,000
Salix Pharmaceuticals, Ltd.	80	\$210,000,000
The Mills Corp.	82	\$202,750,000
WellCare Health Plans, Inc.	83	\$200,000,000
The Bank of New York Mellon Corporation	91	\$180,000,000
Maxim Integrated Products, Inc.	94	\$173,000,000
Robbins Geller Rudman & Dowd		\$15,297,050,000
Enron Corp.	1	\$7,242,000,000
Household International, Inc.	8	\$1,575,000,000
UnitedHealth Group, Inc.	16	\$925,500,000
HealthSouth Corp.	17	\$804,500,000
Wachovia Preferred Securities and Bond/Notes	22	\$627,000,000
Cardinal Health, Inc.	24	\$600,000,000
Countrywide Financial Corp.	27	\$500,000,000
Dynegy Inc.	34	\$474,050,000
Qwest Communications International, Inc.	39	\$445,000,000
Pfizer, Inc.	41	\$400,000,000
J.P. Morgan Acceptance Corp. I	43	\$388,000,000
GS Mortgage Securities Corp.	65	\$272,000,000
Massey Energy Company	66	\$265,000,000
HCA Holdings, Inc.	77	\$215,000,000
Kinder Morgan, Inc.	83	\$200,000,000
Motorola, Inc.	83	\$200,000,000
Pharmacia Corp.	100	\$164,000,000

LEAD / CO-LEAD COUNSEL CASE NAME	RANK	TOTAL SETTLEMENT AMOUNT
Barrack, Rodos & Bacine		\$13,272,700,714
WorldCom, Inc.	2	\$6,194,100,714
Cendant Corp.	3	\$3,319,350,000
McKesson HBOC Inc.	13	\$1,052,000,000
American International Group, Inc.	15	\$970,500,000
Merrill Lynch & Co., Inc.	33	\$475,000,000
Bank of America Corporation	47	\$335,000,000
DaimlerChrysler AG	54	\$300,000,000
3Com Corp.	67	\$259,000,000
The Mills Corp.	82	\$202,750,000
Schering-Plough Corp.	98	\$165,000,000
Milberg		\$9,353,855,304
Tyco International, Ltd.	4	\$3,200,000,000
Nortel Networks Corp.l	9	\$1,142,775,308
Merck & Co., Inc.	12	\$1,062,000,000
Xerox Corp.	18	\$750,000,000
Lucent Technologies, Inc.	21	\$667,000,000
IPO Securities Litigation (Master Case)	26	\$585,999,996
Raytheon Company	36	\$460,000,000
Rite Aid Corp.	49	\$319,580,000
Oxford Health Plans Inc.	54	\$300,000,000
3Com Corp.	67	\$259,000,000
Sears, Roebuck & Co.	77	\$215,000,000
CMS Energy Corp.	83	\$200,000,000
MicroStrategy Inc.	88	\$192,500,000
Kessler Topaz Meltzer & Check		\$ 9,104,575,690
Tyco International, Ltd.	4	\$ 3,200,000,000
Bank of America Corporation	7	\$ 2,425,000,000
Lehman Brothers Holdings, Inc.	19	\$735,218,000

LEAD / CO-LEAD COUNSEL CASE NAME	RANK	TOTAL SETTLEMENT AMOUNT
Wachovia Preferred Securities and Bond/Notes	22	\$627,000,000
IPO Securities Litigation	26	\$585,999,996
Countrywide Financial Corp.	27	\$500,000,000
Tenet Healthcare Corp.	60	\$281,500,000
BNY Mellon, N.A.	61	\$280,000,000
Allergan, Inc.	68	\$250,000,000
Bernard L. Madoff Investment Securities LLC	74	\$219,857,694
Grant & Eisenhofer		\$6,372,722,944
Tyco International, Ltd.	4	\$3,200,000,000
Pfizer, Inc.	30	\$486,000,000
Global Crossing, Ltd.	38	\$447,800,000
Marsh & McLennan Companies, Inc.	41	\$400,000,000
Refco, Inc.	45	\$358,300,000
General Motors Corp.	53	\$303,000,000
DaimlerChrysler AG	54	\$300,000,000
Oxford Health Plans Inc.	54	\$300,000,000
Merck & Co., Inc.	77	\$215,000,000
Safety-Kleen Corp.	87	\$197,622,944
Digex, Inc.	98	\$165,000,000
Labaton Sucharow		\$5,244,400,000
American International Group, Inc.	14	\$1,009,500,000
HealthSouth Corp.	17	\$804,500,000
Countrywide Financial Corp.	23	\$624,000,000
Schering-Plough Corp.	35	\$473,000,000
Waste Management Inc.	37	\$457,000,000
General Motors Corp.	53	\$303,000,000
Bear Stearns Companies, Inc.	58	\$294,900,000
El Paso Corporation	59	\$285,000,000
Massey Energy Company	66	\$265,000,000

LEAD / CO-LEAD COUNSEL CASE NAME	RANK	TOTAL SETTLEMENT AMOUNT
WellCare Health Plans, Inc.	83	\$200,000,000
Bristol-Myers Squibb Co.	90	\$185,000,000
Broadcom Corp.	93	\$173,500,000
Federal National Mortgage Association (Fannie Mae)	95	\$170,000,000
Kaplan Fox & Kilsheimer		\$3,329,000,000
Bank of America Corporation	7	\$2,425,000,000
Merrill Lynch & Co., Inc.	33	\$475,000,000
3Com Corp.	67	\$259,000,000
Federal National Mortgage Association (Fannie Mae)	95	\$170,000,000
Pomerantz		\$3,225,000,000
Petroleo Brasileiro S.A. - Petrobras	5	\$3,000,000,000
Comverse Technology, Inc.	72	\$225,000,000
Heins Mills & Olson		\$2,500,000,000
AOL Time Warner, Inc.	6	\$2,500,000,000
Berman Tabacco		\$2,320,900,000
Xerox Corp.	18	\$750,000,000
IndyMac Mortgage Pass-Through Certificates	46	\$346,000,000
Bristol-Myers Squibb Co.	54	\$300,000,000
Bear Stearns Companies, Inc.	58	\$294,900,000
El Paso Corporation	59	\$285,000,000
BP p.l.c.	92	\$175,000,000
Federal National Mortgage Association (Fannie Mae)	95	\$170,000,000
Stull Stull & Brody		\$2,137,999,996
Merck & Co., Inc.	12	\$1,062,000,000
IPO Securities Litigation (Master Case)	26	\$585,999,996
BankAmerica Corp.	29	\$490,000,000
Kirby McInerney		\$1,830,725,000
Citigroup, Inc.	25	\$590,000,000
Adelphia Communications Corp.	32	\$478,725,000


LEAD / CO-LEAD COUNSEL CASE NAME	RANK	TOTAL SETTLEMENT AMOUNT
Cendant Corp. II	44	\$374,000,000
Waste Management Inc.	73	\$220,000,000
National City Corp.	97	\$168,000,000
Cohen Milstein Sellers & Toll		\$1,785,000,000
Bear Stearns Mortgage Pass-Through Certificates	27	\$500,000,000
Countrywide Financial Corp.	27	\$500,000,000
RALI Mortgage (Asset-Backed Pass-Through Certificates)	47	\$335,000,000
HarborView Mortgage Loan Trust	63	\$275,000,000
BP p.l.c.	92	\$175,000,000
Entwistle & Cappucci		\$1,600,000,000
Royal Ahold, N.V.	10	\$1,100,000,000
DaimlerChrysler AG	54	\$300,000,000
CMS Energy Corp.	83	\$200,000,000
Brower Piven		\$1,062,000,000
Merck & Co., Inc.	12	\$1,062,000,000
Berger & Montague		\$1,014,580,000
Merrill Lynch & Co., Inc.	33	\$475,000,000
Rite Aid Corp.	49	\$319,580,000
Waste Management Inc.	73	\$220,000,000
Hahn Loeser & Parks		\$1,009,500,000
American International Group, Inc.	14	\$1,009,500,000
Bernstein Liebhard		\$985,999,996
IPO Securities Litigation (Master Case)	26	\$585,999,996
Marsh & McLennan Companies, Inc.	41	\$400,000,000
The Miller Law Firm		\$970,500,000
American International Group, Inc.	15	\$970,500,000
Abbey Spanier Rodd Abrams & Paradis		\$968,725,000
BankAmerica Corp.	29	\$490,000,000
Adelphia Communications Corp.	32	\$478,725,000

LEAD / CO-LEAD COUNSEL CASE NAME	RANK	TOTAL SETTLEMENT AMOUNT
Chitwood Harley Harnes		\$963,000,000
BankAmerica Corp.	29	\$490,000,000
Oxford Health Plans Inc.	54	\$300,000,000
Maxim Integrated Products, Inc.	94	\$173,000,000
Cunningham Bounds		\$804,500,000
HealthSouth Corp.	17	\$804,500,000
Wolf Haldenstein Adler Freeman & Herz		\$778,499,996
IPO Securities Litigation (Master Case)	26	\$585,999,996
MicroStrategy Inc.	88	\$192,500,000
Johnson & Perkinson		\$750,000,000
Xerox Corp.	18	\$750,000,000
Girard Gibbs		\$735,218,000
Lehman Brothers Holdings, Inc.	19	\$735,218,000
Wolf Popper		\$705,250,000
J.P. Morgan Acceptance Corp. I	61	\$280,000,000
Bernard L. Madoff Investment Securities LLC	69	\$235,250,000
Motorola, Inc.	89	\$190,000,000
Howard B. Sirota, Esq.		\$585,999,996
IPO Securities Litigation (Master Case)	26	\$585,999,996
Green Schaaf & Jacobson		\$490,000,000
BankAmerica Corp.	29	\$490,000,000
Motley Rice		\$480,000,000
Wells Fargo & Company	31	\$480,000,000
Lite, DePalma, Greenberg & Rivas		\$471,500,000
Tenet Healthcare Corp.	60	\$281,500,000
Motorola, Inc.	89	\$190,000,000
Bleichmar Fonti Tountas & Auld		\$453,257,828
MF Global Holdings Ltd.	71	\$234,257,828
Genworth Financial, Inc.	75	\$219,000,000

LEAD / CO-LEAD COUNSEL CASE NAME	RANK	TOTAL SETTLEMENT AMOUNT
Barrett & Weber		\$410,000,000
Federal Home Loan Mortgage Corp. (Freddie Mac)	40	\$410,000,000
Waite, Schneider, Bayless & Chesley		\$410,000,000
Federal Home Loan Mortgage Corp. (Freddie Mac)	40	\$410,000,000
Lowey Dannenberg Cohen & Hart		\$389,357,694
Bernard L. Madoff Investment Securities LLC	74	\$219,857,694
Juniper Networks, Inc.	96	\$169,500,000
Susman Godfrey		\$311,000,000
Williams Companies, Inc.	51	\$311,000,000
Francis Law		\$310,000,000
Caremark, Rx, Inc. f/k/a MedPartners, Inc.	52	\$310,000,000
Somerville		\$310,000,000
Caremark, Rx, Inc. f/k/a MedPartners, Inc.	52	\$310,000,000
Hare, Wynn, Newell & Newton		\$310,000,000
Caremark, Rx, Inc. f/k/a MedPartners, Inc.	52	\$310,000,000
Nix, Patterson & Roach		\$280,000,000
BNY Mellon, N.A.	61	\$280,000,000
Friedlander & Gorris		\$275,000,000
Activision Blizzard, Inc.	63	\$275,000,000
Bragar Egel & Squire		\$275,000,000
Activision Blizzard, Inc.	63	\$275,000,000
Boies, Schiller & Flexner		\$235,250,000
Bernard L. Madoff Investment Securities LLC	69	\$235,250,000
Lovell Stewart Halebian Jacobson		\$235,250,000
Bernard L. Madoff Investment Securities LLC	69	\$235,250,000
Hagens Berman Sobol Shapiro		\$235,000,000
Charles Schwab & Co., Inc.	70	\$235,000,000
Abbey, Gardy & Squitieri		\$220,000,000
Waste Management Inc.	73	\$220,000,000

LEAD / CO-LEAD COUNSEL CASE NAME	RANK	TOTAL SETTLEMENT AMOUNT
Saxena White		\$210,000,000
Wilmington Trust Corporation	80	\$210,000,000
The Nygaard Law Firm		\$200,000,000
Kinder Morgan, Inc.	83	\$200,000,000
Chimicles & Tikellis		\$200,000,000
Kinder Morgan, Inc.	83	\$200,000,000
Block & Leviton		\$175,000,000
BP p.l.c.	92	\$175,000,000

MOST FREQUENT CLAIMS ADMINISTRATOR IN THE TOP 100³



³ Totals exceed 100 as a number of Top 100 settlements include more than one claims administrator.

*Includes settlements under Garden City Group, Epiq Systems, Inc. and Epiq Class Action & Claims Solutions, Inc. (in June of 2018, Epiq Global acquired Garden City Group).

**Includes settlement under Complete Claim Solutions, Inc.

CLAIMS ADMINISTRATOR PARTICIPATION CLAIMS ADMINISTRATOR CASE NAME	RANK	CASE SETTLEMENT AMOUNT	TOTAL AMOUNT SETTLED
Epiq Global			\$33,970,597,782
WorldCom, Inc.	2	\$6,194,100,714	
Tyco International, Ltd.	4	\$3,200,000,000	
Petroleo Brasileiro S.A. – Petrobras	5	\$3,000,000,000	
Bank of America Corporation	7	\$2,425,000,000	
Nortel Networks Corp.	9	\$1,142,775,308	
Royal Ahold, N.V.	10	\$1,100,000,000	
Nortel Networks Corp.	11	\$1,074,265,298	
Merck & Co., Inc.	12	\$1,062,000,000	
Citigroup Bonds	20	\$730,000,000	
Lucent Technologies, Inc.	21	\$667,000,000	
Wachovia Preferred Securities and Bond/Notes	22	\$627,000,000	
Lehman Brothers Holdings, Inc.	19	\$615,218,000	
Citigroup, Inc.	25	\$590,000,000	
IPO Securities Litigation	26	\$585,999,996	
Countrywide Financial Corp.	27	\$500,000,000	
Bear Stearns Mortgage Pass-Through Certificates	27	\$500,000,000	
Pfizer, Inc.	30	\$486,000,000	
Wells Fargo & Company	31	\$480,000,000	
Schering-Plough Corp.	35	\$473,000,000	
Global Crossing, Ltd.	38	\$447,800,000	
Federal Home Loan Mortgage Corp. (Freddie Mac)	40	\$410,000,000	
Refco, Inc.	45	\$358,300,000	
RALI Mortgage (Asset-Backed Pass-Through Certificates)	47	\$335,000,000	
Merrill Lynch Mortgage Investors, Inc.	50	\$315,000,000	
Williams Companies, Inc.	51	\$311,000,000	
General Motors Corp.	53	\$303,000,000	
DaimlerChrysler AG	54	\$300,000,000	
Bristol-Myers Squibb Co.	54	\$300,000,000	
General Motors Company	54	\$300,000,000	
Oxford Health Plans Inc.	54	\$300,000,000	
Bear Stearns Companies, Inc.	58	\$294,900,000	

CLAIMS ADMINISTRATOR PARTICIPATION CLAIMS ADMINISTRATOR CASE NAME	RANK	CASE SETTLEMENT AMOUNT	TOTAL AMOUNT SETTLED
Tenet Healthcare Corp.	60	\$281,500,000	
J.P. Morgan Acceptance Corp. I	61	\$280,000,000	
BNY Mellon, N.A.	61	\$280,000,000	
Allergan, Inc.	68	\$250,000,000	
MF Global Holdings Ltd.	71	\$234,257,828	
Bernard L. Madoff Investment Securities LLC	74	\$219,857,694	
Genworth Financial, Inc.	75	\$219,000,000	
Washington Mutual, Inc.	76	\$216,750,000	
Merck & Co., Inc.	77	\$215,000,000	
Sears, Roebuck & Co.	77	\$215,000,000	
Wilmington Trust Corporation	80	\$210,000,000	
Salix Pharmaceuticals, Ltd.	80	\$210,000,000	
The Mills Corp.	82	\$202,750,000	
Kinder Morgan, Inc.	83	\$200,000,000	
WellCare Health Plans, Inc.	83	\$200,000,000	
CMS Energy Corp.	83	\$200,000,000	
Safety-Kleen Corp.	87	\$197,622,944	
Bristol-Myers Squibb Co.	90	\$185,000,000	
The Bank of New York Mellon Corporation	91	\$180,000,000	
Broadcom Corp.	93	\$173,500,000	
Maxim Integrated Products, Inc.	94	\$173,000,000	
Gilardi & Co.			\$18,437,130,000
Enron Corp.	1	\$7,242,000,000	
AOL Time Warner, Inc.	6	\$2,500,000,000	
Household International, Inc.	8	\$1,575,000,000	
American International Group, Inc.	15	\$970,500,000	
UnitedHealth Group, Inc.	16	\$925,500,000	
Xerox Corp.	18	\$750,000,000	
Cardinal Health, Inc.	24	\$600,000,000	
Dynegy Inc.	34	\$474,050,000	
Qwest Communications International, Inc.	39	\$445,000,000	
Pfizer, Inc.	41	\$400,000,000	
J.P. Morgan Acceptance Corp. I	43	\$388,000,000	

CLAIMS ADMINISTRATOR PARTICIPATION CLAIMS ADMINISTRATOR CASE NAME	RANK	CASE SETTLEMENT AMOUNT	TOTAL AMOUNT SETTLED
Rite Aid Corp.	49	\$319,580,000	
Caremark, Rx, Inc. f/k/a MedPartners, Inc.	52	\$310,000,000	
GS Mortgage Securities Corp.	65	\$272,000,000	
3Com Corp.	67	\$259,000,000	
Charles Schwab & Co., Inc.	70	\$235,000,000	
HCA Holdings, Inc.	77	\$215,000,000	
Motorola, Inc.	83	\$200,000,000	
MicroStrategy Inc.	88	\$192,500,000	
Pharmacia Corp.	100	\$164,000,000	
Rust Consulting, Inc.			\$4,710,750,000
American International Group, Inc.	14	\$912,000,000	
HealthSouth Corp.	17	\$804,500,000	
Countrywide Financial Corp.	23	\$624,000,000	
Merrill Lynch & Co., Inc.	33	\$475,000,000	
Waste Management Inc.	37	\$457,000,000	
Marsh & McLennan Companies, Inc.	41	\$400,000,000	
IndyMac Mortgage Pass-Through Certificates	46	\$346,000,000	
Bernard L. Madoff Investment Securities LLC	69	\$235,250,000	
Motorola, Inc.	89	\$190,000,000	
Juniper Networks, Inc.	96	\$169,500,000	
American International Group, Inc. ⁴	14	\$97,500,000	
Heffler, Radetich & Saitta, L.L.P.			\$4,529,350,000
Cendant Corp.	3	\$3,319,350,000	
BankAmerica Corp.	29	\$490,000,000	
Bank of America Corporation	47	\$335,000,000	
Waste Management Inc.	73	\$220,000,000	
Schering-Plough Corp.	98	\$165,000,000	
Analytics, Inc.			\$1,502,500,000
McKesson HBOC Inc. ⁵	13	\$1,042,500,000	
Raytheon Company	36	\$460,000,000	
A.B. Data, Ltd.			\$1,015,000,000

⁴ Partial administration under Complete Claim Solutions, Inc.

⁵ Partial administration on the full settlement of the Action.


CLAIMS ADMINISTRATOR PARTICIPATION CLAIMS ADMINISTRATOR CASE NAME	RANK	CASE SETTLEMENT AMOUNT	TOTAL AMOUNT SETTLED
El Paso Corporation	59	\$285,000,000	
Massey Energy Company	66	\$265,000,000	
BP p.l.c.	92	\$175,000,000	
Federal National Mortgage Association (Fannie Mae)	95	\$170,000,000	
Lehman Brothers Holdings, Inc. ⁶	19	\$120,000,000	
Valley Forge Administrative Services, Inc.			\$852,725,000
Adelphia Communications Corp.	32	\$478,725,000	
Cendant Corp. II	44	\$374,000,000	
Kurtzman Carson Consultants			\$550,000,000
HarborView Mortgage Loan Trust	63	\$275,000,000	
Activision Blizzard, Inc.	63	\$275,000,000	
Berdon Claims Administration LLC			\$225,000,000
Comverse Technology, Inc.	72	\$225,000,000	
BMC Group			\$177,500,000
National City Corp.	97	\$168,000,000	
McKesson HBOC Inc. ⁷	13	\$9,500,000	
Digex, Inc.			\$165,000,000
Digex, Inc.	98	\$165,000,000	

⁶ Partial administration on the full settlement of the Action.

⁷ Partial administration on the full settlement of the Action.

CASES INVOLVING ACCOUNTING RESTATEMENTS IN THE TOP 100 SETTLEMENTS

Cases Involving Accounting Restatements in Top 100 Settlements



RESTATEMENTS IN THE TOP 100


RANK	COMPANY NAME	FINAL SETTLEMENT AMOUNT	SETTLEMENT YEAR
1	Enron Corp.	\$7,242,000,000	2010
2	WorldCom, Inc.	\$6,194,100,714	2012
3	Cendant Corp.	\$3,319,350,000	2000
4	Tyco International, Ltd.	\$3,200,000,000	2007
5	Petroleo Brasileiro S.A. - Petrobras	\$3,000,000,000	2018
6	AOL Time Warner, Inc.	\$2,500,000,000	2006
9	Nortel Networks Corp.	\$1,142,775,308	2006
10	Royal Ahold, N.V.	\$1,100,000,000	2006
11	Nortel Networks Corp.	\$1,074,265,298	2006
13	McKesson HBOC Inc.	\$1,052,000,000	2013
14	American International Group, Inc.	\$1,009,500,000	2013
15	American International Group, Inc.	\$970,500,000	2015
16	UnitedHealth Group, Inc.	\$925,500,000	2009



RANK	COMPANY NAME	FINAL SETTLEMENT AMOUNT	SETTLEMENT YEAR
17	HealthSouth Corp.	\$804,500,000	2010
18	Xerox Corp.	\$750,000,000	2009
21	Lucent Technologies, Inc.	\$667,000,000	2003
23	Countrywide Financial Corp.	\$624,000,000	2011
24	Cardinal Health, Inc.	\$600,000,000	2007
32	Adelphia Communications Corp.	\$478,725,000	2013
37	Waste Management Inc.	\$457,000,000	2003
38	Global Crossing, Ltd.	\$447,800,000	2007
39	Qwest Communications International, Inc.	\$445,000,000	2009
40	Federal Home Loan Mortgage Corp. (Freddie Mac)	\$410,000,000	2006
45	Refco, Inc.	\$358,300,000	2011
49	Rite Aid Corp.	\$319,580,000	2003
53	General Motors Corp.	\$303,000,000	2009
54	Bristol-Myers Squibb Co.	\$300,000,000	2004
59	El Paso Corporation	\$285,000,000	2007
67	3Com Corp.	\$259,000,000	2001
72	Comverse Technology, Inc.	\$225,000,000	2010
73	Waste Management Inc.	\$220,000,000	1999
82	The Mills Corp.	\$202,750,000	2009
83	CMS Energy Corp.	\$200,000,000	2007
83	WellCare Health Plans, Inc.	\$200,000,000	2011
87	Safety-Kleen Corp.	\$197,622,944	2006
88	MicroStrategy Inc.	\$192,500,000	2001
93	Broadcom Corp.	\$173,500,000	2012
94	Maxim Integrated Products, Inc.	\$173,000,000	2010
95	Federal National Mortgage Association (Fannie Mae)	\$170,000,000	2015
96	Juniper Networks, Inc.	\$169,500,000	2010



NUMBER OF SETTLEMENTS ADDED TO TOP 50 SEC DISGORGEMENTS⁸



TOP 50 SEC DISGORGEMENTS

Cases Listed in Top 50 Disgorgements Categorized by Settlement Amount

RANK	COMPANY NAME	SETTLEMENT YEAR	TOTAL SETTLEMENT AMOUNT
1	American International Group, Inc.	2008	\$800,000,000
2	WorldCom, Inc.	2003	\$750,000,000
3	Wyeth/Elan Corporation, plc	2016	\$601,832,697
4	BP p.l.c.	2012	\$525,000,000
5	Enron Corp.	2008	\$450,000,000
6	Stanford International Bank Ltd.	2018	\$398,753,165
7	Banc of America Capital Management, LLC	2007	\$375,000,000
8	Federal National Mortgage Association	2007	\$350,000,001
9	Invesco Funds	2008	\$325,000,000
10	Time Warner Inc.	2005	\$308,000,000

⁸ There are 54 companies listed within the Top 50 SEC Disgorgements as five companies are tied with the 50th largest pay-outs.

RANK	COMPANY NAME	SETTLEMENT YEAR	TOTAL SETTLEMENT AMOUNT
11	Citigroup Global Markets Inc.	2017	\$287,550,000
12	Prudential Securities	2010	\$270,000,000
13	Qwest Communications International Inc.	2006	\$252,869,388
14	Alliance Capital Management L.P.	2008	\$250,000,000
14	PBHG Mutual Funds	2004	\$250,000,000
14	Bear Stearns	2008	\$250,000,000
17	NYSE Specialist Firms	2004	\$247,557,022
18	Jay Peak Receivership Entities	2018	\$234,934,964
19	Massachusetts Financial Services Co.	2007	\$225,629,142
20	J.P. Morgan Securities LLC	2017	\$222,415,536
21	JPMorgan Chase & Co.	2015	\$200,000,000
22	Computer Sciences Corporation	2015	\$190,948,983
23	Millennium Partners, L.P.	2007	\$180,575,005
24	Putnam Investment Management, LLC	2007	\$153,524,387
25	Bristol-Myers Squibb Co.	2004	\$150,000,001
25	Bank of America Corporation	2010	\$150,000,001
27	Strong Capital Management, Inc.	2009	\$140,750,000
28	Columbia Funds	2007	\$140,000,000
29	American International Group, Inc.	2004	\$126,366,000
30	Canadian Imperial Holdings Inc./CIBC World Markets Corp.	2010	\$125,000,000
31	Royal Dutch Petroleum / Shell Transport	2008	\$120,000,000
32	Charles Schwab Investment	2011	\$110,000,000
33	Convergex Global Markets	2015	\$109,440,738
34	Credit Suisse Securities	2012	\$101,747,769
35	Capital Consultants, LLC	2002	\$100,000,000
35	HealthSouth Corp.	2007	\$100,000,000
35	Janus Capital Management LLC	2008	\$100,000,000
38	Adelphia Communications Corp.	2009	\$95,000,000

RANK	COMPANY NAME	SETTLEMENT YEAR	TOTAL SETTLEMENT AMOUNT
39	Edward D. Jones & Co.	2004	\$75,000,000
40	J.P. Morgan Securities LLC	2017	\$74,500,000
41	Federated Funds	2010	\$72,000,000
42	American Skandia Investment Services, Inc.	2010	\$68,000,000
43	Knight Securities, L.P.	2004	\$66,841,731
44	Focus Media Holding Limited	2015	\$55,627,865
45	PIMCO Equity Funds	2010	\$55,479,005
46	Vivendi Universal, S.A.	2004	\$51,268,151
47	Federal Home Loan Mortgage Corporation	2007	\$50,755,388
48	Tyco International Ltd.	2010	\$50,000,001
48	MBIA, Inc.	2008	\$50,000,001
50	Adelphia Communications Corp.	2009	\$50,000,000
50	Franklin Advisers, Inc.	2008	\$50,000,000
50	Banc One Investment Advisors Corp.	2007	\$50,000,000
50	AIM Advisors, Inc. / AIM Distributors, Inc.	2008	\$50,000,000
50	McAfee, Inc.	2009	\$50,000,000

GLOSSARY

CLAIMS ADMINISTRATOR	An entity selected by the Lead Counsel or appointed by the court to manage the settlement notification and claim process.
DISGORGEMENT	A repayment of ill-gotten gains that is imposed on wrong-doers by the courts.
FINAL SETTLEMENTS	Settlements that received final approval from the court.
INSTITUTIONAL LEAD PLAINTIFF	An institutional shareholder or group of institutional shareholders appointed by the court to represent the interests of a class or classes of similarly situated shareholders.
LEAD COUNSEL	Law firm, or lawyer, appointed by the court, that prosecutes a class action on behalf of the class members.
PARTIAL SETTLEMENT	A preliminary agreement between some of the identified defendants in the action.
PSLRA (PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995)	Legislation passed by Congress that implemented several substantive changes in the United States, affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation, and awards fees and expenses.
SETTLEMENT YEAR	Corresponds to the year the settlement, or the most recent partial settlement, received final approval from the Court.
TOTAL SETTLEMENT AMOUNT	Refers to the sum of the settlement fund or the gross settlement fund approved by the court.

NEVER MISS AN OPPORTUNITY FOR RECOVERY.

GET STARTED WITH SECURITIES CLASS ACTION SERVICES

Email sales@issgovernance.com or visit issgovernance.com/class-actions for more information.

Managing Editor:

Jeffrey Lubitz, *Executive Director, Head of ISS Securities Class Action Services*

Executive Editor:

Stephanie Bounds, *Vice President, ISS Marketing*

Content Editor:

Mark Lloyd Flores, *Associate Vice President, ISS Securities Class Action Services Research*

Production & Design:

Kiko Sanchez, *Associate Vice President, ISS Marketing*

For questions, comments or suggestions, please email marketing@issgovernance.com.

Founded in 1985 as Institutional Shareholder Services Inc., ISS is the world's leading provider of corporate governance and responsible investment (RI) solutions for asset owners, asset managers, hedge funds, and asset service providers. ISS' solutions include: objective governance research and recommendations; RI data, analytics, and research; end-to-end proxy voting and distribution solutions; turnkey securities class-action claims management (provided by Securities Class Action Services, LLC); and reliable global governance data and modeling tools. Clients rely on ISS' expertise to help them make informed corporate governance decisions. For more information, please visit www.issgovernance.com.

This document and all of the information contained in it is the property of Institutional Shareholder Services Inc. ("ISS") or its subsidiaries. The Information may not be reproduced or disseminated in whole or in part without prior written permission of ISS. ISS makes no express or implied warranties or representations with respect to the information.

© 2019 | Institutional Shareholder Services and/or its affiliates

EXHIBIT C

Bausch Health Companies Inc. / Valeant Pharmaceuticals International, Inc.		
Source: Bloomberg		
Dates	VOLUME	PRICE
1/2/2013	2,440,491	\$60.75
1/3/2013	2,613,482	\$61.07
1/4/2013	3,051,734	\$60.71
1/7/2013	1,212,980	\$61.31
1/8/2013	1,616,273	\$62.29
1/9/2013	1,605,180	\$63.82
1/10/2013	1,279,175	\$63.91
1/11/2013	1,074,197	\$63.63
1/14/2013	697,803	\$63.58
1/15/2013	1,396,744	\$63.70
1/16/2013	1,232,880	\$63.52
1/17/2013	1,594,335	\$63.78
1/18/2013	1,042,933	\$63.77
1/22/2013	1,369,962	\$64.20
1/23/2013	1,074,313	\$63.84
1/24/2013	1,002,885	\$64.55
1/25/2013	1,290,069	\$65.64
1/28/2013	818,236	\$65.55
1/29/2013	1,604,883	\$65.85
1/30/2013	2,315,797	\$66.17
1/31/2013	1,276,536	\$66.32
2/1/2013	1,215,302	\$67.25
2/4/2013	1,606,077	\$66.41
2/5/2013	1,041,721	\$66.64
2/6/2013	627,611	\$66.91
2/7/2013	689,491	\$67.24
2/8/2013	725,317	\$67.80
2/11/2013	852,626	\$67.56
2/12/2013	842,685	\$67.43
2/13/2013	916,362	\$67.50
2/14/2013	1,223,885	\$66.39
2/15/2013	1,040,306	\$66.53
2/19/2013	691,286	\$67.02
2/20/2013	1,087,092	\$66.24
2/21/2013	1,372,140	\$65.69
2/22/2013	862,008	\$65.74
2/25/2013	1,047,789	\$65.46
2/26/2013	1,074,034	\$65.16
2/27/2013	1,180,091	\$66.74
2/28/2013	1,180,403	\$67.46
3/1/2013	2,117,891	\$67.63
3/4/2013	2,537,576	\$69.41
3/5/2013	1,293,727	\$69.79
3/6/2013	894,908	\$68.52
3/7/2013	1,152,005	\$69.84
3/8/2013	1,186,218	\$70.78
3/11/2013	901,778	\$70.53
3/12/2013	999,264	\$70.60
3/13/2013	1,031,780	\$69.93

3/14/2013	1,251,494	\$70.07
3/15/2013	1,708,693	\$69.86
3/18/2013	1,117,805	\$70.54
3/19/2013	2,820,690	\$71.44
3/20/2013	2,211,322	\$73.33
3/21/2013	2,027,748	\$72.86
3/22/2013	1,376,702	\$73.97
3/25/2013	1,264,147	\$73.95
3/26/2013	774,675	\$74.40
3/27/2013	925,063	\$74.12
3/28/2013	845,941	\$75.02
4/1/2013	1,298,248	\$76.05
4/2/2013	1,958,671	\$75.37
4/3/2013	6,156,140	\$71.87
4/4/2013	4,019,334	\$72.61
4/5/2013	1,120,581	\$71.79
4/8/2013	934,206	\$72.12
4/9/2013	1,036,291	\$72.12
4/10/2013	799,729	\$73.00
4/11/2013	888,561	\$73.79
4/12/2013	932,020	\$73.17
4/15/2013	1,130,387	\$72.12
4/16/2013	755,184	\$73.09
4/17/2013	879,951	\$72.86
4/18/2013	814,091	\$72.81
4/19/2013	1,188,202	\$75.52
4/22/2013	1,056,759	\$74.20
4/23/2013	946,133	\$74.98
4/24/2013	942,520	\$74.82
4/25/2013	1,545,251	\$73.59
4/26/2013	1,249,102	\$73.16
4/29/2013	3,607,445	\$75.94
4/30/2013	1,427,554	\$76.08
5/1/2013	1,638,794	\$73.69
5/2/2013	1,830,845	\$72.15
5/3/2013	1,228,639	\$73.68
5/6/2013	835,868	\$73.42
5/7/2013	725,895	\$74.07
5/8/2013	713,719	\$73.86
5/9/2013	1,267,047	\$72.74
5/10/2013	2,889,503	\$73.52
5/13/2013	1,427,283	\$75.89
5/14/2013	1,426,090	\$77.30
5/15/2013	854,081	\$76.33
5/16/2013	724,410	\$75.75
5/17/2013	1,428,714	\$78.17
5/20/2013	1,113,303	\$75.38
5/21/2013	1,035,670	\$75.53
5/22/2013	871,930	\$74.82
5/23/2013	652,291	\$74.67
5/24/2013	10,383,614	\$84.47
5/28/2013	11,535,925	\$91.80
5/29/2013	3,686,109	\$90.81
5/30/2013	1,595,792	\$91.00
5/31/2013	1,825,065	\$91.12

6/3/2013	1,817,685	\$88.21
6/4/2013	1,919,464	\$85.18
6/5/2013	1,627,664	\$84.16
6/6/2013	1,100,376	\$84.87
6/7/2013	1,284,509	\$85.59
6/10/2013	1,019,940	\$85.11
6/11/2013	1,141,127	\$83.77
6/12/2013	1,298,639	\$83.36
6/13/2013	1,131,367	\$85.81
6/14/2013	1,129,905	\$84.20
6/17/2013	909,255	\$84.82
6/18/2013	2,443,519	\$85.86
6/19/2013	8,347,277	\$86.41
6/20/2013	3,789,901	\$83.84
6/21/2013	2,611,365	\$84.42
6/24/2013	1,860,505	\$84.00
6/25/2013	2,052,317	\$85.24
6/26/2013	1,814,426	\$84.95
6/27/2013	2,505,669	\$86.15
6/28/2013	1,555,092	\$86.08
7/1/2013	1,793,378	\$88.00
7/2/2013	2,481,608	\$89.99
7/3/2013	850,965	\$89.50
7/5/2013	798,289	\$88.77
7/8/2013	1,246,951	\$90.03
7/9/2013	1,506,866	\$89.96
7/10/2013	974,883	\$90.20
7/11/2013	1,730,177	\$92.47
7/12/2013	1,346,523	\$92.90
7/15/2013	1,569,097	\$93.80
7/16/2013	1,547,903	\$91.53
7/17/2013	1,282,859	\$91.45
7/18/2013	925,015	\$91.39
7/19/2013	1,081,458	\$90.80
7/22/2013	1,218,980	\$90.81
7/23/2013	1,047,818	\$90.49
7/24/2013	1,425,007	\$91.33
7/25/2013	1,075,012	\$91.99
7/26/2013	457,134	\$91.96
7/29/2013	666,411	\$91.70
7/30/2013	1,001,096	\$91.00
7/31/2013	1,375,561	\$93.60
8/1/2013	2,069,774	\$96.04
8/2/2013	890,428	\$96.45
8/5/2013	671,200	\$95.57
8/6/2013	1,203,944	\$95.72
8/7/2013	2,003,321	\$97.59
8/8/2013	2,147,139	\$101.68
8/9/2013	1,450,724	\$101.87
8/12/2013	1,437,813	\$101.95
8/13/2013	1,649,935	\$103.98
8/14/2013	1,502,534	\$103.90
8/15/2013	1,575,689	\$102.93
8/16/2013	1,045,688	\$103.00
8/19/2013	1,552,738	\$101.06

8/20/2013	801,528	\$101.53
8/21/2013	1,526,411	\$99.77
8/22/2013	1,098,597	\$99.30
8/23/2013	1,323,261	\$99.52
8/26/2013	995,724	\$99.60
8/27/2013	1,638,951	\$95.80
8/28/2013	798,809	\$97.85
8/29/2013	830,594	\$98.95
8/30/2013	1,030,693	\$98.34
9/3/2013	1,070,493	\$99.35
9/4/2013	1,006,312	\$99.94
9/5/2013	829,491	\$99.80
9/6/2013	740,413	\$100.24
9/9/2013	716,281	\$101.33
9/10/2013	958,879	\$100.20
9/11/2013	880,070	\$100.26
9/12/2013	610,388	\$99.57
9/13/2013	832,508	\$99.20
9/16/2013	798,057	\$101.22
9/17/2013	1,232,918	\$102.77
9/18/2013	1,074,628	\$102.83
9/19/2013	1,605,239	\$106.12
9/20/2013	1,450,764	\$104.41
9/23/2013	1,118,213	\$103.08
9/24/2013	1,965,707	\$103.73
9/25/2013	852,294	\$102.34
9/26/2013	449,579	\$103.29
9/27/2013	601,796	\$104.72
9/30/2013	782,145	\$104.33
10/1/2013	1,171,540	\$108.16
10/2/2013	1,529,637	\$109.80
10/3/2013	2,856,007	\$111.40
10/4/2013	1,743,115	\$111.01
10/7/2013	1,248,309	\$110.32
10/8/2013	1,727,848	\$105.92
10/9/2013	1,307,795	\$107.03
10/10/2013	871,091	\$110.00
10/11/2013	407,602	\$109.43
10/14/2013	587,129	\$109.78
10/15/2013	622,565	\$109.73
10/16/2013	627,279	\$110.63
10/17/2013	867,627	\$112.00
10/18/2013	998,527	\$113.02
10/21/2013	965,785	\$112.30
10/22/2013	992,549	\$112.53
10/23/2013	1,162,377	\$114.37
10/24/2013	1,281,521	\$114.29
10/25/2013	801,358	\$112.57
10/28/2013	1,085,402	\$110.42
10/29/2013	1,017,396	\$111.06
10/30/2013	1,543,256	\$109.06
10/31/2013	5,138,923	\$105.72
11/1/2013	2,534,980	\$111.20
11/4/2013	1,148,369	\$110.33
11/5/2013	729,848	\$109.45

11/6/2013	1,517,737	\$106.45
11/7/2013	1,399,433	\$103.04
11/8/2013	858,702	\$105.44
11/11/2013	593,987	\$105.16
11/12/2013	648,811	\$105.74
11/13/2013	1,038,086	\$107.15
11/14/2013	915,017	\$105.86
11/15/2013	1,118,708	\$107.12
11/18/2013	897,745	\$106.74
11/19/2013	620,194	\$105.92
11/20/2013	769,917	\$106.56
11/21/2013	947,406	\$108.68
11/22/2013	1,265,752	\$109.55
11/25/2013	783,160	\$108.99
11/26/2013	758,623	\$109.22
11/27/2013	469,002	\$108.35
11/29/2013	398,943	\$109.63
12/2/2013	836,316	\$109.78
12/3/2013	874,659	\$109.19
12/4/2013	1,096,868	\$107.90
12/5/2013	1,196,298	\$106.40
12/6/2013	946,804	\$107.67
12/9/2013	1,026,917	\$107.97
12/10/2013	1,022,771	\$108.62
12/11/2013	1,228,915	\$106.49
12/12/2013	1,008,785	\$106.24
12/13/2013	798,120	\$106.83
12/16/2013	2,012,646	\$110.92
12/17/2013	938,042	\$109.32
12/18/2013	1,295,597	\$112.41
12/19/2013	726,941	\$111.90
12/20/2013	1,051,402	\$112.00
12/23/2013	634,638	\$112.62
12/24/2013	380,257	\$113.02
12/26/2013	415,942	\$113.56
12/27/2013	543,650	\$113.60
12/30/2013	1,259,550	\$117.42
12/31/2013	1,062,666	\$117.40
1/2/2014	1,937,044	\$116.98
1/3/2014	787,409	\$117.16
1/6/2014	2,402,894	\$112.62
1/7/2014	3,319,543	\$125.35
1/8/2014	3,025,998	\$128.30
1/9/2014	1,383,371	\$132.17
1/10/2014	1,658,010	\$133.50
1/13/2014	1,560,857	\$130.62
1/14/2014	1,756,232	\$135.01
1/15/2014	1,188,750	\$133.50
1/16/2014	1,538,676	\$137.34
1/17/2014	2,320,659	\$137.93
1/21/2014	1,537,486	\$136.88
1/22/2014	897,892	\$137.82
1/23/2014	1,167,258	\$135.02
1/24/2014	1,712,269	\$132.12
1/27/2014	1,638,355	\$131.00

1/28/2014	1,000,331	\$132.80
1/29/2014	920,876	\$132.80
1/30/2014	1,166,037	\$136.60
1/31/2014	1,187,701	\$135.64
2/3/2014	1,531,155	\$133.36
2/4/2014	1,160,198	\$135.56
2/5/2014	1,432,436	\$134.61
2/6/2014	999,849	\$134.43
2/7/2014	1,550,801	\$137.93
2/10/2014	1,122,396	\$138.13
2/11/2014	1,915,328	\$141.31
2/12/2014	1,310,185	\$140.77
2/13/2014	1,281,257	\$141.79
2/14/2014	1,231,249	\$139.57
2/18/2014	2,208,738	\$146.47
2/19/2014	1,788,654	\$145.02
2/20/2014	2,110,264	\$148.00
2/21/2014	1,568,956	\$146.26
2/24/2014	1,544,198	\$145.73
2/25/2014	1,570,428	\$145.06
2/26/2014	2,905,274	\$146.34
2/27/2014	2,122,344	\$148.00
2/28/2014	2,276,748	\$144.86
3/3/2014	2,072,084	\$143.38
3/4/2014	1,499,853	\$146.23
3/5/2014	1,241,591	\$145.13
3/6/2014	4,773,397	\$138.55
3/7/2014	3,641,662	\$141.37
3/10/2014	1,923,329	\$140.74
3/11/2014	1,297,900	\$139.96
3/12/2014	1,768,491	\$141.00
3/13/2014	2,269,580	\$139.33
3/14/2014	1,255,793	\$140.01
3/17/2014	1,251,451	\$140.90
3/18/2014	1,321,478	\$144.18
3/19/2014	1,605,926	\$140.79
3/20/2014	991,331	\$140.40
3/21/2014	2,002,599	\$135.55
3/24/2014	3,474,965	\$131.47
3/25/2014	1,417,466	\$131.53
3/26/2014	2,483,092	\$129.07
3/27/2014	2,705,088	\$127.19
3/28/2014	2,178,878	\$127.68
3/31/2014	2,177,454	\$131.83
4/1/2014	2,060,264	\$133.25
4/2/2014	1,796,094	\$133.69
4/3/2014	1,948,793	\$129.10
4/4/2014	3,311,776	\$124.69
4/7/2014	4,164,465	\$119.23
4/8/2014	5,178,060	\$122.03
4/9/2014	3,226,627	\$129.34
4/10/2014	3,599,136	\$123.33
4/11/2014	2,061,729	\$118.79
4/14/2014	2,640,868	\$116.99
4/15/2014	2,877,066	\$120.12

4/16/2014	1,885,722	\$121.45
4/17/2014	1,358,672	\$122.05
4/21/2014	2,789,973	\$126.01
4/22/2014	17,982,948	\$135.41
4/23/2014	5,003,009	\$133.23
4/24/2014	3,109,829	\$134.42
4/25/2014	3,838,058	\$133.73
4/28/2014	5,589,725	\$133.51
4/29/2014	2,882,115	\$133.63
4/30/2014	2,306,175	\$133.71
5/1/2014	3,616,291	\$138.13
5/2/2014	2,561,880	\$136.35
5/5/2014	2,635,124	\$136.19
5/6/2014	2,243,730	\$133.35
5/7/2014	3,121,860	\$133.35
5/8/2014	2,649,712	\$131.17
5/9/2014	3,023,480	\$131.17
5/12/2014	3,864,072	\$130.16
5/13/2014	2,304,280	\$129.64
5/14/2014	2,966,968	\$126.97
5/15/2014	4,465,522	\$124.04
5/16/2014	3,373,114	\$126.76
5/19/2014	2,177,931	\$127.21
5/20/2014	4,848,673	\$130.97
5/21/2014	1,828,663	\$129.90
5/22/2014	1,900,913	\$130.83
5/23/2014	2,050,822	\$133.46
5/27/2014	4,363,751	\$129.95
5/28/2014	8,032,690	\$126.95
5/29/2014	3,480,497	\$129.22
5/30/2014	11,609,314	\$131.21
6/2/2014	6,252,306	\$134.17
6/3/2014	3,757,663	\$132.26
6/4/2014	4,965,026	\$128.82
6/5/2014	3,782,435	\$128.34
6/6/2014	1,979,523	\$127.46
6/9/2014	1,826,374	\$126.63
6/10/2014	2,497,256	\$125.55
6/11/2014	3,076,870	\$125.18
6/12/2014	6,213,629	\$120.75
6/13/2014	4,139,018	\$119.60
6/16/2014	4,226,568	\$117.75
6/17/2014	5,473,959	\$118.87
6/18/2014	3,683,456	\$118.43
6/19/2014	3,887,140	\$117.55
6/20/2014	4,799,731	\$121.93
6/23/2014	2,369,801	\$121.21
6/24/2014	2,201,761	\$120.52
6/25/2014	4,677,100	\$125.94
6/26/2014	2,757,852	\$126.50
6/27/2014	2,990,900	\$128.85
6/30/2014	2,314,502	\$126.12
7/1/2014	1,582,704	\$125.58
7/2/2014	1,380,760	\$126.00
7/3/2014	748,692	\$126.00

7/7/2014	1,679,756	\$123.29
7/8/2014	1,918,289	\$122.17
7/9/2014	1,186,918	\$120.94
7/10/2014	2,003,292	\$120.68
7/11/2014	1,116,839	\$120.47
7/14/2014	1,006,950	\$121.08
7/15/2014	1,957,091	\$119.45
7/16/2014	2,970,417	\$121.71
7/17/2014	2,543,436	\$121.52
7/18/2014	1,958,699	\$121.97
7/21/2014	3,235,480	\$125.54
7/22/2014	2,999,409	\$122.54
7/23/2014	2,031,367	\$124.62
7/24/2014	1,482,377	\$124.36
7/25/2014	1,014,642	\$123.52
7/28/2014	1,442,876	\$123.53
7/29/2014	1,250,324	\$123.70
7/30/2014	2,579,257	\$125.83
7/31/2014	11,037,063	\$117.39
8/1/2014	4,986,090	\$118.21
8/4/2014	1,913,688	\$116.79
8/5/2014	8,471,651	\$110.66
8/6/2014	3,925,751	\$110.02
8/7/2014	3,362,916	\$106.73
8/8/2014	2,691,632	\$109.17
8/11/2014	3,356,224	\$107.25
8/12/2014	2,076,489	\$108.07
8/13/2014	2,445,201	\$109.17
8/14/2014	4,394,741	\$111.04
8/15/2014	2,921,577	\$112.26
8/18/2014	2,657,609	\$109.78
8/19/2014	3,684,058	\$113.72
8/20/2014	1,784,311	\$113.10
8/21/2014	1,356,281	\$113.81
8/22/2014	3,026,793	\$117.26
8/25/2014	1,716,797	\$115.48
8/26/2014	1,593,183	\$117.10
8/27/2014	1,350,617	\$116.71
8/28/2014	1,104,945	\$116.86
8/29/2014	1,028,401	\$117.30
9/2/2014	1,916,662	\$120.10
9/3/2014	1,498,105	\$119.03
9/4/2014	1,508,458	\$117.32
9/5/2014	1,842,210	\$119.68
9/8/2014	1,355,904	\$120.05
9/9/2014	2,059,729	\$120.03
9/10/2014	1,805,731	\$119.88
9/11/2014	2,088,929	\$120.41
9/12/2014	2,500,847	\$122.05
9/15/2014	2,093,361	\$121.43
9/16/2014	1,491,611	\$122.15
9/17/2014	1,628,560	\$121.85
9/18/2014	1,620,882	\$120.52
9/19/2014	3,333,795	\$117.43
9/22/2014	2,054,508	\$116.28

9/23/2014	3,652,251	\$115.95
9/24/2014	6,956,796	\$124.00
9/25/2014	5,609,219	\$127.80
9/26/2014	2,910,623	\$128.99
9/29/2014	2,663,223	\$130.26
9/30/2014	2,320,935	\$131.20
10/1/2014	3,723,608	\$131.67
10/2/2014	3,947,292	\$126.99
10/3/2014	3,851,337	\$129.62
10/6/2014	1,675,803	\$128.41
10/7/2014	4,235,317	\$125.23
10/8/2014	2,382,843	\$125.90
10/9/2014	2,990,645	\$122.35
10/10/2014	3,191,133	\$118.29
10/13/2014	2,807,442	\$113.56
10/14/2014	2,761,865	\$114.94
10/15/2014	4,135,772	\$114.34
10/16/2014	3,188,192	\$118.54
10/17/2014	3,565,756	\$120.21
10/20/2014	3,400,991	\$124.78
10/21/2014	3,944,008	\$130.38
10/22/2014	1,928,610	\$128.77
10/23/2014	2,088,599	\$128.02
10/24/2014	1,831,757	\$129.13
10/27/2014	2,825,550	\$130.56
10/28/2014	2,741,232	\$131.07
10/29/2014	2,417,161	\$129.76
10/30/2014	1,507,549	\$131.51
10/31/2014	1,225,944	\$133.04
11/3/2014	2,174,644	\$132.85
11/4/2014	2,968,496	\$133.61
11/5/2014	2,314,442	\$131.91
11/6/2014	2,523,632	\$128.77
11/7/2014	2,713,765	\$126.11
11/10/2014	1,850,022	\$127.99
11/11/2014	2,360,916	\$130.03
11/12/2014	2,187,314	\$131.09
11/13/2014	1,482,145	\$131.90
11/14/2014	2,117,625	\$134.21
11/17/2014	8,868,287	\$136.73
11/18/2014	5,743,382	\$141.94
11/19/2014	2,277,791	\$142.47
11/20/2014	2,184,004	\$142.68
11/21/2014	2,258,349	\$145.37
11/24/2014	2,950,847	\$142.56
11/25/2014	1,440,591	\$144.76
11/26/2014	1,142,971	\$144.73
11/28/2014	978,673	\$145.45
12/1/2014	1,526,118	\$145.81
12/2/2014	1,237,274	\$146.39
12/3/2014	1,253,164	\$145.27
12/4/2014	1,254,666	\$144.33
12/5/2014	1,833,793	\$144.89
12/8/2014	1,238,737	\$143.94
12/9/2014	3,028,963	\$141.00

12/10/2014	1,812,813	\$137.96
12/11/2014	1,335,200	\$138.89
12/12/2014	1,062,695	\$138.71
12/15/2014	1,788,110	\$138.16
12/16/2014	1,570,558	\$136.92
12/17/2014	1,367,324	\$140.00
12/18/2014	2,207,293	\$143.00
12/19/2014	2,044,308	\$146.06
12/22/2014	2,214,878	\$144.16
12/23/2014	2,482,161	\$140.55
12/24/2014	593,594	\$140.33
12/26/2014	617,160	\$141.46
12/29/2014	577,641	\$141.87
12/30/2014	1,119,654	\$143.02
12/31/2014	1,188,218	\$143.11
1/2/2015	2,182,337	\$144.45
1/5/2015	2,674,901	\$144.29
1/6/2015	2,641,377	\$142.83
1/7/2015	2,214,315	\$145.12
1/8/2015	5,817,995	\$154.10
1/9/2015	2,039,747	\$153.58
1/12/2015	2,530,041	\$155.50
1/13/2015	3,583,114	\$158.04
1/14/2015	3,143,466	\$156.80
1/15/2015	2,444,900	\$154.29
1/16/2015	1,872,412	\$156.93
1/20/2015	1,959,591	\$156.05
1/21/2015	2,005,810	\$157.02
1/22/2015	2,034,009	\$159.19
1/23/2015	1,908,808	\$159.66
1/26/2015	1,652,760	\$159.86
1/27/2015	1,336,529	\$160.80
1/28/2015	2,141,402	\$160.59
1/29/2015	1,383,591	\$161.51
1/30/2015	1,409,813	\$159.97
2/2/2015	1,625,777	\$161.98
2/3/2015	3,684,925	\$159.71
2/4/2015	1,616,396	\$160.87
2/5/2015	2,237,119	\$161.45
2/6/2015	1,243,517	\$161.99
2/9/2015	2,506,030	\$160.10
2/10/2015	1,712,820	\$164.13
2/11/2015	2,207,722	\$164.34
2/12/2015	2,907,282	\$167.50
2/13/2015	1,206,057	\$167.00
2/17/2015	1,169,445	\$168.63
2/18/2015	974,180	\$168.42
2/19/2015	1,090,897	\$169.13
2/20/2015	3,499,487	\$173.26
2/23/2015	19,636,609	\$198.75
2/24/2015	12,810,324	\$202.00
2/25/2015	6,079,115	\$198.00
2/26/2015	5,874,674	\$201.25
2/27/2015	6,588,161	\$197.48
3/2/2015	6,050,766	\$203.35

3/3/2015	3,441,033	\$202.61
3/4/2015	3,207,068	\$203.15
3/5/2015	2,152,878	\$203.95
3/6/2015	3,756,156	\$198.71
3/9/2015	4,328,437	\$204.69
3/10/2015	2,665,476	\$201.48
3/11/2015	12,144,647	\$193.71
3/12/2015	3,872,461	\$192.62
3/13/2015	4,785,183	\$197.43
3/16/2015	3,917,437	\$202.34
3/17/2015	3,342,493	\$200.73
3/18/2015	1,528,791	\$203.41
3/19/2015	1,520,886	\$202.09
3/20/2015	1,165,763	\$204.26
3/23/2015	1,426,619	\$203.67
3/24/2015	1,274,410	\$203.11
3/25/2015	2,277,057	\$197.01
3/26/2015	1,980,496	\$198.46
3/27/2015	1,016,932	\$197.84
3/30/2015	1,310,585	\$201.38
3/31/2015	1,542,068	\$198.62
4/1/2015	1,876,148	\$197.39
4/2/2015	1,138,503	\$198.45
4/6/2015	1,077,249	\$197.84
4/7/2015	1,109,028	\$198.94
4/8/2015	1,990,232	\$205.96
4/9/2015	1,594,998	\$205.72
4/10/2015	1,162,145	\$207.50
4/13/2015	1,516,985	\$209.46
4/14/2015	1,538,181	\$208.94
4/15/2015	1,539,942	\$206.16
4/16/2015	972,141	\$207.36
4/17/2015	1,485,122	\$205.32
4/20/2015	976,561	\$205.21
4/21/2015	1,506,756	\$210.85
4/22/2015	1,997,812	\$206.93
4/23/2015	1,672,676	\$209.39
4/24/2015	1,515,541	\$210.42
4/27/2015	3,080,051	\$202.02
4/28/2015	3,268,444	\$205.46
4/29/2015	4,563,931	\$214.06
4/30/2015	4,263,626	\$216.93
5/1/2015	2,553,784	\$223.02
5/4/2015	1,627,467	\$222.86
5/5/2015	2,021,039	\$219.24
5/6/2015	1,113,699	\$216.26
5/7/2015	1,295,108	\$218.25
5/8/2015	1,282,841	\$221.88
5/11/2015	1,282,880	\$223.79
5/12/2015	1,691,380	\$222.96
5/13/2015	1,391,488	\$219.90
5/14/2015	931,397	\$222.82
5/15/2015	1,181,189	\$224.63
5/18/2015	1,220,604	\$225.43
5/19/2015	1,267,599	\$227.65

5/20/2015	1,360,291	\$228.47
5/21/2015	1,719,327	\$233.27
5/22/2015	1,945,397	\$237.53
5/26/2015	2,044,177	\$235.31
5/27/2015	2,389,990	\$239.12
5/28/2015	2,645,713	\$241.73
5/29/2015	1,395,498	\$238.77
6/1/2015	1,296,178	\$239.36
6/2/2015	1,374,361	\$238.00
6/3/2015	1,059,630	\$239.44
6/4/2015	1,341,810	\$232.88
6/5/2015	1,094,802	\$235.41
6/8/2015	1,338,678	\$232.85
6/9/2015	1,880,685	\$231.73
6/10/2015	2,786,758	\$229.12
6/11/2015	2,763,031	\$233.87
6/12/2015	1,223,569	\$229.64
6/15/2015	1,119,079	\$230.56
6/16/2015	1,688,847	\$228.70
6/17/2015	1,230,759	\$230.20
6/18/2015	1,174,910	\$233.95
6/19/2015	1,630,257	\$228.22
6/22/2015	1,194,977	\$232.90
6/23/2015	1,234,982	\$233.25
6/24/2015	2,045,344	\$229.19
6/25/2015	2,049,051	\$233.21
6/26/2015	2,578,995	\$228.83
6/29/2015	1,770,703	\$220.31
6/30/2015	2,163,506	\$222.15
7/1/2015	1,392,871	\$228.24
7/2/2015	981,188	\$228.49
7/6/2015	1,677,281	\$226.30
7/7/2015	1,653,350	\$227.40
7/8/2015	1,408,604	\$224.46
7/9/2015	1,374,822	\$223.39
7/10/2015	1,441,147	\$232.32
7/13/2015	1,339,143	\$235.16
7/14/2015	1,110,145	\$236.75
7/15/2015	1,600,777	\$235.84
7/16/2015	1,312,146	\$238.85
7/17/2015	1,376,406	\$236.10
7/20/2015	1,591,865	\$239.88
7/21/2015	1,016,730	\$240.59
7/22/2015	1,388,930	\$238.92
7/23/2015	3,764,536	\$253.84
7/24/2015	2,257,423	\$251.92
7/27/2015	2,066,753	\$257.30
7/28/2015	1,853,808	\$257.95
7/29/2015	2,064,732	\$255.23
7/30/2015	1,479,633	\$254.28
7/31/2015	1,314,040	\$257.53
8/3/2015	1,771,755	\$257.21
8/4/2015	1,152,422	\$259.98
8/5/2015	1,242,167	\$262.52
8/6/2015	3,551,447	\$248.40

8/7/2015	2,158,375	\$247.79
8/10/2015	1,278,108	\$247.15
8/11/2015	1,213,042	\$245.99
8/12/2015	3,042,655	\$244.03
8/13/2015	1,415,104	\$246.17
8/14/2015	949,987	\$246.57
8/17/2015	954,684	\$249.75
8/18/2015	873,743	\$249.97
8/19/2015	1,262,141	\$244.91
8/20/2015	3,305,463	\$229.06
8/21/2015	3,924,010	\$222.19
8/24/2015	4,584,048	\$220.25
8/25/2015	2,595,826	\$220.08
8/26/2015	2,156,165	\$227.24
8/27/2015	1,816,673	\$234.90
8/28/2015	982,983	\$236.12
8/31/2015	1,559,055	\$230.60
9/1/2015	2,059,366	\$224.05
9/2/2015	1,805,983	\$232.18
9/3/2015	1,485,526	\$228.47
9/4/2015	1,228,176	\$229.53
9/8/2015	1,925,268	\$233.80
9/9/2015	1,253,048	\$227.85
9/10/2015	1,781,567	\$228.79
9/11/2015	1,609,884	\$225.64
9/14/2015	1,603,252	\$222.92
9/15/2015	1,465,343	\$228.22
9/16/2015	1,405,466	\$233.21
9/17/2015	1,795,781	\$241.01
9/18/2015	1,754,405	\$242.14
9/21/2015	4,972,044	\$229.00
9/22/2015	4,612,648	\$216.76
9/23/2015	1,958,189	\$217.21
9/24/2015	4,169,919	\$209.50
9/25/2015	6,280,110	\$199.47
9/28/2015	19,751,945	\$166.50
9/29/2015	14,511,879	\$158.08
9/30/2015	11,676,108	\$178.38
10/1/2015	6,384,414	\$179.60
10/2/2015	7,697,345	\$182.32
10/5/2015	11,648,163	\$163.46
10/6/2015	7,376,898	\$166.00
10/7/2015	4,183,341	\$169.83
10/8/2015	3,644,569	\$171.17
10/9/2015	4,358,000	\$175.94
10/12/2015	3,255,799	\$173.85
10/13/2015	3,880,617	\$166.50
10/14/2015	8,142,276	\$177.29
10/15/2015	10,683,872	\$168.87
10/16/2015	6,033,655	\$177.56
10/19/2015	9,997,878	\$163.83
10/20/2015	16,210,064	\$146.74
10/21/2015	88,607,831	\$118.61
10/22/2015	57,766,099	\$109.87
10/23/2015	24,749,273	\$116.16

10/26/2015	27,810,071	\$110.04
10/27/2015	10,871,823	\$109.54
10/28/2015	10,701,638	\$117.00
10/29/2015	18,818,895	\$111.50
10/30/2015	44,882,470	\$93.77
11/2/2015	26,455,480	\$100.47
11/3/2015	15,507,283	\$97.86
11/4/2015	14,566,134	\$91.98
11/5/2015	57,293,517	\$78.77
11/6/2015	25,270,919	\$81.77
11/9/2015	19,976,516	\$85.41
11/10/2015	28,711,708	\$83.68
11/11/2015	16,933,839	\$78.90
11/12/2015	17,453,083	\$73.77
11/13/2015	14,631,969	\$75.41
11/16/2015	10,267,177	\$73.32
11/17/2015	13,442,769	\$70.32
11/18/2015	11,844,381	\$72.60
11/19/2015	25,422,665	\$84.00
11/20/2015	24,969,454	\$91.00
11/23/2015	25,583,183	\$87.41
11/24/2015	16,530,071	\$87.45
11/25/2015	13,068,171	\$87.02
11/27/2015	4,218,736	\$87.09
11/30/2015	14,051,833	\$89.96
12/1/2015	22,989,513	\$98.78
12/2/2015	13,067,448	\$96.23
12/3/2015	9,457,737	\$93.66
12/4/2015	8,677,357	\$95.31
12/7/2015	4,856,583	\$92.24
12/8/2015	7,326,711	\$93.86
12/9/2015	6,273,906	\$94.40
12/10/2015	5,133,587	\$97.19
12/11/2015	8,187,721	\$93.06
12/14/2015	5,393,446	\$94.14
12/15/2015	24,243,151	\$109.59
12/16/2015	23,338,245	\$118.47
12/17/2015	9,504,850	\$111.38
12/18/2015	8,060,601	\$108.52
12/21/2015	3,824,821	\$108.76
12/22/2015	4,725,729	\$113.12
12/23/2015	3,455,829	\$114.94
12/24/2015	2,223,220	\$114.11
12/28/2015	15,441,844	\$102.14
12/29/2015	10,007,808	\$101.39
12/30/2015	8,081,255	\$102.33
12/31/2015	5,863,395	\$101.65
1/4/2016	9,598,155	\$98.50
1/5/2016	6,154,732	\$100.86
1/6/2016	10,380,248	\$102.40
1/7/2016	6,377,553	\$97.39
1/8/2016	7,874,009	\$91.06
1/11/2016	9,928,313	\$85.45
1/12/2016	6,492,973	\$87.91
1/13/2016	4,974,971	\$85.54

1/14/2016	5,001,912	\$89.77
1/15/2016	7,614,805	\$88.70
1/19/2016	4,061,453	\$88.98
1/20/2016	5,863,855	\$89.35
1/21/2016	3,171,471	\$90.27
1/22/2016	3,919,410	\$88.60
1/25/2016	5,658,298	\$92.63
1/26/2016	8,792,371	\$98.57
1/27/2016	5,597,542	\$94.43
1/28/2016	7,920,388	\$86.12
1/29/2016	6,444,314	\$90.22
2/1/2016	6,153,912	\$95.65
2/2/2016	14,245,297	\$91.45
2/3/2016	6,209,853	\$94.19
2/4/2016	7,560,986	\$96.94
2/5/2016	6,103,199	\$96.59
2/8/2016	5,316,010	\$89.63
2/9/2016	6,729,583	\$86.95
2/10/2016	4,484,257	\$85.96
2/11/2016	7,128,622	\$83.44
2/12/2016	5,312,404	\$88.39
2/16/2016	3,870,323	\$91.26
2/17/2016	4,511,549	\$94.65
2/18/2016	4,640,868	\$94.11
2/19/2016	14,770,677	\$84.99
2/22/2016	31,649,013	\$75.92
2/23/2016	15,372,074	\$79.27
2/24/2016	8,903,366	\$83.83
2/25/2016	5,757,198	\$84.71
2/26/2016	10,084,059	\$80.65
2/29/2016	27,302,372	\$65.80
3/1/2016	41,571,126	\$65.45
3/2/2016	18,257,510	\$67.47
3/3/2016	10,829,391	\$64.89
3/4/2016	13,653,409	\$61.31
3/7/2016	14,784,747	\$65.66
3/8/2016	6,742,546	\$63.15
3/9/2016	9,882,241	\$66.86
3/10/2016	6,829,080	\$66.15
3/11/2016	6,906,623	\$69.55
3/14/2016	9,407,547	\$69.04
3/15/2016	138,949,843	\$33.51
3/16/2016	54,134,676	\$33.54
3/17/2016	52,086,899	\$29.69
3/18/2016	58,852,597	\$26.98
3/21/2016	71,332,430	\$28.98
3/22/2016	54,230,628	\$31.89
3/23/2016	39,365,139	\$33.43
3/24/2016	24,030,322	\$31.09
3/28/2016	27,494,117	\$28.86
3/29/2016	26,876,016	\$28.98
3/30/2016	32,980,132	\$27.07
3/31/2016	44,511,922	\$26.30
4/1/2016	39,600,739	\$28.10
4/4/2016	26,096,287	\$26.11

4/5/2016	48,847,311	\$28.73
4/6/2016	75,543,566	\$34.17
4/7/2016	66,830,687	\$35.51
4/8/2016	32,729,673	\$33.67
4/11/2016	44,405,117	\$31.35
4/12/2016	36,609,134	\$31.99
4/13/2016	33,765,574	\$33.10
4/14/2016	32,401,322	\$32.36
4/15/2016	22,162,520	\$32.14
4/18/2016	20,695,324	\$33.34
4/19/2016	19,784,559	\$33.45
4/20/2016	11,327,865	\$33.53
4/21/2016	12,952,764	\$33.35
4/22/2016	26,371,323	\$35.98
4/25/2016	34,326,889	\$35.16
4/26/2016	15,941,143	\$36.23
4/27/2016	13,349,494	\$34.92
4/28/2016	14,667,511	\$35.25
4/29/2016	35,688,308	\$33.36
5/2/2016	55,110,236	\$32.65
5/3/2016	65,690,143	\$35.79
5/4/2016	53,419,784	\$34.79
5/5/2016	24,624,028	\$34.49
5/6/2016	36,436,855	\$29.89
5/9/2016	42,832,806	\$28.07
5/10/2016	35,247,263	\$27.91
5/11/2016	27,739,223	\$26.35
5/12/2016	53,554,858	\$24.93
5/13/2016	33,870,034	\$25.90
5/16/2016	46,843,886	\$27.05
5/17/2016	56,771,068	\$29.08
5/18/2016	32,870,830	\$27.86
5/19/2016	33,025,859	\$26.26
5/20/2016	29,892,225	\$27.47
5/23/2016	24,581,359	\$26.21
5/24/2016	22,379,879	\$26.11
5/25/2016	22,381,893	\$27.12
5/26/2016	14,405,576	\$26.94
5/27/2016	34,206,438	\$28.42
5/31/2016	16,554,423	\$28.45
6/1/2016	32,987,750	\$29.79
6/2/2016	30,095,795	\$29.41
6/3/2016	19,169,376	\$28.87
6/6/2016	20,989,103	\$28.85
6/7/2016	104,121,567	\$24.64
6/8/2016	45,444,223	\$23.92
6/9/2016	41,598,381	\$25.48
6/10/2016	23,881,043	\$24.14
6/13/2016	23,690,637	\$23.78
6/14/2016	24,178,311	\$24.14
6/15/2016	15,405,737	\$23.66
6/16/2016	25,170,351	\$22.42
6/17/2016	22,955,510	\$22.04
6/20/2016	22,765,696	\$22.52
6/21/2016	28,330,550	\$21.64

6/22/2016	21,992,094	\$21.64
6/23/2016	18,161,551	\$22.25
6/24/2016	27,977,033	\$20.27
6/27/2016	25,787,591	\$18.73
6/28/2016	24,809,884	\$20.00
6/29/2016	17,599,930	\$20.27
6/30/2016	14,170,047	\$20.14
7/1/2016	31,070,439	\$20.44
7/5/2016	17,821,190	\$19.95
7/6/2016	47,089,682	\$23.06
7/7/2016	43,015,302	\$23.49
7/8/2016	22,218,674	\$23.25
7/11/2016	15,077,118	\$23.09
7/12/2016	19,457,031	\$23.22
7/13/2016	66,542,099	\$21.62
7/14/2016	49,842,743	\$23.02
7/15/2016	19,623,839	\$22.86
7/18/2016	23,979,680	\$23.50
7/19/2016	24,888,654	\$23.54
7/20/2016	33,733,699	\$24.57
7/21/2016	15,567,933	\$24.48
7/22/2016	23,491,879	\$22.82
7/25/2016	15,622,074	\$22.85
7/26/2016	10,845,407	\$23.05
7/27/2016	12,580,043	\$23.49
7/28/2016	8,352,429	\$23.13
7/29/2016	12,476,851	\$22.30
8/1/2016	20,760,716	\$20.89
8/2/2016	13,989,238	\$21.17
8/3/2016	14,920,190	\$22.36
8/4/2016	12,359,603	\$22.24
8/5/2016	11,437,463	\$21.96
8/8/2016	14,474,640	\$22.45
8/9/2016	105,849,824	\$28.16
8/10/2016	52,210,001	\$27.32
8/11/2016	56,209,755	\$24.49
8/12/2016	20,621,851	\$24.92
8/15/2016	28,895,668	\$26.59
8/16/2016	22,899,739	\$26.60
8/17/2016	81,238,338	\$30.00
8/18/2016	66,032,440	\$29.19
8/19/2016	22,528,925	\$28.74
8/22/2016	55,897,737	\$31.27
8/23/2016	29,808,770	\$31.20
8/24/2016	48,332,774	\$30.54
8/25/2016	39,696,774	\$31.09
8/26/2016	23,714,589	\$30.83
8/29/2016	19,088,304	\$30.25
8/30/2016	17,148,958	\$30.25
8/31/2016	23,178,257	\$29.03
9/1/2016	15,449,178	\$29.12
9/2/2016	19,162,985	\$28.76
9/6/2016	13,252,699	\$29.47
9/7/2016	14,236,056	\$30.27
9/8/2016	11,589,146	\$29.96

9/9/2016	19,959,804	\$28.06
9/12/2016	18,092,149	\$28.62
9/13/2016	21,595,669	\$27.53
9/14/2016	19,434,043	\$27.38
9/15/2016	11,867,252	\$27.37
9/16/2016	10,477,284	\$27.28
9/19/2016	12,333,161	\$27.10
9/20/2016	14,359,636	\$26.33
9/21/2016	13,216,375	\$26.97
9/22/2016	8,628,320	\$26.85
9/23/2016	12,135,176	\$27.72
9/26/2016	19,655,105	\$25.89
9/27/2016	11,977,302	\$26.28
9/28/2016	7,811,795	\$26.42
9/29/2016	17,081,164	\$25.05
9/30/2016	14,489,117	\$24.55
10/3/2016	12,321,789	\$24.41
10/4/2016	12,471,902	\$23.74
10/5/2016	13,084,714	\$24.59
10/6/2016	11,268,265	\$23.68
10/7/2016	14,096,098	\$23.16
10/10/2016	11,946,329	\$23.59
10/11/2016	10,650,739	\$22.94
10/12/2016	9,873,024	\$22.69
10/13/2016	14,797,754	\$22.77
10/14/2016	11,831,367	\$22.18
10/17/2016	12,690,470	\$21.40
10/18/2016	17,199,064	\$22.07
10/19/2016	8,379,431	\$22.06
10/20/2016	7,940,310	\$22.06
10/21/2016	7,747,729	\$21.96
10/24/2016	12,896,054	\$21.59
10/25/2016	14,525,452	\$22.05
10/26/2016	6,710,589	\$21.84
10/27/2016	7,517,440	\$22.10
10/28/2016	26,366,308	\$20.35
10/31/2016	35,852,448	\$17.84
11/1/2016	64,927,259	\$23.86
11/2/2016	50,295,266	\$21.12
11/3/2016	21,163,664	\$19.32
11/4/2016	16,183,659	\$19.18
11/7/2016	18,799,551	\$19.13
11/8/2016	96,468,277	\$14.98
11/9/2016	32,269,602	\$16.09
11/10/2016	24,416,031	\$16.82
11/11/2016	22,110,559	\$18.00
11/14/2016	20,413,927	\$17.55
11/15/2016	26,873,307	\$18.22
11/16/2016	13,343,114	\$17.86
11/17/2016	38,121,523	\$17.98
11/18/2016	17,564,267	\$17.95
11/21/2016	13,163,407	\$18.35
11/22/2016	12,463,319	\$17.83
11/23/2016	20,973,975	\$16.94
11/25/2016	8,772,323	\$17.00

11/28/2016	11,564,208	\$17.44
11/29/2016	8,095,753	\$17.16
11/30/2016	34,801,612	\$15.79
12/1/2016	10,423,205	\$15.31
12/2/2016	8,596,498	\$15.45
12/5/2016	11,792,704	\$15.34
12/6/2016	9,710,067	\$15.63
12/7/2016	19,265,847	\$15.08
12/8/2016	12,862,581	\$15.44
12/9/2016	9,223,041	\$15.46
12/12/2016	22,002,589	\$14.68
12/13/2016	13,313,731	\$14.78
12/14/2016	25,026,598	\$14.12
12/15/2016	41,124,094	\$13.60
12/16/2016	16,184,769	\$14.10
12/19/2016	16,610,353	\$14.53
12/20/2016	9,829,264	\$14.65
12/21/2016	13,316,751	\$14.20
12/22/2016	11,405,792	\$14.27
12/23/2016	9,347,689	\$14.35
12/27/2016	10,488,902	\$14.09
12/28/2016	11,587,219	\$14.23
12/29/2016	10,845,002	\$14.15
12/30/2016	18,498,930	\$14.52
1/3/2017	14,870,822	\$15.24
1/4/2017	17,268,553	\$15.57
1/5/2017	11,054,141	\$15.71
1/6/2017	10,435,892	\$15.29
1/9/2017	9,533,247	\$15.35
1/10/2017	42,444,776	\$16.40
1/11/2017	28,591,678	\$15.33
1/12/2017	15,764,164	\$15.63
1/13/2017	11,117,733	\$15.33
1/17/2017	10,228,189	\$15.24
1/18/2017	14,998,539	\$15.11
1/19/2017	9,508,286	\$14.90
1/20/2017	9,367,967	\$14.73
1/23/2017	18,864,122	\$13.99
1/24/2017	14,203,802	\$13.58
1/25/2017	15,236,955	\$13.99
1/26/2017	10,858,669	\$13.62
1/27/2017	8,550,628	\$13.47
1/30/2017	12,241,465	\$13.33
1/31/2017	12,876,288	\$13.78
2/1/2017	9,040,164	\$13.73
2/2/2017	23,337,367	\$14.31
2/3/2017	10,467,177	\$14.22
2/6/2017	9,207,732	\$14.59
2/7/2017	9,496,765	\$14.25
2/8/2017	10,421,566	\$14.68
2/9/2017	9,888,543	\$14.92
2/10/2017	8,468,670	\$15.04
2/13/2017	9,809,368	\$14.97
2/14/2017	18,792,379	\$15.98
2/15/2017	27,696,326	\$16.86

2/16/2017	31,055,829	\$16.22
2/17/2017	11,642,780	\$16.04
2/21/2017	9,435,692	\$16.40
2/22/2017	9,699,738	\$16.35
2/23/2017	10,961,507	\$16.58
2/24/2017	10,635,267	\$16.18
2/27/2017	16,950,151	\$16.71
2/28/2017	56,133,024	\$14.38
3/1/2017	41,398,611	\$13.59
3/2/2017	18,474,430	\$13.75
3/3/2017	33,593,527	\$13.06
3/6/2017	30,879,177	\$12.41
3/7/2017	37,137,373	\$11.71
3/8/2017	26,568,236	\$11.88
3/9/2017	16,392,761	\$11.57
3/10/2017	20,865,652	\$12.24
3/13/2017	24,670,411	\$12.11
3/14/2017	77,795,085	\$10.89
3/15/2017	33,025,863	\$11.01
3/16/2017	19,762,965	\$11.20
3/17/2017	34,529,134	\$11.03
3/20/2017	17,890,713	\$10.64
3/21/2017	20,446,317	\$10.72
3/22/2017	14,081,903	\$10.71
3/23/2017	15,675,249	\$10.86
3/24/2017	8,928,415	\$10.75
3/27/2017	8,982,106	\$10.81
3/28/2017	8,421,556	\$10.68
3/29/2017	26,944,434	\$11.18
3/30/2017	21,361,825	\$11.08
3/31/2017	8,956,136	\$11.03
4/3/2017	19,768,005	\$10.47
4/4/2017	18,766,263	\$10.17
4/5/2017	41,897,554	\$9.50
4/6/2017	16,749,456	\$9.63
4/7/2017	16,235,951	\$9.59
4/10/2017	9,917,874	\$9.85
4/11/2017	8,940,775	\$9.55
4/12/2017	6,645,990	\$9.60
4/13/2017	9,025,189	\$9.48
4/17/2017	5,062,792	\$9.48
4/18/2017	21,649,030	\$8.95
4/19/2017	9,822,200	\$9.02
4/20/2017	12,321,701	\$8.88
4/21/2017	28,061,921	\$8.51
4/24/2017	15,671,069	\$8.60
4/25/2017	12,658,332	\$9.02
4/26/2017	16,668,445	\$9.29
4/27/2017	11,490,672	\$9.38
4/28/2017	9,062,943	\$9.25
5/1/2017	16,365,723	\$9.66
5/2/2017	26,518,588	\$10.31
5/3/2017	20,085,884	\$9.80
5/4/2017	14,081,403	\$9.84
5/5/2017	8,831,877	\$10.07

5/8/2017	12,522,350	\$9.71
5/9/2017	125,273,992	\$12.05
5/10/2017	64,442,362	\$12.68
5/11/2017	107,069,634	\$13.80
5/12/2017	38,714,975	\$13.59
5/15/2017	40,294,812	\$14.17
5/16/2017	34,368,669	\$14.08
5/17/2017	29,369,179	\$13.25
5/18/2017	22,681,361	\$13.47
5/19/2017	24,297,911	\$13.52
5/22/2017	11,359,711	\$13.45
5/23/2017	12,692,087	\$13.31
5/24/2017	19,759,380	\$12.93
5/25/2017	11,085,271	\$12.79
5/26/2017	8,900,226	\$12.83
5/30/2017	17,595,073	\$12.24
5/31/2017	18,941,906	\$12.05
6/1/2017	18,269,695	\$12.58
6/2/2017	12,565,952	\$12.51
6/5/2017	13,636,223	\$12.34
6/6/2017	12,521,080	\$12.56
6/7/2017	11,901,741	\$12.17
6/8/2017	31,707,943	\$13.26
6/9/2017	22,255,558	\$12.52
6/12/2017	12,359,370	\$12.65
6/13/2017	10,685,589	\$12.46
6/14/2017	8,329,979	\$12.46
6/15/2017	10,640,593	\$12.12
6/16/2017	14,674,829	\$12.66
6/19/2017	24,885,807	\$13.47
6/20/2017	15,644,888	\$13.15
6/21/2017	19,726,975	\$13.68
6/22/2017	69,036,614	\$15.50
6/23/2017	37,840,381	\$15.80
6/26/2017	56,838,616	\$17.08
6/27/2017	38,429,769	\$16.65
6/28/2017	22,072,177	\$17.15
6/29/2017	48,984,338	\$17.31
6/30/2017	21,308,008	\$17.30
7/3/2017	9,905,524	\$16.97
7/5/2017	16,280,738	\$17.14
7/6/2017	18,722,062	\$16.60
7/7/2017	19,318,367	\$16.23
7/10/2017	14,591,573	\$16.66
7/11/2017	10,177,676	\$16.57
7/12/2017	11,483,931	\$16.99
7/13/2017	15,643,169	\$17.29
7/14/2017	12,442,295	\$17.24
7/17/2017	14,901,404	\$17.37
7/18/2017	13,133,660	\$17.16
7/19/2017	8,685,475	\$17.25
7/20/2017	10,846,373	\$17.60
7/21/2017	10,086,075	\$17.50
7/24/2017	8,602,084	\$17.54
7/25/2017	13,417,050	\$17.71

7/26/2017	9,316,527	\$17.77
7/27/2017	15,359,085	\$17.13
7/28/2017	12,242,293	\$16.84
7/31/2017	15,890,457	\$16.46
8/1/2017	9,534,501	\$16.75
8/2/2017	9,280,087	\$16.42
8/3/2017	21,287,446	\$15.45
8/4/2017	18,721,769	\$15.13
8/7/2017	16,487,830	\$15.37
8/8/2017	48,546,639	\$15.64
8/9/2017	39,170,357	\$14.07
8/10/2017	21,254,522	\$13.81
8/11/2017	12,747,107	\$13.89
8/14/2017	10,049,055	\$13.77
8/15/2017	9,001,474	\$13.90
8/16/2017	13,556,665	\$14.15
8/17/2017	21,846,271	\$14.34
8/18/2017	10,472,002	\$14.39
8/21/2017	6,715,112	\$14.14
8/22/2017	7,126,409	\$14.35
8/23/2017	7,550,544	\$14.42
8/24/2017	10,891,682	\$14.75
8/25/2017	13,814,603	\$14.14
8/28/2017	8,166,597	\$14.23
8/29/2017	28,933,823	\$13.24
8/30/2017	14,556,947	\$13.19
8/31/2017	10,348,338	\$13.42
9/1/2017	8,658,751	\$13.33
9/5/2017	11,566,196	\$13.10
9/6/2017	9,648,624	\$13.16
9/7/2017	7,232,603	\$13.38
9/8/2017	6,917,473	\$13.61
9/11/2017	12,728,187	\$14.19
9/12/2017	9,178,727	\$14.43
9/13/2017	8,006,477	\$14.11
9/14/2017	5,308,228	\$13.99
9/15/2017	6,937,885	\$13.92
9/18/2017	9,400,136	\$13.79
9/19/2017	5,070,707	\$13.77
9/20/2017	5,923,963	\$14.07
9/21/2017	6,225,626	\$14.23
9/22/2017	4,770,255	\$14.01
9/25/2017	6,080,884	\$14.09
9/26/2017	5,036,126	\$14.10
9/27/2017	6,206,086	\$14.39
9/28/2017	20,569,958	\$13.76
9/29/2017	14,266,304	\$14.33
10/2/2017	11,014,374	\$14.62
10/3/2017	10,833,890	\$14.36
10/4/2017	6,574,470	\$14.38
10/5/2017	8,286,518	\$14.57
10/6/2017	4,184,994	\$14.46
10/9/2017	3,985,782	\$14.42
10/10/2017	5,490,229	\$14.46
10/11/2017	6,262,458	\$14.29

10/12/2017	8,507,300	\$13.83
10/13/2017	15,955,232	\$13.39
10/16/2017	14,128,432	\$12.92
10/17/2017	10,741,383	\$12.81
10/18/2017	15,476,309	\$12.39
10/19/2017	19,618,246	\$12.48
10/20/2017	9,259,123	\$12.13
10/23/2017	7,854,293	\$12.05
10/24/2017	7,973,833	\$12.12
10/25/2017	9,602,318	\$12.06
10/26/2017	11,426,006	\$11.65
10/27/2017	9,650,715	\$11.41
10/30/2017	8,661,335	\$11.41
10/31/2017	14,202,961	\$11.69
11/1/2017	9,045,192	\$11.93
11/2/2017	19,200,884	\$11.06
11/3/2017	16,220,809	\$11.49
11/6/2017	20,317,419	\$12.04
11/7/2017	68,952,377	\$14.10
11/8/2017	43,449,992	\$14.88
11/9/2017	28,140,354	\$15.35
11/10/2017	19,960,214	\$15.38
11/13/2017	19,821,010	\$14.60
11/14/2017	16,274,449	\$14.28
11/15/2017	10,572,267	\$14.45
11/16/2017	8,341,534	\$14.34
11/17/2017	10,932,463	\$14.69
11/20/2017	21,638,763	\$15.57
11/21/2017	20,365,689	\$15.99
11/22/2017	21,463,626	\$16.54
11/24/2017	6,896,304	\$16.57
11/27/2017	9,713,086	\$16.48
11/28/2017	11,048,649	\$16.40
11/29/2017	16,904,189	\$16.45
11/30/2017	16,174,384	\$16.75
12/1/2017	17,372,380	\$17.25
12/4/2017	13,516,750	\$17.49
12/5/2017	13,498,264	\$17.75
12/6/2017	21,575,201	\$16.85
12/7/2017	13,397,632	\$17.63
12/8/2017	44,858,864	\$19.70
12/11/2017	33,873,472	\$20.55
12/12/2017	41,243,376	\$21.87
12/13/2017	48,398,780	\$22.05
12/14/2017	53,353,795	\$19.68
12/15/2017	23,793,867	\$19.71
12/18/2017	27,027,242	\$21.20
12/19/2017	13,576,161	\$20.86
12/20/2017	21,775,344	\$20.89
12/21/2017	16,506,188	\$21.67
12/22/2017	13,460,288	\$21.55
12/26/2017	10,703,269	\$21.65
12/27/2017	11,668,241	\$21.55
12/28/2017	14,604,447	\$21.16
12/29/2017	10,325,043	\$20.78

1/2/2018	12,771,494	\$21.79
1/3/2018	22,542,303	\$23.01
1/4/2018	15,342,570	\$23.05
1/5/2018	22,334,545	\$23.85
1/8/2018	16,153,383	\$23.11
1/9/2018	11,360,280	\$23.87
1/10/2018	11,788,904	\$23.43
1/11/2018	11,704,648	\$23.81
1/12/2018	10,214,503	\$23.84
1/16/2018	14,893,804	\$22.98
1/17/2018	11,423,336	\$22.70
1/18/2018	12,931,239	\$22.10
1/19/2018	15,382,505	\$21.52
1/22/2018	9,440,655	\$22.03
1/23/2018	8,550,879	\$22.30
1/24/2018	32,840,560	\$19.88
1/25/2018	23,904,080	\$19.71
1/26/2018	14,696,139	\$19.32
1/29/2018	9,781,971	\$19.39
1/30/2018	12,980,228	\$18.65
1/31/2018	11,458,850	\$18.51
2/1/2018	7,989,202	\$18.58
2/2/2018	9,190,879	\$18.00
2/5/2018	14,745,570	\$17.28
2/6/2018	16,730,431	\$18.26
2/7/2018	13,666,631	\$17.77
2/8/2018	12,428,813	\$17.47
2/9/2018	12,678,746	\$17.79
2/12/2018	8,087,371	\$18.03
2/13/2018	6,639,846	\$17.95
2/14/2018	6,730,257	\$18.37
2/15/2018	8,392,371	\$18.67
2/16/2018	10,169,588	\$18.88
2/20/2018	8,706,132	\$18.58
2/21/2018	5,795,253	\$18.61
2/22/2018	7,962,732	\$18.27
2/23/2018	7,717,779	\$18.68
2/26/2018	7,980,047	\$18.87
2/27/2018	13,106,978	\$18.50
2/28/2018	39,514,108	\$16.39
3/1/2018	29,902,975	\$15.26
3/2/2018	21,276,035	\$14.88
3/5/2018	23,097,600	\$15.40
3/6/2018	15,992,615	\$15.32
3/7/2018	11,763,641	\$15.31
3/8/2018	6,363,277	\$15.27
3/9/2018	9,852,132	\$15.38
3/12/2018	8,383,066	\$15.79
3/13/2018	8,596,142	\$16.08
3/14/2018	18,705,310	\$16.95
3/15/2018	9,572,495	\$16.78
3/16/2018	7,036,139	\$16.73
3/19/2018	9,535,067	\$16.19
3/20/2018	7,460,920	\$15.98
3/21/2018	5,268,995	\$16.42

3/22/2018	8,573,082	\$15.96
3/23/2018	7,129,025	\$15.37
3/26/2018	5,600,244	\$15.74
3/27/2018	4,312,015	\$15.35
3/28/2018	6,287,396	\$15.47
3/29/2018	6,485,798	\$15.92
4/2/2018	7,804,619	\$15.07
4/3/2018	6,339,967	\$15.67
4/4/2018	4,410,823	\$15.79
4/5/2018	4,121,689	\$15.79
4/6/2018	5,982,608	\$15.44
4/9/2018	4,672,215	\$15.77
4/10/2018	4,182,287	\$15.94
4/11/2018	6,240,527	\$16.23
4/12/2018	5,028,485	\$16.63
4/13/2018	10,802,535	\$17.15
4/16/2018	6,274,280	\$17.23
4/17/2018	6,963,193	\$17.23
4/18/2018	6,898,508	\$17.40
4/19/2018	7,464,890	\$17.33
4/20/2018	4,933,810	\$17.18
4/23/2018	6,386,411	\$17.54
4/24/2018	6,478,384	\$17.47
4/25/2018	4,865,953	\$17.54
4/26/2018	5,269,627	\$17.76
4/27/2018	5,664,572	\$18.07
4/30/2018	6,301,775	\$18.07
5/1/2018	4,046,223	\$18.31
5/2/2018	5,720,262	\$18.01
5/3/2018	6,538,247	\$17.76
5/4/2018	5,478,651	\$18.02
5/7/2018	8,132,224	\$18.16
5/8/2018	55,117,113	\$19.77
5/9/2018	17,024,802	\$20.25
5/10/2018	12,022,649	\$20.01
5/11/2018	10,885,417	\$20.85
5/14/2018	11,348,911	\$20.81
5/15/2018	16,189,374	\$21.56
5/16/2018	9,462,608	\$22.08
5/17/2018	7,761,541	\$22.03
5/18/2018	5,488,345	\$22.14
5/21/2018	4,726,397	\$22.07
5/22/2018	4,496,246	\$22.03
5/23/2018	5,988,637	\$22.20
5/24/2018	4,636,585	\$22.22
5/25/2018	3,470,573	\$22.24
5/29/2018	8,664,356	\$21.75
5/30/2018	5,338,423	\$22.18
5/31/2018	3,678,377	\$22.00
6/1/2018	3,990,433	\$22.08
6/4/2018	4,783,840	\$22.00
6/5/2018	13,037,210	\$23.59
6/6/2018	20,968,866	\$25.41
6/7/2018	10,730,532	\$24.95
6/8/2018	10,602,499	\$25.79

6/11/2018	9,461,566	\$26.46
6/12/2018	9,160,353	\$26.60
6/13/2018	10,925,862	\$26.86
6/14/2018	6,969,183	\$26.80
6/15/2018	6,070,686	\$26.86
6/18/2018	24,556,884	\$23.56
6/19/2018	10,253,826	\$24.24
6/20/2018	6,792,812	\$24.64
6/21/2018	5,390,121	\$24.72
6/22/2018	6,174,842	\$24.27
6/25/2018	6,897,371	\$23.06
6/26/2018	6,142,830	\$23.31
6/27/2018	6,506,118	\$22.81
6/28/2018	5,004,949	\$23.37
6/29/2018	5,921,194	\$23.24
7/2/2018	4,061,726	\$22.93
7/3/2018	2,242,233	\$23.00
7/5/2018	3,935,766	\$22.93
7/6/2018	4,637,283	\$22.96
7/9/2018	6,931,107	\$23.55
7/10/2018	3,912,302	\$23.80
7/11/2018	6,140,549	\$23.76
7/12/2018	5,562,987	\$24.23
7/13/2018	6,571,593	\$23.40
7/16/2018	3,504,034	\$23.05
7/17/2018	4,044,461	\$23.10
7/18/2018	4,011,651	\$23.03
7/19/2018	4,077,006	\$22.67
7/20/2018	2,305,780	\$22.59
7/23/2018	2,895,798	\$22.67
7/24/2018	2,941,339	\$22.62
7/25/2018	2,897,302	\$22.79
7/26/2018	3,013,992	\$22.50
7/27/2018	2,566,810	\$22.51
7/30/2018	4,263,600	\$21.71
7/31/2018	3,452,405	\$21.74
8/1/2018	2,820,318	\$21.87
8/2/2018	3,796,322	\$22.37
8/3/2018	4,099,045	\$22.80
8/6/2018	5,092,047	\$22.50
8/7/2018	11,439,857	\$23.52
8/8/2018	5,029,306	\$23.71
8/9/2018	5,448,751	\$23.17
8/10/2018	7,001,122	\$21.85
8/13/2018	4,659,749	\$21.38
8/14/2018	2,449,085	\$21.52
8/15/2018	4,587,458	\$20.89
8/16/2018	3,651,553	\$21.69
8/17/2018	3,185,602	\$21.89
8/20/2018	2,813,608	\$22.32
8/21/2018	2,863,909	\$22.37
8/22/2018	4,665,470	\$23.30
8/23/2018	3,529,255	\$23.24
8/24/2018	3,276,906	\$22.93
8/27/2018	3,160,368	\$23.33

8/28/2018	2,085,602	\$23.46
8/29/2018	3,276,167	\$23.39
8/30/2018	4,331,303	\$23.60
8/31/2018	3,339,427	\$23.11
9/4/2018	9,904,879	\$21.81
9/5/2018	4,015,253	\$21.34
9/6/2018	4,049,250	\$20.85
9/7/2018	3,250,280	\$20.64
9/10/2018	3,372,461	\$20.67
9/11/2018	2,379,384	\$20.67
9/12/2018	15,974,307	\$23.54
9/13/2018	5,789,022	\$23.12
9/14/2018	4,842,657	\$22.35
9/17/2018	4,607,140	\$22.55
9/18/2018	8,668,473	\$23.81
9/19/2018	4,661,090	\$24.07
9/20/2018	7,099,193	\$25.01
9/21/2018	3,981,122	\$24.92
9/24/2018	3,991,097	\$24.86
9/25/2018	4,415,066	\$24.78
9/26/2018	4,041,395	\$25.04
9/27/2018	3,291,550	\$25.08
9/28/2018	6,215,297	\$25.67
10/1/2018	10,662,996	\$27.34
10/2/2018	6,309,331	\$27.26
10/3/2018	9,708,487	\$28.32
10/4/2018	8,144,638	\$26.50
10/5/2018	4,519,463	\$26.32
10/8/2018	5,267,344	\$26.49
10/9/2018	3,970,450	\$25.70
10/10/2018	7,157,231	\$24.34
10/11/2018	5,953,478	\$24.12
10/12/2018	4,206,579	\$24.66
10/15/2018	2,558,056	\$24.68
10/16/2018	4,351,057	\$25.92
10/17/2018	4,942,032	\$24.88
10/18/2018	2,770,609	\$24.58
10/19/2018	3,462,147	\$24.26
10/22/2018	3,438,054	\$24.45
10/23/2018	4,155,348	\$24.22
10/24/2018	4,522,461	\$22.53
10/25/2018	4,762,364	\$23.21
10/26/2018	3,601,976	\$22.85
10/29/2018	5,141,049	\$21.95
10/30/2018	3,773,490	\$22.19
10/31/2018	3,701,595	\$22.88
11/1/2018	6,769,135	\$24.78
11/2/2018	4,001,739	\$24.17
11/5/2018	7,846,409	\$25.57
11/6/2018	12,013,961	\$26.72
11/7/2018	6,127,835	\$27.12
11/8/2018	6,082,145	\$27.29
11/9/2018	3,900,114	\$27.20
11/12/2018	3,616,487	\$26.21
11/13/2018	3,235,708	\$26.63

11/14/2018	4,442,804	\$26.45
11/15/2018	3,892,699	\$25.67
11/16/2018	3,096,714	\$25.33
11/19/2018	6,050,930	\$23.50
11/20/2018	5,376,022	\$22.75
11/21/2018	3,147,354	\$23.11
11/23/2018	1,447,018	\$23.26
11/26/2018	2,925,500	\$23.56
11/27/2018	3,796,241	\$22.77
11/28/2018	3,209,698	\$23.30
11/29/2018	2,825,770	\$23.72
11/30/2018	3,519,197	\$24.35
12/3/2018	4,554,718	\$25.28
12/4/2018	4,883,105	\$24.47
12/6/2018	4,116,029	\$24.25
12/7/2018	2,761,691	\$23.66
12/10/2018	4,368,643	\$22.85
12/11/2018	2,604,801	\$23.08
12/12/2018	5,917,390	\$24.13
12/13/2018	2,715,499	\$23.65
12/14/2018	8,167,042	\$22.87
12/17/2018	6,880,769	\$21.56
12/18/2018	6,470,067	\$20.86
12/19/2018	7,978,535	\$19.69
12/20/2018	9,940,195	\$18.72
12/21/2018	9,349,222	\$18.11
12/24/2018	3,851,852	\$17.64
12/26/2018	4,787,362	\$18.85
12/27/2018	4,767,533	\$18.56
12/28/2018	4,542,315	\$18.79
12/31/2018	4,476,725	\$18.47
1/2/2019	7,643,517	\$20.23
1/3/2019	5,689,930	\$20.49
1/4/2019	6,179,415	\$21.25
1/7/2019	7,167,673	\$22.36
1/8/2019	6,050,348	\$22.68
1/9/2019	5,199,004	\$23.33
1/10/2019	5,534,075	\$22.53
1/11/2019	3,633,698	\$22.62
1/14/2019	3,684,331	\$22.25
1/15/2019	3,228,437	\$22.34
1/16/2019	3,189,419	\$22.35
1/17/2019	3,289,947	\$23.03
1/18/2019	3,910,608	\$23.09
1/22/2019	4,243,038	\$22.92
1/23/2019	3,572,342	\$23.29
1/24/2019	3,128,238	\$23.33
1/25/2019	3,070,136	\$23.79
1/28/2019	3,521,395	\$24.18
1/29/2019	2,327,607	\$24.16
1/30/2019	4,001,120	\$24.16
1/31/2019	2,973,556	\$24.55
2/1/2019	3,149,517	\$24.64
2/4/2019	4,871,574	\$25.20
2/5/2019	4,662,261	\$25.74

2/6/2019	3,127,225	\$25.49
2/7/2019	5,466,603	\$24.61
2/8/2019	2,951,748	\$24.48
2/11/2019	3,048,003	\$25.09
2/12/2019	2,611,684	\$25.34
2/13/2019	3,329,515	\$25.30
2/14/2019	3,344,967	\$25.50
2/15/2019	3,743,784	\$25.45
2/19/2019	8,856,225	\$25.19
2/20/2019	21,873,049	\$24.05
2/21/2019	6,334,900	\$23.51
2/22/2019	4,888,450	\$23.75
2/25/2019	5,380,052	\$23.35
2/26/2019	5,669,118	\$23.16
2/27/2019	5,243,642	\$24.03
2/28/2019	4,779,032	\$23.70
3/1/2019	3,991,071	\$24.23
3/4/2019	4,783,646	\$24.18
3/5/2019	4,390,465	\$23.96
3/6/2019	3,103,740	\$23.56
3/7/2019	3,281,926	\$23.52
3/8/2019	2,464,805	\$23.37
3/11/2019	1,778,259	\$23.47
3/12/2019	2,070,009	\$23.77
3/13/2019	1,607,058	\$23.91
3/14/2019	2,364,255	\$24.14
3/15/2019	1,999,144	\$23.98
3/18/2019	4,451,254	\$24.54
3/19/2019	8,738,871	\$26.29
3/20/2019	7,044,588	\$25.37
3/21/2019	3,223,529	\$25.47
3/22/2019	3,576,338	\$24.69
3/25/2019	2,462,706	\$24.14
3/26/2019	2,490,787	\$24.22
3/27/2019	1,699,727	\$24.31
3/28/2019	1,872,760	\$24.52
3/29/2019	2,193,196	\$24.70
4/1/2019	3,142,637	\$25.07
4/2/2019	3,169,413	\$24.92
4/3/2019	2,147,801	\$24.80
4/4/2019	1,972,167	\$24.96
4/5/2019	2,040,290	\$25.12
4/8/2019	3,111,556	\$25.82
4/9/2019	6,045,543	\$26.15
4/10/2019	2,029,495	\$26.12
4/11/2019	2,996,063	\$26.01
4/12/2019	5,851,032	\$24.77
4/15/2019	3,421,653	\$24.34
4/16/2019	2,306,234	\$24.13
4/17/2019	7,382,071	\$23.05
4/18/2019	4,216,700	\$23.13
4/22/2019	3,500,388	\$22.92
4/23/2019	3,772,643	\$23.47
4/24/2019	3,700,536	\$23.01
4/25/2019	4,484,396	\$23.72

4/26/2019	2,216,062	\$23.80
4/29/2019	2,265,505	\$23.63
4/30/2019	2,692,948	\$23.09
5/1/2019	3,965,636	\$22.78
5/2/2019	3,943,774	\$23.51
5/3/2019	4,009,807	\$23.44
5/6/2019	11,994,367	\$25.48
5/7/2019	9,884,414	\$25.49
5/8/2019	7,384,847	\$26.45
5/9/2019	3,526,323	\$26.09
5/10/2019	5,104,217	\$25.32
5/13/2019	4,919,501	\$24.57
5/14/2019	3,710,638	\$24.93
5/15/2019	3,816,219	\$25.28
5/16/2019	2,541,692	\$25.24
5/17/2019	3,193,658	\$25.06
5/20/2019	3,377,125	\$24.23
5/21/2019	4,095,121	\$24.49
5/22/2019	2,648,993	\$24.44
5/23/2019	3,180,398	\$23.67
5/24/2019	1,695,670	\$23.52
5/28/2019	4,850,249	\$22.57
5/29/2019	5,173,080	\$22.08
5/30/2019	5,373,565	\$21.45
5/31/2019	5,578,832	\$20.73
6/3/2019	4,108,555	\$20.52
6/4/2019	4,319,245	\$21.36
6/5/2019	3,054,196	\$21.32
6/6/2019	2,500,393	\$21.11
6/7/2019	3,530,241	\$21.24
6/10/2019	2,699,542	\$21.68
6/11/2019	3,816,618	\$22.13
6/12/2019	3,206,522	\$21.61
6/13/2019	2,018,463	\$21.82
6/14/2019	1,626,291	\$21.47
6/17/2019	2,331,286	\$22.00
6/18/2019	2,145,205	\$22.44
6/19/2019	2,674,649	\$22.88
6/20/2019	8,616,739	\$24.30
6/21/2019	2,860,657	\$23.82
6/24/2019	2,478,209	\$23.76
6/25/2019	7,709,288	\$24.38
6/26/2019	6,175,222	\$25.00
6/27/2019	5,173,902	\$24.84
6/28/2019	4,016,210	\$25.22
7/1/2019	3,901,541	\$25.06
7/2/2019	3,871,007	\$25.23
7/3/2019	3,219,308	\$25.66
7/5/2019	2,235,061	\$25.28
7/8/2019	3,350,235	\$24.89
7/9/2019	1,578,829	\$24.99
7/10/2019	1,594,713	\$24.92
7/11/2019	4,948,204	\$23.87
7/12/2019	2,967,667	\$23.61
7/15/2019	2,037,909	\$23.44

7/16/2019	1,665,551	\$23.17
7/17/2019	2,726,566	\$22.91
7/18/2019	1,897,311	\$23.10
7/19/2019	2,414,482	\$23.18
7/22/2019	2,297,774	\$23.26
7/23/2019	2,066,566	\$23.65
7/24/2019	1,759,595	\$23.79
7/25/2019	1,955,097	\$23.51
7/26/2019	1,481,330	\$23.81
7/29/2019	3,253,547	\$24.44
7/30/2019	2,373,633	\$24.65
7/31/2019	2,792,889	\$23.97
8/1/2019	3,216,538	\$23.85
8/2/2019	2,697,066	\$23.90
8/5/2019	4,824,471	\$23.32
8/6/2019	11,401,042	\$22.58
8/7/2019	4,996,484	\$22.39
8/8/2019	3,780,040	\$22.75
8/9/2019	2,039,206	\$22.62
8/12/2019	1,201,806	\$22.30
8/13/2019	2,380,060	\$22.69
8/14/2019	3,843,567	\$21.08
8/15/2019	3,841,361	\$20.88
8/16/2019	2,716,392	\$21.30
8/19/2019	1,981,687	\$21.83
8/20/2019	2,294,641	\$21.26
8/21/2019	3,521,520	\$22.40
8/22/2019	2,855,403	\$22.10
8/23/2019	2,141,237	\$21.33
8/26/2019	2,267,232	\$21.48
8/27/2019	2,156,537	\$20.98
8/28/2019	1,932,989	\$21.00
8/29/2019	2,074,996	\$21.51
8/30/2019	1,789,673	\$21.34
9/3/2019	2,788,538	\$21.55
9/4/2019	2,136,897	\$21.33
9/5/2019	2,067,720	\$21.72
9/6/2019	2,136,866	\$22.18
9/9/2019	2,176,787	\$22.09
9/10/2019	3,859,884	\$22.49
9/11/2019	5,018,053	\$23.09
9/12/2019	4,872,657	\$23.75
9/13/2019	2,890,184	\$23.24
9/16/2019	2,299,079	\$23.37
9/17/2019	3,552,023	\$23.08
9/18/2019	2,356,588	\$23.19
9/19/2019	2,454,026	\$23.15
9/20/2019	2,667,985	\$22.86
9/23/2019	2,502,445	\$22.56
9/24/2019	4,056,483	\$22.02
9/25/2019	4,087,605	\$21.79
9/26/2019	3,124,813	\$21.85
9/27/2019	2,014,254	\$21.70
9/30/2019	2,702,081	\$21.85
10/1/2019	10,342,260	\$19.67

10/2/2019	5,974,589	\$18.89
10/3/2019	4,048,910	\$19.50
10/4/2019	3,466,787	\$19.10
10/7/2019	2,569,254	\$19.29
10/8/2019	3,377,248	\$19.40
10/9/2019	2,376,441	\$19.22
10/10/2019	2,891,991	\$19.28
10/11/2019	5,336,819	\$20.62
10/14/2019	2,712,502	\$20.90
10/15/2019	8,720,771	\$21.34
10/16/2019	7,333,411	\$22.17
10/17/2019	6,130,779	\$22.80
10/18/2019	2,997,980	\$22.54
10/21/2019	3,162,984	\$22.86
10/22/2019	2,786,381	\$22.58
10/23/2019	2,026,864	\$22.56
10/24/2019	2,192,825	\$22.66
10/25/2019	5,424,260	\$23.53
10/28/2019	3,908,037	\$24.05
10/29/2019	2,925,969	\$24.47
10/30/2019	3,113,049	\$24.89
10/31/2019	2,781,977	\$24.84
11/1/2019	9,342,877	\$25.92
11/4/2019	10,281,919	\$26.19
11/5/2019	5,040,544	\$26.13
11/6/2019	5,067,427	\$25.67
11/7/2019	3,304,483	\$26.01
11/8/2019	2,765,318	\$26.20
11/11/2019	3,634,656	\$26.52
11/12/2019	3,750,137	\$27.01
11/13/2019	2,771,647	\$27.38
11/14/2019	5,223,133	\$27.75
11/15/2019	5,232,654	\$28.48
11/18/2019	3,547,900	\$28.40
11/19/2019	2,806,615	\$28.21
11/20/2019	3,586,005	\$27.73
11/21/2019	2,624,480	\$27.75
11/22/2019	2,827,694	\$27.58
11/25/2019	2,968,514	\$27.70
11/26/2019	4,688,929	\$27.96
11/27/2019	3,097,880	\$28.17
11/29/2019	1,455,683	\$28.24
12/2/2019	3,840,351	\$28.54
12/3/2019	3,300,740	\$28.27
12/4/2019	3,719,985	\$28.68
12/5/2019	3,514,540	\$28.95
12/6/2019	4,074,414	\$29.11
12/9/2019	4,677,499	\$29.21
12/10/2019	4,565,808	\$29.24
12/11/2019	5,611,660	\$29.33
12/12/2019	13,209,415	\$31.89
12/13/2019	4,951,002	\$31.00
12/16/2019	5,526,532	\$30.32
12/17/2019	4,125,432	\$29.50
12/18/2019	3,407,494	\$29.12

12/19/2019	3,817,007	\$29.90
12/20/2019	2,947,471	\$30.00
12/23/2019	1,659,579	\$29.91
12/24/2019	778,317	\$29.87
12/26/2019	1,427,474	\$29.69
12/27/2019	1,808,230	\$29.70
12/30/2019	3,153,372	\$29.44
12/31/2019	2,200,470	\$29.92
1/2/2020	2,833,292	\$29.91
1/3/2020	2,704,547	\$29.42
1/6/2020	2,493,813	\$28.86
1/7/2020	3,837,588	\$28.57
1/8/2020	3,122,394	\$28.50
1/9/2020	3,549,165	\$28.01
1/10/2020	2,782,120	\$27.65
1/13/2020	3,071,221	\$28.12
1/14/2020	3,914,427	\$28.52
1/15/2020	2,751,531	\$29.05
1/16/2020	4,836,789	\$29.75
1/17/2020	5,212,621	\$30.25
1/21/2020	4,093,776	\$29.73
1/22/2020	2,654,006	\$29.51
1/23/2020	1,997,932	\$29.19
1/24/2020	4,813,102	\$28.40
1/27/2020	2,189,145	\$28.35
1/28/2020	2,438,275	\$29.21
1/29/2020	1,880,639	\$29.15
1/30/2020	2,394,339	\$28.35
1/31/2020	4,708,224	\$27.43
2/3/2020	2,371,570	\$27.92
2/4/2020	3,472,632	\$28.82
2/5/2020	2,037,498	\$29.06
2/6/2020	1,382,090	\$28.92
2/7/2020	2,318,869	\$28.15
2/10/2020	1,730,753	\$28.19
2/11/2020	3,825,711	\$28.17
2/12/2020	1,925,050	\$28.55
2/13/2020	4,603,576	\$27.43
2/14/2020	3,621,051	\$27.74
2/18/2020	3,462,853	\$28.05
2/19/2020	13,545,948	\$26.46
2/20/2020	6,885,151	\$26.41
2/21/2020	4,197,526	\$26.50
2/24/2020	5,075,964	\$26.00
2/25/2020	6,098,991	\$24.77
2/26/2020	7,018,088	\$24.44
2/27/2020	7,963,365	\$22.52
2/28/2020	8,332,685	\$22.13
3/2/2020	7,152,741	\$23.09
3/3/2020	8,672,069	\$23.02
3/4/2020	4,211,747	\$23.13
3/5/2020	4,654,685	\$22.45
3/6/2020	7,639,076	\$20.96
3/9/2020	7,891,996	\$18.27
3/10/2020	6,628,200	\$19.36

3/11/2020	6,336,810	\$18.45
3/12/2020	10,725,819	\$16.22
3/13/2020	6,963,370	\$18.80
3/16/2020	7,643,604	\$14.96
3/17/2020	6,972,186	\$14.71
3/18/2020	10,129,260	\$12.98
3/19/2020	7,162,576	\$14.13
3/20/2020	10,121,136	\$13.66
3/23/2020	6,983,643	\$13.27
3/24/2020	4,898,301	\$14.91
3/25/2020	7,518,179	\$15.77
3/26/2020	6,341,814	\$15.44
3/27/2020	5,141,710	\$14.51
3/30/2020	5,998,797	\$15.25
3/31/2020	4,296,457	\$15.50
4/1/2020	4,360,799	\$13.75
4/2/2020	4,162,554	\$13.58
4/3/2020	6,869,580	\$13.31
4/6/2020	6,191,344	\$14.62
4/7/2020	7,380,206	\$14.85
4/8/2020	5,413,504	\$15.68
4/9/2020	10,867,937	\$18.01
4/13/2020	5,593,622	\$17.84
4/14/2020	4,268,122	\$18.36
4/15/2020	3,219,466	\$17.54
4/16/2020	2,363,656	\$16.90

EXHIBIT D

Bausch Health Announces Launch Of Private Offering Of Senior Notes

December 17, 2019

LAVAL, Quebec, Dec. 17, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it has launched an offering of a combined \$1,250,000,000 aggregate principal amount of new senior notes due 2028 (the "2028 Notes") and new senior notes due 2030 (the "2030 Notes" and, together with the 2028 Notes, the "Notes"). Bausch Health intends to use the proceeds from the offering of the Notes to finance amounts owed under the Company's recently announced \$1.21 billion settlement agreement (the "Settlement") relating to the U.S. putative securities class litigation filed in the U.S. District Court for the District of New Jersey (which is subject to court approval) and to pay transaction fees and expenses, with any remaining proceeds going to cash on the balance sheet for general corporate purposes.

The Notes will be guaranteed by each of the Company's subsidiaries that are guarantors under the Company's credit agreement and existing senior notes. Consummation of the offering of the Notes is subject to market and other conditions, and there can be no assurance that the Company will be able to successfully complete this transaction on the terms described above, or at all.

The Notes will not be registered under the Securities Act of 1933, as amended (the "Securities Act"), or any state securities law and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the Securities Act and applicable state securities laws. The Notes will be offered in the United States only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act and outside the United States to non-U.S. persons pursuant to Regulation S under the Securities Act. The Notes have not been and will not be qualified for sale to the public by prospectus under applicable Canadian securities laws and, accordingly, any offer and sale of the Notes in Canada will be made on a basis which is exempt from the prospectus requirements of such securities laws.

This news release is being issued pursuant to Rule 135c under the Securities Act and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About Bausch Health

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health.

Forward-looking Statements

This news release may contain forward-looking statements, including, but not limited to, our financing plans, including the offering of the Notes and the details thereof, including the proposed use of proceeds therefrom, the pending Settlement and other expected effects of the offering of the Notes. Forward-looking statements may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the U.S. District Court for the District of New Jersey may not approve the Settlement, other risks related to our business, including risks related to our pending legal and governmental proceedings, legislative and policy efforts, actions by the U.S. Food and Drug Administration and other regulators, our substantial debt, uncertainties associated with acquisitions and product launches, particularly in light of our active consideration of acquisition opportunities within our core therapeutic areas, some of which could be sizable, and risks and uncertainties discussed in our most recent annual and quarterly reports and detailed from time to time in our other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which risks and uncertainties are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. We undertake no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, except as required by law.

Investor Contact:

Arthur Shannon

arthur.shannon@bauschhealth.com

(514) 856-3855

(877) 281-6642 (toll free)

Media Contact:

Lainie Keller

lainie.keller@bauschhealth.com

(908) 927-1198

©

View original content to download multimedia:<http://www.prnewswire.com/news-releases/bausch-health-announces-launch-of-private-offering-of-senior-notes-300976025.html>

SOURCE Bausch Health Companies Inc.

EXHIBIT E

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

IN RE: VALEANT PHARMACEUTICALS
INTERNATIONAL, INC. SECURITIES
LITIGATION,
MASTER FILE NO. 15-7658 (MAS) (LHG)

TRANSCRIPT OF
PROCEEDING

IN RE: VALEANT PHARMACEUTICALS
INTERNATIONAL, INC. THIRD-PARTY
PAYOR LITIGATION,
MASTER FILE NO. 16-3087 (MAS) (LHG)

B E F O R E:

SPECIAL MASTER:

HONORABLE DENNIS M. CAVANAUGH (Retired)
dcavanaugh@mdmc-law.com
(By telephone)

T R A N S C R I P T of proceeding taken
stenographically by and before MARGARET
VOLLMUTH-CORSON, a Certified Court Reporter of the
State of New Jersey, at the offices of McCARTER &
ENGLISH, LLP, Four Gateway Center, 100 Mulberry
Street, Newark, New Jersey, on Tuesday, January 21,
2020, commencing at approximately 10:01 a.m.

<p style="text-align: right;">Page 2</p> <p>1 ASSISTANTS TO THE SPECIAL MASTER: 2 McELROY, DEUTSCH, MULVANEY & CARPENTER, LLP 1300 Mount Kemble Avenue 3 Morristown, New Jersey 07962 (973) 993-8100 4 BY: JILL J POMEROY, ESQ jpomeroy@mdmc-law.com 5 BY: JENNIFER M JONES, ESQ jjones@mdmc-law.com 6 BY: DANIEL GILBERT, ESQ (New York office) dgilbert@mdmc-law.com 7 8 9 10 11 A P P E A R A N C E S : 12 13 ROBBINS GELLER RUDMAN & DOWD, LLP 655 West Broadway, Suite 200 San Diego, California 92101 14 (312) 674-4674 BY: JAMES E BARZ, ESQ 15 jbarz@rgrdlaw.com BY: THEODORE J PINTAR, ESQ 16 tpintar@rgrdlaw.com BY: FRANK A RICHTER, ESQ (Chicago office) 17 frichter@rgrdlaw.com BY: ROBERT J ROBBINS, ESQ (Boca Raton office) 18 rrobbins@rgrdlaw.com and 19 SEEGER WEISS, LLP 77 Water Street, 8th Floor 20 New York, New York 10005 (212) 584-0700 21 BY: CHRISTOPHER A SEEGER, ESQ cseeger@seegerweiss.com 22 Counsel for the Plaintiffs in the Securities Class Action 15-cv-07658(MAS)(LHG) 23 24 25</p>	<p style="text-align: right;">Page 4</p> <p>1 A P P E A R A N C E S : (Continued) 2 LIEFF CABRASER HEIMANN & BERNSTEIN, LLP 250 Hudson Street, 8th Floor 3 New York, New York 10013-1413 (212) 355-9500 4 BY: MICHAEL J MIAMI, ESQ mmiarmi@lieffcabraser.com 5 Counsel for Plaintiffs in Case No 18-cv-00343 6 HGT LAW 250 Park Avenue, 7th Floor 7 New York, New York 10177 (646) 453-7292 8 BY: JOOYUN KIM, ESQ jooyun@hgtlaw.com 9 Counsel for Plaintiffs in Case Nos 18-cv-00383 and 18-cv-00846 10 11 QUINN EMANUEL URQUHART & SULLIVAN, LLP 51 Madison Avenue, 22nd Floor New York, New York 10010 12 (212) 849-7036 BY: JESSE A BERNSTEIN, ESQ 13 jessebernstein@quinnemanuel.com Counsel for Plaintiffs Hound Partners 14 15 SIMPSON THACHER & BARTLETT, LLP 425 Lexington Avenue New York, New York 10017 16 (212) 455-2000 BY: CRAIG S WALDMAN, ESQ 17 cwaldman@stblaw.com BY: JACOB LUNDQVIST, ESQ 18 jacob.lundqvist@stblaw.com and 19 MCCARTER & ENGLISH, LLP Four Gateway Center 20 100 Mulberry Street Newark, New Jersey 07102 21 (973) 622-4444 BY: RICHARD HERNANDEZ, ESQ 22 rherandez@mccarter.com BY: OMAR A BARENTTO, ESQ 23 obarentto@mccarter.com Counsel for the Defendants Valeant Pharmaceuticals 24 International, Inc , Robert L. Rosiello, Ari S Kellen, Ronald H Farmer, Collen Goggins, Robert A 25 Ingram, Theo Melas-Kyriazi, Robert N Power, Norma Provencio, and Katharine B Stevenson</p>
<p style="text-align: right;">Page 3</p> <p>1 A P P E A R A N C E S : (Continued) 2 BERNSTEIN LITOWITZ BERGER & GROSSMANN, LLP 1251 Avenue of the Americas, 44th Floor 3 New York, New York 10020 (212) 554-1400 4 BY: SALVATORE J GRAZIANO, ESQ sgraziano@blbglaw.com 5 BY: JAMES M FEE, ESQ (By telephone) james.fee@blbglaw.com 6 Third Party Payor lead counsel, interim class counsel, counsel for the Plaintiffs 7 AirConditioning and Refrigeration Industry Health and Welfare Trust Fund, Fire and Police Health 8 Care Fund, San Antonio, and Plumbers Local Union No 1 Welfare Fund 16-cv-03087(MAS)(LHG) 9 Opt-Out Plaintiffs in the Securities Class Action (Institutional Investors) Case Nos 16-cv-05034, 10 16-cv-06127, 16-cv-06128, 17-cv-06365, 16-cv-07212, 17-cv-07552, 17-cv-12808, 17-cv-13488 11 12 KASOWITZ BENSON TORRES, LLP One Gateway Center, Suite 2600 Newark, New Jersey 07102-5323 13 (973) 645-9462 BY: STEPHEN W TOUNTAS, ESQ 14 stountas@kasowitz.com Counsel for the Plaintiffs in Case Nos 17-cv-07625 15 and 18-cv-12673 and local counsel for Plaintiffs in Case Nos 17-cv-07636, 18-cv-08595, and 18-cv-15286 16 17 LABATON SUCHAROW 140 Broadway New York, New York 10005 18 (212) 907-0700 BY: TOM W WATSON, ESQ 19 twatson@labaton.com Counsel for Plaintiffs in Case Nos 17-cv-07636, 20 18-cv-08595, and 18-cv-15286 21 GRANT & EISENHOFER, P A 485 Lexington Avenue 22 New York, New York 10017 (646) 722-8513 23 BY: CAITLIN M MOYNA, ESQ cmoyna@gelaw.com 24 Counsel for Plaintiffs in Case No 17-cv-12088 25</p>	<p style="text-align: right;">Page 5</p> <p>1 A P P E A R A N C E S : (Continued) 2 DEBEVOISE & PLIMPTON, LLP 801 Pennsylvania Avenue N W 3 Washington, D C 20004 (202) 383-8036 4 BY: SAMANTHA H GRUNBERG, ESQ shgrunberg@debevoise.com 5 Counsel for the Defendant J Michael Pearson 6 WINSTON & STRAWN, LLP 200 Park Avenue 7 New York, New York 10166-4193 (212) 294-4636 8 BY: BENJAMIN SOKOLY, ESQ bsokoly@winston.com 9 Counsel for the Defendant Howard B Schiller 10 COOLEY, LLP 55 Hudson Yards 11 New York, New York 10001-2157 (212) 479-6000 12 BY: KAITLAND KENNELLY, ESQ kkennelly@cooley.com 13 Counsel for the Defendant Tanya Carro 14 GIBBONS P C One Gateway Center 15 Newark, New Jersey 07102-5310 (973) 596-4500 16 BY: KATE E JANUKOWICZ, ESQ kjanukowicz@gibbonslaw.com 17 Counsel for the Defendants Jeffrey W Ubben, ValueAct Capital Management L P , ValueAct Capital Master Fund, 18 L P , ValueAct Co-Invest Master Fund, L P , VA Partners I, LLC, and ValueAct Holdings, L P 19 20 21 22 23 24 25</p>

Page 6

1 A P P E A R A N C E S: (Continued)
 2 KING & SPALDING, LLP
 1700 Pennsylvania Avenue N W , 2nd Floor
 3 Washington, D C 20006
 (202) 737-0500
 4 BY: KENNETH Y TURNBULL, ESQ
 kturnbull@kslaw.com
 5 and
 6 CHIESA SHAHINIAN & GIANTOMASI, P C
 One Boland Drive
 West Orange, New Jersey 07052
 7 (973) 530-2100
 BY: A ROSS PEARLSON, ESQ
 8 rpearlson@csglaw.com
 Counsel for the Defendant PricewaterhouseCoopers, LLP
 9
 ENTWISTLE & CAPPUCCI, LLP
 10 299 Park Avenue, 20th Floor
 New York, New York 10171
 11 (212) 894-7200
 BY: ANDREW J ENTWISTLE, ESQ
 12 aentwistle@entwistle-law.com
 BY: ROBERT N CAPPUCCI, ESQ
 13 rcappucci@entwistle-law.com
 Counsel for Timber Hill
 14
 LITE DEPALMA GREENBERG, LLC
 15 570 Broad Street, Suite 1201
 Newark, New Jersey 07102
 16 (973) 877-3820
 BY: BRUCE D GREENBERG, ESQ (By telephone)
 17 bgreenberg@litedepalma.com
 Counsel for Första AP-Fonden, Stichting
 18 Bedrijfstakpensioenfondsvoor het
 Schilders-Afwerkingsen Glaszetbedrijf, Stichting PGGM
 19 Depository, Contra Costa County Employees Retirement
 Association, Pacific Select Fund, and Pacific Funds
 20 Series Trust
 21
 22
 23
 24
 25

Page 7

1 JUDGE CAVANAUGH: First of all, at the
 2 last minute I decided I was going to call in because
 3 something came up. Hold on just one sec.
 4 (Discussion off the record.)
 5 JUDGE CAVANAUGH: In any event, we're
 6 here today for the preliminary approval of the
 7 settlement of the Valiant Pharmaceuticals securities
 8 litigation pursuant to Rule 23E. This is the
 9 plaintiff's motion for an order seeking preliminary
 10 approval of the settlement pursuant to the
 11 stipulation of settlement of December 15, 2019. The
 12 settling parties, I understand, have consented to
 13 the settlement, and the appropriate papers were
 14 filed.
 15 I would ask someone to place something
 16 on the record as to exactly where we are and what
 17 occurred. I don't know whether that would be
 18 Mr. Seeger or whomever, but I'd like to make a short
 19 record here before we go forward.
 20 MR. SEEGER: So Judge, this is Chris
 21 Seeger. I'm here with Jim Barz of Robbins Geller,
 22 and he can introduce his colleagues that are here
 23 with him today, but Jim will give you that overview
 24 right now, if you're ready for it, or anybody else.
 25 JUDGE CAVANAUGH: Yes, that's fine.

Page 8

1 MR. SEEGER: All right. We're good.
 2 MR. BARZ: Good morning, Your Honor.
 3 Jim Barz on behalf of the plaintiffs. I also have
 4 my colleague Ted Pintar, who is a partner in our
 5 settlement department who can also answer any
 6 questions that you may have. I'll give you an
 7 overview from the plaintiff's perspective of how
 8 we've arrived here today to seek preliminary
 9 approval of what we consider to be an excellent
 10 result for the class.
 11 This is a complex securities fraud
 12 class action, as you know, Your Honor, and this
 13 result was reached after four years of hard fought
 14 litigation. It's an extremely complex case that has
 15 a three-year class period, over 20 defendants, over
 16 200 false and misleading statements that were
 17 alleged and sustained in the complaint through Judge
 18 Shipp's order on the motion to dismiss and 22
 19 corrective disclosures. We were only able to
 20 achieve this result of a \$1,210,000,000.00 all cash
 21 settlement after four years of hard fought
 22 litigation, careful analysis from documents culled
 23 from over 153 parties, over 13 million pages in the
 24 production. It's the ninth largest securities fraud
 25 class action settlement ever. It's the second

Page 9


1 largest in the Third Circuit. The only comparable
 2 one in the Third Circuit is Cendant from almost 20
 3 years ago. And what we believe makes this result
 4 particularly notable is Valeant's financial
 5 condition which we've laid out in our papers, which
 6 we believe both provided an impetus to try to settle
 7 this case and avoid further risk of Valeant's
 8 deteriorating financial condition. Hopefully it
 9 doesn't deteriorate. Hopefully it turns around, but
 10 that possibility exists. And the settlement is over
 11 150 percent of their cash on hand, so we had to
 12 navigate all of those issues.
 13 When we filed this case, Your Honor,
 14 the stock price of Valeant was \$110.00 per share.
 15 Thereafter it dropped as low as \$8.50 per share, and
 16 there was concern from the analysts that the company
 17 could be heading towards bankruptcy. It's now
 18 stabilized in the high 20s, low 30s, and we're happy
 19 for that.
 20 I thought it was also notable that when
 21 the settlement was reported analysts, including from
 22 Wells Fargo, reported that the settlement was "much
 23 larger than expected," and we believe that's an
 24 independent outside viewpoint on the success that
 25 the plaintiffs were able to achieve in this case.

<p style="text-align: right;">Page 10</p> <p>1 It didn't come easy. We had two full 2 mediations. We were unsuccessful in convincing one 3 another. It came as a result of a mediator's 4 proposal, Professor Eric Green, who is extremely 5 experienced, he was the mediator in Enron, so he's 6 done some of the big securities fraud class actions, 7 and as a result of his mediation proposal which both 8 sides accepted, that brings us here today. 9 Now, we've laid out in our papers why 10 we believe that this settlement satisfies all of the 11 criteria for preliminary approval under Rule 23 as 12 amended and under the Girsh factors, and I will tell 13 you a lot of the points I've just given you I think 14 highlight that, some of the highlights of why we 15 believe it's the result of an arm's length process. 16 I think a further note on that is this 17 isn't global peace. We have not reached a 18 settlement with PWC, and we are continuing full 19 steam ahead with the litigation as to that part. So 20 there's still a lot more work to be done by counsel 21 and the plaintiffs in this case to continue to 22 prosecute this, but we are very pleased that we were 23 able to reach settlement with the majority of 24 defendants for what we believe is an excellent 25 recovery that provides certainty to the class, it</p>	<p style="text-align: right;">Page 12</p> <p>1 through the 23 factors in particular if you'd like 2 that. Otherwise, we'd rest on our briefs and be 3 available for any questions you have. 4 JUDGE CAVANAUGH: Okay. Let me turn 5 to the defendants. Do any of the defendants have 6 anything they want to add? 7 MR. WALDMAN: It's Craig Waldman from 8 Simpson Thacher on behalf of the Valeant defendants. 9 While we continue to deny the allegations made in 10 the complaint and some of what the factual 11 background Mr. Barz laid out, the settling 12 defendants all support preliminary approval. 13 JUDGE CAVANAUGH: Thank you. All 14 right. As I said, I did review the papers. 15 Significant papers were filed. I don't think it's 16 necessary to go through each of the factors as set 17 forth. I have reviewed everything. This is a 18 preliminary approval, not the final approval, and I 19 find that the settlement should be approved for the 20 reasons that are stated in the order that will be 21 entered. There will be certain dates in that order 22 with the final approval date, I believe, to be set 23 on May 27 at the federal courthouse in Trenton. 24 There are certain other dates that we will fill in, 25 and the order will be signed and filed either later</p>
<p style="text-align: right;">Page 11</p> <p>1 avoids the risks of litigating this case against a 2 multitude of defendants, it avoids the risks of 3 Valeant's financial condition potentially 4 deteriorating, and as I noted, we didn't just simply 5 take -- you know, it could have been easy enough to 6 get 5- or \$600 million in this case, which would 7 have been the vast majority of their cash, but we 8 pressed harder, and the company's announced that 9 it's actually issuing debt to try to raise funds, 10 and we believe that's another reflection of the 11 excellent result here is that we didn't settle for 12 the cash on hand. We did a careful analysis -- we 13 actually did a lot of analysis, Your Honor, 14 internally as to, you know, what their ability to 15 pay would be. Now, that's a difficult task for 16 sure, but we have some folks in house that are 17 economists and accountants by background, and we 18 studied their financial statements, and we tried to 19 come up with a view that we could push beyond their 20 cash balance, that they did have an ability to 21 withstand a payment higher than the 800 million in 22 cash that they publicly report that they have 23 available, and we think this result achieves that. 24 So that's the overview, Your Honor. 25 We're delighted to answer any questions or to walk</p>	<p style="text-align: right;">Page 13</p> <p>1 today or tomorrow morning. 2 Okay. I think that's all that I need. 3 Is there anything else, Counsel, that you can think 4 of? 5 MR. BARZ: No, Your Honor. I just 6 want to confirm so the final approval will be held 7 in Judge Shipp's courtroom in Trenton? 8 JUDGE CAVANAUGH: For the moment, yes. 9 Even though I will probably be presiding for it, but 10 for the moment that's what will happen. We'll firm 11 that up prior to the date. 12 MR. BARZ: Okay. And we'll put that 13 in the notice then because as Your Honor knows, 14 objectors, you know, should there be any, would have 15 a right to appear. 16 JUDGE CAVANAUGH: Right. 17 MR. BARZ: And so we'll make that, and 18 we can go ahead, if you'd like, Your Honor, we can 19 input a final approval hearing date of May 27 as you 20 have noted, and then we can back in all the other 21 dates that of course tie off of that and submit that 22 electronically to your office if you'd like us to. 23 JUDGE CAVANAUGH: Yes. Submit it to 24 Ms. Pomeroy, but give me a day so I can check with 25 Judge Shipp and make sure about the use of the</p>

Page 14

1 courtroom. All right?
 2 MR. BARZ: Absolutely.
 3 JUDGE CAVANAUGH: Okay. Anything
 4 else, Counsel, that we can think of?
 5 MR. WALDMAN: No, Your Honor. Thank
 6 you.
 7 MR. SEEGER: That's it for plaintiffs.
 8 JUDGE CAVANAUGH: Well, I just want to
 9 let you know I think it's been a job well done so
 10 far. I hope you continue, and we'll continue to see
 11 you as we move along.
 12 MR. WALDMAN: Thank you, Your Honor.
 13 JUDGE CAVANAUGH: This hearing is
 14 over.
 15 MR. BARZ: Thanks, Judge.
 16 (Proceeding concluded at 10:11 a.m.)
 17
 18
 19
 20
 21
 22
 23
 24
 25

Page 15

1
 2 CERTIFICATE
 3
 4 I, MARGARET VOLLMUTH-CORSON, a Certified
 5 Court Reporter of the State of New Jersey, DO HEREBY
 6 CERTIFY that, the foregoing is a true and accurate
 7 transcript of the proceeding as taken
 8 stenographically by and before me at the time and
 9 place and on the date hereinbefore set forth
 10 I DO FURTHER CERTIFY that I am neither a
 11 relative nor employee nor attorney nor counsel of
 12 any of the parties to this action and that I am
 13 neither a relative nor employee of such attorney or
 14 counsel and that I am not financially interested in
 15 this action
 16
 17
 18 
 19 MARGARET VOLLMUTH-CORSON, C C R 30XI00158400
 20
 21 This transcript was prepared in accordance with
 22 N J A C 13:43-5.9
 23
 24
 25

[& - afwerkingsen]

Page 1

&	10:11 14:16	22 8:18	655 2:13
& 1:18 2:2,12 3:2 3:21 4:2,10,14,19 5:2,6 6:2,5,9	110.00 9:14	22nd 4:11	674-4674 2:14
0	1201 6:15	23 10:11 12:1	7
00343 4:5	12088 3:24	23e 7:8	722-8513 3:22
00383 4:9	1251 3:2	250 4:2,6	737-0500 6:3
00846 4:9	12673 3:15	2600 3:12	77 2:19
03087 3:8	12808 3:10	27 12:23 13:19	7th 4:6
05034 3:9	13 8:23	294-4636 5:7	8
06127 3:10	1300 2:2	299 6:10	8.50 9:15
06128 3:10	13488 3:10	2nd 6:2	800 11:21
06365 3:10	13966 15:18	3	801 5:2
07052 6:6	13:43-5.9. 15:21	30s 9:18	849-7036 4:12
07102 4:20 6:15	140 3:17	30xi00158400 15:19	877-3820 6:16
07102-5310 5:15	15 2:22 7:11	312 2:14	894-7200 6:11
07102-5323 3:12	15-7658 1:4	355-9500 4:3	8th 2:19 4:2
07212 3:10	150 9:11	383-8036 5:3	9
07552 3:10	15286 3:15,20	4	907-0700 3:18
07625 3:14	153 8:23	425 4:15	92101 2:13
07636 3:15,19	16 3:8,9,10,10,10	44th 3:2	973 2:3 3:13 4:21 5:15 6:7,16
07658 2:22	16-3087 1:7	453-7292 4:7	993-8100 2:3
07962 2:3	17 3:10,10,10,10 3:14,15,19,24	455-2000 4:16	a
08595 3:15,20	1700 6:2	479-6000 5:11	a.m. 1:21 14:16
1	18 3:15,15,15,20 3:20 4:5,9,9	485 3:21	ability 11:14,20
1 3:8	1900 2:13	5	able 8:19 9:25 10:23
1,210,000,000.00 8:20	2	5 11:6	absolutely 14:2
100 1:19 4:20	20 8:15 9:2	51 4:11	accepted 10:8
10001-2157 5:11	200 5:6 8:16	530-2100 6:7	accountants 11:17
10005 2:20 3:17	20004 5:3	55 5:10	accurate 15:6
10010 4:11	20006 6:3	554-1400 3:3	achieve 8:20 9:25
10013-1413 4:3	2019 7:11	570 6:15	achieves 11:23
10017 3:22 4:15	202 5:3 6:3	584-0700 2:20	action 2:22 3:9 8:12,25 15:12,15
10020 3:3	2020 1:21	596-4500 5:15	actions 10:6
10166-4193 5:7	20s 9:18	6	add 12:6
10171 6:10	20th 6:10	600 11:6	aentwistle 6:12
10177 4:7	21 1:20	622-4444 4:21	afwerkingsen 6:18
10:01 1:21	212 2:20 3:3,18 4:3,12,16 5:7,11 6:11	645-9462 3:13	
		646 3:22 4:7	

[ago - courtroom]

Page 2

<p>ago 9:3 ahead 10:19 13:18 airconditioning 3:7 allegations 12:9 alleged 8:17 amended 10:12 americas 3:2 analysis 8:22 11:12,13 analysts 9:16,21 andrew 6:11 announced 11:8 answer 8:5 11:25 antonio 3:8 anybody 7:24 ap 6:17 appear 13:15 appropriate 7:13 approval 7:6,10 8:9 10:11 12:12 12:18,18,22 13:6 13:19 approved 12:19 approximately 1:21 ari 4:24 arm's 10:15 arriven 8:8 assistants 2:1 association 6:19 attorney 15:11,13 available 11:23 12:3 avenue 2:2 3:2,21 4:6,11,15 5:2,6 6:2,10 avoid 9:7 avoids 11:1,2</p>	<p style="text-align: center;">b</p> <p>b 1:9 4:25 5:9 back 13:20 background 11:17 12:11 balance 11:20 bankruptcy 9:17 barentto 4:22 bartlett 4:14 barz 2:14 7:21 8:2 8:3 12:11 13:5,12 13:17 14:2,15 bedrijfstakpensi... 6:18 behalf 8:3 12:8 believe 9:3,6,23 10:10,15,24 11:10 12:22 benjamin 5:8 benson 3:11 berger 3:2 bernstein 3:2 4:2 4:12 beyond 11:19 bgreenberg 6:17 big 10:6 blbglaw.com 3:4,5 boca 2:17 boland 6:6 briefs 12:2 brings 10:8 broad 6:15 broadway 2:13 3:17 bruce 6:16 bsokoly 5:8</p> <p style="text-align: center;">c</p> <p>c 1:15 2:11 3:1 4:1 5:1 6:1 15:2,2</p>	<p>c.c.r. 15:19 cabraser 4:2 caitlin 3:23 california 2:13 call 7:2 capital 5:17,17 cappucci 6:9,12 care 3:8 careful 8:22 11:12 carpenter 2:2 carro 5:13 case 3:9,14,15,19 3:24 4:5,9 8:14 9:7,13,25 10:21 11:1,6 cash 8:20 9:11 11:7,12,20,22 cavanaugh 1:11 7:1,5,25 12:4,13 13:8,16,23 14:3,8 14:13 cendant 9:2 center 1:19 3:12 4:19 5:14 certain 12:21,24 certainty 10:25 certified 1:17 15:4 certify 15:6,10 check 13:24 chicago 2:16 chiesa 6:5 chris 7:20 christopher 2:21 circuit 9:1,2 class 2:22 3:6,9 8:10,12,15,25 10:6 10:25 cmoyna 3:23 colleague 8:4 colleagues 7:22</p>	<p>collen 4:24 come 10:1 11:19 commencing 1:21 company 9:16 company's 11:8 comparable 9:1 complaint 8:17 12:10 complex 8:11,14 concern 9:16 concluded 14:16 condition 9:5,8 11:3 confirm 13:6 consented 7:12 consider 8:9 continue 10:21 12:9 14:10,10 continued 3:1 4:1 5:1 6:1 continuing 10:18 contra 6:19 convincing 10:2 cooley 5:10 cooley.com 5:12 corrective 8:19 corson 1:17 15:4 15:19 costa 6:19 counsel 2:22 3:6,6 3:6,14,15,19,24 4:5,9,13,23 5:5,9 5:13,17 6:8,13,17 10:20 13:3 14:4 15:11,14 county 6:19 course 13:21 court 1:17 15:5 courthouse 12:23 courtroom 13:7 14:1</p>
---	---	--	--

[craig - h]

Page 3

craig 4:16 12:7 criteria 10:11 cseeger 2:21 csglaw.com 6:8 culled 8:22 cv 2:22 3:8,9,10,10 3:10,10,10,10,10 3:14,15,15,15,15 3:19,20,20,24 4:5 4:9,9 cwaldman 4:17	deutsch 2:2 dgilbert 2:6 diego 2:13 difficult 11:15 disclosures 8:19 discussion 7:4 dismiss 8:18 documents 8:22 dowd 2:12 drive 6:6 dropped 9:15	exists 9:10 expected 9:23 experienced 10:5 extremely 8:14 10:4	frank 2:16 fraud 8:11,24 10:6 frichter 2:17 full 10:1,18 fund 3:7,8,8 5:17 5:18 6:19
d	e	f	f
d 6:16 d.c. 5:3 6:3 daniel 2:6 date 12:22 13:11 13:19 15:9 dates 12:21,24 13:21 day 13:24 dcavanaugh 1:11 debevoise 5:2 debevoise.com 5:4 debt 11:9 december 7:11 decided 7:2 defendant 5:5,9,13 6:8 defendants 4:23 5:17 8:15 10:24 11:2 12:5,5,8,12 delighted 11:25 dennis 1:11 deny 12:9 depalma 6:14 department 8:5 depository 6:19 deteriorate 9:9 deteriorating 9:8 11:4	e 1:9,9 2:11,11,14 3:1,1 4:1,1 5:1,1 5:16 6:1,1 15:2,2 easy 10:1 11:5 economists 11:17 eisenhofer 3:21 either 12:25 electronically 13:22 emanuel 4:10 employee 15:11,13 employees 6:19 english 1:19 4:19 enron 10:5 entered 12:21 entwistle 6:9,11 6:12,13 eric 10:4 esq 2:4,5,6,14,15 2:16,17,21 3:4,5 3:13,18,23 4:4,8 4:12,16,17,21,22 5:4,8,12,16 6:4,7 6:11,12,16 event 7:5 exactly 7:16 excellent 8:9 10:24 11:11	f 1:9 15:2 factors 10:12 12:1 12:16 factual 12:10 false 8:16 far 14:10 fargo 9:22 farmer 4:24 federal 12:23 fee 3:5 file 1:4,7 filed 7:14 9:13 12:15,25 fill 12:24 final 12:18,22 13:6 13:19 financial 9:4,8 11:3,18 financially 15:14 find 12:19 fine 7:25 fire 3:7 firm 13:10 first 7:1 floor 2:19 3:2 4:2 4:6,11 6:2,10 folks 11:16 fonden 6:17 foregoing 15:6 forth 12:17 15:9 forward 7:19 fought 8:13,21 four 1:19 4:19 8:13,21	frank 2:16 fraud 8:11,24 10:6 frichter 2:17 full 10:1,18 fund 3:7,8,8 5:17 5:18 6:19 funds 6:19 11:9 further 9:7 10:16 15:10 första 6:17
			g
			gateway 1:19 3:12 4:19 5:14 gelaw.com 3:23 geller 2:12 7:21 giantomasi 6:5 gibbons 5:14 gibbonslaw.com 5:16 gilbert 2:6 girsh 10:12 give 7:23 8:6 13:24 given 10:13 glaszetbedrijf 6:18 global 10:17 go 7:19 12:16 13:18 goggins 4:24 going 7:2 good 8:1,2 grant 3:21 graziano 3:4 green 10:4 greenberg 6:14,16 grossmann 3:2 grunberg 5:4
			h
			h 4:24 5:4

[hand - michael]

Page 4

<p>hand 9:11 11:12 happen 13:10 happy 9:18 hard 8:13,21 harder 11:8 heading 9:17 health 3:7,7 hearing 13:19 14:13 heimann 4:2 held 13:6 hereinbefore 15:9 hernandez 4:21 het 6:18 hgt 4:6 hgtlaw.com 4:8 high 9:18 higher 11:21 highlight 10:14 highlights 10:14 hill 6:13 hold 7:3 holdings 5:18 honor 8:2,12 9:13 11:13,24 13:5,13 13:18 14:5,12 honorable 1:11 hope 14:10 hopefully 9:8,9 hound 4:13 house 11:16 howard 5:9 hudson 4:2 5:10</p>	<p>institutional 3:9 interested 15:14 interim 3:6 internally 11:14 international 1:3 1:6 4:24 introduce 7:22 invest 5:18 investors 3:9 issues 9:12 issuing 11:9</p>	<p>k</p> <p>kaitland 5:12 kasowitz 3:11 kasowitz.com 3:14 kate 5:16 katharine 4:25 kellen 4:24 kemble 2:2 kennelly 5:12 kenneth 6:4 kim 4:8 king 6:2 kjanukowicz 5:16 kkennelly 5:12 know 7:17 8:12 11:5,14 13:14 14:9 knows 13:13 kslaw.com 6:4 kturnbull 6:4 kyriazi 4:25</p>	<p>lite 6:14 litedepalma.com 6:17 litigating 11:1 litigation 1:4,6 7:8 8:14,22 10:19 litowitz 3:2 llc 5:18 6:14 llp 1:19 2:2,12,19 3:2,11 4:2,10,14 4:19 5:2,6,10 6:2 6:8,9 local 3:8,15 lot 10:13,20 11:13 low 9:15,18 lundqvist 4:17</p>
<p>i</p>	<p>j</p> <p>j 2:4,15,17 3:4 4:4 5:5 6:11 jacob 4:17 jacob.lundqvist 4:18 james 2:14 3:5 james.fee 3:5 january 1:20 janukowicz 5:16 jbarz 2:15 jeffrey 5:17 jennifer 2:5 jersey 1:18,20 2:3 3:12 4:20 5:15 6:6 6:15 15:5 jesse 4:12 jessebernstein 4:13 jill 2:4 jim 7:21,23 8:3 jjones 2:5 job 14:9 jones 2:5 jooyun 4:8,8 jpomeroy 2:4 judge 7:1,5,20,25 8:17 12:4,13 13:7 13:8,16,23,25 14:3 14:8,13,15</p>	<p>l</p> <p>l 4:24 l.p. 5:17,18,18,18 labaton 3:16 labaton.com 3:19 laid 9:5 10:9 12:11 larger 9:23 largest 8:24 9:1 law 4:6 law.com 1:11 2:4 2:5,6 6:12,13 lead 3:6 length 10:15 lexington 3:21 4:15 lhg 1:4,7 2:22 3:8 lieff 4:2 lieffcabraser.com 4:4</p>	<p>m</p> <p>m 1:11 2:5 3:5,23 madison 4:11 majority 10:23 11:7 management 5:17 margaret 1:16 15:4,19 mas 1:4,7 2:22 3:8 master 1:4,7,10 2:1 5:17,18 mccarter 1:18 4:19 mccarter.com 4:22,23 mcelroy 2:2 mdmc 1:11 2:4,5,6 mediation 10:7 mediations 10:2 mediator 10:5 mediator's 10:3 melas 4:25 miarmi 4:4 michael 4:4 5:5</p>

[million - refrigeration]

Page 5

million 8:23 11:6 11:21 minute 7:2 misleading 8:16 mmiarmi 4:4 moment 13:8,10 morning 8:2 13:1 morristown 2:3 motion 7:9 8:18 mount 2:2 move 14:11 moyna 3:23 mulberry 1:19 4:20 multitude 11:2 mulvaney 2:2	noted 11:4 13:20 notice 13:13 o o 1:9 obarentto 4:23 objectors 13:14 occurred 7:17 office 2:6,16,17 13:22 offices 1:18 okay 12:4 13:2,12 14:3 omar 4:22 opt 3:9 orange 6:6 order 7:9 8:18 12:20,21,25 outside 9:24 overview 7:23 8:7 11:24 p p 1:15 2:11,11 3:1 3:1 4:1,1 5:1,1 6:1 6:1 p.a. 3:21 p.c. 5:14 6:5 pacific 6:19,19 pages 8:23 papers 7:13 9:5 10:9 12:14,15 park 4:6 5:6 6:10 part 10:19 particular 12:1 particularly 9:4 parties 7:12 8:23 15:12 partner 8:4 partners 4:13 5:18 party 1:6 3:6	pay 11:15 payment 11:21 payor 1:6 3:6 peace 10:17 pearlson 6:7 pearson 5:5 pennsylvania 5:2 6:2 percent 9:11 period 8:15 perspective 8:7 pggm 6:18 pharmaceuticals 1:3,5 4:23 7:7 pintar 2:15 8:4 place 7:15 15:9 plaintiff's 7:9 8:7 plaintiffs 2:22 3:6 3:9,14,15,19,24 4:5,9,13 8:3 9:25 10:21 14:7 pleased 10:22 plimpton 5:2 plumbers 3:8 points 10:13 police 3:7 pomeroy 2:4 13:24 possibility 9:10 potentially 11:3 power 4:25 preliminary 7:6,9 8:8 10:11 12:12 12:18 prepared 15:20 presiding 13:9 pressed 11:8 price 9:14 pricewaterhouse... 6:8	prior 13:11 probably 13:9 proceeding 1:3,15 14:16 15:7 process 10:15 production 8:24 professor 10:4 proposal 10:4,7 prosecute 10:22 provencio 4:25 provided 9:6 provides 10:25 publicly 11:22 pursuant 7:8,10 push 11:19 put 13:12 pwc 10:18 q questions 8:6 11:25 12:3 quinn 4:10 quinnemanuel.c... 4:13 r r 1:9,15,15 2:11 3:1 4:1 5:1 6:1 15:2 raise 11:9 raton 2:17 rcappucci 6:13 reach 10:23 reached 8:13 10:17 ready 7:24 reasons 12:20 record 7:4,16,19 recovery 10:25 reflection 11:10 refrigeration 3:7
n n 1:15 2:11 3:1 4:1 4:25 5:1 6:1,12 n.j.a.c. 15:21 n.w. 5:2 6:2 navigate 9:12 necessary 12:16 need 13:2 neither 15:10,13 new 1:18,20 2:3,6 2:20,20 3:3,3,12 3:17,17,22,22 4:3 4:3,7,7,11,11,15 4:15,20 5:7,7,11 5:11,15 6:6,10,10 6:15 15:5 newark 1:20 3:12 4:20 5:15 6:15 ninth 8:24 norma 4:25 nos 3:9,14,15,19 4:9 notable 9:4,20 note 10:16			

[relative - urquhart]

Page 6

relative 15:11,13 report 11:22 reported 9:21,22 reporter 1:17 15:5 rest 12:2 result 8:10,13,20 9:3 10:3,7,15 11:11,23 retired 1:11 retirement 6:19 review 12:14 reviewed 12:17 rgrdlaw.com 2:15 2:16,17,18 rhernandez 4:22 richard 4:21 richter 2:16 right 7:24 8:1 12:14 13:15,16 14:1 risk 9:7 risks 11:1,2 robbins 2:12,17 7:21 robert 2:17 4:24 4:24,25 6:12 ronald 4:24 rosiello 4:24 ross 6:7 rpearlson 6:8 rrobbins 2:18 rudman 2:12 rule 7:8 10:11	schilders 6:18 schiller 5:9 sec 7:3 second 8:25 securities 1:3 2:22 3:9 7:7 8:11,24 10:6 see 14:10 seeger 2:19,21 7:18,20,21 8:1 14:7 seegerweiss.com 2:21 seek 8:8 seeking 7:9 select 6:19 series 6:20 set 12:16,22 15:9 settle 9:6 11:11 settlement 7:7,10 7:11,13 8:5,21,25 9:10,21,22 10:10 10:18,23 12:19 settling 7:12 12:11 sgraziano 3:4 shahinian 6:5 share 9:14,15 shgrunberg 5:4 shipp 13:25 shipp's 8:18 13:7 short 7:18 sides 10:8 signature 15:18 signed 12:25 significant 12:15 simply 11:4 simpson 4:14 12:8 sokoly 5:8 spalding 6:2 special 1:10 2:1	stabilized 9:18 state 1:18 15:5 stated 12:20 statements 8:16 11:18 stblaw.com 4:17 4:18 steam 10:19 stenographically 1:16 15:8 stephen 3:13 stevenson 4:25 stichting 6:17,18 stipulation 7:11 stock 9:14 stountas 3:14 strawn 5:6 street 1:20 2:19 4:2,20 6:15 studied 11:18 submit 13:21,23 success 9:24 sucharow 3:16 suite 2:13 3:12 6:15 sullivan 4:10 support 12:12 sure 11:16 13:25 sustained 8:17	thank 12:13 14:5 14:12 thanks 14:15 theo 4:25 theodore 2:15 think 10:13,16 11:23 12:15 13:2 13:3 14:4,9 third 1:6 3:6 9:1,2 thought 9:20 three 8:15 tie 13:21 timber 6:13 time 15:8 today 7:6,23 8:8 10:8 13:1 tom 3:18 tomorrow 13:1 torres 3:11 tountas 3:13 tpintar 2:16 transcript 1:3 15:7,20 trenton 12:23 13:7 tried 11:18 true 15:6 trust 3:7 6:20 try 9:6 11:9 tuesday 1:20 turn 12:4 turnbull 6:4 turns 9:9 twatson 3:19 two 10:1
s		t	
s 1:15 2:11 3:1 4:1 4:16,24 5:1 6:1 salvatore 3:4 samantha 5:4 san 2:13 3:8 satisfies 10:10		t 1:15,15 15:2,2 take 11:5 taken 1:15 15:7 tanya 5:13 task 11:15 ted 8:4 telephone 1:12 3:5 6:16 tell 10:12 thacher 4:14 12:8	u
			ubben 5:17 understand 7:12 union 3:8 unsuccessful 10:2 urquhart 4:10

[use - york]

Page 7

use 13:25	year 8:15
v	years 8:13,21 9:3
va 5:18	york 2:6,20,20 3:3
valeant 1:3,5 4:23	3:3,17,17,22,22
9:14 12:8	4:3,3,7,7,11,11,15
valeant's 9:4,7	4:15 5:7,7,11,11
11:3	6:10,10
valiant 7:7	
valueact 5:17,17	
5:18,18	
vast 11:7	
view 11:19	
viewpoint 9:24	
vollmuth 1:17	
15:4,19	
voor 6:18	
w	
w 3:13,18 5:17	
waldman 4:16	
12:7,7 14:5,12	
walk 11:25	
want 12:6 13:6	
14:8	
washington 5:3	
6:3	
water 2:19	
watson 3:18	
we've 8:8 9:5 10:9	
weiss 2:19	
welfare 3:7,8	
wells 9:22	
west 2:13 6:6	
winston 5:6	
winston.com 5:8	
withstand 11:21	
work 10:20	
y	
y 6:4	
yards 5:10	